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Abstract(!The! neuronal! ceroid! lipofuscinoses! (NCLs)! are! a! group! of! inherited! lysosomal!storage! disorders! that! cause! profound! neurodegeneration! and! predominantly!affect!children.!Currently,!there!are!no!effective!treatments!available!for!any!form!of!NCL.!This!thesis!focuses!on!novel!applications!of!gene!therapy!for!CLN1!disease,!which! is! caused! by! a! deficiency! in! the! lysosomal! enzyme! palmitoyl! protein!thioesteraseA1! (PPT1)! and! CLN3! disease,!which! results! from!mutations! in!CLN3,!which!encodes!a!lysosomal!transmembrane!protein!of!unknown!function.!!Therapy!for!transmembrane!proteinAdeficient!NCLs!is!complicated!because!uptake!of! therapeuticallyAdelivered! enzyme! or! “crossAcorrection”! is! not! possible.! Gene!therapy!could!theoretically!correct!the!CLN3!defect,!but!would!require!widespread!transduction,! and! overexpression! of! CLN3! may! have! safety! concerns.! We! used!AAV2/9!vectors!to!deliver!either!mouse!or!human!Cln3/CLN3!to!the!brains!of!wildAtype! and! Cln3Adeficient! mice,! and! assessed! the! shortA! and! longAterm! response.!Although! a! neuroinflammatory! response! to! Cln3! overAexpression! was! initially!seen,! this! declined! over! time,! and! no! obvious! toxicity! was! associated! with! this!overexpression.!!Compared!to!the!brain,!little!is!known!about!NCL!systemic!pathology,!but!we!show!that! both! Cln1A! and! Cln3Adeficient! mice! display! functional! and! pathological!phenotypes! including! heart! rate! abnormalities,! sinoatrial! node! pathology,! left!ventricular!hypertrophy!and!cardiac!remodeling,!thus!providing!a!more!complete!picture!of!NCL!pathology!and!where!to!target!therapy.!!Although! gene! therapy! has! been! partly! successful! for! treating! murine! CLN1!disease,! it! has! shown! limited! ability! to! extend! lifespan.!One!way! to! enhance! this!efficacy!would!be!to!combine!CNS!gene!therapy!with!treating!systemic!pathology,!and!we!used!neonatal!intracranial!AAV2/9Amediated!gene!therapy!combined!with!enzyme! replacement! therapy! (ERT)! to! treat! the! brain! and! body,! respectively.!While!gene!therapy!alone!significantly! improved!neuropathological!changes,!ERT!conferred! little! additional! benefit,! and! appeared! to! negate! the! positive! effects! of!gene!therapy.!!
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Ppt1%/%$ and$ Cln3%/%$ mutant$ mice$ and$ corresponding$ control$ (wildNtype)$ mice$included$ in$ this$ thesis$ were$ performed$ at$ the$ PSDL,$ IoPPN$ by$ Yewande$ Pearse,$under$ the$ supervision$ of$ Professor$ Jonathan$ Cooper$ and$ Dr$ Sandrine$ Thuret.$Additional$ supervision$ was$ provided$ by$ our$ collaborators$ from$ KCL’s$Cardiovascular$ Division,$ Dr$ Min$ Zhang$ and$ Dr$ Daniel$ Martin$ whose$ input$ was$fundamental$ to$ the$ cardiovascular$ study$ in$ this$ thesis.$ Some$ of$ the$ histological$procedures$used$for$assessing$cardiac$pathology$in$Ppt1%/%$and$Cln3%/%1mutant$mice$and$ corresponding$ control$ (wildNtype)$mice$were$ carried$ out$ together$with$ Carl$Hobbs$ at$ the$Wolfson$ Centre$ for$ Age$ Related$ Diseases$ (Wolfson$ CARD)$ at$ KCL,$
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The$ neuronal$ ceroid$ lipofuscinoses$ (NCLs),$ are$ a$ group$ of$ fatal$ autosomal:recessive$ neurodegenerative$ diseases,$ primarily$ affecting$ children$ and$ young$adults,$for$which$no$effective$therapies$currently$exist$(Goebel,$1995;$Schulz$et#al.,#2013;$ Alroy$ et# al.,# 2011;$ Zeman$ and$ Dyken,$ 1969;$ Santavouri,$ 1988).$ With$ an$incidence$of$approximately$1$ in$100,000$ live$births$worldwide$and$a$particularly$high$ incidence$ of$ as$ many$ as$ 1$ in$ 12,5000$ live$ births$ in$ Scandinavia,$ the$ NCLs$collectively$ represent$ the$ most$ common$ cause$ of$ childhood$ dementia$ (Goebel,$1995;$ Santavouri,$ 1988;$ Kyttälä$ et#al.,#2006;$ Jalanko$ and$ Braulke,$ 2009).$ While$these$ disorders$ represent$ a$ distinct$ category$ of$ relatively$ rare$ diseases,$ they$belong$ to$ a$ much$ broader$ collection$ of$ at$ least$ 70$ lysosomal$ storage$ disorders$(LSDs)$(De$Duve,$1963;$Hers$1965;$Vellodi,$2005;$Sands$and$Davidson,$2006).$As$with$all$other$LSDs,$the$mutations$linked$to$the$NCLs$lead$to$lysosomal$dysfunction$and$the$characteristic$accumulation$of$storage$material$from$undegraded$material$or$ catabolic$ products$ (Hers,$ 1965,$ 1972;$ De$ Duve,$ 1963,$ 1975;$ Wong$ 2010;$Peltonen,$2000).$What$sets$ the$NCLs$apart$ from$the$rest$of$ the$LSDs$however,$ is$that$ besides$ the$ build$ up$ of$ storage$material$ in$ the$ cells$ of$ affected$ individuals,$these$ disorders$ show$ a$ number$ of$ shared$ clinical$ features,$ including$ blindness,$seizures,$cognitive$impairment$and$motor$deficits$(Cooper$et#al.,#2015;$Chang$et#al.,$2008;$ Pontikis$ et#al.,$ 2004;$ Kühl$ et#al.,$ 2013;$ Kuronen$ et#al.,$ 2012;$ Kielar$ et#al.,$2007).$ Based$ on$ our$ understanding$ of$ NCL$ pathogenesis$ so$ far,$ a$ number$ of$experimental$ therapeutic$ strategies$ have$been$ attempted$ to$prevent$ or$ slow$ the$progression$ of$ disease$ (Wong$ et#al.,#2010).$ However,$ although$ some$ have$ led$ to$improvements$pre:clinically,$none$to$date$have$resulted$in$an$appreciable$increase$in$ quality$ of$ life$ or$ lifespan$ in$ patients,$ and$ so$ the$ NCLs$ continue$ to$ result$ in$premature$ death$ after$ a$ devastating$ disease$ course$ (Santavuori,$ 1988;$ Goebel,$1999;$ Haltia,$ 2003;$ Mole,$ 2005;$ Williams,$ 2006).$ The$ aim$ of$ this$ thesis$ is$ to$
! 33!
investigate$gene$ therapy$as$a$potential$ treatment$ for$ two$very$different$ forms$of$NCL:$CLN1$and$CLN3$disease.$The$progress$ that$has$been$made$ in$ treating$these$two$forms$of$NCL$with$gene$therapy$has$reached$quite$different$stages.$Although$CLN1$ and$ CLN3$ are$ classified$ as$ part$ of$ the$ same$ group$ of$ disorders,$ like$ all$individual$NCLs$they$are$separate$diseases,$and$therefore$using$gene$therapy$as$a$potential$ treatment$ raises$different$ issues$based$on$ the$particular$ genetic$ defect$and$pathological$nuances$of$these$diseases.$Gene$therapy$approaches$for$treating$CLN3$disease$are$ in$ their$ infancy,$ and$ this$ thesis$ investigates$ the$ safety$of$using$adeno:associated$ virus$ (AAV):mediated$ gene$ therapy$ for$ the$ treatment$ of$ CLN3$disease.$ Gene$ therapy$ is$ a$ more$ established$ approach$ for$ CLN1$ disease,$ but$ its$therapeutic$efficacy$is$still$suboptimal,$and$this$thesis$explores$the$combination$of$enzyme$replacement$therapy$(ERT)$with$AAV:mediated$gene$therapy$as$a$way$to$improve$gene$ therapy$ for$ this$ form$of$NCL.$Cardiac$pathology$ in$both$CLN1$and$CLN3$disease$ is$ also$ investigated$ in$order$ to$ improve$our$understanding$of$NCL$disease$beyond$ its$neurological$manifestations,$and$evaluate$whether$ the$viscera$should$be$considered$an$important$therapeutic$target.$Before$addressing$what$we$know$ about$ the$ pathogenesis$ of$ the$NCLs$ and$ the$ therapeutic$ options$ available,$the$function$of$the$lysosome$and$how$lysosome$dysfunction$gives$rise$to$the$LSDs$will$be$discussed.$$
1! The(lysosome(
1.1! The(function(of(the(lysosome(In$his$endeavour$to$understand$the$intracellular$distribution$of$enzymes,$Christian$de$Duve$instead$discovered$the$lysosome$in$1955,$and$was$subsequently$awarded$the$ Nobel$ Prize$ for$ this$ work$ (De$ Duve$ et# al.,# 1955;$ Appelmans$ et# al.,# 1955).$
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Lysosomes$ are$ membrane:bound$ organelles,$ which$ were$ for$ a$ long$ time$considered$ simply$ as$ ‘cellular$ incinerators’$ responsible$ only$ for$ degrading$ and$recycling$cellular$waste$products$(Settembre$et#al.,$2013).$However,$it$is$now$clear$that$lysosomes$play$an$important$role$in$many$cellular$processes,$and$are$essential$for$ regulating$ cellular$ homeostasis$ (Settembre$ et# al.,$ 2013;$ Sachse$ et# al.,$ 2002;$Eskelinen$et#al.,$2003;$Eskelinen,$2005;$Luzio$et#al.,$2007).$This$is$substantiated$by$the$growing$number$of$diseases$identified$that$develop$as$a$result$of$defects$within$the$lysosomal$system$and$will$be$described$in$section(2((Vellodi,$2005;$Parkinson:Lawrence$ et# al.,#2010).( The$ formation$ of$ mature$ lysosomes$ involves$ a$ complex$series$of$ events,$which$have$been$described$extensively$ elsewhere$ (Saftig,$ 2009;$Jalanko$ and$ Braulke$ et#al.,#2009;$ Luzio,$ 2007;$ Pfeffer,$ 1991;$ Zerial$ and$McBride,$2001;$Rink$et#al.,#2005;$Luzio$et#al.,#2009;$Sridhar$et#al.,#2013).$Briefly,$ lysosomes$are$ formed$by$ clathrin:coated$ transport$ vesicles$ that$ are$ budded$ from$ the$ trans#Golgi$ network$ fusing$with$ early$ endosomes$ that$ contain$molecules$ taken$ up$ by$endocystosis$at$ the$plasma$membrane$ (Cooper,$2000;$Luzio$et#al.,$2000,$Luzio$et#
al.,#2007;$ Settembre$et#al.,#2013;$Appelqvist$et#al.,#2013).$Membrane$ components$are$then$recycled,$as$early$endosomes$gradually$mature$into$late$endosomes$:$the$precursors$to$lysosomes$(Cooper,$2000).$ $Several$models$have$been$proposed$for$how$material$ from$ the$ late$ endosome$ is$ transferred$ to$ clathrin:coated$ transport$vesicles$in$order$to$form$lysosomes$as$shown$in$Figure(1((reviewed$in$Luzio$et#al.,#2007).$In$any$of$these$proposed$pathways,$a$key$step$in$the$transformation$of$the$late$endosome$to$the$mature$lysosome$is$the$lowering$of$the$pH$of$the$endosomal$lumen$ in$preparation$ for$ receiving$acid$hydrolases$ from$ the$ trans#Golgi$network$(Cooper,$ 2000;$ Huotari$ and$ Helenius,$ 2011).$ As$ will$ be$ explained$ in$ the$ next$section$ (section(1.1.a),$ once$ the$ late$ endosome$ acquires$ the$ full$ complement$ of$
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a)! Lysosomal(enzymes(Two$ broad$ categories$ of$ proteins$ are$ essential$ for$ the$ function$ of$ lysosomes:$hydrolytic$ proteins$ and$ integral$ lysosomal$ membrane$ proteins$ (Xu$ et#al.,#2015;$Winchester,$ 2001).$ Lysosomes$ contain$ over$ 50$ different$ hydrolytic$ enzymes,$which$allow$them$to$degrade$proteins$(proteases),$nucleic$acids$(nucleases),$lipids$(lipases),$and$carbohydrates$(glycosidases)$as$well$as$viruses$and$bacteria,$which$are$delivered$to$them$by$endocytosis,$phagocytosis,$and$autophagy$(Appelqvist$et#
al.,$2013; Sleat$et#al.,#2005;$Saftig$and$Klumperman,$2009;$Luzio$et#al.,$2007).$The$degradation$of$ these$macromolecules$ is$ a$key$part$of$many$ cellular$processes$ in$
Figure(1.(Proposed(paradigms(for(trafficking(of(lysosomal(enzymes(to(the(prelysosome.$ (A)$ In$ the$maturation$model,$endosomes$mature$into$lysosomes$via$the$gradual$addition$of$lysosomal$ features.$ (B)$In$the$vesicular$model,$vesicles$bud$from$the$late$endosome$and$transport$their$contents$to$the$lysosome.$(C)$In$the$‘kiss$and$run’$model,$late$endosomes$and$lysosomes$fuse$temporarily$to$allow$the$exchange$of$material$(D)$In$the$hybrid$model,$endosomes$and$lysosomes$fuse$permanently$to$form$a$hybrid$organelle,$and$then$lysosomes$are$re:formed$by$retrieval$of$endosomal$components.$Taken$from$(Luzio$et#al.,$2007).$$
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the$ body;$ from$ digesting$ obsolete$ or$ abnormal$ cellular$ components,$ to$phagocytosis$of$pathogenic$organisms$and$antigen$processing$and$presentation$to$major$ histocompatibility$ class$ (MHC)$ class$ II$ molecules$ (Boustany,$ 2013;$ Saftig$and$ Klumperman,$ 2009;$ Luzio$ et# al.,$ 2007;$ Mullins$ and$ Bonifacino,$ 2001).$ The$majority$ of$ lysosomal$ enzymes$ are$ proteases,$ most$ of$ which$ are$ expressed$ubiquitously$ (Brix$ and$ Jordans,$ 2005).$ The$ main$ class$ of$ proteases$ is$ the$cathepsins,$ which$ can$ be$ divided$ into$ three$ categories$ according$ to$ the$ amino$acids$ at$ their$ active$ sites$ that$ determine$ their$ catalytic$ activity$ and$ include,$cysteine,$ aspartyl$ and$ serine$ cathepsins$ (Conus$ and$ Simon,$ 2008).$However,$ the$precise$ enzymatic$ content$ of$ lysosomes$ varies$ according$ to$ the$ type$ of$ cell$ they$belong$to$and$their$catabolic$demands$(Brix$and$Jordans,$2005).$$Soluble$ lysosmal$ proteins$ are$ synthesized$ as$ inactive$ precursors$ in$ the$ rough$endoplasmic$reticulum$(ER)$(Kornfeld,$1986).$Following$their$synthesis,$lysosomal$enzymes$undergo$a$number$of$ important$post–translational$modifications,$which$are$ important$ for$ their$ correct$ trafficking$ to$ lysosomes$ where$ they$ become$functional$ (Kornfeld,$ 1992;$Braulke$ and$Bonifacino,$ 2009).$ This$highly$ regulated$process$is$necessary$to$ensure$that$acidic$lysosomal$proteins$do$not$harm$the$cell$(Kornfeld,$1992;$Braulke$and$Bonifacino,$2009).$Although$several$pathways$have$been$proposed$(Ginsel$and$Fransen,$1991;$Glickmann$and$Kornfeld,$1993;$Ludwig$
et# al.,#1994;$ Dittmer$ et# al.,#1999),$ the$ best$ described$ route$ for$ the$ targeting$ of$lysosomal$ enzymes$ to$ the$ lysosome$ is$ via$ the$ mannose$ 6:phosphate$ (M6P)$pathway$ (Kornfeld,$ 1985).$ Lysosomal$ enzymes$ are$ first$ glycosylated$ by$ the$addition$of$oligosaccharides$ in$the$rough$ER,$and$then$phosphorylated$ in$the$cis-Golgi$ apparatus,$ allowing$ them$ to$ be$ recognized$ by$ the$ mannose$ 6:phosphate/insulin:like$growth$factor$II$receptor$(M6P/IGF$IIr)$in$the$trans:Golgi:
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network$ (Ghosh$ et#al.,$ 2003;$ Luzio$ et#al.,$ 2000;$ Luzio$ et#al.,$ 2007).$ The$ resulting$enzyme:receptor$ complex$ is$ packaged$ into$ clathrin:coated$ vesicles$ and$subsequently$transported$through$the$endosomal$system$where$the$clathrin$coat$is$ removed,$ and$ the$ transport$ vesicle$ fuses$ with$ the$ late$ endosome$ (Kornfeld,$1986;$von$Figura$and$Hasilik,$1986).$Here,$ the$acidic$pH$of$ the$ lumen$causes$ the$enzyme$ to$ dissociate$ from$ the$ M6P/IGF$ IIr$ receptor,$ thus$ releasing$ it$ into$ the$endosomal$ lumen,$ leaving$ the$membrane:bound$M6P/IGF$ IIr$ receptor$ free$ to$be$eventually$trafficked$to$the$Golgi$apparatus$for$recycling$(Seaman,$2004; Gonzalez:Noriega$et#al.,#1980).$As$described$ in$ the$previous$ section$ (section(1.1),$ it$ is$ the$acquisition$ of$ acid$ hydrolases$ that$ enables$ the$ late$ endosome$ to$ mature$ into$ a$lysosome$ (Cooper,$ 2000).$ However,$ a$ proportion$ of$ lysosomal$ enzymes$ are$released$ into$ the$ cytosol$ instead$ of$ being$ targeted$ to$ the$ endosomal/lysosomal$system$to$facilitate$a$number$of$processes$such$as$apoptosis,$or$released$into$the$extracellular$space$to$degrade$extracellular$material$(Eskelinen$et#al.,$2003;$Luzio$
et#al.,$2007;$Schröder$et#al.,$2007;$Braulke$and$Bonifacino,$2009;$Lübke$et#al.,$2009;$Schröder$ et$ al.,$ 2010).$ Lysosomal$ enzymes$ in$ the$ extracellular$ milieu$ can$ be$endocytosed$ back$ into$ the$ same$ cell$ or$ neighbouring$ cells$ via$ the$ M6P/IGF$ IIr$described$ above,$ or$ the$ mannose$ receptor$ (ManR),$ a$ process$ termed$ “cross:correction”,$ illustrated$ in$Figure(2)$ (Sands$ and$Davidson,$ 2006;$Kornfeld,$ 1992;$Fratantoni$ et#al.,#1968;$ Bach$ et#al.,#1973).$ This$ system$ of$ “cross:correction”$ can$mediate$ the$ endocytosis$ and$ lysosomal$ targeting$ of$ therapeutically$ supplied$enzyme$and$provides$a$way$to$extend$any$therapeutic$effects$beyond$a$single$cell$to$multiple$cells,$as$will$be$discussed$in$section(5.1((Sands$and$Davidson,$2006).$$
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transport$H+$ions$into$the$lysosomes$from$the$cytosol$(Brix,$2005;$Steinman$et#al.,#1976;#Mullins$ and$ Bonifacino,$ 2001;$ Nishi$ and$ Forgac,$ 2002;$ Luzio$ et#al.,$ 2007,$Saftig$ and$ Klumperman,$ 2009).$ The$ ability$ of$ lysosomes$ to$ carry$ out$ their$degradative$ function$ then,$ is$ dependent$ on$ more$ than$ just$ lysosomal$ enzyme$activity,$but$also$a$number$of$lysosomal$membrane$proteins$as$will$be$described$in$the$following$section.$$
b)! Lysosomal(membrane(proteins(As$ mentioned$ in$ the$ previous$ section,$ section( 1.1.a,$ the$ lysosomal$ membrane$separates$potentially$harmful$lysosomal$enzymes$from$the$rest$of$the$cytosol$and$maintains$an$optimal$intralysosomal$pH$for$them$to$function$within$its$lumen,$and$this$is$mediated$by$lysosmal$membrane$proteins.$A$special$feature$of$the$lysosomal$membrane$ is$ its$ high$ carbohydrate$ content$ owing$ to$ the$ heavily$ glycosylated$lysosomal$proteins,$which$are$contained$within$it$(Cooper,$2000).$Glycosylation$of$the$ luminal$ domains$ forms$ a$ glycocalyx,$ which$ protects$ the$ internal$ membrane$from$the$ luminal$hydrolytic$ lysosomal$enzymes$(Granger$et#al.,#1990).$More$ than$120$ lysosomal$membrane$ proteins$ have$ been$ identified$ (Schröoder$ et#al.,#2007,$2010$;$Lubke$et#al.,#2009).$However,$beyond$their$roles$in$maintaining$the$integrity$of$the$lysosome,$lysosomal$membrane$proteins$have$a$broader$and$diverse$range$of$ functions$ (Fukunda,$ 1991).$ Like$ the$ enzymatic$ repertoire$ of$ different$ cells,$lysosomal$proteins$are$differentially$expressed$according$to$the$cell$type$or$tissue$(Furuta$ et# al.,# 1999;$ Suarez:Quian$ et# al.,# 1992).$ The$ most$ abundant$ and$ubiquitously$ expressed$ lysosomal$ membrane$ proteins$ include$ the$ lysosome:associated$membrane$proteins$:1$and$:2$(LAMP:1$and$LAMP:2)$and$the$lysosomal$integral$ membrane$ proteins$ :1$ and$ :2$ (LIMP:1$ and$ LIMP:2),$ which$ together$
! 40!
represent$half$of$the$total$number$of$lysosomal$membrane$proteins,$making$them$a$ popular$ lysosomal$marker$ (Hunziker$ et#al.,#1996;$Marsh$ et#al.,#1987;$ Kornfeld$and$Mellman,$1989;$Eskelinen$et#al.,#2003;$Schroder$et#al.,#2007,$2010;$Lewis$et#al.,$1985;$Chen$et#al.,$1985;$Lippincott:Schwartz$and$Fambrough,$1986;$Barriocanal$et#
al.,$1986).$These$proteins$are$depicted$in$Figure(3(alongside$the$less$abundant,$but$equally$ important,$ lysosomal$membrane$proteins$such$as$ the$V:type$H+$ :$ATPase$proton$pump,$responsible$for$maintaining$the$acidic$environment$of$the$lysosomal$lumen$ discussed$ in$ section( 1.1.a$ (Forgac,$ 1999;$ Winchester,$ 2001).$ Generally,$more$ is$known$about$the$function$and$biogenesis$of$ lysosomal$enzymes$than$the$proteins$of$the$lysosomal$membrane$(Saftig$et#al.,#2010).$The$exact$role$of$LAMP:1$and$ LAMP:2$ proteins$ is$ still$ under$ investigation,$ however,$ LAMP:1$ and$ LAMP:2$deficient$mice$have$offered$clues$(Eskelinen$et#al.,#2003,$2006).$Surprisingly,$mice$lacking$either$LAMP:1$or$LAMP:2$are$viable$and$fertile$(Andrejewski$et#al.,#1999),$however,$ if$mice$ are$ deficient$ in$ both$ genes,$ this$ results$ in$ an$ embryonic$ lethal$phenotype$(Eskelinen$et#al.,#2003).$While$ the$normal$ functions$of$LAMP:1$can$be$compensated$ by$ LAMP:2$ in$ the$ event$ of$ its$ deficiency$ (Eskelinen$ et# al.,#2006),$LAMP:2$deficiency$has$more$ severe$ consequences$ (Tanaka$et#al.,#2000).$ $Beyond$its$shared$common$functions$with$LAMP:1,$LAMP:2$knock:out$mice$have$revealed$additional$roles$for$LAMP:2$including$lysosomal$enzyme$targeting,$autophagy$and$lysosomal$ biogenesis$ (Eskelinen$ et# al.,# 2006).$ Moreover,$ in$ humans,$ LAMP:2$deficiency$ leads$ to$ a$ glycogen$ storage$ disorder$ called$ Danon$ disease,$ a$ fatal$disorder$ effecting$ the$ heart$ and$ skeletal$ muscle$ (Eskelinen$ et# al.,# 2003,$ 2006;$Nishino$et#al.,#2000).$$$Various$roles$of$LIMP:1$and$LIMP:2$have$also$been$suggested.$$LIMP:1,$sometimes$referred$ to$ as$ cluster$ of$ differentiation$ (CD3),$ is$ thought$ to$ be$ involved$ in$ a$
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2! Commonalities(amongst(the(LSDs(As$ described$ in$ the$ previous$ section,$ lysosomal$ function$ is$ integral$ to$ proper$cellular$ function$ and$ depends$ upon$ a$ multitude$ of$ different$ lysosomal$ proteins$(Saftig$ and$ Klumperman,$ 2009;$ Braulke$ and$ Bonifacino,$ 2009).$ Therefore,$ a$deficiency$in$any$single$lysosomal$protein$can$have$profound$effects$on$lysosomal$biology,$as$is$exemplified$by$the$LSDs$(Ballabio$and$Gieselmann,$2009).$As$well$as$the$ primary$ lysosomal$ defect,$ the$ activity$ of$ other$ membrane:bound$ organelles$are$also$derailed$in$these$disorders$and$therefore,$LSDs$could$more$accurately$be$
Figure(3.(Schematic(representation(of(the(lysosomal(membrane(and(soluble(lysosomal(proteins(that(
are(involved(in(normal( lysosomal(function(and(NCL(pathogenesis.$Proteins$ implicated$ in$NCLs:$ PPT1$(CLN1),$TPP1$(CLN2),$CLN3,$CLN4,$CLN5,$CLN6,$CLN7,$CLN8,$CtsD$(CLN10),$CLN11,$CLN12,$CLN13,$CLN14.$Although$CLN3$ is$most$likely$to$be$ localized$to$the$late$endosomal/lysosomal$membrane$(late$endosomal$location$not$pictured$here),$several$other$other$sub:cellular$locations$have$also$been$suggested$e.g.$nucleus$(Margraf$et#al.,#1999),$Golgi$ (Golabek$et#al.,#1999),$mitochondria$(Katz$et#al.,#1997)$and$plasma$membrane$(Magraf$et#al.,#1999).$Abbreviations:$ABC$=$adenosine$5′:triphosphate:binding$cassette$ transporter,$CLN3,$CLN4,$CLN5,$CLN6,$CLN7,$CLN8,$CLN11:14$=$ ceroid:lipofusinosis,$neuronal$ 3,$4,$5,$ 6,$7$and$11:14,$CtsD$=$cathepsin$D,$Cystinosin,$LALP70$=$lysosomal$apyrase:like$protein,$LAMP1$=$lysosome$associated$membrane$protein:1,$ LAMP2$ =$ lysosome$ associated$ membrane$ protein:2,$ LAPTM4$ =$ lysosome:associated$ protein$transmembrane$4,$LIMP1$=$lysosomal$integral$membrane$protein:1,$LIMP2$=$lysosomal$integral$membrane$protein:2,$PPT1$=$palmitoyl$protein$thioesterase$1,$Sialin,$TPP1$=$tripeptidyl$peptidase$1$and$V:type$H+$:ATPase$=$V:type$H+$:$adenosine$triphosphatase 
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defined$as$“cellular$storage$disorders”$(as$reviewed$in$Platt$et#al.,#2012).$The$LSDs$are$a$large$and$heterogeneous$group$of$metabolic$diseases,$with$an$overall$$$$$$$$$$$$$$$$$$$$$$incidence$of$~1$ in$5,000$ live$births,$not$ counting$ the$number$of$undiagnosed$or$misdiagnosed$ cases$ (Miekle$ et# al.,#1999).$ With$ the$ exception$ of$ x:linked$ Fabry$disease,$MPS$type$II$(Hunter$syndrome),$and$an$adult$form$of$autosomal$dominant$NCL$(Parry$disease),$all$LSDs$have$an$autosomal:recessive$pattern$of$ inheritance$
Figure(4.(Various(functions(of(the(lysosome.(The$lysosome$is$an$acidic$organelle,$capable$of$degrading$macromolecules$through$the$activity$of$its$constituent$lysosomal$hydrolases.$Lysosomes$play$a$key$role$in$ the$ maturation$ of$ phagosomes$ to$ phagolysosomes$ during$ the$ process$ of$ phagocytosis,$ which$ is$important$for$protecting$the$cell$against$various$pathogens.$The$macroautophagy$pathway$facilitates$the$turnover$ of$ redundant$ cytoplasmic$ components$ e.g.$ organelles$ and$ is$ important$ in$ the$process$ of$ cell$death$ and$ proliferation.$ Macroautophagy$ is$ only$ possible$ through$ the$ fusion$ of$ lysosomes$ with$autophagosomes,$ which$ result$ in$ the$ creation$ of$ autolysosomes$ –$ the$ site$ for$ degredation.$Macroautophagy$ and$ chaperone:mediated$ autophagy,$ are$ transport$ processes$ utilized$ by$ cytosolic$proteins$ and$ are$ directly$ regulated$ by$ lysosome:associated$ membrane$ proteins$ (LAMPs).$ Lysosomal$exocytois$ and$ plasma$ membrane$ repair$ involve$ Ca2+$ and$ synaptotagmin$ 7$ (SYT7):dependentfusion,$which$may$be$ implicated$ in$pathogen$ entry,$ autoimmunity$ and$neurite$ outgrowth.$The$ lysosomal$ cell$death$pathway$is$initiated$by$the$release$of$lysosomal$cathepsin,$although$the$mechanism$by$which$this$occurs$is$unknown.$Cellular$cholesterol$homeostasis$is$regulated$by$lysosomal$cholesterol$efflux$through$Niemann:Pick$ C1$ protein$ (NPC1).$Major$ histocompatibility$ complex$ (MHC)$ class$ II:dependent$ antigen$presentation$ involves$ lysosomal$proteases$ and$membrane$proteins.$The$release$of$ exosomes$has$been$implicated$ in$ adaptive$ immune$ responses.$ Lysosomal$ membrane$ proteins$ like$ lysosomal$ integral$membrane$protein$2$(LIMP:2)$also$play$ a$part$ in$ the$ transport$of$newly$synthesized$hydrolases$ to$ the$lysosome,$while$lysosomal$membrane$proteins$e.g.$the$V:type$H+$:ATPase$complex$and$chloride$channel$protein$7$(CLC7),$are$also$involved$in$the$transport$of$new$hydrolases$across$the$lysosomal$membrane.$Adapted$from$Saftig$and$Klumperman,$2009. 
(
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(Desnick$et#al.,#1989;$Hopwood$et#al.,#1993;$Nijssen$et#al.,#2003).$This$makes$them$ideal$candidates$for$gene$therapy$approaches,$as$will$be$described$in$section(5.5.$The$majority$of$these$disorders$are$the$result$of$mutations$in$lysosomal$enzymes,$but$can$also$result$ from$mutations$ in$non:enzymatic$ lysosomal$proteins$ (soluble$and$ integral$ membrane$ associated$ proteins),$ as$ well$ as$ non:lysosomal$ proteins$residing$ in$ the$ ER,$ Golgi$ apparatus$ or$ endosomal$ pathway,$ leading$ to$ the$accumulation$of$storage$material$within$organelles$of$ the$endosomal:autophagic:lysosomal$ system$ (Filocamo$ and$ Morrone,$ 2011;$ Platt$ et# al.,#2012;$ Hers,$ 1963,$Winchester,$2004;$Saftig$and$Klumperman,$2009;$Ballabio$and$Gieselmann,$2008;$Ruivo$ et# al.,# 2009;$ Walkley,$ 2009).$ The$ specific$ characteristics$ of$ each$ LSD,$including$ the$organ$system(s)$most$affected,$age$of$onset$and$severity$of$disease$progression,$vary$considerably$depending$on$the$normal$function$of$the$deficient$protein$ and$ the$ cellular$ pathways$ it$ is$ involved$ in,$ the$ level$ of$ residual$ protein$activity$and$the$nature,$quantity$and$distribution$of$the$storage$material$(Platt$et#
al.,#2012).$Nonetheless,$the$LSDs$share$a$number$of$common$clinical$features.$With$the$exception$of$LSDs$involving$the$accumulation$of$storage$material$in$bone$and$cartilage$ (Staretz:Chacham$ et# al.,# 2009;$ Boudes,$ 2013),$ most$ LSDs$ are$asymptomatic$at$birth$and$affected$children$usually$achieve$early$developmental$milestones,$ suggesting$ that$ lysosomal$ dysfunction$ does$ not$ significantly$ impact$upon$early$brain$development$(Schultz$et#al.,#2011).$Eventually,$most$LSDs$develop$a$ neurological$ component,$ sometimes$ accompanied$ by$ somatic$ symptoms,$while$others,$like$Type$1$Gaucher$disease$have$very$little$neurological$involvement$and$are$ therefore$perhaps$ less$challenging$ to$ treat,$as$will$be$discussed$ in$section(5.$‘Neuropathic’$ LSDs$ display$ a$ range$ of$ clinical$manifestations$ including$ cognitive$deficits,$ dementia,$ blindness$ and/or$ deafness,$ motor$ dysfunction,$ seizures$ and$sleep$ disturbances,$ all$ of$ which$ become$ progressively$ debilitating$ and$ result$ in$
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premature$death$(Wraith,$2004;$Walkley,$2009;$Mole$et#al.,#2011;$Cox$and$Cachòn:González,$2012).$$$LSDs$ were$ originally$ characterized$ by$ the$ type$ of$ accumulating$ substrates$ e.g.$glycosphingolipidoses$ (e.g.$ Gaucher$ disease$ and$ GM1$ and$ GM2$ gangliosidoses)$(Brady$ et# al.,# 1965;$ Young$ et# al.,$ 1975;$ Mutoh,$ 1986,$ 1988),$mucopolysaccharosidoses$ (MPS)$ (Dorfman$ and$ Matalon,$ 1976;$ Neufeld$ et# al.,#2001),$ glycoproteinoses$ (reviewed$ in$ Michalski$ and$ Klein,$ 1999),$ and$mucolipidoses$(Type$I$–$IV)$(Thomas,$2001;$Reitman$et#al.,#1981;$Kornfeld$and$Sly,$1991;$ Bargal$ et# al.,# 2000;$ Bassi$ et# al.,# 2000;$ Folkerth,$ 1995).$ While$ this$classification$ has$ been$ clinically$ useful,$ in$ most$ LSDs,$ more$ than$ one$ substrate$usually$accumulates$and$the$storage$material$can$contain$multiple$components$for$various$ reasons$ (Ballabio$ and$Gieselmann,$ 2009).$ Therefore,$ from$a$ biochemical$standpoint,$this$purely$storage:based$classification$is$of$limited$value$(Ballabio$and$Gieselmann,$2009).$ Instead,$a$wider$grouping$based$on$ the$characteristics$of$ the$defective$ protein$ is$ more$ often$ used,$ which$ includes$ disorders$ that$ involve$ the$biosynthesis$ of$ lysosomal$proteins,$ protein$ trafficking,$ and$ lysosomal$membrane$proteins$and$can$be$applied$to$the$NCLs,$which$will$be$described$in$section(3,$and$is$summarised( in$Table(1$ (Futerman$and$van$Meer,$2004;$Bellettato$and$Scarpa,$2010;$Schultz$et#al.,#2011;$Cox$and$Cachòn:González,$2012).$$$$Since$ the$1960s,$many$ investigations$have$been$ carried$out$ into$ the$ genetic$ and$biochemical$ basis$ of$ LSDs$ (Futerman$ and$ van$ Meer,$ 2004;$ Walkley,$ 2009;$Ballettato$and$Scarpa,$2010;$Schultz$et#al.,#2011;$Cox$and$Cachòn:González,$2012).$Numerous$pathogenic$mechanisms$have$been$associated$with$the$perturbation$of$lysosomal$ homeostasis$ including$ altered$ Ca2+$ homeostasis,$ oxidative$ stress,$
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inflammation,$lipid$trafficking,$autophagy,$ER$stress,$and$autoimmunity$(reviewed$in$Vitner$et#al.,#2010).$Despite$ their$different$ genetic$origins,$ these$pathways$are$common$ to$ many$ LSDs$ resulting$ in$ a$ number$ of$ shared$ biochemical$ features,$which$clinically$link$these$disease$as$described$above$(Vitner$et#al.,#2010;$Ballabio$and$ Gieselmann,$ 2009;$Walkley,$ 2009;$ Bellettato$ and$ Scarpa,$ 2010;$ Lloyd:Evans$and$Platt,$2011;$Cox$and$Cachòn:González,$2012).$This$mechanistic$overlap$makes$it$ difficult$ to$ define$ clear$ correlations$ between$ genotype$ and$ phenotype$ for$individual$LSDs.$However,$advances$in$our$understanding$of$one$specific$LSD$can$potentially$ further$our$understanding$of$ the$other$disorders.$This$has$ important$implications$ for$ developing$ therapies,$ as$ targeting$ shared$ pathways$ may$ have$applications$ for$ more$ than$ one$ LSD$ (Walkley,$ 2009;$ Vitner$ et# al.,# 2010).$Furthermore,$ some$ of$ the$ pathological$ features$ displayed$ by$ the$ LSDs,$ such$ as$neuroinflammation,$ also$ occur$ in$ other$ neurodegenerative$ disorders$ such$ as$Parkinson$(PD)$and$Alzheimer$disease$(AD)$(Bosch$and$Kielian,$2015;$Heneka$et#
al.,#2015;$ Lee$ and$MacLean,$ 2015),$ potentially$ further$ broadening$ the$ scope$ for$mechanistically$based$therapeutic$interventions$(Zhang$et#al.,$2009;$Bellettato$and$Scarpa,$2010;$Wong$and$Cuervo,$2010).$
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this%group%has%changed,%and%the%implications%of%this%for%our%understanding%of%these%disorders%and%devising%therapies.%The%NCLs%have%worn%many%faces,%they%were%first%described%as%belonging%to%the%‘amaurotic)family)idiocies’,%a%term%which%denotes%the%predominant% clinical% features% of% the% disease% –% blindness,% a% marked% familial%incidence%and%an%association%with%progressive%mental%deterioration%(Sachs,%1896).%Since% the% first% cases% of% NCL% identified% had% an% infantile% age% of% onset,% they% were%considered% to% be% the% same% as% TayHSachs% disease,% an% infantile% ‘amaurotic) family)
idiocy’,% now% referred% to% as% GM2Hgangliosidosis% type% A,% see%Table& 1& (Mole% et)al.,)2011).% However,% over% the% century% that% followed,% a% number% of% important%discoveries%began%to%alter%this%original%view%of%the%NCLs.%Familial%cases%of%diseases%termed%as% ‘amaurotic)family)idiocy’,% but%with%varying%ages%of%onset% (late% infantile,%juvenile,% adult% onset)% began% to% emerge% (Batten,% 1903,% 1914;% Batten% and% Mayou,%1915;% Vogt,% 1905,% 1909;% Spielmeyer,% 1905a,% 1905b,% 1908,% 1908;% Jansky,% 1908;%Bielschowsky,%1913;%Janksy,%1908;%Bielschowsky,%1913;%Kufs,%1925),%together%with%the% discovery% of% lipidHlike% storage% material% accumulation% in% these% nerve% cells%(Schäffer,% 1906,% 1910),% with% different% histochemical% and% ultrastructural%characteristics% (Zeman% and%Donahue,% 1963;% Zeman%et)al.,)1970).%With%hints% from%genealogical% studies,% it% gradually% became% clear% that% these% diseases% differed% from%TayHSachs% disease% and% together% represented% a% distinct% group% of% genetically% and%biochemically%heterogeneous%diseases%(Zeman%and%Dyken,%1969).%Eventually,% this%group% of% diseases% was% termed% the% NCLs,% owing% to% the% lipopigment% resembling%ceroid% and% lipofuscin,% which% accumulates% in% cells% (Zeman% and% Dyken,% 1969).%Subsequently,%with%the%addition%of%a%new%infantile%form%(Haltia%et)al.,)1973a,%1973b;%Santavuori%et)al.,)1973),%the%NCLs%were%reHclassified%based%on%the%age%of%onset%and%ultrastructure% of% the% storage% material% present% (Zeman,% 1976).% This% group% grew%over% the% following% decades% to% include% an% originally% excluded% congenital% form%
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(Norman%and%Wood,%1941,%Brown%et)al.,)1954,%Sandbank,%1968),%and%new%cases%of%‘atypical’% or% ‘variant’% forms.% Based% on% this% categorization,% the% NCLs% came% to% be%divided%into%infantile%(INCL),%late%infantile%(LINCL),%juvenile%(JNCL)%and%adult%subHtypes% with% a% number% of% variant% late% infantile% forms,% plus% a% congenital% form,% as%summarized%in%Table&2&alongside%their%original%eponyms%(Mole%et)al.,)2011).%%Since% the% 1980s,% advances% in% biochemical% analyses% of% storage% material% have%revealed% that%as%well% as% ‘lipopigment’,% storage%material% in%different% forms%of%NCL%also%consists%of%a%heterogeneous%combination%of%proteins,%proteolipids%and%traces%of% metal% ions% (Brunk% and% Terman,% 2002).% The% main% protein% components% are%subunit%c%of%mitochondrial%ATPase%(SCMAS)%and%sphingolipid%activator%proteins%A,%and% D% (SAPs),% which% appear% to% dictate% the% pattern% of% ultrastructure:% storage% of%SAPs% are% associated% with% granular% osmiophilic% deposits% (GROD),% while% the%accumulation% of% SCMAS% is% associated%with% curvilinear,% rectilinear% or% ‘fingerprint’%patterns%(Mole%et)al.,)2011).%The%stored%protein%and%the%characteristic%patterns%of%storage%material%displayed%in%the%different% forms%of%NCL%are% included%in%Table&2.&Although% the% morphological% characteristics% of% storage% material% have% helped% to%define% the%NCLs,% alongside% the%age%of%onset,% this% classification%offers%very% limited%insight%into%the%pathological%cascade%that%leads%to%the%accumulation%of%the%storage%material% in% the% first% place.% Moreover% this% is%misleading,% as% there% is% considerable%overlap% between% the% appearance% and% composition% of% storage% material% found% in%different% forms%of%NCL,%with%some%forms%of%NCL%displaying%storage%material%with%several%different%ultrastructural%morphologies%(Vitner%et)al.,)2010).%%%Considerable%progress%in%molecular%genetic%studies%have%enabled%us%to%identify%the%primary% genetic% defects% responsible% for% causing%most% forms% of%NCL,% leading% to% a%
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a)! The(use(of(animal(models(Clinically,&one&of& the&benefits&of& identifying& the&genes&responsible& for&causing& the&NCLs& is& that& it& aids& diagnosis,& which& is& important& for& genetic& counselling& and&optimal& delivery& of& care& (Schulz& et# al.,#2013).& & In& terms& of& understanding& NCL&pathogenesis&however,&a&major&advantage&of&identifying&NCL>causing&genes&is&the&ability& to& generate& animal& models& in& which& these& genes& are& mutated& to& create&phenotypes&that&model&each&form&of&NCL,&or&to&identify&spontaneous&mutations&in&animals&(Cooper&et#al.,#2015;&Bond&et#al.,#2013).&A&wide&range&of&model&organisms&are& available& or& are& being& developed& including;& single& celled& yeast,& Drosophila,&zebrafish,&mouse&and&larger&animal&models&such&as&dogs,&sheep,&cattle&and&recently&pigs&(Fan&and&Lai,#2013;&Flisikowska&et#al.,#2014),&which&are&summarized&in&Table(
3,( and& have& been& comprehensively& reviewed& recently& (Bond& et# al.,#2013).& Each&species&has& its&advantages&and&disadvantages& for&experimental&studies,&but&many&of& them&have&made&a& significant& contribution& towards&our&understanding&of&NCL&pathology&and&the&development&of&therapies&(Bond&et#al.,#2013).&For&example,(the&first(evidence&for&the&idea&that&neuroinflammation&proceeds&neurodegeneration&in&NCL&was&provided&by&studies&in&the&South&Hampshire&CLN6&sheep&model,&and&led&to&the& investigation&of&anti>inflammatory&drugs&as&a&novel&therapeutic&strategy& in&these&sheep,&as&well&as&other&animal&models&(Oswald&and&Palmer,&2005;&Kay&et#al.,#2006).&Furthermore,&the&Longhaired&Dachshund,&found&to&carry&a&mutation&in&CLN2&has&been&used&to&test&a&variety&of&methods&for&the&delivery&of&TPP1&enzyme&to&the&canine& brain& and& evaluate& the& safety& and& therapeutic& efficacy& of& treatment,&resulting&in&a&clinical&trial&for&rhTPP1&treatment&in&CLN2&patients&(Katz&et#al.,#2014;&
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Katz& et# al.,# 2015;& Vuillemenot& et# al.,# 2011,& 2015;&
https://clinicaltrials.gov/ct2/show/NCT01907087).&&&The& most& widely& used& animal& species& for& studying& the& NCLs& is& genetically&engineered&mutant&mice,&with&models&available& for&almost&every& form&of&NCL,&as&shown& in( Table( 3,(which& display& a& remarkable& likeness& to& the& pathological& and&clinical& features& of& these& disorders& (Shacka,& 2012).& As& is& the& case& in& human&NCL&patients,& the&end>point&of&disease& for&most&of& these&models& is&an&atrophied&brain&with&fewer&neurons,&containing&a&substantial&amount&of&storage&material,&profound&glial&activation&and&in&some&cases,&a& low&level& infiltration&of& lymphocytes& into&the&NCL& brain& (Radke& et#al.,#2015;& Tyynelä& et#al.,#2004;& Groh& et#al.,#2013;& Lim& et#al.,#2007).& A& key& advantage& of& using& animal& models,& is& that& by& carrying& out&experiments&at&different&ages&we&can&define&the&course&of&disease&not&only&in&terms&of& the&pathology&outlined& above,& but& also& in& terms&of& the&behavioural& and&motor&deficits& they& display,& which& is& obviously& not& possible& using& post>mortem& tissue&from&NCL&patients.&For&mice&an& important&achievement&was& crossing&each&of& the&different&models& onto& the& same& strain& background,&making& it& easier& to& compare&disease& progression& between& these&models& (Cooper& et#al.,#2006,& 2010;& Palmer& et#

































order,& and&how& this&might& relate& to& the& intracellular& location&and& function&of& the&deficient&gene&products&in&different&forms&of&NCL&(Cárcel:Trullols&et#al.,#2015).&&There&are&some&important&caveats&to&consider&regarding&the&use&of&animal&models,&firstly,&most&NCL&models&are&not&genetically&faithful&to&the&human&disease&as&is&the&case& for&both&the&Ppt1+/+#and&Cln3∆ex1+6&mice&used& in& this& thesis&(Bond&et#al.,#2013).&Secondly,& the& extent& of& brain& pathology& is& less& pronounced& in&mice& compared& to&larger&species&that&model&the&same&form&of&NCL&or&in&the&human&disease,&perhaps&owing&to&the&fact&that&mice&have&a&relatively&simple&neuroanatomical&organization,&and&do&not& live& long& enough& to& develop& the& complete& range& of& human&pathology&(Weber&and&Pearce,&2013;&Cooper&et#al.,#2015).&Therefore,&data&obtained&from&both&natural& history& and& therapeutic& studies& in& mice& needs& to& be& extrapolated& with&caution&to&human&studies,&which&is&why&larger&animal&models,&which&better&mimic&human& anatomy& and& physiology& are& an& equally& important,& albeit& not& as& widely&used,&tool&(Bond&et#al.,#2013).&&&
b)! Selective*neuron*loss*in*the*NCLs*Initially,& it&was& thought& that&neuron& loss&occurred&uniformly& throughout& the&NCL&brain;&however,&it&is&now&clear&that&there&is&a&great&deal&of&selectivity&in&the&earlier&stages&of&disease&(Cooper,&2010).&This&selectivity&was&first&identified&in&populations&of&hippocampal&and&cortical&interneurons&in&CLN8&mice&(Cooper&et#al.,&1999),&and&subsequently&in&the&South&Hampshire&sheep&model&of&CLN6&disease&and&in&multiple&mouse&models&of&NCL&(Bible&et#al.,#2004;&Cooper&et#al.,#1999;&Morgan&et#al.,#2013;&Oswald&et#al.,#2008;&Pontikis&et#al.,#2004,&2005).&Comparing&interneuron&loss&within&these&regions&has&revealed&further&selective&vulnerability&according&to&which&Ca2+&
 !
65!
binding& proteins& or& neuropeptides& they& express,& as& well& as& which& hippocampal&subfields& or& cortical& regions& they& are& located& in& (Bible& et#al.,#2004,& Cooper& et#al.,#1999;& Oswald& et# al.,# 2001;& Cooper& et# al.,# 2015).& Furthermore,& a& confounding&observation&is&that&the&pattern&of&this&interneuron&loss&is&markedly&different&across&mouse&models&of&NCL&(Bible&et#al.,#2004;&Kuronen&et#al.,#2012;&Morgan&et#al.,#2013;&Pontikis&et#al.,#2004,&2005).&There&is&still&no&definitive&mechanistic&explanation&for&why& these& subpopulations& are& particularly& vulnerable,& although& it& has& been&suggested&that&the&location&and&connectivity&of&these&neuronal&populations,&may&be&a&relevant&factor&as&discussed&in&section*3.1.c*(Cooper,&2010).&Nonetheless,&these&findings&highlight&the&fact&that&shared&pathological&features&are&complex&and&do&not&necessarily&occur&in&the&same&way&(Cooper&et#al.,#2015).&&&Selective&neuron&loss&has&also&been&identified&in&the&cerebellum&of&mouse&model&of&both&CLN1&and&CLN3&disease&(Jalanko&et#al.,#2005;&Macauley&et#al.,#2009;&Weimer&et#
al.,# 2009).* Cortical& neurodegeneration& is& a& conserved& feature& between& large&animals&and&NCL&patients,&particularly&within&the&superficial&layers&of&the&occipital&and&somatosensory&cortices& (Palmer&et#al.,&2011;& Jolly&et#al.,&1989;&Mayhew&et#al.,&1985;&Oswald&et#al.,&2005;&Oswald&et#al.,&2008).&However,&in&most&mouse&models&of&NCL,&cortical&regions&are&relatively&spared&and& largely&only&affected& in&relation&to&the&loss&of&thalamic&neurons&(Cooper,&2010).&&It&appears&that&neuron&loss&within&the&thalamus&occurs&relatively&early&in&disease,&and&the&loss&of&specific&thalamic&relay&neurons&preceeds&neuron& loss& in&the&corresponding&cortical&region&to&which&they&project& (Cooper,& 2010,& Cooper&et#al.,#2014).& This& observation&has&been&pivotal& to&our&understanding&of&neurodegeneration&in&NCL,&occuring&in&several&mouse&models&of&NCL&including&CLN10,&CLN1,&CLN2,&CLN3&and&CLN8&disease&and&offering&a&new&prespective& for& targeting& the&delivery&of& therapies& to& the&CNS&(Kielar&et#al.,&2007,&
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Kuronen& et# al.,& 2012;& Morgan& et# al.,#2013;& Partanen& et# al.,& 2008;& Weimer& et# al.,&2006;&Pontikis&et#al.,#2005;&Hobert&and&Dawson,&2006;&Shacka,&2012).& Indeed,& the&relative& timing& of& these& events&within& the& thalamocortical& system& is& not& uniform&between&forms&of&NCL&(reviewed&in&Palmer&et#al.,#2013),&again&emphasizing&the&fact&that&although&different&forms&of&NCL&may&share&the&same&pathological&features,&the&underlying&pathological&mechanisms&are&specific&to&the&genes&that&are&mutated&in&different&sub:types&of&NCL&(Cooper&et#al.,#2015).&The&most&extreme&example&comes&from& Cln5& mutant& mice& in& which& cortical& neuron& loss& occurs& before& the& loss& of&thalamic& neurons& (von& Schatz& et# al.,# 2009).& For& the& other& forms& of& NCL,& the&difference& is& subtler&as&described& for&Cln1:&and&Cln3:deficient&mice&at& the&end&of&
section*3.1.d.ii*&
c)! Pathway*dependent*pathology*and*synaptopathology*in*the*NCLs*The&progressive& loss&of&neurons&within& the& thalamocortical& system&suggests& that&connectivity,&rather&than&neuronal&phenotype&may&be&an&important&determinant&of&the&order& in&which&neuronal&populations&are& lost& in& the&NCL&brain& (Cooper&et#al.,#2015).& This& is& perhaps& not& surprising& as& general& pathology& in& any& single& area& is&likely&to&disrupt& interactions&with&connected&areas&at&a&distance& in&some&way&e.g.&via& diminished& excitatory& input& or& a& loss& of& trophic& support& (Saxena& and&Caroni,&2011;&Perlson&et#al.,#2010).&&This&idea&of&neurodegeneration&spreading&along&axonal&pathways&in&either&an&anterograde&or&retrograde&direction&to&influence&neurons&in&other& regions& has& been& proposed& for& a& number& of& neurodegenerative& disorders&including& AD,& Huntington& disease& (HD),& Amyotrophic& lateral& sclerosis& (ALS)& and&Multiple&sclerosis&(MS)&(reviewed& in&Fornito&et#al.,#2015).&Numerous&mechanisms&have& been& proposed& to& explain& how& these& pathway:specific& events& are&mediated&
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(Fornito&et#al.,#2015).&Using&AD&as&an&example,&it&is&thought&that&the&accumulation&of&amyloid:β& in&specific&regions&of& the&brain& impairs& their& functional&connectivity&with& distal& areas& which& do& not& display& amyloid:β& pathology,& resulting& in&hypometabolism,&a&predictor&of&neuron&cell&death&(Myers&et#al.,#2014;&Klupp&et#al.,#2014;&Zhou&et#al.,#2012).&While&no&such&specific&mechanisms&have&been&proposed&for&the&NCLs,&evidence&for&synaptic&vulnerability&is&apparent&for&a&number&of&sub:types& e.g.& CLN1& (Kielar& et# al.,# 2009),& CLN6& (Kielar& et# al.,# 2009)& and& CLN10&(Partanen&et#al.,#2008;&Koch&et#al.,#2011),&with& synaptic& rearrangement&preceding&synaptic& loss,&which& in&turn&occurs&before&the& loss&of&neurons&(Gillingwater&et#al.,#2013).& Indeed,& morphological& and& functional& alterations& of& the& pre:synaptic&compartment,&as&well&as&reduced&miniature&excitatory&post:synaptic&currents&have&been&well& described& in& Ctsd+/+#mice,& which&model& the& earliest& congenital& form& of&NCL,&CLN10&disease,&and&this&occurs&during&the&early&stages&of&disease&(Partanen&et#
al.,#2008;&Koch&et#al.,#2011).&Synaptic&pathology&has&also&been&identified&in&mouse&models& of& CLN1& disease,& including& a& reduction& in& the& frequency& of& miniature&synaptic& currents,& a& decrease& in& the& size& of& the& synaptic& vesicle& pool,& defects& in&synaptic&vesicle&recycling&and&altered&expression&of&synaptic&protein&markers&(Kim&
et# al.,# 2008;& Virmani& et# al.,# 2005;& Kielar& et# al.,# 2009;& Bond& et# al.,# 2013).&Furthermore,&synaptic&pathology&in&the&spinal&cord&and&CNS&has&been&reported&in&CLN8&mouse&models,&in&association&with&altered&expression&of&glutamate&receptors,&increased& glutamate& levels& and& neuronal& hyper:excitability& (Mennini& et#al.,#2002;&Griffin&et#al.,#2002;&Bigini&et#al.,#2012;&Melo&et#al.,#2010;&Bond&et#al.,#2013).&Synaptic&pathology&has&not&been&well&characterized&across& the&rest&of& the&NCLs,&but&based&on&the&few&studies&that&have&investigated&this&pathological&phenotype,&it&is&likely&to&manifest& in& different& ways.& Another& early& predictor& of& neuron& loss& is& glial&
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activation,& which& invariably& occurs& before& the& loss& of& neurons& and& this& will& be&discussed&in&the&following&section.&&
d)! Neuroinflammation*Neural& signalling& within& the& CNS& requires& a& highly& regulated& microenvironment&(Abbott& et#al.,#2010;& Galea& et#al.,#2007).& This& is& achieved& by& the& presence& of& the&blood:brain& barrier& (BBB),& blood:cerebrospinal& fluid& (CSF)& barrier& and& the&arachnoid& barrier,& which& together& form& an& interface& between& the& blood& and& the&CNS&(Abbott&et#al.,#2010).&The&BBB&is&also&important&in&protecting&the&brain,&which&is&a&sensitive&organ&with&poor&regenerative&capacity&(Galea&et#al.,#2007).&Indeed,&the&brain& is& considered& to& be& an& immunologically& and& pharmacologically& privileged&site,&although&several&misconceptions&about&the&degree&of&“immune&privilege”&have&been& addressed,& and& this& privilege& is& now& recognized& as& being& only& partial&(reviewed&in&Galea&et#al.,#2007).&&&Since&the&brain&is&a&relatively& immune&privileged&organ,& it&requires&its&own&innate&immune&system,& involving&specific&cell& types&and&complex& immune&reactions& that&give& rise& to& distinctive& immune& responses& referred& to& as& “neuroinflammation”&(Czirr& and& Wyss:Coray,& 2012).& However,& despite& this& apparently& immune:privileged& environment,& both& innate& and& adaptive& inflammatory& responses& still&occur& in& the&CNS& (Amor&et#al.,#2009).&As&will&be&explained& in&more&detail& later& in&this&section,&astrocytes&and&microglia,&which&constitute&the&innate&immune&system&of&the&brain&carefully&monitor&their&surrounding&environment&and&respond&to&any&disturbances& i.e.&pathogens&or& injury,&by&becoming&activated&and&recruiting&other&(including& adaptive)& immune& cells& (Galea& and& Perry,& 2007;& Skaper& et# al.,#2014;&
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Garden&and&Moller,&2006;&Sofroniew&and&Vinters,&2010).&The&activation&of&the&self:contained&innate&immune&response&is&driven&by&interactions&between&neurons&and&astrocytes&and&microglia,&and&involves&changes&in&their&morphology&and&behaviour&(Garden&and&Moller,&2006;&Sofroniew&and&Vinters,&2010;&Rivest,&2009).&Activation&of& astrocytes& (astrocytosis)& and& microglia& (microglial& activation)& also& leads& to&modifications&of&the&BBB&and&recruitment&of&adaptive&immune&cells&(T:cell,&B:cell,&NK,& macrophages,& monocytes)& from& outside& the& CNS& by& releasing& various& pro:inflammatory&cytokine&and&chemokines&(Amor&et#al.,#2009).&There&is&considerable&evidence& for& both& a& neuroprotective& and& neurodestructive& role& for& the&innate/adaptive& response,& and& this& has& been& reviewed& extensively& elsewhere&(Nguyen&et#al.,#2002;&Glezer&et#al.,#2007;&Allan&and&Rothwell,&2003;&Wyss:Coray&and&Mucke,&2002;&Finsen&and&Owens,&2011;&Ransohoff&and&Brown,&2012;&Lucas&et#al.,#2006).&Generally,& it& is&thought&that&it& is&the&persistent&activation&of&these&immune&responses,&as&certain&processes&go&unchecked,&that&lead&to&neurodegeneration,&thus&initiating& a& cycle& of& more& inflammation& and& further& CNS& pathology& (Amor& et#al.,#2009;&Bosch&and&Kielian,&2015).&Indeed,&neuroinflammation&is&a&common&feature&in&diseases& of& the& CNS,& and& is& associated& with& all& LSDs& that& have& a& neuronal&component&and&the&NCLs&are&no&exception&(Baudry&et#al.,#2003;&Farfel:Becker&et#al.,#2011;&Wilkinson&et#al.,#2012;&Kollmann&et#al.,#2011;&Castaneda&et#al.,#2008;&Bosch&and&Kielian,&2015).&&The& spatiotemporal& pattern& of& neuron& loss& in& the& NCLs& (as& discussed& in& the&previous& section,&Section*3.1.a)& appears& to& be& closely& related& to& glial& activation.&This& was& first& described& in& CLN6& sheep,& in& which& glial& activation& was& shown& to&spread& from&specific& cerebral& regions&and&precede&neurodegeneration&before& the&onset&of&disease&symptoms&&(Oswald&et#al.,#2005).&Later,&further&studies&in&the&CLN6&
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sheep&model&revealed&that&glial&activation&was&even&apparent&as&early&as&40&to&20&days&before&birth&(Kay&et#al.,#2006).&Glial&activation&has&since&been&described&in&all&mouse&models& of&multiple&NCLs& including&CLN1,&CLN2,&CLN3,&CLN5,&CLN6,&CLN8&and& CLN10& disease&mice& (Kielar& et#al.,#2007;&Morgan& et#al.,#2013;& Pontikis& et#al.,#2004;&Schmiedt&et#al.,#2012;&von&Schantz&et#al.,#2009;&Thelen&et#al.,#2012;&Kuronen&
et#al.,#2012;&Partanen&et#al.,#2008).&Collectively,&these&studies&show&that&the&location&of&glial&activation&appears&to&be&an&accurate&predictor&of&subsequent&neuron&loss,&and&is&now&widely&accepted&as&a&pathological&marker&for&NCL&disease&progression&(Cooper& et# al.,# 2015).& However,& whether& inflammatory& responses& provoke&neurodegeneration,& or& are& simply& a& consequence& of& sensing& danger:associated&molecular& patterns& (DAMPs)& released& from& damaged/dying& neurons& is& unclear&(Thundyil&and&Lim,&2014;&Bosch&and&Kielian,&2015).&While&“glial&activation”&is&used&to&describe&the&activation&of&astrocytosis&and&microglial&activation,&their&individual&contribution& to& neuroinflammation& is& different& and& occurs& via& distinct,& yet&interconnected& mechanisms& (Lui& et# al.,#2011).& Generally,& astrocytes& function& as&regulators& of& neuroinflammation;& whilst& microglia& are& considered& as& the& main&immune&cell&of&the&CNS,&as&will&be&discussed&in&the&following&two&sections&(Ridet&et#
al.,#1997;& John& et#al.,#2003;& Farina& et#al.,#2007;& Ricci& et#al.,#2009;& Ransohoff& and&Brown,&2012;&Lehnardt,&2010,&Kettenmann&et#al.,#2011).&&



















 &&&&&&&&&&&&&&  Besides& their& functions& in& the& healthy& CNS,& astrocytes& can& become& “activated”& in&response& to& both& acute& and& chronic& CNS& damage,& injury& or& disease& and& this& is&referred&to&as&‘reactive&astrocytosis’&or&simply&astrocytosis,&as&it&will&be&referred&to&in& this& thesis& (Ridet& et#al.,#1997;& Sofroniew,& 2009;& Sofroniew& and& Vinters,& 2010;&Colangelo&et#al.,#2012;&Parpura&et#al.,#2012).&Astrocyte&activation&involves&a&number&of&molecular,&functional&and&morphological&changes,&and&can&be&divided&into&three&categories& along& a& continuum& of& severity& (Ridet& et# al.,# 1997;& Sofroniew,& 2009;&
Figure*5.*Astrocyte*function*in*the*healthy*CNS.*Schematic*representation&of&astrocyte&targets&and&their&various& functions.&Astrocytes&make& extensive& contact&with&blood& vessels& via& their& endfeet,& protoplasmic&astrocytes& envelop& synapses& via& their& complex& processes,& while& fibrous& astrocytes& contact& nodes& of&Ranvier&and&astrocytes&also&make&contact&with&other&adjacent&astrocytes&via&gap&junctions,&where&they&can&communicate& via& the& release& of& soluble& factors& e.g.& K+& and& Ca++.& An& important& physiological& feature& of&astrocytes&is&that&they&express&potassium&and&sodium&channels,&allowing&them&to&initiate&inward&currents&although&they&are&unable&to&produce&or&propagate&action&potentials&along&their&processes&(Nedergaard&et#
al.,#2003;&Seifert&et#al.,#2006).&Nonetheless,&astrocyte&excitability&is&represented&by&regulated&increases&in&intracellular& calcium& concentration& [Ca++]i,& which& is& important& for& astrocyte:astrocyte& and& astrocyte:neuron& intercellular& communication& (Sofronview&and&Vinters,& 2010).&Arachidonic& acid& (AA)& released&by&astrocytes&stimulates&the&contraction&of&blood&vessels,&while&prostaglandin&(PGE)&induces&nitric&oxide&(NO)&mediated&dilation&of& the& vessels,&while& astrocytes& can& take& up& glucose& and&water& (H20)& from& the& blood.&Astrocytes&can&regulate&synaptic&activity&via&the&release&and&uptake&of&several&different&neuro:&and&glial:active& factors&(shown& in&brackets).&Abbreviations:&ATP&=& adenosine& triphosphate,&BDNF&=&brain&derived&neurotrophic&factor,&TNF:α&=&tumor&necrosis&factor,&NGF&=&nerve&growth&factor,&IL&=&interleukin&(Adapted&from&Sofroniew&and&Vinters,&2010).&
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Sofroniew&and&Vinters,&2010;&Colangelo&et#al.,#2012;&Parpura&et#al.,#2012).&Firstly,&mild& to&moderate&reactive&astrocytosis& involves& the&variable&upregulation&of&glial&fibrillary&protein& (GFAP)&and&other&genes& including&vimentin& (Wilhelmsson&et#al.,#2006;& Mucke& and& Eddleston,& 1993;& Pekny& et#al.,#1999;& Pekny& and& Pekna,& 2004).&GFAP&and&vimentin&belong&to&a&wider&family&of&intermediate&filament&(IF)&proteins,&which&form&an&integral&part&of&the&astrocyte&cytoskeleton&(Pekny&and&Pekna,&2004).&Since& studies& have& shown& that& GFAP& in& particular,& is& essential& for& reactive&astrocytosis&to&occur&and&is&only&detectable&during&this&process&(Pekny&and&Pekna,&2004;& Pekny& et#al.,#2005;& Herrmann& et#al.,#2009),& it& is& considered& to& be& a& robust&marker& for& reactive& astrocytosis& as& described& in& section* 6.3* of& Chapter* 2.& The&upregulation&of& these&genes& is& accompanied&by&hypertrophy&of& the& cell&body&and&processes&within& the&boundaries&of& their& individual&domains& (Wilhelmsson&et#al.,#2006).&Because&there&is&little,&if&any,&rearrangement&of&the&tissue&architecture&in&the&event& of&mild& to&moderate& astrocytosis,& these& changes& are& easily& reversed& if& the&pathological&stimulus&is&removed&and&astrocytes&will&revert&to&their&appearance&in&healthy&tissue&(Sofroniew,&2009;&Wilhelmsson&et#al.,#2006).&&&Secondly,& severe& diffuse& reactive& astrocytosis& also& involves& the& upregulation& of&GFAP&and&other&genes&and&hypertrophy&of&the&astrocyte&soma&and&processes,&but&this& is&more&pronounced& and& accompanied&by& astrocyte&proliferation& (Sofroniew&and& Vinters,& 2010).& Astrocytes& are& considered& to& be& post:mitotic& in& the& healthy&adult& brain,& but& via& mechanisms& that& are& not& entirely& understood,& retain& their&ability& to& proliferate& under& certain& circumstances& e.g.& infections& or& ongoing&neurodegeneration& (Latov& et#al.,#1979).& Such& proliferation& of& astrocytes& leads& to&the& extension& of& their& processes& beyond& the& domains& of& pre:existing& astrocytes,&causing& them& to& intermingle& and& overlap& substantially& with& the& processes& of&
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neighbouring& astrocytes,& thereby& diminishing& individual& astrocyte& domains&(Sofroniew,& 2009;& Sofroniew& and& Vinters,& 2010).& Although& these& changes& do& not&include&scar&formation,&they&involve&a&significant&amount&of&reorganization&of&the&tissue& architecture,& which& is& not& readily& reversed.& & Finally,& severe& reactive&astrocytosis& involves& all& the& aforementioned& changes,& but& with& substantive&astrocyte&proliferation.&This&leads&to&the&formation&of&dense,&narrow&and&compact&glial& scars& as& astrocyte& boundaries& are& completely& lost& and& the& processes& of&reactive&astrocytes&become&even&more&interrelated&(Sofroniew&and&Vinters,&2010).&&&For&over&a&century,& it&was&thought&that&the&process&of&reactive&astrocytosis&was&a&generally&maladaptive&phenomenon,&based& largely&on&the& fact& that&glial&scars&had&been& shown&many& years& ago& to& inhibit& axon& regeneration& and& therefore,& impede&functional&recovery&after&CNS&injury&or&disease&(Sofroniew&and&Vinters,&2010;&Cajal,&1928).&However,&it&is&now&thought&that&astrocytosis&and&the&formation&of&glial&scars&have& both& negative& and& many& positive& effects& (reviewed& in& detail& in& Sofroniew,&2009)&upon& injury&and&disease&progression&(Eddleston&and&Mucke,&1993;& John&et#
al.,#2003).& For& example,& numerous& studies& suggest& that& glial& scars& act& as&barriers&against& harmful& inflammatory& cells& and& infectious& agents,& limiting& their& spread&from&areas&of&damage&or&disease&into&healthy&CNS&parenchyma&(Bush&et#al.,&1999;&Voskuhl&et#al.,#2009;&Drogemuller&et#al.,#2008;&Faulkner&et#al.,#2004;&Herrmann&et#













Figure* 6.* The* complex* pathways* involved* in* reactive* astrocytosis.& Schematic& representations&depicting&the&cross:talk&among&astrocytes,&immune&cells&and&neurons&during&reactive&astrocytosis&(A)*and&neuritic&extension&(B).&The&production&of&growth&factors&and&cytokines&by&activated&astrocytes&is&regulated&via& multifarious& autocrine& and& paracrine& loops.& The& formation& of& the& glial& scar& in& a& regulated& process&involving& paracrine& and& autocrine& influences& between&microglial& cells,& immune& cells& and& astrocytes& via&numerous& cytokines& and& growth& factors,& particularly& IL:1,& NGF,& FGFs& (A).& Reactive& astrocytes& produce&various&recognition&molecules,&the&production&of&which&may&be&modulated&by&certain&neurotrophic&factors.&It&is&thought&that&NGF,&directly&or&indirectly&via&FGF,&controls&the&production&of&PSA:NCAM&and&APP,&thus&regulating&adhesive& interactions&between&axons&and&surrounding&reactive&astrocytes&involved& in&neuritic&extension&(B).&Astrocytes&secrete&a&number&of&proteinases&and&proteinase&inhibitors&after&damage,&which&may&be& involved& in& the&development&of& reactive&gliosis.&The&regulation&of& the&expression&of&proteinases&and& proteinase& inhibitors& may& affect& the& degradation& of& cellular& matrix,& and& lead& to& alterations& of&astrocyte–neuron& interactions& (B).& Arrows& =& binding& of& the& ligand& to& its& receptor& or& secretion& of& a&molecule.& Ambiguous& interactions& are& symbolized& by& broken& lines.& Abbreviations:& APP& =& amyloid&precursor&protein;&BDNF&=&&brain:derived&neurotrophic&factor;&CNTF&=&ciliary&neurotrophic&factor;&CSPG&=&chondroitin&sulfate&proteoglycan;&EGF&=&epidermal&growth&factor;&FGF&=&fibroblast&growth&factor;&GDN&=&glial:derived& nexin;& GDNF& =& glial& cell& line:derived& neurotrophic& factor;& GFAP& =& glial& fibrilarry& acidic&protein;& GHBP& =& glial& hyaluronate:binding& protein;& G:NCAM& =& glial& cell& adhesion& molecule;& HBGAM& =&heparin:binding& growth:associated& molecule;& HSP& =& heat& shock& protein;& HSPG& =& heparan& sulfate&proteoglycan;&IFN&=&interferon;&IGF:1&=&insulin&growth&factor&1;&IL&=&interleukin;&LIF&=&leukemia&inhibitory&factor;& MAG& =& myelin:associated& glycoprotein;& MAP& =& microtubule:associated& protein;& NCad& =& neural&cadherin;&NCAM& =&neural& cell& adhesion&molecule;&NGF& =&nerve& growth& factor;& NO&=&nitric& oxide;&NOS& =&nitric& oxide& synthase;& NSE& =& neuron:specific& enolase;& NT:3& =& neurotrophin& 3;& PDGF& =& platelet:derived&growth&factor;&PGs&=&proteoglycans;&PSA:NCAM&=&polysialylated&NCAM;&TCad&=&truncated&cadherin;&TGF&=&transforming& growth& factor;& TNF& =& tumor& necrosis& factor;& trk& =& tyrosine& kinase;& VCAM& =& vascular& cell&adhesion&molecule.&Taken&from&Ridet&et#al.,#1997.&&
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the& repair& of& the& BBB& (Bush& et#al.,#1999),& all& of&which& are& associated&with& brain&injury& and& neurodegenerative& disease.& Reactive& astrocytosis& is& an& incredibly&complex&and&versatile&process&involving&interactions&between&several&cell&types,&a&wide& variety& of& cell& surface& receptors& and& an& extensive& range& of& soluble& factors,&which&would&be&beyond&the&scope&of&this&chapter&to&describe&here&in&detail&but&is&summarized&in&Figure*6*and&has&been&reviewed&elsewhere&(Ridet&et#al.,#1997)&&Focusing& on& the& role& of& reactive& astrocytosis& in& regulating& CNS& inflammation,& as&discussed& in& section* 3.1.d,& reactive& astrocytes& secrete& a&wide& array& of& pro:& and&anti:inflammatory&cytokines&(including&chemokines)&in&response&to&various&stimuli&(Christopherson&et#al.,&2005;&Garwood&et#al.,&2011;&Macauley&et#al.,&2011;&Parpura&
et# al.,& 2012;& Vardjan& et# al.,& 2012;& Zamanian& et# al.,& 2012),& which& have& either&neuroprotective&or&harmful&effects&on&neurons,&or&sometimes&both&effects&(Ridet&et#
al.,#1997;& John& et#al.,#2003;& Farina& et#al.,#2007;& Ricci& et#al.,#2009;& Ransohoff& and&Brown,& 2012;& Trendelenburg& and& Dirnagl,& 2005).& In& general,& pro:inflammatory&cytokines&e.g.&interleukin:1&(IL:1)&are&neurotoxic&and&anti:inflammatory&cytokines&(e.g.& interleukin:10& [IL:10])&are&neuroprotective& (for&a&more& in&depth& review&see&Allen,& 2000).& However,& some& molecules& like& interleukin:1β& (IL:1β)& or& tumor&necrosis& factor& α& (TNF:α)& display& both& neurotoxic& or& neuroprotective& effects&depending&on&the&context&(Allen,&2000).&These&events&are&part&of&a&bigger&process,&involving& a& sophisticated& cross& talk& among& astrocytes,& immune& cells& (microglia,&macrophages,&T:cells)&and&neurons&via&complicated&autocrine&and&paracrine&loops&(Ridet&et#al.,#2007).&These&eventually&lead&to&the&survival&or&death&of&neurons,&and&axonal& regeneration& or& withdrawal& (Fok:Seang& et#al.,#1998;& Allan& and& Rothwell,&2001;&Liberto&et#al.,#2004;&Ricci&et#al.,#2009;&Liu&et#al.,#2011).&&
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While& cross& talk& (involving&neurotransmitters& such&as&glutamate&and&modulators&e.g.&NO),&between&neurons&and&glia&has&received&increasing&attention&over&the&past&two& decades& (Lui& et#al.,#2006,& 2011),& the& communication& between&microglia& and&astrocytes&is&still&not&well&understood&(Lui&et#al.,#2006,&2011;&Verge&et#al.,#2004).&So&far,& it& is& thought& that& in& pathological& conditions& microglia& and& astrocytes&communicate& via& signalling& molecules& such& as& adenosine& triphosphate& (ATP),&transforming& growth& factor& β& (TGF:β)& and& IL:1& (Lui& et# al.,# 2011).& As& will& be&explained& in& the& following& section,& microglia,& the& first& line& of& defence,& are& often&activated&before&astrocytes&and&subsequently&promote&astrocytosis&(which&can&also&occur& independently& of&microglia& activation)& (Lui& et#al.,#2011).& In& turn,& activated&astrocytes& recruit&and& facilitate& the&activation&of&more&distant&microglia,&but&also&simultaneously& inhibit& some&of& their& effector& functions,& and& in& this&way,& regulate&the& inflammatory& response& (Hailer& et#al.,#2001;& Lui& et#al.,#2011;&Min& et#al.,#2006;&Tian&et#al.,#2012).&Understanding&the&interplay&between&the&activation&of&astrocytes&and&microglia& is& important& if&we& are& to& fully& understand& the& role& of& glial& cells& in&neuropathology,& which& could& ultimately& abet& treatments& for& various&neurodegenerative&diseases&(Lui&et#al.,#2011).&
 Turning&our&attention&to&the&NCLs,&astrocytosis&is&one&of&the&first&pathological&signs&of&disease&in&Ppt1+/+#mice&(Kielar&et#al.,&2007).&The&question&of&whether&astrocytosis&is&beneficial&or&detrimental&in&CLN1&disease&has&recently&been&addressed&in&GFAP:,&vimentin:,& PPT1:deficient& (triple:knockout)&mice,& in&which& astrocyte& reactivity& is&attenuated&(Pekny&et#al.,#1999;&Macauley&et#al.,#2011).&This&reduction& in&astrocyte&reactivity& had& a& worsening& effect& on& disease& pathology,& resulting& in& a& marked&reduction& in& lifespan,& a& reduction& in& brain& mass& and& cortical& thickness,& more&widespread&and&rapidly&progressing&neurodegeneration,&and&a&significant&increase&
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in& storage& burden& (Macauley& et# al.,#2011).& Further& analysis& revealed& that& these&changes& were& accompanied& by& an& increase& in& microglial& activation,& and& the&presence& of&more&monocytes/macrophages& and& infiltrating& T:cells& (although& the&integrity& of& the& BBB&was& not& profoundly& affected)& (Macauley& et#al.,#2011).& These&data& suggest& that& reactive& astrocytosis& has& a& protective& role& in& CLN1& disease&progression,& by& regulating& the& neuroinflammatory& response& and& controlling& the&extent& of&microglial& activation& and&monocyte& infiltration& (Macauley& et#al.,#2011).&Furthermore,&Rag1/Ppt1& double& knockout&mice,&which& lack& lymphocytes,& had& an&extended& lifespan& compared& to&mice& deficient& in& PPT1& alone& (Groh& et#al.,#2013),&consistent&with&the&finding&that&the&attenuation&of&astrocytosis&led&to&an&increase&in&T:cell& infiltration& in& the& vimentin/GFAP/Ppt1:deficient& CNS& (Macauley& et# al.,#2011).&Therefore,&it&is&possible&that&dysfunction&of&astrocytes&or&reactive&astrocytes&in& PPT1:deficient& mice,& may& prevent& these& cells& from& carrying& out& their& normal&functions& and& may& partly& explain& how& astrocytes& might& contribute& to&neurodegeneration&in&CLN1&disease.&&&The& question& of& how& dysfunctional& astrocytes& might& contribute& to&neurodegeneration& has& been& addressed& for& CLN3& disease,& using& astrocytes& that&were& isolated& from& Cln3:deficient& mice& (Parvianinen& PhD& thesis).& This& study&revealed&that&the&basic&biological&characteristics&of&these&astrocytes&were&altered,&impacting& their& ability& to& respond& to& pharmacological& stimuli& and& compromising&their& function& (Parvianinen,& PhD& thesis).& A& disruption& to& their& actin& and&intermediate& filament&cytoskeleton&was&also&observed,& together&with&pronounced&defects&in&glutamate&uptake,&their&ability&to&secrete&a&number&of&proteins&including&cytokines,& neuroprotective& factors& and& anti:oxidants& and& impaired&Ca2+&signalling&(important& for& astrocyte:astrocyte& and& astrocyte:neuron& communication),&
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ii)! Microglial*activation*Microglia& are& a& specialized& sub:population& of& cells& related& to& monocytes& and&dendritic&cells,&which&represent&the&first&line&of&defence&for&the&brain&parenchyma&(Kreutzberg,&1996;&Raivich,&2005;& van&Rossum&et#al.,#2004;&Vilhardt,&2005).&They&are& derived& from& myeloid& precursor& cells,& which& migrate& to& the& CNS& during&development& to& represent& the&most& abundant& immune& effector& cell& of& the& brain,&comprising& 10%& of& the& CNS& cell& population& in& live& mice& under& healthy& brain&conditions& (Gordon&and&Taylor,&2005;&Ransohoff& and&Perry,&2009;&Raivich,&2005;&Fetler& et#al.,#2005;&Nimmerjahn& et#al.,#2005).& &Microglia& display& characteristically&elongated& cell& processes& that& are& ramified,& with& a& sophisticated& tertiary& and&quaternary& branch& structure& and& occupy& their& own& territory,& rarely& overlapping&with& the& cell& body& or& branches& of& neighbouring& microglia& (Gordon& and& Taylor,&2005;&Ransohoff&and&Perry,&2009;&Raivich,&2005;&Fetler&et#al.,#2005;&Nimmerjahn&et#
al.,#2005).&Furthermore,&microglia&display&morphological& and& functional&diversity&within& the& CNS,& including& the& ramified& “resting”& phenotype& and& amoeboid,&cytokine:releasing& and& phagocytic& phenotypes& in& disease& states& (Gyoneva& et# al.,#2014).& & In& the&neurologically&normal&mammalian&brain,&microglia&were&originally&regarded&as&being&quiescent&cells,&virtually&dormant&and&static&(Fetler&et#al.,#2005).&However,& the& ability& of& microglia& to& respond& rapidly& to& a& variety& of& signalling&molecules&has&been&recognized&for&over&a&century,&suggesting&that&they&are&instead&in& a& state& of& vigilance,& readied& to& detect& changes& to& their& local& surroundings&(Kreutzberg,&1996;&Merzbacher,&1909;&Nissl,&1899).&This&was&first&demonstrated&a&
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decade&ago&using&in#vivo#two:photon&microscopy,&which&revealed&that&microglia&are&highly& active& in& their& supposed& “resting”& state,& constantly& surveying& the&surrounding&environment&with&their&extremely&mobile&processes&and&filopodia:like&protrusions& (Nimmerjahn& et# al.,# 2005;& Davalos& et# al.,# 2005).& Unlike& neurons,&astrocytes&and&oligodendrocytes,&which&are& largely& fixed& in& space,& the&motility&of&microglial& branches& allow& them& to& actively& “creep”& through& the& extracellular&matrix,&allowing&them&to&sense&molecules&or&cellular&structures&at&a&distance&that&might&otherwise&not&make&contact&with&them&(Raivich,&2005).&Microglia&have&also&been&shown&to&directly&contact&astrocytes,&neuronal&cell&bodies&and&blood&vessels,&allowing& them& to& communicate& with& these& cells& and& monitor& the& CNS& in& a&coordinated& fashion& (Kreutzberg,& 1996).& For& example,& as& mentioned& in& section*
3.1.d.i,&neighbouring&astrocytes&act&as&informers&for&the&microglia,&recruiting&them&to& sites& of& damage,& injury& or& disease& (Raivich,& 2005),& and& because& microglia&express& receptors& for& neurotransmitters& such& as& glutamate& this& permits& them& to&respond&to&a&wide&range&of&stimuli&by&either&triggering&an&inflammatory&cascade,&or&adopting&a&neuroprotective&phenotype& (Pocock&and&Kettenmann,&2007;&Lui&et#al.,#2006;&Verge&et#al.,#2004).&One&of&the&key&characteristics&of&microglia&is&their&rapid&response& to& a& pathological& stimulus& e.g.& injury,& infection,& neuronal&dysfunction/death,& abnormal& protein& aggregation,& or& immune& cell& interaction,&going&from&a&stochastic&state&to&extending&their&processes&directly&to&the&region&of&the& pathological& stimulus& (Perry& et#al.,#1993;& Gehrmann& et#al.,#1995;& Streit& et#al.,#1988;& Dickson& et# al.,# 1991;& Giulian& et# al.,# 1989;& McGreer,& 1988;& Davalos& et# al.,#2005),& which& usually& precedes& the& activation& of& other& cell& types& in& the& brain,&including& astrocytes& (Kreutzberg,& 1996).& Indeed& microglia& are& very& sensitive,&responding& to& even& very& subtle& changes& in& their&microenvironment,& such& as& any&disequilibrium& in& ion& homeostasis,& which& usually& occurs& before& pathological&
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changes&that&are&detectable&histologically,&and&as&such&microglia&are&often&regarded&as&a&sensitive&marker&of& inflammation&(Kreutzberg,&1996;&Gehrmann&et#al.,#1993).&Studies& involving& tissue& damage& via& micro:lesions& have& demonstrated& a& rapid&chemotactic&response&of&microglial&branches&that&quickly&move&towards&the&lesion&site& and& surround& it& with& a& “dense& sphere& of& arborizations”& (Raivich,& 2005;&Nimmerjahn& et#al.,#2005;& Davalos& et#al.,#2005).& One& of& the& key&molecular& signals&that& mediates& this& process& is& the& high:energy& purine& nucleotide& ATP,& which& is&released&from&the&site&of&injury&and&acts&as&the&primary&chemo:attractor,&attracting&microglial& processes& via& P2Y& receptors& expressed& on& the& surface& of& microglia&(Fetler,&2005).&&Once&a&pathological&signal&has&been&detected,&thus&triggering&their&process&motility&as&described&above,&microglia&abandon&their&“resting”&state&(Vilhardt,&2005).&&This&involves&the&upregulation&of&several&effector& functions,&which&enable&microglia& to&respond& to& the& stimulus& by& tissue& repair,& neurotrophic& support,& induction& of&inflammation,& or& the& activation& of& lymphocytes& (Vilhardt,& 2005).& The& gradual&acquisition&of&these&functions&is&referred&to&as&microglial&“activation”&and&involves&a& number& of& morphological& and& phenotypic& changes& as& a& result& of& discrete&temporal&changes&in&the&genes&that&are&expressed,&and&the&expression&of&numerous&molecular&mediators&(Vilhardt,&2005;&Perego&2011).&&&Two& key& morphological& modifications& occur& over& time,& firstly,& microglia& retract&their&processes,&which&together&with&their&cell&bodies&become&thicker,&leading&to&a&conversion& to& an& amoeboid& macrophage:like& state& (Vilhardt,& 2005;& Perry& and&Teeling,&2013).&Secondly,&if&the&pathological&stimulus&continues&in&the&presence&of&neuronal& death& for& instance,& microglia& undergo& a& further& transformation& from&
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amoeboid& cells& into& phagocytic& cells,& allowing& them& to& contain& the& spread& of&cellular&debris&(Ravich&et#al.,#1999;&Kettenmann&et#al.,#2013).&These&morphological&changes&are&accompanied&by&the&up:regulation&of&numerous&cell&surface&receptors&including& cluster& of& differentiation& 68& (CD68),& a& highly& glycosylated& type& I&transmembrane& protein,& which& belongs& to& the& glycoprotein& family& of&lysosomal/endosomal:associated& membrane& proteins& (LAMP)& (Gottfried& et# al.,#2008),& and& scavenger& receptor& family& of& proteins& (Yamanda& et# al.,# 1998).& As&discussed&in&section*6.3*of&Chapter*2,&CD68&is&a&reliable&marker&for&inflammation&and&was& used& in& this& thesis& to& identify&microglia& in&Chapters* 3* and&5.& EGF:like&module:containing&mucin:like& hormone& receptor:like& 1& or& F4/80,& belongs& to& the&family&of&adhesion&G&protein:coupled&receptors&(adhesion&GPCRs)&and&can&also&be&used&as&a&microglial&marker,&but&is&considered&less&sensitive&as&it&is&only&expressed&by&microglia&once&they&gain&macrophage:like&morphology&(McKnight&et#al.,#1996).&&&Further& effector& functions& that& are& acquired& once& microglia& become& activated&include& cell& proliferation,&migration,& up:regulation& of& innate& immune& cell& surface&receptors,& up:regulation& of& antigen:presenting& cell& capabilities& (Vilhardt,& 2005;&Aloisi,&2001),&and&the&recruitment&of&macrophages&(Jin&et#al.,#2010;&Schilling&et#al.,#2005).& Like& astrocytes,& activated& microglia& and& newly& recruited& macrophages&(which&are&“antigenically&indistinguishable”)&have&both&protective&and&detrimental&effects& (Perego&et#al.,#2011).&Together,& they&can&promote&neurogenesis&and& lesion&repair& (Capone&et#al.,#2007;& Lalancette:Hebert&et#al.,#2007;&Neumann&et#al.,#2006)&through&their&positive&influence&on,&for&example,&glutamate&uptake&(Nakajima&et#al.,#2008).&Other&examples&of&the&positive&influence&of&activated&microglia&include&the&removal& of& cellular& debris& (Stoll& et# al.,# 1999),& as& well& as& the& production& of&neurotrophic& factors& including& insulin& growth& factor& 1& (IGF:1),& glial& cell& line:
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derived&neurotrophic&factor&(GDNF)&and&brain&derived&neurotrophic&factor&(BDNF)&(Thored&et#al.,#2009;&Lu&et#al.,#2005;&Batchelor&et#al.,#1999),&and&anti:inflammatory&compounds&e.g& IL:10&and&TGF:β&(Vilhardt,&2005).&Conversely,&activated&microglia&and&macrophages& also& have& the& ability& to& secrete& a& number& of& pro:inflammatory&molecules&including&cytokines&such&as&TNF:α,&IL:1β&and&chemokines,&as&well&as&the&secretion& of& proteases& and& reactive& oxygen& species& (ROS)& and& nitrogen&intermediates& (Aloisi,& 2001;&Vilhardt,&2005;&Block&et#al.,#2007;&Hanisch,&2002).& In&this&way,&microglia&are&neither&exclusively&neuroprotective&or&neurotoxic,& instead&assuming& both& roles& depending& on& a& number& of& factors& (Block& and&Hong,& 2005).&However,& although& microglial& activation& does& not& categorically& lead& to& neuron&death,& sustained& microglial& functions& such& as& the& release& of& pro:inflammatory&molecules,& can& result& in& the& brain& becoming& chronically& inflamed,& leading& to&neuronal& dysfunction& and& cell& death& (Aloisi,& 2001;& Vilhardt,& 2005;& Block& et# al.,#2007;& Hanisch,& 2002).& Indeed,& through& their& association& with& the& initiation& and&propagation&of&chronic&inflammation,&microglia&are&thought&to&be&critical&players&in&inflammation:mediated& neurodegeneration& (reviewed& in& Block& and& Hong,& 2005;&Gao& et#al.,#2002;& Lee& et#al.,#2000;& Streit,& 2002;&Wu& et#al.,#2003;& Shimohama& et#al.,#2000;&Vilhardt&et#al.,#2002;&Liberatore&et#al.,#1999).&&
Microglial& dysfunction,& as& a& result& of& a& genetic& defect,& may& disturb& their& normal&functions& and& incite& unconstrained& neuroinflammation.& For& example,&concentrating& on& the& NCLs,& primary& microglia& isolated& from& Cln3:deficient& mice&have&been&shown&to&exist&in&a&“primed&pro:inflammatory&state”&(Xiong&and&Kielan,&2013;& Bosch& and& Kielian,& 2015),& producing& elevated& levels& of& numerous& pro:inflammatory& molecules& including& TNF:α,& IL:9,& IL:1β,& IL:1α,& IL:15,& and& IL:10&
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following& exposure& to& DAMPs,& which& are& abundant& in& the& NCL& brain& and&recognized&by&a&number&of&microglial&cell&surface&receptors&e.g&Toll:like&receptors&(Xiong&and&Kielian,&2013;&Puranam&et#al.,#1997;&Mencarelli&and&Martinez:Martinez,&2013;&Hanke&and&Kielian,&2011;&Thundyil&and&Lim,&2001;&Bosch&and&Kielian,&2015).&Interestingly,& in&Cln3∆7/8&mice,&microglial& activation& does& not& reach& the& extent& of&displaying& macrophage# morphology,& even& in& regions& where& astrocytosis& is&relatively& profound,& suggesting& that& the& underlying& molecular& cues& triggering&astrocytosis&are&not&sufficient&to&stimulate&the&full&morphological&transformation&of&microglia&(Pontikis&et#al.,#2005).&
&&Generally,& despite& what& we& know& about& the& normal& behaviour& of& microglia,&microglial& activation& typically& occurs& after# astrocytosis& in& most& forms& of& NCL&according& to& different& spatiotemporal& patterns& of& activation& (to& a& level& that& is&detectable&histologically)&(Cooper&et#al.,#2006;&Pontikis&et#al.,#2004;&Teismann&and&Schulz,&2004;&Pontikis&et#al.,#2005;&Block&et#al.,#2007;&Weimer&et#al.,#2009;&Garwood&
et#al.,#2011;& Lui& et#al.,#2011).& For& example,& in& Cln5:/:& mice,& localized& astrocytosis&within&the&thalamocortical&system&is&detectable&at&1&month&of&age,&whilst&microglial&activation&in&the&same&region&is&only&detectable&at&3&months&of&age&(Schmiedt&et#al.,#2012).&In&Ppt1+/+&mice,&studies&have&shown&that&astrocytosis&also&occurs&within&the&thalamocortical& system& but& at& 3& months,& whilst& microglia& activation& is& only&detected& at& 5& months& of& age,& and& displays& a& much& more& restricted& pattern& of&distribution& even& at& the& end& stages& of& disease,& unlike& astrocytosis,&which& can& be&detected&in&every&region&of&the&CNS&by&the&end&of&disease&(Kielar&et#al.,#2007;&Bible&
et#al.,#2004).&Conversely,&in&Cln3+/+#mice,&astrocytosis&and&microglia&activation&have&been& shown& to& occur& together& at& 5& months& within& the& hippocampus,& dentate,&
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striatum&and&cerebellum&as&indicated&by&the&upregulation&of&CD68&(Pontikis&et#al.,#2004).&However,&even&by&14&months&of&age,&astrocytosis&and&microglial&activation&is&not&pronounced&(i.e.&as&indicated&by&astrocyte&hypertrophy,&and&the&presence&of&microglia&with&brain&macrophage:like&morphology).&&Regardless&of&where&and&when&such&reactive&changes&occur&relative&to&one&another,&astrocytes& and& microglia& invariably& appear& to& be& activated& before&neurodegeneration,& as& a& result& of& processes& that& are& most& likely& to& be&interconnected,& as& we& have& seen& throughout& this& section.& Thus,& a& better&understanding& of& the& precise& relationship& between& astrocytosis& and& microglial&activation&will&be&valuable&for&better&determining&how&to&most&appropriately&target&therapies.&
 
i)! Storage*material*As& discussed& in& section* 3,* a& unifying& feature& of& the& NCLs& is& the& intralysosomal&accumulation& in& all& cells& of& the& body& of& autofluorescent& storage& material&resembling& the& lipopigments& ceroid& and& lipofuscin& (Haltia,& 2003;& Cooper,& 2003;&Mole&et#al.,#2005;&Palmer&et#al.,#2013;&Jalanko&and&Braulke,&2009).&Lipofuscin,&often&referred&to&as&“age&pigment”,&is&a&yellow:brown&intralysosomal&insoluble&polymeric&material& that& cannot& be& degraded& by& lysosomal& hydrolases& and& forms& in& post:mitotic& cells& over& time.& & However,& it& is& the& early& age:independent& disposition& of&lipofuscin& pigment& that& is& referred& to& as& “ceroid”& (Terman& and&Brunk,& 2004).& As&described& previously& (section* 3),* although& observed& simply& as& autofluorescent&material&under&a& light&microscope,&biochemically& the&main&storage&component&of&lipofuscin& e.g.& SAPs& in& CLN1& disease& (Tyynelä& et#al.,#1993)& and& SCMAS& in& CLN3&disease& (Palmer&et#al.,#1992).& Characteristically& the& ultrastructural& appearance& of&
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this& stored&material& has& been& considered& to& vary& between& different& sub:types& of&NCL& (Zeman& and& Donahue,& 1963;& Zeman& et# al.,# 1970).& Indeed,& before& the&identification& of& the& NCL& disease:causing& genes&were& identified,& the& diagnosis& of&NCL&was&based&largely&on&the&structural&appearance&of&storage&material,&which&was&thought& to& align&with& the& specific& form&of&NCL,&however,& this& view& is&now&rather&outdated&(Williams&et#al.,#2006).&&&&In&some&LSDs,&there&is&a&clear&relationship&between&the&nature&of&the&undegraded&storage& material& that& accumulates& in& cells,& and& the& protein& (especially& enzyme)&deficiency,& that& is& caused& by& a& specific& genetic& mutation& (Boustany,& 2013).& For&example& in& Type& II& Glycogen& storage& disease& (Pompe),& the& defective& lysosomal&enzyme&is&α:glucosidase&and&results&in&the&accumulation&of&glycogen&(Hers,&1963).&However,& for& the& NCLs,& the& nature& of& the& undegraded& storage&material& does& not&obviously& relate& to& the& protein& defect,& including& those& caused& by& mutations& in&genes& encoding& lysosomal& enzymes& e.g.& PPT1& (Tyynelä& et# al.,# 1993).& Given& the&diversity& of& the& proteins& involved& in& NCL,& and& the& little& we& know& about& their&normal& function& as& discussed& in& the& next& section& (section* 4),& identifying& causal&links& between& deficiencies& in& specific& proteins& and& the& accumulation& of& storage&material&is&unlikely.&Instead,&the&accumulation&of&storage&material&is&most&likely&to&be&a&downstream&effect&of& lysosomal&dysfunction&in&general&(Walkley&and&Vanier,&2009).&&&Once&storage&material&accumulates,&what& role&does& it&play& in& the&pathogenesis&of&NCL?&Initially,&efforts&to&explain&the&cause&of&neuron&loss&in&the&NCLs&concentrated&upon&storage&material&as&the&most&obvious&pathological&hallmark&of&disease,&with&suggestions& that& it& played& a& central& role& in& pathogenesis,& perhaps& even& having&
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neurotoxic& effects& as& proposed& for& some&LSDs& (Cooper&et#al.,#2015;& Palmer&et#al.,#2013;& Ballabio& and& Gieselmann,& 2008).& However,& at& least& within& the& CNS,& more&recent&evidence&suggests&that&there&does&not&appear&to&be&a&direct&link&between&the&accumulation&of&storage&material&and&cell&death&(Cooper&et#al.,#2015).&Instead,&the&distribution&of&storage&material&does&not&directly&correlate&with&where&neuron&loss&occurs& (Cooper,& 2010;& Cooper& et# al.,# 2006,& and& Palmer& et# al.,# 2013)& and&furthermore,&the&few&neurons&that&do&survive&into&the&end&stages&of&disease&display&huge& amounts& of& autofluorescent& storage& material& (Tyynelä& et# al.,# 2004).&Additionally,& studies& have& shown& that& clearing&much& of& the& storage& burden& does&not& improve& the& outcome& of& disease& (Griffey& et# al.,# 2006),& whilst& conversely&increasing&the&storage&load&by&inhibiting&lysosomal&enzymes,&does&not&kill&neurons&(Ivy,& 1992,& Ivy& et# al.,#1984).& Despite& our& lack& of& understanding& of& how& storage&material& accumulates&and&contributes& to&disease&pathogenesis,& it& still& serves&as&a&valuable&read:out&for&therapeutic&efficacy,&as&used&in&this&thesis&(Chapter*3*and&5),&and&as&discussed&in&section*5,&recent&therapeutic&interventions&that&directly&target&the& accumulation& of& storage& material& have& been& shown& to& have& some&moderate&positive& effects& (Sarkar& et# al.,#2013;& Cooper& et# al.,#2015).& Nevertheless,& storage&material&is&detected&in&all&cells&of&the&body,&but&has&not&received&as&much&attention&as& storage& material& within& the& brain& (Zeman& and& Dyken,& 1969).& The& topic& of&visceral&storage&in&NCL&disease&will&be&covered&in&more&detail&in&Chapter*4.&&As&we&have&seen,&the&NCLs&share&a&number&of&pathological&features,&which&display&disease:specific&patterns& (summarized& in&Figure*7).&Regardless&of& this& similarity,&how&these&pathological& features&unfold&begins&with&the&specific&mutation&and&the&consequential&protein&deficiency.&Therefore,&an&understanding&of&the&location&and&
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function& of& these& NCL& proteins& is& necessary& to& better& understand& this& group& of&diseases.&&&&&&&&&
&
4! NCL*proteins*–*between*gene*and*function?*&Generally,&very&little&is&known&about&the&normal&intracellular&location&and&function&of&NCL&proteins&and&as&discussed&in&the&previous&section,&the&nature&of&the&storage&material& that& accumulates& in&NCLs&has&offered& little& clarity& (Cárcel:Trullols&et#al.,#2015).&Nonetheless,&gaining&a&better&understanding&of&the&normal&function&of&these&proteins& is& crucial& if&we& are& to& untangle& the& pathways& that& are& affected& by& their&dysfunction,&and& lead& to& the&common&clinical&and&pathological& features& that&have&been&described&in&this&chapter&so&far&(Cárcel:Trullols&et#al.,#2015).&As&discussed&in&
section*3,&there&are&13&NCL:associated&proteins&to&date&(CLN1–13),&which&differ&in&function& and& cellular& location& but& all& appear& to& impact& lysosomal& function,& as& is&summarized& in& Table* 4.& The& majority& of& CLN& proteins& have& been& localized& to&




lysosomes&(CLN1,&CLN2,&CLN3,&CLN5,&CLN7,&CLN10,&CLN12&and&CLN13),&but&some&have&also&been& localized&to&the&endoplasmic&reticulum&(ER)&(CLN6&and&CLN8),&or&the&cytosol&associated&to&vesicle&membranes&(CLN4&and&CLN14)&(Mole&and&Cotman,&2015;& Simonati& et# al.,# 2014;& Kousi& et# al.,# 2012;& Cárcel:Trullols& et# al.,# 2015).&Generally,& as& already&mentioned& in& section*3,& these& proteins& fall& into& two& broad&categories& –& soluble& lysosomal& proteins& or& lysosomal& transmembrane& proteins&(Getty& and& Pearce,& 2011).& Soluble& lysosomal& enzymes& include:& CLN1,& which& is&palmitoyl& protein& thioesterase& 1& (PPT1);& CLN2,& which& is& tripeptidyl:peptidase& 1&(TPP1);&CLN5,&the&function&of&which&is&still&unknown;&CLN10,&which&is&cathepsin&D;&and& CLN13,& which& is& cathepsin& F;& whilst& possible& lysosomal& transmembrane&proteins&include:&CLN3,&CLN7&and&CLN12&(Getty&and&Pearce,&2011;&Cárcel:Trullols&
et#al.,#2015;&Kollmann&et#al.,#2013).&Despite&years&of&research,&the&exact&functions&of&these& proteins& occupy& a& spectrum&between& unknown& and& inconclusive.&With& the&exception& of& PPT1& and& CtsD,& most& of& the& NCL& proteins& do& not& have& known&definitive&functions&but&several&comprehensive&reviews&provide&an&overview&of&the&suggested& functions& of& the& different& NCL& gene& products& (Cárcel:Trullols& et# al.,#2015)&and&these&are&summarized& in&Table*4.&However,&here,&we&will&concentrate&on&what&we&know&about&the&CLN1&and&CLN3&proteins.&&
4.1! CLN1*(palmitoyl*protein*thioesterase*1)*Mutations& of& the& CLN1# gene& cause& infantile& CLN1& disease,& which& (with& the&exception& of& CLN10& disease)& is& the& most& aggressively& progressing& form& of& NCL,&with& symptoms& arising& between& 1& to& 2& years& of& age,& and& typically& leads& to& a&premature&death&by&8&–&11&years&old&(Haltia&and&Goebel,&2013).&Other&mutations&in&
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CLN1# have& been& reported,& leading& to& milder& disease& forms& with& late& infantile,&juvenile&and&adult&ages&of&onset&(Khan&et#al.,#2013;&Michison&et#al.,#1998).&&A& major& breakthrough& in& CLN1& disease& research& was& the& discovery& that& the&ubiquitously& expressed& CLN1& gene& (Camp& and& Hofmann,& 1993;& Isosomppi& et#al.,#1999;& Salonen& et# al.,# 1998;& Schrinder& et# al.,# 1996)& encodes& palmitoyl& protein&thioesterase&1&(PPT1),&a&protein&with&a&known&biological&function,&an&enzyme&that&cleaves& palmitate& groups& from& S:fatty& acylated& proteins& (Vesa& et#al.,#1995;& Camp&and&Hofmann,&1993;&Verkruyse&and&Hofmann,&1996;&Hellsten&et#al.,#1996;&Bellizzi&




































































































































































































































Hornemann( et# al.,# 2015).( Generally,( protein( palmitoylation/depalmitoylation( is(important( for( controlling( membrane( interactions( of( proteins( and( protein(trafficking((Smotrys(and(Linder,(2004).(Therefore,(defects(in(enzymes(that(regulate(palmitoylation(are( likely( to(have( implications( for(many(cell(processes(depending(on( the( protein( being( depalmitoylated( (Hornemann( et#al.,#2015).( Several( targets(have(been(suggested(including(the(F1(complex(of(mitochondrial(ATP(synthase,(HKRas,( palmitoylKCoA,( α( subunits( of( heterotrimeric( G( proteins( or( neuronKspecific(growth(associated(protein((GAP43)(and(rhodopsin((Camp(and(Hofmann,(1993;(Cho(
et# al.,# 2000;( Verkruyse( and( Hofmann,( 1996;( Bannan( et# al.,# 2008).( Mechanistic(pathways( to( accompany( these( findings( are( largely( lacking,( but( cells( with( PPT1(deficiency(show(elevated(markers(for(oxidative(and(ER(stress(and(activation(of(the(unfolded( protein( response( (UPR),( and( subsequent( apoptosis( (Kim( et#al.,#2006b;(Wei( et#al.,#2008;( Zhang( et#al.,#2006).( For( example,( there( is( evidence( that( GAP43(accumulates( in( the(ER( in( affected( lymphoblasts,( perhaps( giving( rise( to(ERKstress(induced(UPR,(which(is(associated(with(caspaseK4(and(caspaseK3(activation(and(cell(death((Kim(et#al.,#2006a).(((In( terms( of( its( location,( in# vitro# experiments( have( demonstrated( that( PPT1Kmediated( depalmitoylation( of( certain( substrates( e.g.( GAP43( and( rhodopsin(peptides( is( more( efficient( at( a( neutral( pH( (cytosol)( than( a( more( acidic( pH((lysosome)((Cho(et#al.,#2000),(and(other(studies(have(shown(that(PPT1(associates(with( lipid(raft(domains,( suggesting( that(PPT1(has(some(extralysosomal( functions((CárcelKTrullols(et#al.,#2015).(This( is( especially( true( in(neurons,(where(PPT1(may(also( be( expressed( in( the( preKsynaptic( area( where( it( could( perform( a( synapseKspecific( function( (Ahtiainen( et#al.,#2003;( Heinonen( et#al.,#2000;( Lehtovirta( et#al.,#2001;(CárcelKTrullols(et#al.,#2015).(Consistent(with(the(role(of(depalmitoylation(in(
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trafficking,( Ppt1# lossKofKfunction( studies( in( Drosphilia( have( revealed( that( PPT1(plays( a( part( in( endocytosis( by( regulating( the( early( stages( of( vesicle( formation((Stephanie(et#al.,#2010).(The(ability(of(terminals(at(the(neuromuscular( junction(to(recover( from( repetitive( stimulation( is( also( compromised( in( Ppt1# Drosophila#mutants,(providing(evidence(for(synaptic(vesicle(exoK(and(endocytosis(having(been(altered.(This(suggestion(was(further(supported(by(studies(showing(a(reduction(in(
FM1543®( (a( commercial( dye)( uptake( in( Ppt15mutant# larval( terminals,( which(indicates( an( impairment( in( activityKdependent( vesicle( cycling( and( thus( neuron(activity((Aby(et#al.,#2013).(These(findings(have(been(corroborated(by(studies(using(tissue(from#Ppt15/5#mice((Kim(et#al.,#2008).(Neuronal(communication(depends(on(a(continuous( cycle( of( exoK( and( endocytosis( of( synaptic( vesicles( (SVs)( containing(neurotransmitter(molecules(at( the(nerve( terminal( (De(Camilli(et#al.,#2004;#Sudhof(
et# al.,# 2004;( Ryan( et# al.,# 2006;( Murthy( et# al.,# 2003),( and( this( was( found( to( be(compromised( in( the( absence( of( Ppt1( protein,( with( palmitoylated( SV( proteins(including( vesicleKassociated( membrane( proteinK2( (VAMP2)( and( synaptosomalKassociated(protein(25((SNAP25)(remaining(anchored(to(the(nerve(membrane((Kim(
et#al.,#2008).(However,( the( localization( of( PPT1( in( synaptic( vesicles( is( somewhat(contentious( (Ahtiainen(et#al.,#2003;(Heinonen(et#al.,#2000;( Lehtovirta(et#al.,#2001;(Virmani(et#al.,#2005).(Other( suggested(neuronKspecific( locations( for(PPT1( include(the(soma,(dendrites(and(axonal(varicosities,(providing(further(evidence(for(neuronKspecific(roles(of(PPT1((Kollmann(et#al.,#2013),(some(of(which(might(be(involved(in(cholesterol(metabolism( (Lyly(et#al.,#2008)( and(Ca2+(homeostasis( (Ahtiainen(et#al.,#2007)(to(name(a( few.(Evidently,(studies(to(date(have( largely(been(focused(on(the(potential(neuronKspecific(roles(of(PPT1,(but(an(understanding(of(the( location(and(function( of( PPT1( and( its( substrates( and( interactions( in(non5neural( tissue( is( also(
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important( if( we( are( to( fully( understand( the( mechanistic( pathways( that( lead( to(CLN1(disease((Getty(and(Pearce,(2011).(((
4.2! CLN3((Mutations( in(CLN3( cause( juvenile( CLN3(disease( and(will( be( described( in( greater(detail( in( section(1.1(of(Chapter(3.( Despite( being( one( of( the( first( proteins( to( be(cloned((The(International(Batten(Disease(Consortium,(1995),(the(normal(function(of(CLN3(still(remains(elusive.(This(is(largely(because(the(tools(that(are(available(for(determining( the( topology,( location,( postKtranslational( modifications,( protein(interacting( partners( and( functions( of( CLN3( are( very( poor( (Cooper,( personal(communication).(With(regards(to(localization(studies,(a(variety(of(CLN3(antibodies,(expression(constructs,(epitope(tags,(and(cell(types(have(all(been(used(with(limited(success( (Getty( and( Pearce,( 2011),( as( has( been( critically( reviewed( elsewhere((Phillips(et#al.,#2005).(For(example,(the(low(expression(levels(of(endogenous(CLN3(together(with(its(highly(hydrophobic(structure(has(made(it(difficult(to(generate(an(antibody( for( studying( endogenously( expressed( CLN3( protein( (Getty( and( Pearse,(2011;( CárcelKTrullols( et#al.,#2015).( PeptideKderived( polyclonal( antibodies( are( the(most(widely( used( tools( to( study( overKexpressed( CLN3( (Phillips( et#al.,#2005),( but(few(studies(have( succeeded(at( showing( true(CLN3(specificity( (Ezaki(et#al.,#2003).(To( use( another( example,( while( epitope( tags( provide( a( means( to( trace( gene(products,( there( are( concerns( that( these( tags( may( interfere( with( the( normal(structure,( trafficking( and( function( of( CLN3( protein,( giving( rise( to( misleading(conclusions( about( the( characteristics( of( CLN3( (Cooper,( personal( communication;(Jarvik( and( Telmer,( 1998;( Phillips( et#al.,#2005).(Without( an( understanding( of( the(normal( functions(of(CLN3,( it( is(difficult( to(determine(how(mutations( in( the(CLN3(
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gene( lead( to( juvenile(CLN3(disease.(Therefore,(despite(over(a(decade(of( research(into( the( primary( cause( of( this( disease,( we( have( amassed( a( large( number( of(suggested(functions(but(very(little(in(the(way(of(any(solid(proof(for(its(function((for(a(comprehensive(review(of(CLN3(protein(see(Getty(and(Pearce,(2011).(((
CLN3( encodes( a( 438Kamino( acid( putative( type( III( lysosomal( transmembrane(protein(of(ambiguous(topology((Kollmann(et#al.,#2013;(Getty(and(Pearce,(2011),(it(is(thought( that( CLN3( has( 6( transmembrane( domains( with( both( NK( and( CKtermini(facing(into(the(cytosol((Ratajczak(et#al.,#2008;(Nugent(et#al.,#2008;(Ezaki(et#al.,#2003;(Kyttala(et#al.,#2004),(but(a(5(membrane(domain(topology(has(also(been(suggested((Phillips( et# al.,#2005;( Mao( et# al.,#2003).( mRNA( and( protein( expression( analyses(suggest(that(CLN3(is(ubiquitously(expressed(in(various(human(and(mouse(tissues((Käkelä(et#al.,#2003;(The( International(Batten(Disease(Consortium,(1995;(Ezaki(et#
al.,#2003;(Chattopadhyay(and(Pearce,(2000;(Margraf(et#al.,#1999;(Su(et#al.,#2004).(In(mammalian(cells(within( these(various( tissues,(CLN3(has(mostly(been( localized( to(the( endosome( and( lysosome( (Golabek( et#al.,#1999;( Kida( et#al.,#1999;( Ezaki( et#al.,#2003;( Storch( et#al.,#2007).( However( there( have( also( been( suggestions( that( CLN3(also( localizes( to( the( nucleus( (Margraf( et# al.,#1999),( within( the( Golgi( apparatus((Golabek(et#al.,#1999;(Kida(et#al.,#1999;(Kremmiodiotis(et#al.,#1999),(mitochondria((Katz( et#al.,#1997),( plasma( membrane( (Margraf( et#al.,#1999)( neuronal( processes(and(synaptosomes((Luiro(et#al.,#2001;(Jarvela(et#al.,#1999).(While(these(reports(are(not(necessarily(proven,(it(could(be(that(CLN3(has(functions(within(multiple(cellular(regions,(or(perhaps(that(CLN3(has(cellKspecific(or(conditional(functions((Getty(and(Pearce,(2011).(However,(it(is(more(likely(that(CLN3(functions(at(the(lysosome(but(carries( out( a( transient( role( in( vesicles( that( interact( with( lysosomes( in( specific(cellular(regions(under(specific(conditions((Getty(and(Pearce,(2011).((
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(The(idea(of(CLN3(as(a(protein(that(may(have(diverse(functions,(makes(it(difficult(to(determine,(which( (if( any)( of( these( is( the( key( role( of( CLN3( (CárcelKTrullols( et#al.,#2015;(Getty(and(Pearce,(2011).(Indeed,(CLN3(has(been(linked(to(numerous(cellular(processes( including( lysosomal( pH( regulation,( autophagy,( endocytosis,( protein(transport( from( the( transKGolgi,( proliferation( and( apoptosis( (reviewed( in( CárcelKTrullols(et#al.,#2015).(Therefore,(delineating(which(of(these(processes(are(affected(as( a( primary( consequence( of( CLN3( deficiency,( and(which( of( these( processes( are(affected(as(a(downstream(effect,(is(somewhat(challenging.((Unlike(PPT1,(CLN3(does(not(appear(to(have(any(fundamental(homology(with(any(known( proteins( or( functional( domains,( but( is( highly( conserved( across( different(species((Taschner(et#al.,#1997;(Muzaffar(and(Pearce,(2008)(and(human(CLN3(is(able(to(complement( functions(of( its(yeast(orthologue(Btn1p((Saccharomyces#cerevisiae#and(S.#pombe),(which(has(been(shown(to(play(a(key(role(in(the(transport(of(proteins(between( the( yeast( equivalent( of( the( lysosome( (vacuole)( and( the( transKGolgi(network((Gachet(et#al.,#2005;(Kim(et#al.,#2003;(Pearce(and(Sherman,(1998;(Kama(et#
al.,# 2011;( Codlin( and( Mole,( 2009).( However,( these( orthologues( may( produce(different( topologies( compared( to( the( human(protein,( and( have( been( localized( to(the(Golgi(apparatus((Nugent(et#al.,#2008;(Codlin(and(Mole,(2009;(Kama(et#al.,#2011).(However,( extensive( research(using( a(number(of(different( species( including(yeast(and(invertebrate(models(have(provided(some(clues(as(to(possible(specific(functions(of(CLN3.(Concentrating(on(just(two(examples(of(neuronKspecific(cellular(processes,(CLN3( is( thought( to( have( several( interacting( proteins( such( as( the( cytoskeletal(protein(βKfodrin(and(Na+,(K+(ATPase(complex,( the(cellular(processes(of(which(are(possibly(mediated(by(CLN3(and(appear(to(be(affected(in(CLN3(patient( fibroblasts(
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and(Cln35/5(mouse(neurons((Uusi(et#al.,#2008;(Getty(and(Pearce,(2011).(Both(of(these(proteins(have(neuronKspecific(roles,(βKfodrin(is(thought(to(be(involved(in(processes(at(synaptic(compartments((Uusi(et#al.,#2008),(whilst(the(Na+,(K+(ATPase(complex(is(directly( involved( in( glutamatergic( transmission( (Finn( et#al.,#2011;( Kovacs( et#al.,#2006),( perhaps( explaining( the( excitotoxicity( observed( in( CLN3( disease( mouse(models( (Killmann(et#al.,#2013;(Zhang(et#al.,#2009;(Rose(et#al.,#2009).(There( is( also(newly(emerging(data(to(suggest(a(significant(role(for(CLN3(in(Ca2+(flow(across(the(neuronal( membranes( involving( “resting( K+”( or( “leak( channels”( and( altered( Ca2+(homeostasis(within(lysosomes(as(a(result(of(CLN3Kdeficiency((Chandrachud(et#al.,#2015).(However,( although( identifying( neuronKspecific( functions( for( CLN3(will( be(needed( in( order( to( better( understand( the( mechanisms( by( which(neurodegeneration( occurs( in( CLN3( disease,( it( is( also( important( to( consider( the(evidence(of(pathology(outside(of(the(CNS,(especially(within(the(heart(as(discussed(in(Chapter(4((Hofman(et#al.,#2001;(Østergaard(et#al.,#2011).((For(example,(despite(a(lack(of(obvious(kidney(pathology(in(CLN3(disease,(there(is(evidence(to(suggest(an(osmoregulated(function(for(CLN3(in(renal(control(of(water(and(K+(balance((Stein(et#
al.,#2010).(((While(evidence(continues(to(mount(for(yet(more(possible(functions(of(CLN3,(we(are(still( far( off( identifying( its( primary( function,(which(might( help( reveal( a( causative(pathway( in( CLN3( disease( and( could( be( targeted( by( therapy.( Instead,( most(therapeutic( efforts( so( far( have( been( aimed( at( addressing( downstream(pathology(with( limited(success(as(discussed( in( the(next( section.(This( thesis(aims( to( take(an(alternative( approach( by( directly( targeting( the( genetic( defect( (Chapter( 3).(Furthermore,( this( thesis( also( aims( to( explore( the( presence( of( cardiac( pathology(
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(Chapter(4),(perhaps(pointing( towards( the(possibility(of( cardiac(specificKroles(of(CLN3(protein(that(have(not(yet(been(identified.((
5! Therapeutic(approaches(for(the(treatment(of(the(NCLs(As( no( specific( therapies( currently( exist( for( the( treatment( of( any( form( of( NCL,(patient( care( is( mainly( palliative,( chiefly( focusing( on( managing( symptoms( e.g.(seizures,( behavioural( disturbances( and( depression( (Hobert( and( Dawson,( 2006).(Anticonvulsants(are(the(most(widely(used(therapy(for(most(forms(of(NCL((Hobert(and(Dawson,(2006).(However,( some(clinical( reports( suggest( that( certain( types(of(these( drugs( e.g.( Phenytoin( (Dilantin),( can( worsen( clinical( symptoms,( with(increases( in( seizure( activity,( underlying( the( importance( of( carefully( selecting(appropriate( patient( medication( (Philippart,( 1988,( 1994;( Wisniewski,( 2005).(Furthermore,( antiKdepressants( such( as( diazepam,( haloperidol( and( lithium( have(also( been( used( to( treat( depression( in( patients( with( juvenile( CLN3( disease,( who(frequently( experience( this( complication( (Boustany,( 1993),( and( physiotherapy( is(often( used( to( help( patients( retain( their( physical( abilities( for( as( long( as( possible((Hobert(and(Dawson,(2006).((Based(on(what( little(we(do(know(about( the(normal( function(of( the(CLN(proteins,(and( how( their( deficiencies(might( lead( to( disease,( together(with( the( pathological(features( that( manifest,( a( series( of( therapeutic( approaches( have( been( devised.(These( try( to( target( the( primary( genetic( defect,( the( protein( deficiency( or( some(downstream( aspect( of( pathology,( as( will( be( described( in( the( following( sections.(NCL( mutations( fall( into( two( broad( categories,( being( those( that( affect(transmembrane(proteins(and(those( that(affect(soluble( lysosomal(enzymes((Wong(
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et# al.,# 2010).( As( will( be( described( in( sections( 5.1,( 5.2( and( 5.5,( a( variety( of(therapeutic(approaches,(aimed(at(replacing(the(missing(enzyme(product((Griffey(et#
al.,#2004,(2005,(2006;(Passini(et#al.,#2006;(Sondhi(et#al.,#2007;(CabreraKSalazar(et#al.,#2007)(have(been(explored(for(enzymeKdeficient(forms(of(NCL(like(CLN1(and(CLN2(disease(based(on(the(principle(of(“crossKcorrection”(as(described(in(section(1.1.a((Cooper(et#al.,#2008).(However,(for(transmembrane(forms(of(the(disease(for(which(“crossKcorrection”(cannot(occur,(therapeutic(possibilities(are(more(limited((Cooper(
et#al.,#2008).(There(are(several(reviews(of(the(current(state(of(developing(therapies(for( the(NCLs( in(general( (Neverman(et#al.,#2015;(Cotman(et#al.,#2015;(Kohan(et#al.,#2011;(Hobert(and(Dawson,(2006;(Pierret(et#al.,#2008),(while(others(are(available,(which(focus(on(soluble(lysosomal(enzymeKdeficient(forms((Wong(et#al.,#2010)(and(transmembrane(proteinKdeficient(forms,(specifically(CLN3(disease((Cooper,(2008),(and(are(summarized(in(Figure(8(and(Table(5.(However,(this(section(will(focus(on(the(current(treatments(that(have(been(most(promising(for(CLN1(and(CLN3(disease.((
5.1! Enzyme(replacement(therapy((ERT)(As( mentioned( in( the( previous( section,( NCLs( that( are( caused( by( mutations( in( a(soluble(lysosomal(enzyme(like(PPT1,(could(in(theory(be(treated(by(the(exogenous(administration( of( recombinant( enzyme( via( the( principle( of( “crossKcorrection”,((Wong(et#al.,#2010).(However,(one(of(the(main(obstacles(to(the(success(of(ERT(is(the(inability( of( exogenously( supplied( lysosomal( enzyme( to( effectively( cross( the( BBB((Hobert( and( Dawson,( 2006).( Therefore,( clinical( success( via( systemic( delivery( of(recombinant(enzymes(has(largely(been(limited(to(nonKneuronopathic(LSDs(such(as(Type(1(Gaucher(disease((GD(type(1)((Beutler(et#al.,#1991;(Barton(et#al.,#1991)(and(Fabry(disease((Eng(et#al.,#2001)((reviewed(in(Neufeld,(2004;(Rohrbach(and(Clarke,(
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2007;( Desnick( and( Scuchman,( 2012).( However,( progress( has( been( made( preKclinically( to( overcome( the( BBB( by( using( alternative( routes( of( enzyme(administration( such( as( via( the( CSF,( convection( enhanced( delivery( to( the( brain(parenchyma,(or(intracerebroventricular(or(intrathecal(infusions,(and(have(proved(promising( for( LSDs( that( are( predominantly( neuropathic( (Hemsley( et# al.,# 2009;(Lonser(et#al.,#2005;(Dodge(et#al.,#2009).((
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CLN3( Small(Molecule(Therapy(–(Mycophenolate(Mofetil((NCT01399047)( Recruiting( University(of(Rochester(
(More(recently(such(CSFKmediated(approaches(have(been(tested(preKclinically( in(a(canine(model( of( CLN2(disease( (Katz( et#al.,#2014;( Vuillemenot( et#al.,#2011,( 2015),(and(based(on(positive(preKclinical(outcomes(a(Phase(II(ERT(clinical(trial( for(CLN2(disease(is(currently(underway((https://clinicaltrials.gov/ct2/show/NCT01907087).((
Table( 5.( Promising( therapeutic( developments.( Mice( have( been( the( primary( animal( model( for(investigating(NCL(pathogenesis,( exhibiting( key(pathological( features( of( their( corresponding( NCL( subKtype(e.g.( autofluorescent( cellular( storage( and( progressive( neurodegeneration( and( therefore,( mice( have( been(instrumental( for( the( assessment( of( novel( therapeutic( interventions( (Neverman( et#al.,#2015,( Cooper( et#al.,#2006).( Larger,( naturally( occurring( ovine( and( canine( NCL( models( are( routinely( used( for( preKclinical(investigation(of(potential(therapies(in(order(to(evaluate(safety(and(efficacy(of(experimental(therapies(prior(to(human(clinical(investigation((Neverman(et#al.,#2015).(So(far(human(clinical(trials(have(been(completed(or(are(underway(for(CLN1,(CLN2(and(CLN3(disease.(Abbreviations:(WCMC(=(Weill(College(of(Medicine,(Cornell(University,(NICHD( =(Eunice( Kennedy( Shriver( National( Institute( of( Child( Health( and(Human(Development.(Adapted(from(Neverman(et#al.,#2015(and(Bond(et#al.,#2013.((
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Unfortunately,(no(such(advances(have(yet(been(made(for(CLN1(disease.(A(study(in(which( intravenous( highKdose( ERT( in( Ppt15/5#mice( was( administered( at( 3( and( 8(weeks(showed(that(if(mice(received(treatment(at(3(weeks((before(the(closure(of(the(BBB),( the( onset( of( motor( deterioration( was( slightly( delayed( and( lifespan( was(modestly(extended((Hu(et#al.,#2012).(However,(if(treatment(was(administered(at(8(weeks((after( the(closure(of( the(BBB),( the(effects(of(ERT(were(minimal(within(the(brain,( but( in( the( rest( of( the( body(where(most( of( the( enzyme(was( detected,( ERT(significantly( cleared( the( visceral( storage( burden( and( markedly( decreased( the(presence(of(macrophages((Hu(et#al.,#2012).(In(a(more(recent(study,(a(single(dose(of(intrathecally( delivered( PPT1( enzyme( was( shown( to( have( a( similar( moderate(positive(impact(upon(behaviour,(lifespan(and(neuropathology((Lu(et(al.,(2015).(As(such(this(approach(may(yet(prove(to(be(of(some(therapeutic(value,(but(this(remains(to(be(realised,(as(no(large(animal(model(of(CLN1(disease(currently(exists.((
5.2! Stem(cell(therapy(Stem( cells( are( undifferentiated( cells( with( the( capacity( to( divide( by( mitosis( to(produce( more( stem( cells( or( differentiate( into( multiple( specialized( cell( types((Macarthur( et#al.,#2009;( Jones( and(Wagers,( 2008).( Neural( stem( cells( (NSCs)( are(described( as( multipotent( cells( and( are( capable( of( generating( neurons,(oligodendrocytes(and(astrocytes((Flax(et#al.,#1998;(McKay,(1997).(Stem(cell(therapy(is( an( attractive( therapeutic( prospect( for( the( treatment( of( neurodegenerative(disorders( based( mainly( on( two( different( rationales( i)( cellular( replacement,( ii)(environment(enrichment((Lindvall(et#al.,#2006;(Kim(and(Vellis,(2009;(Lindvall(and(Kokaia,( 2005).( For( neurodegenerative( diseases( like( NCLs( and( other( LSDs((Jeyakumar(et#al.,#2009;(Lee(et#al.,#2010),(which(are(caused(by(enzyme(deficiencies,(
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the( objectives( of( stem( cell( therapy( centre( more( on( the( latter( rationale( and( the(potential( of( stem( cells( to( deliver( the( deficient( enzyme( to( the( host( via( “crossKcorrection”,(in(a(similar(way(to(ERT((Wong(et#al.,(2010;(Hobert(and(Dawson,(2006).(However,(as(stem(cells(have(the(potential(to(survive(within(the(host(CNS,(stem(cell(therapy(has(the(additional(potential(advantage(of(providing(a(longKterm(source(of(enzyme,( unlike( ERT(which(must( be( repeatedly( administered( (Wong( et#al.,( 2010;(Mole( et#al.,#2011).( To( investigate( the( therapeutic( safety( and( efficacy( of( stem( cell(therapy(for(the(treatment(of(CLN1(disease,(NPCs(capable(of(producing(PPT1(were(implanted( into( neonatal( Ppt15/5(mice( back( crossed( onto( the( nonobese( diabeticKsevere(combined(immunodeficiency((NODKSCID)(background(to(prevent(xenograft(immune( rejection( (Tamaki( et# al.,( 2009).( The( transplanted( cells( survived( and(migrated(extensively(throughout(the(CNS(and(a(proportion(underwent(siteKspecific(differentiation(into(neurons,(astrocytes(and(oligodendrocytes((Tamaki(et#al.,(2009).(Although(the(majority(of(cells(remained(undifferentiated,(the(engraftment(of(these(cells( led( to( a( reduction( in( storage( material,( preservation( of( specific( neuronal(populations(and(a(delay(in(the(rate(of(decline(in(motor(performance((Tamaki(et#al.,(2009).( This( proof( of( principle( led( to( the( initiation( of( a( phase( I( clinical( trial( to(evaluate( the( safety( and( tolerability( of( stem( cell( transplantation( in( CLN1( disease((ClinicalTrials.gov#identifier#NCT00337636).(Using(allogenic(foetal(neural(stem(cells((HuCNSKSC)( for( the( first( time( in( a(human(neurodegenerative( condition( (Kruer(et#
al.,#2013),(this(trial(showed(that(the(therapy(was(well(tolerated(but(did(not(result(in(any(significant(functional(improvements,(perhaps(owing(to(the(fact(that(patients(were( enrolled( in( the( advanced( stages( of( disease( (Selden( et# al.,# 2013).(Unfortunately,(despite(the(fact(that(the(initial(trial(showed(no(safety(concerns,(an(anticipated(phase(II(trial(to(further(investigate(therapeutic(efficacy(was(halted(for(unknown(reasons.(
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5.3! Bone(marrow(transplantation((BMT)(Bone(marrow(transplantation((BMT),(another( form(of(stem(cell( therapy,( involves(the( donation( of( healthy( haematopoietic( stem( cells( (HSCs)( to( diseased( patients((Mole( et#al.,#2011).( HSCs( have( the( capacity( to( differentiate( into( a( variety( of( cell(types( including( immune( cells,( lymphocytes,(macrophages( and(microglia( and( like(NPCs,(represent(a(potential(vehicle(for(delivering(the(deficient(enzyme((Mole(et#al.,#2011;(Pierret(et#al.,#2008).(BMT,( like(ERT( is(already(an(approved( treatment( for(a(number( of( LSDs,( which( have( little( CNS( involvement,( such( as( MPS( I,( VI( and(NiemannKPick( Type( b( (reviewed( in( Malatack( et# al.,# 2003).( However,( clinical(attempts(at(BMT(in(CLN1(disease(have(proved(unsuccessful,(apparently(due(to(the(inability(of(donor(HSCs(to(reach(the(CNS((Lonnqvist(et#al.,#2001).( (Rather(modest(improvements(in(neurological(function(have(been(reported(following(BMT(in(some(neuropathic(LSDs,(perhaps(owing(to(the(fact(that(microglia(in(the(brain(are(derived(from( bone( marrow( and( therefore,( some( donorKderived( macrophages( can(theoretically( enter( the( brain( to( secrete( functional( enzyme( (Krivit( et# al.,( 1999;(Walkley(et#al.,(1994;(Lucke(et#al.,(2007).(However,(because(only(a(select(proportion(of( donated( HSCs( appear( to( reach( the( brain( in( this( way( and( differentiate( into(microglia,(the(CNS(remains(largely(unaffected(by(BMT((Platt(and(Lachmann,(2009).(As( such,( BMT( can( only( confer( systemic( benefits,( which( are( insufficient( in(preventing(the(inevitably(fatal(progression(of(CLN1(disease.((
5.4! Small(molecule(therapy(The( majority( of( small( molecule( drug( treatments( target( downstream( effects( of(disease,( and( therefore(may(be(expected( to(have( limited(efficacy( in(CLN1(disease,(compared(with( ERT,( BMT( and( gene( therapy(which( directly( address( the( primary(
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Glial( activation( is( prominent( in( the( early( stages( of( CLN1( disease,(with( astrocyte(activation(preceding(neurodegeneration(and(microglial(activation(accompanying(it((Kielar( et#al.,( 2007;( Kuhl,( PhD( thesis).( The( most( recent( small( molecule( therapy(tested(for(CLN1(disease(in(Ppt15/5#mice(was(a(glialKspecific(antiKinflammatory(drug(called( MW151,( which( targets( the( cytokine( cascades( associated( with( this(neuroinflammation((Macauley(et#al.,#2014),(and(has(been(shown(to(attenuate(glial(cytokine( upKregulation( in( models( of( Alzheimer( disease( (SomeraKMolina( et# al.,#2007;( Karpus( et# al.,( 2008;( Chrzaszcz( et# al.,# 2010;( Bachstetter( et# al.,# 2012).(However,( MW151Ktreatment( had( very( little( impact( upon( disease( phenotypes( in(
Ppt15/5#mice# (Macauley( et# al.,#2014),( suggesting( this( particular( compound( to( be(ineffective.((
5.5! Gene(therapy(The(principles,(advantages(and(disadvantages(of(gene(therapy(will(all(be(discussed(in( further( detail( in( Chapters( 2,( 3( and( 5.( There( are( several( reasons( why( AAVKmediated(gene(therapy(is(potentially(an(attractive(option(for(the(treatment(of(CLN1(disease.( Firstly,( unlike( all( the( other( therapeutic( approaches( discussed( in( this(section,( gene( therapy( has( the( potential( to( “cure”( the( disease( with( a( single(treatment,( provided( that( longKterm( transgene( expression( can( be( achieved( (Platt(and( Lachmann,( 2009).( By( transferring( DNA( encoding( the( missing( functional(protein(to(deficient(cells,(these(transduced(cells(will(be(able(to(produce(the(missing(protein(independently(rather(than(relying(on(exogenously(supplied(enzyme((Sands(and( Davidson,( 2006).( Secondly,( gene( therapy( approaches( take( advantage( of( the(process(of(“crossKcorrection”((Fratantoni(et#al.,#1968;(Sands(and(Davidson,(2006),(meaning( that( only( a( subset( of( cells( would( need( to( be( transduced( (Sands( and(
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Davidson,( 2006,( Neufeld,( 2004).( Finally,( by( directly( injecting( the( transgeneKexpressing( vector( into( specific( brain( regions,( the( complications( of( the( BBB( are(negated;( meaning( that( the( predominant( neuropathology( that( ultimately( causes(death(can(theoretically(be(corrected((Brooks(et#al.,#2002).(However,(more(than(20(gene(therapy(clinical( trials(have(been(carried(out( in(patients(with(different(LSDs,(and(none(so(far(have(reached(phase(III((Tomanin(et#al.,#2012).(((Intracranial( gene( therapy(was( first( attempted( in(Ppt15/5(mice(using(AAV2(vectors(injected( bilaterally( into( two( locations( in( the( forebrain,( but( this( produced( only(modest( success( (reduction( in( storage,( increase( in( brain( mass( and( cortical(thickness)( (Griffey( et# al.,# 2004),( compared( to( previous( studies( using( a( similar(vector( and( the( same( injection( sites( in( a( mouse(model( of( MPSVII( (Frisella( et#al.,#2001).(A(subsequent(study(then(found(that(targeting(the(same(AAV2(vector(to(both(the( forebrain( and( the( cerebellum( of( Ppt15/5( mice( at( the( same( time( was( more(effective,( improving( on( previous( results( with( increased( motor( function( and(decreased( seizure( activity( but( unfortunately( no( effect( on( lifespan( (Griffey( et#al.,#2006).( In(an(attempt( to( improve( the( therapeutic(outcome(of(AAVKmediated(gene(therapy,( a( secondKgeneration( AAV2/5KPPT1( vector( was( developed( and( its(intracranial(injection(led(to(modest(increases(in(longevity(as(well(as(improvements(in(brain(architecture(and(motor(function,(thus(highlighting(the(value(of( increased(PPT1( distribution( and( expression( achieved( with( such( vectors( (Macauley( et# al.,#2009).( The( advent( of(AAV( serotypes( that( can( spread( further( and( transduce( cells(more( efficiently( (Cearley( and( Wolfe,( 2006)( and( the( identification( of( key( target(areas(that(are(affected(in(the(brain((Kielar(et#al.,#2007;(Macauley(et#al.,#2009)(have(improved( the( prospect( of( effective( gene( therapy( treatment( for( CLN1( disease.(Nevertheless,( the( resulting( extension( of( lifespan( is( still( limited(with( a( period( of(
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poor(motor(capability(towards(the(end(of(life((Griffey(et#al.,#2004,(2006;(Macauley(
et#al.,#2012;(HawkinsKSalsbury(et#al.,#2013).((Despite( the( progress( being( made( for( these( therapeutic( approaches,( no( single(therapy( has( been( able( to( completely( prevent( or( vastly( improve( CLN1( disease.((Indeed,(although(some(very(positive(improvements(in(lifespan(have(been(achieved((e.g.(AAV2/5Kmediated(gene( therapy(has(been(shown(to(extend( life(span(to(~(13(months( in(PPT1Kdeficient(mice( [Macauley(et#al.,#2012]),( these(mice( still( succumb(prematurely(to(the(disease((HawkinsKSalsbury(et#al.,#2013).( It(may(be(that(simply(supplying( the(missing( enzyme( is( not( enough,( and( that( other( components( of( the(pathogenic( cascade( in( CLN1( disease( also( need( to( be( addressed.( Emerging( data(from( approaches( that( combine( more( than( one( therapy( suggest( that( these(treatments( might( be( more( effective,( either( by( targeting( different( parts( of(pathology,( or( effects( of( the( disease( in( different( parts( of( the( body( (HawkinsKSalsbury(et#al.,#2013;(Cooper(et#al.,#2015).(Such(combinatorial(approaches(have(not(yet(been(tested(clinically,(but(experimental(therapies(in(mice,(are(now(beginning(to(pave(the(way(towards(this(goal,(as(is(discussed(in(the(following(section.((
5.6! Combination(therapies(–(a(new(approach(To(date,(three(studies(have(been(published,(which(have(attempted(to(improve(the(efficacy( of( gene( therapy( for( CLN1( disease( by( combining( it( with( either( a( bone(marrow( transplant( or( with( a( small( molecule( treatment,( following( two( different(rationales.(The(first(attempt(at(gene(therapy(based(combination(therapy(for(CLN1(disease( was( carried( out( in( Ppt15/5(mice( using( BMT( and( CNSKdirected( AAV2/5Kmediated(gene(therapy((Macauley(et#al.,#2012).(At(birth,(Ppt15/5(and(wildKtype(mice(
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were(given(either( intracranial( injections(of(AAV2/5KPPT1,(or(received(BMT(alone((described( in(section(5.3(and(5.5)(or( in(combination( in(order( to(assess(whether(the( addition(of(BMT(had( any( synergistic( or( additive( beneficial( effects( on(disease(progression( and( lifespan( in( these( mice.( As( mentioned( earlier( in( this( section,(AAV2/5Kmediated( gene( therapy( significantly( improved( cortical( thickness,(decreased( storage( burden( and( glial( activation,( improved( motor( function( and(increased(lifespan((Macauley(et#al.,#2012).(However,(combining(AAV2/5(with(BMT(resulted( in( remarkably(pronounced( further( improvements( in( lifespan(and(motor(function( (Macauley( et# al.,#2012).( One( explanation( for( this( dramatic( increase( in(efficacy(may(be(that(that(BMT(had(an( immunomodulatory(effect,(which( impacted(on(the(neuroinflammatory(component(of(CLN1(disease.(Another(explanation(may(be(that(BMT(had(a(positive(effect(on(systemic(pathology,(which(together(with(the(AAV2/5KPPT1Kmediated( correction( of( CNS( pathology,( resulted( in( an( overall(synergistic(effect((Macauley(et#al.,#2012).(((The(data(from(this(study(initially(appeared(to(be(very(exciting(as(for(the(first(time,(a( significant( increase( in( lifespan( had( been( produced( in( Ppt1Kdeficient( mice((Macauley(et#al.,#2012),(meaning( that( this(combination(strategy(had( the(potential(to(be(of(substantial(clinical(interest.(Importantly(however,(the(experimental(design(lacked( a( vital( control( group( of( mice( treated( just( with( the( conditioning( dose( of(radiation( required( for( the( BMT.( Such( doses( of( radiation( have( been( reported( to(increase( transduction(by( elevating( vector( copy(number( in#vitro( (Alexander(et#al.,#1994;(Yalkinoglu(et#al.,#1988),(and(without(a( ‘radiation(only’(control(group(in(this(study,( it( is( unclear(whether( the( striking( data( collected( from( the( BMT( +( AAV2/9(treatment( group( were( due( to( additive( effects( of( BMT( or( radiation( induced(increases( in( vector( genome( level( and( subsequently( the( level( of( PPT1( activity.(
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Furthermore,( when( this( experiment( was( repeated( with( this( control( group,( the(initial(results(could(not(be(replicated(for(reasons(that(remain(unclear.((The( first( attempt( to( combine( gene( therapy( with( the( administration( of( a( small(molecule( treatment( in(Ppt15/5#mice(was( carried( out( using( CNSKdirected( AAV2/5Kmediated( gene( therapy( alone,( and( in( combination(with( systemic( delivery( of( the(lysosomotropic(PPT1(mimetic(phosphocysteamine( (described( in(section(5.4(and(
5.5)( (Roberts( et# al.,# 2012).( The( reasoning( behind( this( study( was( that(phosphocysteamine( treatment( would( complement( the( levels( of( AAV2/5Kderived(levels(of(PPT1(activity(in(the(regions(of(the(brain(where(this(was(subKtherapeutic,(effectively( boosting( the( overall( level( of( PPT1( activity( throughout( the( brain((Roberts( et# al.,# 2012).( As( expected,( CNSKdirected( gene( therapy( resulted( in(increased(PPT1(activity(and(was(able(to(decrease(brain(atrophy((until(7(months),(improve(brain(weight,( reduce( the(neuroinflammatory(response(and(clear(storage(material,(as(well(as( improving(motor( function(and( lifespan((Roberts(et#al.,#2012).(However,( the( addition( of( phosphocysteamine,(which( on( its( own( resulted( in( only(very( small( incremental( improvements( in( these( biochemical( and( histological(responses,(had(no(effect(on(motor(function(and/or(lifespan((Roberts(et#al.,#2012).(Moreover( phosphocysteamine( treatment( alone( did( not( improve( the( biochemical(and(histological(effects(associated(with(AAV2/5Kmediated(gene(therapy(or(lifespan(but(did(elicit(additional(improvements(in(motor(function((Roberts(et#al.,#2012).(The(combination( of( AAV2/5Kmediated( gene( therapy( and( phosphocysteamine( did( not(have(pronounced(positive(effects(on(any(of(these(outcome(measures.(However,(the(fact(that(this(drug(was(apparently(safe(and(did(not(reduce(the(effects(of(the(gene(therapy,(together(with(its(improvements(in(motor(function(suggest(this(compound(may(yet(have(some(limited(value(as(a(therapeutic(approach.(While(gene(therapy(for(
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CLN1(disease(is(yet(to(reach(clinical(trial,(a(clinical(trial(in(CLN1(patients(using(oral(
Cystagon®( and( mucomyst( showed( some( limited( benefits((https://clinicaltrials.gov/ct2/show/NCT00028262;( Levin( et#al.,#2014),(which(may(ultimately(warrant(clinical(combination(therapy(together(with(gene(therapy,(if(this(is(itself(approved(for(clinical(testing(in(the(future.((Another(combinatorial(approach(that(has(been(tested( in(Ppt15/5#mice( involves( the(use(of(AAV2/5Kmediated(gene( therapy( together(with( the( antiKinflammatory(drug(MW151((described(in(section(5.4(and(5.5)((Macauley(et#al.,#2014).(As(mentioned(in(
section( 3.1.d,( PPT1Kdeficient(mice,( like( CLN1( patients,( display( pronounced( glial(activation( (Kielar( et# al.,#2007;( Macauley( et# al.,#2012),( which( may( play( a( role( in(disease(pathogenesis(and(contribute(to(neuron(loss.(Therefore,(by(simultaneously(targeting( the( upKregulation( of( proKinflammatory( cytokines( as( a( result( of( gliosis((already( mentioned( in( section( 5.4),( as( well( as( directly( addressing( the( PPT1(deficiency( in( the(CNS,( the( effects( of( gene( therapy( alone(might( be( enhanced(with(MW151( treatment( (Macauley( et#al.,#2014).( When( Ppt15/5#mice( were( treated( with(CNSKdirected( AAV2/9KPPT1( alone,( supraphysiological( levels( of( PPT1( enzyme(activity(were(observed(giving(rise(to(a(reduction(in(brain(atrophy(and(increases(in(regional(volumes(together(with(a(decrease(in(astrocytosis(and(microglial(activation(in( key( brain( areas( (hippocampus,( cerebellum,( cortex( and( thalamus).( These(neuropathological(effects(were(accompanied(by(improvements(in(motor(function,(a(reduction(in(seizure(frequency(and(an(extension(of(lifespan((Macauley(et#al.,#2014).((However,( for( the(most( part,( MW151( did( not( have( any( additive( affects( on( these(outcome(measures(but(did(give(rise(to(slightly(improved(motor(performance((that(was( no( longer( present( at( 10(months)( and(moderately( prolonged( life( expectancy((Macauley( et#al.,#2014).( Although(MW151( treatment( produced( only( intermediate(
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effects(upon(cytokine( levels,(whether(alone(or( in(combination(with(gene(therapy,(this( antiKinflammatory( drug( was( by( itself( able( to( significantly( reduce( seizure(activity((Macauley(et#al.,#2014).(((As(will(be(discussed(in(Chapter(5,(the(attempts(at(combination(treatment(for(CLN1(disease( that( have( been( made( so( far,( have( not( been( particularly( successful(compared(to(single(treatment.(Nevertheless,(these(studies(have(helped(to(move(us(closer(towards(the(development(of(other(combination(treatments(that(may(prove(to(be(more(successful.(Although(we(have(concentrated(on(combination(therapy(for(CLN1(disease(here,(the(same(principle(of(combining(treatments(in(order(to(achieve(better( therapeutic( efficacy( could( be( applied( to( all( of( the( NCLs,( especially(transmembrane(proteinKdeficient( forms( like(CLN3,(which,( as(will(be(discussed( in(the(next(section,(are(categorically(more(difficult(to(treat.((
5.7! Treatment(for(CLN3(disease(Having( considered( combination( therapies( for( the( treatment(of(CLN1(disease(and(other( enzymeKdeficient( forms( of( NCL,( we( still( struggle( to( find( effective( single(treatments( for( transmembrane(proteinKdeficient( forms(of(NCL,( like(CLN3(disease((Cooper,( 2008).( As( discussed( in( section( 4.2,( the( normal( function( of( the( CLN3(protein( is( still( not( understood,( making( it( difficult( to( devise( mechanistically(targeted(therapies((Cooper,(2008;(Haskell(et#al.,(2000;(Mao(et#al.,(2003),(and(this(is(further( compounded( by( the( fact( that( CLN3( is( a( transmembrane( protein( as(discussed(in(section(5.(Instead,(therapeutic(efforts(have(been(focused(primarily(on(dealing(with(the(pathological(effects(of( the(disease((Cooper(et#al.,#2008).(This(has(involved( using( animal( models( (Pearce( and( Serman,( 1998;( Pearce( et# al.,# 1999;(
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Gachet( et#al.,#2005;( de( Voer( et#al.,#2005;( Michison( et#al.,#Katz( et#al.,#1999,( 2007;(Cotman(et#al.,#2002;(Eliason(et#al.,#2007),(and(clinical(data(from(human(patients(to(investigate( the( consequences( of( Cln3/CLN3#mutations( (described( in( section( 3.1(and(4.2),(and(subsequently(trying(to(block(these(effects(as(will(be(explained(in(the(following(sections.((
a)! Autoimmunity(in(JNCL(The(analysis(of(Cln3(mutant(mice(revealed(that(there(is(an(autoimmune(response(early( in( disease( progression,( which( appears( to( be( specific( to( this( form( of( NCL((Chattopadhyay,( 2002a,( 2002b).( Immunoglobulins( raised( against( multiple( brain(autoantigens(have(been(implicated(in(this(autoimmune(response((Lim(et#al.,#2006),(but(the(most(commonly(cited(are(those(against(glutamate(decarboxylase((GAD65)((Finn( et# al.,# 2011;( Kovacs( et# al.,# 2006;( Herrmann( et# al.,# 2008;( Chattopadhyay,(2002b).(Interestingly,(these(immunoglobulins(have(been(shown(to(breach(the(BBB(to(gain(access(to(the(CNS(before(being(deposited(there,(suggesting(that(the(BBB(is(phenotypically(leaky(in(CLN3(disease((Lim,(2006,(2007).(Paradoxically,(this(may(be(advantageous(for(drug(delivery,(which(is(typically(complicated(by(the(presence(of(an( impermeable( BBB( (Cooper( et# al.,# 2008).( Although( the( exact( role( of(autoimmunity( in( CLN3( disease( pathogenesis( remains( ambiguous,( therapeutic(strategies( that( target( this( autoimmune( component( have( produced( promising(results( in( mice( (Seehafer( et# al.,( 2011).( These( effects( have( been( considered(sufficiently( positive( to( justify( a( phase( II( trial( for( the( immunosuppressant(Mycophenolate(mofetil,(which(is(currently(underway(at(the(University(of(Rochester((https://www.clinicaltrials.gov/ct2/show/NCT01399047).(((
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As(mentioned(in(section(5.6,(combination(treatments(may(be(a(sensible(approach(for( therapeutic(use( in(CLN3(disease,( and( this(approach(has(already(started( to(be(explored( by( testing( different( combinations( of( antiKinflammatory( and(neuroprotective( drugs,( with( one( of( these( combinations( showing( partial( positive(effects( upon( behavioural( and( histological( outcomes( (Tarczyluk( and( Cooper,(personal(communication).((
b)! Excitotoxicity(in(CLN3(disease(Excitotoxicity,( mediated( through( the( αKaminoK3KhydroxyK5KmethylK4Kisoxazolepropionic( acid( (AMPA)( or( NKmethylKDKaspartate( receptor( (NMDA)(glutamate(receptor,(may(also(contribute( to(neuron( loss( in(CLN3(disease((Cooper,(2008).(Autoantibodies(against(GAD65( tamper(with( the( function(of(GAD65,(which(normally( converts( glutamate( to( gammaKaminobutyric( acid( (GABA)(and( results( in(elevated(levels(of(glutamate(and(reduced(levels(of(GABA(within(the(CLN3(disease(brain( early( in( disease( progression( (Chattopadhyay,( 2002a;( Pears,( 2005).( ( This(glutamate( appears( to( accumulate( presynaptically,( which(may( plausibly( result( in(damage( of( postKsynaptic( neurons( (Chattopadhyay,( 2002a;( Cooper,( 2008).( To(investigate( whether( this( excitotoxic( effect( could( be( pharmacologically( blocked(using( glutamate( receptor( antagonists,( it( was( first( important( to( identify( which(glutamate( receptors(may(be( involved( (Cooper(et#al.,#2008).( In#vitro#studies( using(cerebellar(cultures(from(Cln35deficient(mice,(showed(that(cerebellar(cultures(were(sensitive( to( overKactivation( of( AMPA( receptors,( but( not( NMDA( type( glutamate(receptors(and(this(could(be(blocked(using(AMPA/kainite(receptor(antagonist(GYKI(52466( (Kovács( et# al.,# 2006).( Interestingly,( this( was( not( observed( in( cortical(cultures(suggesting(these(excitotoxic(effects(are(specific(to(the(cerebellum((Cooper(
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et#al.,#2008),(which(is(consistent(with(in#vivo#studies(implicating(the(cerebellum(as(a( site( for( early( neurodegeneration( (Weimer( et# al.,# 2009).( Following( these(experiments,( further( studies# testing( the( effects( of( the( nonKcompetitive( AMPA(receptor( antagonist,( EGISK8332,( on( rotarod( performance( (measure( of( cerebellar(motor( coordination( [Autti( et#al.,#1996])( in( Cln35deficient(mice( provided( the( first(evidence(for(a(drugKmediated(improvement(in(a(disease(relevant(phenotype(in(this(model( of( CLN3( disease( (Cooper( et# al.,#2008).( Building( on( this( data,( EGISK8332(administered(at( two(different(ages( revealed( that(while( the(attenuation(of(AMPAKtype(glutamate(receptor(activity( in(1(month(old(Cln3Kdeficient(mice(resulted( in(a(immediate( improvement(of( their(motor( skills,( the( temporary( inhibition(of(AMPA(receptors(in(6(–(7(month(old(Cln3Kdeficient(mice(induced(a(delayed(but(prolonged(improvement( in( motor( performance( (Kovács( et# al.,( 2011).( Interestingly,( acute(inhibition( of( NMDAKtype( glutamate( receptors( by( memantine( resulted( in( an( age(specific((ineffective(at(1(month(of(age)(motor(improvement(in(6(K(7(month(old(Cln3(mutant( mice( (Kovács( et# al.,( 2012),( identifying( NMDA( receptors( as( a( valid(therapeutic( target( for( CLN3( disease( after( all.( However,( with( little( effect( on(neuropathology(and(only(minor(improvements(in(motor(function,(it(remains(to(be(seen(whether(such(moderate(effects(are(worth(pursuing(clinically.(
(
c)! Gene(therapy(for(CLN3(disease?(As( will( be( discussed( in( more( detail( in( Chapter( 3,( gene( therapy( has( remained(largely(unexplored( for( the( transmembrane( forms(of(NCL.(This( is( largely(because(the( defective( protein( resides( within( an( intracellular( membrane( and( therefore,(cannot( be( secreted( to( “crossKcorrect”( neighbouring( cells( (Sinntola( et# al.,#2006).(However,( evidence( is( beginning( to( emerge( that( this( approach( may( not( exclude(
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CLN3(disease(after(all( (Sondhi(et#al.,#2014).(A( logical(deduction(would(be(that( for(gene(therapy(to(be(effective(for(a(transmembrane(defect,(the(missing(gene(would(have(to(be(transferred(to(each(cell(directly.(However,(gene(therapy(approaches(for(CLN3( also( need( to( consider( the( potential( toxic( effects( of( overKexpressing( CLN3((Tuxworth( et#al.,( 2009),( as( discussed( in( section( 3.1.a( of( Chapter( 3.( Therefore,(unlike( the( enzymeKdeficient( forms( of(NCL( for(which(wider( transduction( leads( to(better(pathological(and(behavioural(outcomes( (Sondhi(et#al.,#2010),(gene( therapy(for( CLN3(would( require( careful( control( and( it( is( possible( that( at( low( expression(levels,( this(approach(could(positively( impact( the(disease.(Furthermore,(as( “crossKcorrection”(restricts(the(distribution(of(the(CLN3(protein,(it(is(important(to(identify(the(most(advantageous(injection(sites,(i.e.(thalamus,(cortex(and(cerebellum,(where(neuronal(loss(and(glia(activation(is(localized((Pontikis(et#al.,#2004,(2005;(Weimer(et#
al.,#2009),(all(of(which(will(be(discussed(in(the(next(chapter.((
6! Pathology(outside(of(the(brain.((The(focus(of(much(of(this(chapter(has(been(on(neuropathology(and(the(therapeutic(interventions,( which( might( prevent( or( reverse( it.( ( However,( although( the( NCLs(mainly(affect( the(brain,( the(defective(genes(are(expressed( in(all( cells(of( the(body((Haltia,( 2003)( and( storage(material( also( accumulates( within( the( viscera( (Haltia,(2003;( Cooper,( 2003;(Mole( et#al.,#2005;( Palmer( et#al.,#2013;( Jalanko( and( Braulke,(2009).( Therefore,( there( are( likely( to( be( undetected( pathological( and( functional(consequences( in( nonKCNS( tissue,( as( in( other( LSDs,( which( often( display( both(neurological( and( systemic(dysfunction.(As(mentioned( in(section(4.2,( CLN3(has(a(cardiac( involvement(and( this( is(also( true(of(Kufs(disease( (Armstrong(et#al.,#1986;(Sakajiri( et# al.,#1995;( Hofman( et# al.,#2001;( Fealey( et# al.,#2009;( Østergaard( et# al.,#
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2011),(which(will(be(discussed(in(much(more(detail(in(Chapter(4.(Therefore,(whilst(finding( treatments( for( the( neurological( aspects( of( CLN3( is( paramount,( it( is( also(important(to(consider(treating(the(visceral(aspects(of(disease(if(we(are(to(achieve(clinical( success( in( the( longKrun.( For( most( NCLs,( the( severity( of( neuronal(dysfunction(takes(precedence(over(any(systemic(dysfunction,(which(doesn’t(appear(to(manifest(symptomatically((Schulz(et#al.,#2013).(This(is(not(to(say(however,(that(systemic(pathology(does(not(have(an(effect(on(overall(disease(or(that(it(might(not(become( clinically( significant( and( life( threatening( if( the( CNS( can( be( successfully(treated( (Wong(et#al.,#2010;(Cooper(et#al.,#2015).(Thus,( it( is( important( to( turn(our(attention(towards(the(systemic(disease(and(devise(therapies,(which(treat(the(whole(body(and(not(just(the(brain(and(this(topic(will(be(the(focus(of(Chapter(4.(
7! Aims(of(thesis(and(hypotheses(
 The(NCLs(are(a(devastating(group(of(diseases( for(which( there(are(no( treatments.(This( thesis(aims(to(explore(novel(ways( to(extend(the(application(of(gene( therapy(for( treating( two( different( forms( of( NCL:( a( soluble( lysosomal( enzyme( proteinKdeficient(form((CLN1(disease)(and(a(transmembrane(proteinKdeficient(form((CLN3(disease).((This(thesis(also(aims(to(investigate(cardiac(pathology(in(CLN1(and(CLN3(disease(and(consider(how(this(might(be(relevant( to( the(development(of(potential(therapies.(((We(hypothesised(that(gene(therapy(may(be(a(possible(treatment(for(CLN3(disease(but( that(practical( issues( surrounding( the( response( to( the(vector( and(CLN3(overKexpression( would( need( to( be( addressed.( We( also( hypothesised( that( identifying(sites(of(pathology(outside(the(CNS(would(be(important(for(targeting(therapies,(and(given(existing(clinical(data(chose(to(analyse(cardiac(tissue(in(our(mouse(models(of(
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This!chapter!collectively!outlines! in!detail!all! the!materials!and!methods!relevant!to!each!individual!results!chapter!with!the!ingredients!for!all!solutions!included!in!the!Appendices,(where!appropriate.! In!addition!each!results!chapter! includes!an!additional! methods! section,! which! briefly! outlines! the! specific! experimental!approach!employed!in!each!chapter!using!the!detailed!techniques!described!here.!
(
1.!Mice(Four! different! genotypes! of! mice! were! used! in! this! study,! including! one! mouse!model!of!CLN1!disease,!two!different!CLN3!disease!mouse!models!and!a!common!control! strain.!A! summary!of! each! study! and! the! corresponding!mice! (and! ages)!used! are! included! in!Table( 6! (below).! All! animal! housekeeping! and! procedures!were! carried! out! in! accordance!with! the!UK! Scientific! Procedures! (Animals)! Act!(1986)! under! the! authority! of! Project! Licences! 70/6567! and! 70/7364,! or! for!procedures!performed!by!collaborators!outside!the!UK,!under!the!guidance!of!the!corresponding!local!institutional!committee!on!animal!use.!!
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!(BSU)!of!the!James!Black!Centre!(JBC)!at!The!Institute!of!Psychiatry,!Psychology!&!Neuroscience! (IoPPN),! King’s! College! London! (KCL),! UK.! Typically,! Cln3%/%! mice!have!a!life!expectancy!of!approximately!22!months!(Mitchison!et)al.,!1999;!Cooper!
et)al.,!2006).!!
!
To! investigate! the! feasibility! of! CLN3! gene! therapy! for! the! treatment! of! CLN3!disease! (Chapter( 3),(we! used!mice! at! 3!months! of! age! as! shown! in!Table( 6.! 3!month!old!Cln3%/%!mice!are!asymptomatic!with!little!neuropathology!and!represent!a! preSsymptomatic! stage.! Accumulation! of! storage! material! can! be! detected! in!multiple! brain! regions! including! the! striatum! (caudate! putamen,! CPu),! but!astrocytosis! and! microglial! activation! is! negligible! and! there! is! no! neuron! loss!(Mitchison!et)al.,)1999).!Therefore,!at!this!age,!we!were!able!to!assess!the!effects!of!the!experimental!vectors!described! in!section(3.1(on!mice!with!no!overt!disease!phenotype!and!compare!this!to!older!mice.!
!To!identify!cardiac!pathology!in!a!mouse!model!of!CLN3!disease!in!Chapter(5,!mice!at!12!and!18!months!of!age!were!used.!12!month!old!Cln3%/%!mice!show!moderate!neurological!symptoms!and!neuropathology!and!represent!animals!at! the!middle!stage! of! disease,! while! 18! month! old! Cln3%/%! mice! show! moderate! to! severe!neurological! symptoms!and!neuropathology!and!represent!mice!approaching! the!end! stage! of! disease! (21! months).! Although! neuropathology! can! be! detected! at!both!these!stages,!little!characterisation!of!visceral!pathology!has!been!conducted!in! these!mice.! Therefore,! we!wanted! to! assess! whether! these! neuropathological!changes!are!accompanied!by!a!cardiac!phenotype.!
!
! 129!
Although!Cln3%/%!mice!are!not! faithful! genetic! replicas!of!CLN3!disease,! they!have!been! extensively! characterised! and! display! the! typical! neuropathological!phenotypes! of! CLN3! disease! and! are! considered! a! robust!model! of! this! form! of!NCL.!However,!to!allow!comparisons!between!different!models!of!CLN3!disease!a!small! cohort! of!Cln3! ‘knockSin’!mice! (Cln3Δex7/8)!were! included! in! the! CLN3! gene!therapy!study!(Chapter(3).!
!
1.2! Cln3Δex7/8(mouse(model(for(CLN3(disease(Most! cases! of! CLN3! disease! are! caused! by! the! recessive! inheritance! of! a! ~1! kb!deletion!in!the!CLN3!gene!(The!International!Batten!Disease!Consortium,!1995).!To!more!precisely!recreate!this!mutation,!a!Cln3Δex7/8)mouse!model!was!generated!by!introducing!an! identical!genomic!DNA!deletion! into! the!murine!CLN3!homologue!(Cln3).! This! was! accomplished! by! replacing! exons! 7,! 8! and! flanking! nonScoding!DNA!with!a!neo! cassette!(Cln3Δex7/8)!as!described!previously!by!Dr!Susan!Cotman!and!colleagues!(Cotman!et)al.,!2002).!These!mice!were!backcrossed!for!more!than!10!generations!onto!the!C57/bl/6J!background!at!Massachusetts!General!Hospital,!Boston,!MA.! !Due!to!biosecurity! issues,! these!mice!were!rederived!at! JAX!Labs! in!Bar!Harbor,!ME.!Cln3Δex7/8)mice!were!supplied!as!heterozygous!breeding!pairs!and!maintained! in! the! BSU! of! the! JBC.! The! Cln3Δex7/8)mice! generally! have! a! similar!lifespan! as!Cln3%/%!mice! of!~22!months.!Due! to! funding! and! logistical! constraints!these! mice! were! not! available! in! sufficient! quantities! to! incorporate! the! longer!survival! times! needed! for! the! CLN3! gene! therapy! or! cardiac! pathology! studies.!Therefore,! only! a! small! subset! of! Cln3Δex7/8)mice! was! used! in! Chapter( 3( as! a!comparison!to!investigate!the!feasibility!of!gene!therapy!for!the!treatment!of!CLN3!disease!at!7.5!months!of!age,!as!shown!in!Table(6.!7.5!month!old!Cln3Δex7/8)mice!are!
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asymptomatic! but! display!mild! neuropathology! and! represent!mice! at! the! early!stage! of! disease! progression! (Pontikis! et)al.,)2005).!Cln3Δex7/8)mice! have! not! been!extensively! characterised! at! 7.5!months! of! age,! however,! as! these!mice! exhibit! a!progressive! neurological! disease,! the! approximate! degree! of! pathology! can! be!surmised!from!their!characterisation!at!1!and!10!months!(Cotman!et)al.,)2002).!At!1!month!of!age!storage!material!is!present!throughout!the!brain!and!at!10!months!of!age!reactive!gliosis!(without!morphological!changes)!occurs!in!the!motor!cortex,!cerebellum!and!midbrain!and!some!motor!impairment!is!observed!(Cotman!et)al.,)2002).! Therefore,! at! 7.5! months! of! age,! striatal! astrocytosis! and! microglial!activation!is!most!likely!to!be!minimal!with!limited!neuron!loss!(instead!selective!in!other!regions!like!the!cortex)!if!any.!The!experimental!vectors!were!injected!into!the! right! striatum! as! described! in! section( 3.2.(Therefore,! at! this! time! point! we!were!able!to!compare!the!effects!of!the!experimental!vectors! in!mice!in!the!early!stage! of! disease! compared! to! mice! at! 3! months! of! age! with! no! overt! disease!phenotype!without!the!effects!of!the!vectors!being!obscured!by!existing!pathology!(Mitchison!et)al.,)1999;!Cotman!et)al.,)2002;!Pontikis!et)al.,)2004,!2005).!!
!
1.3! Ppt1///(mouse(model(for(CLN1(disease(Originally,! the! Ppt1Sdeficient! mice! used! in! this! study! were! generated! as! null!mutants! by! targeted! disruption! of! the! Ppt1! gene.! They! were! created! by! Dr!Praveena! Gupta! and! colleagues! at! The! Hamon! Center! for! Therapeutic! Oncology!Research,! USA! by! replacing! a! portion! of! exon! 9,! the! last! exon! in! the! coding!sequence,!with!a!neo! cassette!containing!an! inSframe!stop!codon,!resulting! in! the!premature!termination!of!the!Ppt1!polypeptide!as!described!previously!(Gupta!et)
al.,! 2001).! These! mice! were! subsequently! bred! onto! C57/bl/6J! mouse!
! 131!
backgrounds.!Professor!Mark!Sands!at!Washington!University!Medical!School!(St.!Louis,!MO,!USA),!kindly!supplied!the!Ppt1%/%!mice!used!in!this!particular!study.!The!life! expectancy! of! these! mice! is! approximately! 8.5! months! and! the! onset! and!progression! of! pathological! changes! that! take! place! have! previously! been! well!characterised!(Kielar!et)al.,!2007).!In!this!thesis,!we!used!mice!at!5!and!7!months!of!age!to!investigate!the!impact!of!AAV!+!ERT!combination!therapy!on!the!thalamus!and!cortex!of!Ppt1%/%!mice!(Chapter(5).!Ppt1%/%)mice!at!5!and!7!months!of!age!both!represent! relatively! severe! (5!month)! and! near! end! stage! of! disease! (7!months)!(life! expectancy! 8.5! months! of! age).) In! 5! month! old! Ppt1%/%! mice,! there! is! wideSspread! accumulation! of! autofluorescent! storage! material! throughout! the! brain,!particularly! in! the! primary! somatosensory! barrel! field! cortex! (S1BF)! and! the!ventral! posteromedial! nucleus/ventral! posterolateral! (VPM/VPL)! nuclei! of! the!thalamus!(Kielar!et)al.,)2007).!Pronounced!astrocytosis!can!be!detected!across!all!laminae!of! the!primary!motor!cortex!(M1),!but!not! the!S1BF,!and!within!discrete!thalamic!nuclei! including! the!VPM/VPL.!There! is! also!more!microglial! activation,!but!this!is!a!lot!more!subtle!and!prominent!only!in!the!deeper!laminae!of!the!cortex!(Kielar!et)al.,)2007).!Neuron! loss! is! apparent! in! the!VPM/VPL!of! the! thalamus!as!well!as!a!significant!loss!of!cortical!granule!and!interneuron!populations!within!the!primary!visual!cortex!(V1)!but!at!this!stage,!not!in!the!S1BF!(Kielar!et)al.,)2007).!!As!such,! this! time! point! provides! obvious! disease! phenotypes!within! the! VPM/VPL!and! S1BF! against!which! the! efficacy! of! treatments! can! be!measured! and! subtler!changes!observed!(Kielar!et)al.,)2007).!!
!
In! 7! month! old! Ppt1%/%! mice,! glial! activation! and! neuron! loss! has! become! more!severe! and! widespread! with! astrocytosis! intensifying! within! the! cortex! and!
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thalamus!and! further! thalamic!nuclei!displaying!astrocytosis! (Kielar!et)al.,)2007).!Microglial! activation! is! more! pronounced! and! accompanied! by! morphological!changes! and! microglia! are! distributed! within! both! deeper! and! more! superficial!laminae! of! various! cortical! subfields! now! including! S1BF! and! is! even! more!pronounced!in!individual!thalamic!nuclei!including!VPM/VPL!(Kielar!et)al.,)2007).!At! 7! months,! gliosis! is! even! more! intense! and! there! are! fewer! neurons! in! the!VPM/VPL!as!well!as!other!thalamic!nuclei!and!the!number!of!granule!neurons!and!interneurons! in! the! S1BF! are! also! reduced! (Kielar! et) al.,)2007).! ! Therefore,! by!analysing!the!VPM/VPL!and!S1BF!regions!at!this!stage!of!disease,!the!upperSlimit!of!therapeutic!power!can!be!evaluated.!!
!





1.4! Wild@type(mice(for(controls(All! wildStype! mice! used! in! this! study! were! animals! bred! on! a! C57/bl/6J!background!and!were!made!available! either!by!breeding!heterozygous!Cln3+/%! or!
Ppt1+/%! mice! or! by! purchasing! them! commercially! via! Charles! River!(http://www.criver.com/find%a%model).! The! average! survival! of! these! mice! is!between!27S28!months!(Crawley!et)al.,!2007).! !Mice!were!bred!and!housed!either!in! our! own! animal! facility! at! King’s! College! London,! or! at! our! collaborators!facilities! in! Washington! University! and! the! tissues! (brains! and! spinal! cords)!subsequently!shipped!to!us!for!histological!analysis.!
!
2! Primary(neuronal(cultures(
Before! carrying!out! a! large! scale! in!vivo! investigation! into! the! feasibility! of!CNSSdirected!AAVSmediated!Cln3/CLN3! gene! therapy! for! CLN3! disease! in!Chapter(3,!we!designed!a!series!of!pilot!experiments.!The!purpose!of!these!experiments!was!to! first! determine! a)!what! cell! types! the! vectors! are! capable! of! transducing! b)! a!suitable!multiplicity! of! infection! (MOI)! to!use! and! c)!whether! there!was! any! cell!death! associated! with! vectorSdriven! gene! expression.! Recombinant! adenoSassociated!virus!vectors! (rAAV)! can! transduce! cells! of! the!CNS! resulting! in! longSterm!gene!expression!(Bartlett!et)al.,)1998,!Xiao!et)al.,)1997;!Wu!et)al.,)1998;!Lo!et)
al.,)1999,!McCown!et)al.,)1996,!1999,!reviewed!in!McCown,!2005).!The!tissue!of!the!CNS!is!heterogeneous!and!consists!of!a!number!of!different!cell!types!and!studies!have!shown!that!different!AAV!serotypes!have!different!transduction!efficacies!and!cellStype! tropisms!when! administered! to! the! brain! (Cearley! and!Wolfe,)2006).! It!has! been! reported! in! previous! studies! that! AAV2/9! viralSmediated! vectors!
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predominantly! transduce! cortical! neurons! and!occasionally! astrocytes! (Aschauer!
et) al.,)2013;! reviewed! in! Weinberg! et) al.,)2013).! To! determine! which! cell! types!AAV2/9! transduces! in) vitro,! we! infected! E15S17! striatal! neuronal! cultures! with!each!of!the!vectors!described!in!section(3.1.!We!chose!to!infect!striatal!neurons!in!order! to! predict! transduction! efficacy! in)vivo! following! vector! injections! into! the!striatum! as! described! in! section( 3.2.! Many! studies! have! taken! advantage! of!recombinant!viral!vectors!derived!from!AAV!as!a!tool!for!gene!delivery.!The!ability!of!AAV!viral!vectors!to!deliver!a!gene!of!interest!to!a!specific!cell!type!depends!not!only!on!the!particular!AAV!serotype!but!also!the!dose!at!which!it!is!administered.!The! multiplicity! of! infection! (MOI)! is! the! term! used! to! describe! the! ratio! of!infectious! virions! per! cell! in! culture! and! is! used! to! calculate! the! dose! of! vector!needed!to!transduce!a!particular!density!of!cells!(Ellis!et)al.,)2013).!To!determine!the!MOI!needed!for!efficient!vector!transduction!in!cultured!neuronal!cells,!a!range!of!MOI! values!were! used! to! infect!wildStype! and!Cln3%/%! E15S17! striatal! neuronal!cultures! (MOI! =! 100,! 000! (100k),! 10,000! (10K),! 1,000! (1K),! 100! and! 10).! As!described!in!section(3.1,(the!vectors!used!in!this!study!include!a!cytomegalovirus!(CMV)! promoter,! which! has! been! shown! to! achieve! rapid! and! ubiquitous!expression! of! transgenes! upon! cell! transduction! (Kaplitt! et)al.,)1994;! Gray! et)al.,)2011).! To! assess! whether! vector! expression! under! this! promoter! had! any!associated! cell! death! at! these! MOI’s,! we! carried! out! LIVE/DEAD®! staining!experiments!described!in!section(6.8.!
!
!Striatal! neurons!were! generated! from!wildStype! E15S17! embryos! under! the! UK!Animal!Scientific!Procedures!Act!(1986)!(Project!Licenses!70/6567!and!70/7364).!Whole! litters! were! collected! from! timeSmated! pregnant! females! following! CO2!
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euthanasia! followed! by! cervical! dislocation.! The! striatum! of! individual! embryos!was!dissected!out!in!Hanks’!Balanced!Salt!Solution!(HBSS)!(Gibco®!media,!Thermo!Fischer! Scientific,! Loughborough,! UK)! then! incubated! in! trypsinS!ethylenediaminetetraacetic! acid! (EDTA)! (0.5! mg/ml,! SigmaSAldrich,! Gillingham,!UK)!for!5!minutes!at!37°C!followed!by!the!addition!of!an!equal!volume!of!trypsin!inhibitor! (0.5! mg/ml,! SigmaSAldrich).! The! trypsinised! tissue! was! dissociated! by!passing!3! S! 5! times! through! a! 21! g! then! a! 23! g! needle! using! a! 1!ml! hypodermic!syringe.!After!washing!twice!in!HBSS!(by!centrifugation!at!900!rpm!for!5!minutes)!cells!were!reSsuspended! in!modified!Sato’s!medium!(see!Appendices(2.1( for! full!recipe)!and!plated!onto!preSprepared,!dried!polySDSlysine!(PDL,!25!μg/ml,!SigmaSAldrich)! coated! 13! mm! glass! coverslips! that! had! been! placed! in! 24! wellSplates!(Corning®)Costar®,!SigmaSAldrich)!at!a!density!of!2!x!105!cells/well!in!50!µl!drops.!After! leaving! cells! to! attach! to! the! coverslips! for! 1! hour! at! 37°C! in! a! humidified!incubator! (5%! CO2),! 0.5!ml! of!modified! Sato’s!medium!was! added! to! each!well.!Cultures!were! then! incubated!overnight!at!37°C.!The!next!day!half!of! the!culture!medium!was! replaced!with! fresh!medium.! On! day! 3,! 4! coverslips!were! infected!with!the!vector!and!then!on!day!6!they!were!given!a!complete!media!change!with!modified!Sato’s!medium.!On!day!7,!cells!were! treated!with!a!LIVE/DEAD®! fixable!cellular! marker! conjugated! to! a! red! (excited! with! 488! nm! laser,!excitation/emission! 595/615)! fluorochrome! (Invitrogen! [Thermo! Fisher!Scientific],! Loughborough,! UK:! Cat.! L23102)! and! fixed! in! 4%! PFA! for!immunocytochemistry!as!described!in!section(6.8.!(
(
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3! CNS@directed(AAV@mediated(CLN3(gene(therapy(AAVSmediated!gene!transfer!for!the!treatment!of!CLN2!disease!has!been!used!as!an!experimental!therapy!for!human!subjects!(Crystal!et)al.,)2004;!Worgall!et)al.,)2008)!and! preSclinical! studies! in! mouse!models! of! CLN1! disease! have! been! promising!(Griffey! et) al.,)2004,! 2005,! 2006).! However,! relatively! little! is! known! about! the!safety! or! efficacy! of! AAVSmediated! gene! therapy! in! CLN3! disease.! Therefore,! in!
Chapter(3,(we!investigated!the!impact!of!AAVSmediated!gene!therapy!on!the!brain!of!Cln3Sdeficient!mice!and!the!procedures!included!in!this!section!pertain!to!these!studies.(The!cohorts!of!mice!used! for! this!study! included:!1))Cln3%/%!and!wildStype!mice!injected!at!3!months!of!age!and!sacrificed!2!months!after!injection!2)!Cln3%/%!and!wildStype! mice! injected! at! 3! months! of! age! and! sacrificed! 6! months! after!injection)3)!Cln3%/%!and!wildStype!mice!injected!at!7.5!months!of!age!and!sacrificed!2!months!after! injection!4))Cln3%/%! and!wildStype!mice! injected!at!7.5!months!of!age!and!sacrificed!6!months!after!injection!and!an!additional!5))Cln3Δex7/8)mice!group!of!mice! injected! at! 7.5! months! of! age! and,! sacrificed! 2! months! after! injection.! As!discussed!in!section(1.1(and!1.2(Cln3%/%!and!Cln3Δex7/8)mice!have!been!characterised!at! various! ages! throughout! their! lifespan.! Unlike! Ppt1%/%) mice,! the! onset! and!progression!of!pathological!phenotypes!in!these!mice!are!more!protracted!with!no!obvious!gliosis!or!neuron!loss!until!10!S!12!months!of!age,!reflecting!the!difference!between! CLN1! and! CLN3! disease.! Therefore,! these! timeSpoints! were! chosen! to!assess!how!the!effect!of!the!vectors!may!change!over!time!during!the!early!stages!of! disease.! Three! different! vectors! expressing! eGFP! alone,! human! CLN3! and! the!murine! CLN3)homologue! Cln3! were! produced! by! our! collaborators! at! UCL! and!injected!into!the!right!brain!hemisphere!of!the!5!different!cohorts!of!mice!(n!=!5!S!6)!(Figure(9).!!
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To! assess! the! glial! responses! to! these! vectors! and! or! vectorSdriven! transgene!expression!and!the!effect!on!neuron!number,!two!important!control!groups!were!included!in!this!study!as!a!result!of!our!in)vivo)pilot!work,!outlined!in!section(2.4(of!
Chapter(3).!These!were!1)!WildStype!mice!that!underwent!shamSoperated!surgery!(no!fluid!injected)!to!control!for!the!mechanical!trauma!created!by!the!needle!and!2)! WildStype! mice! that! received! a! vehicle! only! injection! of! phosphateSbuffered!saline! (PBS)! to! control! for! the! pressure! imposed! upon! the! brain! as! a! result! of!injecting! a! volume! (1!µl)! into! it.! ShamSoperated! and! vehicleSinjected!mice!were!sacrificed!2!or!6!months!after!injection!and!analysed!alongside!the!vectorSinjected!mice! sacrificed! at! the! same! time! point! using! the! various! histological! and!microscopy!techniques!described!later!in!this!chapter!(section(6.3(and!8@10).!!
(
3.1! Production(of(recombinant(adeno@associated(viral((rAAV)(vectors((Recombinant!adenoSassociated!viral!(rAAV)!vectors!have!proven!to!be!a!useful!tool!for! efficient! and! longSterm! gene! transfer! in! a! verity! of! tissues! (Zolotukhin! et)al.,)1999).! AAV! has! a! linear! singleSstranded!DNA! (ssDNA)! genome! of! approximately!4.7!kilobases!(kb),!with!two!145!nucleotideSlong!inverted!terminal!repeats!(ITR)!at!the!termini,!that!drive!viral!replication!(Choi!et)al.,)2005).!The!ITRs!flank!two!viral!genes,! the! rep! (replication)! genes! which! encode! nonSstructural! proteins!responsible! for! replication! and! packaging! and! the! cap! (capsid)! genes,! which!encode! structural! proteins! that! form! the! icosahedral! viral! capsid! as! shown! in!
Figure( 10( (Gonçalves,! 2005).! Generally,! AAVSbased! vectors! involve! the!replacement! of! the! rep)and! cap)genes!with! a! transgene! of! interest,! retaining! the!ITRs!and!packaging!sequences!needed!to!direct!replication!and!packaging!of!the(
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!
Figure( 9.( Schematic( representation( of( treatment( groups( and( survival( times( used( to( investigate( the(
impact( of( viral( vectors( on( various( histological( parameters.( The! diagram! represents! Cln3///( mice! or!
Cln3Δex7/8!mice!or!wildStype!mice.!In!total,!5!cohorts!of!mice!were!used!and!included!Cln3Δex1%6!or!Cln3Δex7/8!plus!wildStype!mice!injected!with!AAV2/9.eGFP!(n!=!4!S!6),!AAV2/9.mCln3.eGFP!(n!=!6)!or!AAV2/9.hCLN3.eGFP!(n!=!6).!!!genome! (Kremer! et) al.,) 1995).! As! AAV! is! ‘replicationSincompetent’,! additional!genes! from! a! helper! virus! (naturally! adenovirus! [Ad]! or! Herpes! Simplex! Virus![HSV])!was!once!necessary,!often!leading!to!helper!virus!contamination!(reviewed!in! Verma! and! Somia,)1997).! Now,! “helperSfree”! methods! of! AAV! production! as!described! in! this! chapter,! are! readily! used! and! considerably! less! immunogenic!!(Xiao!et)al.,)1998;!Clark!et)al.,)1999).!!!
!
AAV!exists!in!various!serotypes,!arising!from!differences!in!the!surface!topology!of!VP1,! VP2! and! VP3! capsid! proteins! (Wu! et) al.,) 2000).! There! is! accumulating!evidence!that!the!capsid!protein!is!a!major!determinant!of!cellular!tropism!and)
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!
Figure( 10.( Schematic( representation( of( wild@type( adeno@associated( virus( (AVV).( Rep! genes! code! for!packaging! proteins! with! four! possible! variants:!Rep78,! Rep68,! Rep52,! and! Rep40;! required! for! genome!replication!and!necessary!for!integration.!Rep!proteins!from!most!serotypes!can!be!interchangeably!used!with!any! inverted! terminal! repeat! (ITR)!serotype,!except! for!AAV5,!which! requires!AAV5!Rep! and!AAV5! ITRs! for!packaging!(Kyöstiö!et)al.,)1994).!!Cap!genes!code!for!structural!capsid!proteins!with!three!variants:!VP1,!VP2,!and!VP3;!which!are!crucial! for!correct!virion!assembly!and!determines!the!serotype/viral!tropism!(Jay!et)al.,)1981).!The!AAV!virus!uses!two!promoters!to!generate!the!four!Rep!proteins!and!a!third!promoter!to!generate!the!transcript!for!the!three!Cap!proteins.(!
transduction! efficiency!of!AAV! (Van!Vliet!et)al.,)2008).! Indeed,! the! viral! capsid! is!the! first!part!of! the!virus! that! cellular! receptors! encounter!during!viral! infection!(Choi! et)al.,)2005).! Therefore,! in! addition! to! naturally! occurring! AAV! serotypes,!several! strategies! have! been! used! to! create! hybrid! AAV! serotypes! as! a! way! to!optimise! targeted! gene! therapy! techniques! ! (reviewed! in! Van! Vliet! et)al.,)2008).!The!hybrid!serotype!AAV2/9!is!engineered!using!the!rep!element!of!AAV!serotype!2! and! the! cap! element! of! AAV! serotype! 9,! and! has! been! shown! to! achieve! good!rostralScaudal!distribution!within!the!CNS!and!specifically!target!neurons!(Cearley!and! Wolfe,! 2006).! As! such,! we! used! AAV2/9Sserotype! vectors! in! this! study,!produced!by!Sophia!kleine!Holthaus!at!UCL!from!Professor!Robin!Ali’s!laboratory!at! the! Institute! of! Ophthalmology,! London,! UK.! Numerous! methods! have! been!established!to!produce!rAAV!vector!(Xiao!et)al.,!1998;!Grimm!et)al.,!1998;!Collaco!et)
al.,! 1999;! Matsushita! et) al.,! 1998;! Salvetti! et) al.,! 1998;! Clark! et) al.,! 1995,! 1996;!1999b;!Gao!et)al.,!1998;!Zhang,!1999,!2001a,!2001b;!Conway!et)al.,!1999;!Qiao!et)
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al.,!2002;!Inoue!and!Russell,!1998;!Urabe!et)al.,!2002;!Ruffing!et)al.,!1992).(!For!this!study,! a! tripartite! transfection!method!was! used! as! first! described! in! Xiao! et)al.,)1999.!!
!
The! rAAV2/9! vectors! contained! a! CMV! promoter,! a! rabbit! βSglobin!polyadenylation! (Poly(A))! signal,! the! transgene(s)! of! interest,! and! flanking! ITRs!from!AAV2!and!was!packaged!using! the!AAV5!capsid!protein! (Figure(11).!Large!quantities!of!plasmids!were!needed! to!generate! these!vectors!and! this!was!done!using!the!Endofree®)Plasmid)Mega)Kit!(QIAGEN,!Manchester,!UK)!according!to!the!manufacturer’s! instructions.! These! plasmids! included! helper! plasmid! pHGTI!carrying! Ad! helper! accessory! genes,! plasmid! carrying! AAV2! rep) and! AAV9! cap)genes!and!recombinant!catabolic!plasmid,!pD10!comprising!a!CMV!promoter!at!the!5’! end! driving! the! expression! of! either! 1)! enhanced! green! fluorescent! protein!(eGFP)! derived! from! the! jellyfish! Aequorea) Victoria) alone! (pD10.CMV.eGFP)! 2)!!mouse! Cln3) (mCln3),! an! internal! ribosome! entry! site! (IRES)! and! eGFP!(pD10.CMV.mCln3SIRESSeGFP)! or! 3)! human! CLN3) (hCLN3),) IRES! and! eGFP!(pD10.CMV.hCLN3SIRESSeGFP)! and! a! rabbit!βSglobin!Poly(A)! signal! at! the!3’! end.!





Figure( 11.( Schematic( representation( of( the( recombinant( AAV( vector( genomes.( Abbreviations:! ITR! =!inverted! terminal! repeats,! CMV! =! Cytomegalovirus;! eGFP! =! enhanced! green! fluorescent! protein,! mCln3! =!mouse! CeroidSlipofiscinosis,! neuronal! 3,! hCLN3! =! human! CeroidSlipofiscinosis,! neuronal! 3,! IRES! =! internal!ribosome!entry!site,!Poly(A)!=!rabbit!βSglobin!polyadenylation!signal.!The!CMV!promoter!drives!expression!of!the!eGFP,!mouse!Cln3)and!human!CLN3)cDNA!via!an!IRES!sequence!where!indicated.!This!expression!cassette!also! contains! the! 3’! untranslated! region! from! rabbit! βSglobin! ! gene! encoding! the! Poly! (A)! signal.! The!transcription!initiation!site!is!indicated!by!the!black!arrow.!The!expression!cassette!is!flanked!by!the!AAV2!ITR!sequences.!!!of!5!EU/ml.!
!For!the!purification!of!recombinant!adenoSassociated!viral!vectors,!HEK293T!cells!were! seeded! into! 15! cm!plates! at! a! concentration! of! 106! cells! per! unit! area! and!grown! overnight! at! 37°C.! The! following! day,! when! the! plates! had! reached! the!appropriate! confluency! (70! S! 90%),! the! tripartite! transfection! was! carried! out!using! the! transfection! reagent! polyethylenimine! (PEI)! and! helper,! caspid! and!transgene! plasmids! in! Dulbecco’s! Modified! Eagle’s! Medium! (DMEM)! (SigmaSAldrich).!For!a!single!15!cm!plate!the!following!mix!was!assembled!in!the!following!order:! DMEM! 261! µl;! Transgene! plasmid! 1.5! µg;! Capsid! plasmid! 5! µg;! Helper!plasmid! 5! µg;! polyethylenimine! (PEI)! 60! µl.! To! allow! for! complexation,! the!
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transfection!mix!was!kept!at!room!temperature!for!10!minutes!before!2.5!ml!of!the!solution!was!added!to!the!media!of!each!plate.!The!cells!were!then!incubated!for!72!hours! at! 37°C! without! replacing! the! media! until! full! confluency! was! achieved.!Following!a!72!hours!incubation!period,!the!293T!cells!were!harvested!using!a!cell!scraper,!spun!down!at!2000!rpm!for!5!minutes!and!reSsuspended!in!Tagmentation!DNA!(TD)!buffer!(see!Appendices(2.2(for!recipe).!Next,!the!cell!lysate!underwent!three! freezeSthaw! cycles! at! S80°C! and! 37°C!with! vigorous! vortexing! inSbetween.!Benzonaze!(SigmaSAldrich)!was!then!added!to!a!final!concentration!of!50!units/ml,!in!order!to!remove!any!remaining!plasmid!DNA.!The!lysate!was!then!incubated!at!37°C! for! 1! hour! and! centrifuged! at! 18000! rpm! for! 30! minutes! at! 18°C.! The!supernatant!was! retained! and! filtered! through! a! 45!µm! syringe! filter.! Exchange!chromatography! purification! was! performed! utilizing! an! AKTA! prime! FPLC!apparatus!(GE!Healthcare!Life!Sciences,!Buckinghamshire,!UK)!in!conjunction!with!an!anionic!sephacryl!S300!and!POROS!50HQ!column!(GE!Healthcare!Life!Sciences)!for!rAAV2/9.!The!virus!was!then!aliquoted!and!stored!at!S80°C.!
!
Several! batches! of! vector!were! produced! for! this! investigation! yielding! different!concentrations.! Virus! was! diluted! to! 1! x! 1012! vp/µl! under! the! hood! using!endotoxinSfree!PBS!prior!to!injection.!The!details!of!each!batch!of!virus!are!listed!in!
Table(7.!
!




(vp/mL)(AAV2/9.eGFP! 1! 1!x!1012!2! 1!x!1012!AAV2/9.mCln3.eGFP! 1! 4.34!x!1012!2! 2.85!x!1012!AAV2/9.hCLN3.eGFP! 1! 2.2!x!1012!2! 3!x!1012!!
Table(7.(Vector(batch(and(concentration.((All!viruses!were!produced!in!the!same!way!as!outlined!in!section(
3.1.(However,!the!first!batch!of!each!vector!was!originally!titrated!and!measured!by!dot!blotting!and!then!later!(after! injections! had! been! administered)! reSmeasured! by! qRTSPCR,!which! revealed!minor! differences! (later!values!included!here).!The!second!batch!of!each!vector!was!titrated!and!measured!by!qRTSPCR.!All!virus!was!diluted!to!1!x!1012!vp/µl,!apart!from!the!second!batch!of!AAV2/9.hCLN3.eGFP,!which!was!injected!neat.!!
comprehensive!video!made!by!JoVE!Science!Education!Database,!available!on!the!Jove! website! (http://www.jove.com/science%education/5205/rodent%stereotaxic%
surgery).! In!brief,! the! fur!between! the!ears!and!covering! the! top!of! the!skull!was!removed! from! the! isofluraneSanaesthetized!mouse!using!an!electric! razor! (Wella!Contura,! Darmstadt,! Germany).! The! mouse! was! then! mounted! prone! onto! the!platform! (Stoelting,!Woodpale,! Ill,! USA)! of! the! stereotactic! frame! (Kopf,!Harvard!Apparatus,!USA)!with!the!nose!positioned!into!the!nose!cone!and!supplied!with!0.5!S! 1.5%! isoflurane! to! 99.5! S! 98.5%! oxygen! to! maintain! anaesthesia.! A! topical!anaesthetic!was! applied! (ELMA®)Cream,! AstraZeneca,! Luton,!UK)! to! the! inside!of!the! ears!before!placing! the! ear!bars! into! the! ear! canal! and! tightening! into!place,!allowing! for! the! skull! to! be! positioned! in! an! elevated,! level! position.! ProvidoneSIodine! antiseptic! solution! was! used! to! clean! the! shaved! area! (Vetasept®,! Alstoe!animal!health,!York,!UK)!and!Lacri%lube®)(occular!lubricant)!(Alstoe!animal!health)!was!applied!to!the!animal’s!eyes.!The!animal!was!given!an!intraperitoneal!injection!
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of! general! anaesthetic! (100! μl! of! Vetergesic®! 0.3! mg/ml! solution,! Alstoe! animal!health).!An!anterior/posterior! incision!(1!cm!long)!was!made!on!the!scalp!with!a!sterile!scalpel!and!blade!(Swann%Morton®,!SwannSMorton,!Sheffield,!UK))extending!from!lambda!to!just!inSbetween!the!eyes!of!the!animal!and!all!soft!tissue!from!the!surface! of! the! skull! was! removed.! In! addition! to! the! frame,! the! stereotactic!apparatus! also! included! a! UltraMicroPump! (UMP3)! (one)! with! SYS%Micro4™)
Controller!(World!Precision!Instruments,!Hertforshire,!UK),!which!was!fitted!with!the!Hamilton®)syringe!(62!RN!2.5!µl)!and!needle!(30Sgauge,!20!mm,!Point!Style!T!3)!reserved!for!each!vector!(Hamilton,!supplied!by!ESS!Laboratory,!Cranston,!UK).!The! stereotactic! coordinates! from! bregma! were! located! using! the! Paxinos! and!Franklin! atlas,! 2001! and!marked! on! the! surface! of! the! skull! (0.3!mm! rostral! to!bregma,!S2.5mm!medial/lateral!of!midline!and!S2.7!mm!dorsal!ventral!to!the!skull’s!surface).!A!small!hole!was!made!using!a!hand!held!micro!drill!(Stoelting)!and!1!μl!(1×1012!vp/ml)!of!freshly!diluted!virus!was!bilaterally!injected!into!the!striatum!at!a! rate! of! 3! nl! per! second! and! the! needle!withdrawn! slowly! over! 2.5!minutes! to!minimise!backtracking!of!the!virus.!!
!




Figure(12.(Schematic(representation(of(injection(loci.(Red!dots!represent!injected!vector!into!the!caudate!putamen!(CPu)!(striatum)!shown!by!sagittal!and!coronal!schematic!distinction!in!Paxinos!and!Franklin,!2001.!Coordinates! from!bregma:!0.3!mm!rostral! to!bregma,! S2.5!mm!medial/lateral!of!midline!and!S2.7!mm!dorsal!ventral!to!the!skull’s!surface.!!
one!week!postSsurgery,!animals!were!weighed!daily!and!stiches!were!inspected!to!assess!recovery!and!general!well!being.!!
!
4! AAV2/9@PPT1(and(ERT(combination(therapy((Through! the! utilization! of! different! hybrid! serotypes,! exploring! new! routes! of!administration! and! targeting! new! areas! of! the! brain,! progress! has! been! made!towards! improving! gene! therapy! for! the! treatment! of! CLN1! disease.! However,!
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preclinical! studies! in!Ppt1%/%! mice! using! gene! therapy! alone! has! resulted! in! only!modest! histological! and! biochemical! improvements,! little! or! no! impact! upon!behavioral!function,!and!no!substantial!increase!in!lifespan!(Macauley!et)al.,)2012).!As!discussed! in!section(5.1(of!Chapter(1,(ERT! is! traditionally!used! to! treat!nonSneuropathic! enzymeSdeficient! lysosomal! storage! disorders! because! lysosomal!enzymes! do! not! readily! cross! the! BBB! when! administered! systematically!(HawkinsSSalsbury! et) al.,) 2013).! As! such,! when! recombinant! human! PPT1! is!delivered! to!Ppt1S/S!mice,! levels! of!PPT1!activity! in! the!brain! are!minimal,!whilst!levels! of! PPT1! activity! in! the! rest! of! the! body! of! treated!Ppt1%/%)mice! are! almost!normal,!therefore!alleviating!the!systemic!disease!(Lu!et)al.,)2010).! !In!Chapter(5,!we! aimed! to! explore! whether! combining! CNSSdirected! AAV2/9Smediated! gene!therapy! with! systemically! administered! ERT! could! be! an! effective! approach! to!treating! the! complex! manifestations! of! CLN1! disease! by! targeting! unknown!pathology! in! the! rest! of! the! body! as! well! as! the! brain! using! the! procedures!described!in!this!section.!The!therapeutic!groups!used!included:!1)!WildStype!mice,!2)!Untreated!Ppt1%/%!mice,!3)!Ppt1%/%!mice! treated!with! intravenous!ERT!alone,!4)!
Ppt1%/%!mice! treated!with! AAV2/9SPPT1! alone)and! 5)!Ppt1%/%!mice! treated!with! a!combination! of! AAV2/9SPPT1! and! ERT.! Pathology! in! Ppt1%/%!mice!has! been! well!characterised!at!1,!3,!5!and!7!months!of!age!(Kielar!et)al.,)2007).!At!5!and!7!months!of! age,! neuropathological! hallmarks! are! relatively! advanced! and! therefore,! these!time!points!were!chosen!as!end!points!following!the!course!of!treatment!to!assess!the!impact!of!the!combination!therapy!on!disease!progression.!It!should!be!noted!here,!that!no!ERT!was!administered!to!5!month!old!Ppt1%/%!mice,!see!Figure(15.!
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4.1! AAV2/9@PPT1(vector(production(As! discussed! in! section( 1.3,( AAV2/9Smediated! gene! therapy! spreads! well!throughout! the! CNS,! preferentially! targeting! neurons.! For! the! same! reasons,!AAV2/9!was!also!utilised!in!Chapter(5.!The!vector!was!produced!and!purified!by!Dr! Joshua! Dearborn! from! Professor! Mark! Sands! laboratory! at! Washington!University! Medical! School,! also! using! a! similar! tripartite! transfection! method,!based! on! previously! described! protocols! (Grimm! et) al.,)1998;! Daly! et) al.,! 1999;!Zolotukhin! et) al.,! 1999).! As! illustrated! in! Figure( 13,( the! rAAV2/9SPPT1! vector!contained! a! chicken! βSactin! promoter,! CMV! enhancer,! rabbit! βSglobin!polyadenylation! (Poly(A))! signal,! cDNA! for! human! PPT1,! and! flanking! inverted!terminal!repeats!from!AAV2!and!was!packaged!using!the!AAV5!capsid!protein.!The!CMV! enhancer/chicken!βSactin! (aka! CAG)! promoter! has! been! shown! to! result! in!higher! expression! than! an! AAV! vector! with! just! the! CMV! promoter! as! used! in!





Figure(13.( Schematic( representation(of( the(recombinant(AAV2/9@PPT1(vector(genome.(Abbreviations:!ITR!=!inverted!terminal!repeats;!CMV!=!Cytomegalovirus,!βSactin!=!chicken!βSactin,!PPT1!=!human!palmitoylSprotein!thioesterase!1,!Poly(A)!=!(rabbit!βSglobin)!polyadenylation!signal.!The!chicken!βSactin!promoter!and!CMV! enhancer! drive! expression! of! the! human! PPT1! cDNA.! This! expression! cassette! also! contains! the! first!intron! from!chicken!βSactin!gene!and! the!3’!untranslated!region! from!the!rabbit!βSglobin!gene!encoding! the!Poly(A)! signal.! The! transcription! initiation! site! is! indicated! by! the! black! arrow.! This! expression! cassette! is!flanked!by!AAV2!ITR!sequences.!!For!the!purification!of!recombinant!adenoSassociated!viral!vectors,!HEK293T!cells!were! seeded! into! 15! cm!plates! at! a! concentration! of! 106! cells! per! unit! area! and!grown! overnight! at! 37°C.! After! 48! hours,! when! the! plates! had! reached! the!appropriate! confluency! (70! S! 90%),! the! tripartite! transfection!was!performed!by!calcium!phosphate!precipitation.! For! a! single!15! cm!plate! the! following!mix!was!assembled!in!the!following!order:!8!µg!helper!plasmid!(Ad!helper!accessory!genes!and!AAV2!rep);!10!ug!AAV9!capsid!plasmid;!22.5!ug!transgene!plasmid;!1012.5!µl!1x!TE! (TrisSEDTA)!buffer;!112.5!µl!2.5M!CaCl;!1125!µl!2x!HEPESSbuffered!saline!(HBS)!(see!Appendices(2.3(for!recipe).!To!allow!for!complexation,!the!transfection!mix! was! added! to! the! media! in! each! 15! cm! plate! and! the! cells! were! incubated!overnight!(12!S!16!hours)!at!37°C.!The!media!was!removed!the!following!morning!and! replaced! with! fresh! media.! Following! a! 48! hours! incubation! period,! the!HEK293T!cells!were!harvested!using!a!cell!scraper,!spun!down!at!2000!rpm!for!5!minutes!and!reSsuspended!in!Tagmentation!DNA!(TD)!Buffer!(see!Appendices(2.2(for!recipe).!Next,! the!cell! lysate!underwent!three! freezeSthaw!cycles!at! S80°C!and!37°C! with! vigorous! vortexing! inSbetween.! An! iodixanol! gradient! centrifugation!step! was! carried! out! in! order! to! remove! any! remaining! plasmid! DNA.! The!supernatant!was! retained! and! filtered! through! a! 45!µm! syringe! filter.! Exchange!
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chromatography! purification! was! performed! utilizing! an! AKTA! prime! FPLC!apparatus! (GE!Healthcare!BioSSciences,! Pittsburgh,! PA,!USA)! in! conjunction!with!an!anionic!sephacryl!S300!and!POROS!50HQ!column!(GE!Healthcare!BioSSciences)!for!rAAV2/9.!The!virus!was!then!aliquoted!and!stored!at!S80°C.!!
!
4.2! AAV2/9@PPT1(vector(and(human(recombinant(PPT1(production(As!defined!in!section(1.1.a(of!Chapter(1,(PPT1!enzyme!is!synthesised!in!ER!then!during! maturation! in! the! Golgi! apparatus! acquires! the! M6P! recognition! marker!allowing!it!to!be!trafficked!to!the!lysosome!through!the!M6PR!(Camp!and!Hofman!1993;!Hellensten!et)al.,)1996;!Verkruyse!and!Hoffman!1996;!reviewed! in!Dawson!and! Cho! 2000;! Virmani! et)al.,)2005).!Within! the! endolysomal! compartment! (and!possibly! cytoplasm),! PPT1! acts! as! a! depalmitoylating! enzyme! that! cleaves!palmitate! or! fatty! acyl! chains! from! proteins! and! peptide! (Vesa! et) al.,! 1995;!reviewed! in! Linder! and! Deschenes,! 2007;! Resh,! 2006;! Smotrys! et)al.,! 2004).! In!order!for!therapeutically!supplied!PPT1!protein!to!carry!out!its!roles!and!alleviate!disease! symptoms,! it! must! be! functional,! tolerated! and! delivered! to! the! correct!location!within!the!cell.!To!achieve!this,!human!recombinant!PPT1!(hrPPT1)!was!produced! by! Dr! Sandy! Hofmann’s! laboratory! at! the! University! of! Texas! using!standard!methods!in!Chinese!hamster!ovary!(CHO)!cells!as!described!previously!in!Lu! et) al.,) 2010.! The! hrPPT1! enzyme! was! shipped! to! Professor! Mark! Sands!laboratory! at! Washington! University! Medical! School! where! it! was! diluted,!aliquoted!out!and!stored.!The!fullSlength!human!PPT1!cDNA!fragment!(nucleotides!233!to!1153!of!NM_000310![GenBank])!was!generated!by!PCR!amplification!from!a!pCMV5ShPPT1! plasmid! and! cloned! into! XhoI! sites! in! the! polylinker! region! of! a!plasmid! expression! vector! containing! the! dihydrofolate! reductase! resistance!
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marker! (pMSXND1)! and! used! to! transfect! CHO! cells.! High! and! stable! levels! of!expression!in!CHO!cells!was!achieved!by!multiple!rounds!of!selection!in!increasing!concentrations!of!methotrexate!over! a!period!of!9!months.!To!do! this,! CHO!cells!(obtained! from! the! ATCC,! #CCLS61TM)! were! maintained! in! FS12! medium!(Invitrogen! [Thermo! Fisher! Scientific,! Inc.],! Vista,! CA,! USA)) supplemented! with!10%!(v/v)! fetalSbovine!serum!(FBS)!and!were!transfected!with!pMSXND1ShPPT1!using!FuGENE!6!(Roche,!Indianapolis,!IN,!USA).!Cells!were!selected!with!Geneticin!(G418)! and! resistant! clones! isolated! using! cloning! cylinders.! Subclones! were!analyzed! for! secretion! of! PPT1! by! measuring! enzyme! activity! in! conditioned!medium!using!a!fluorescence!assay!based!on!hydrolysis!of!an!artificial!substrate,!4SmethylumbelliferylS6SthiopalmitoylSβSDSglucoside! (MUS6SSPalmSβGlc).! Highest!producing!clones!were!grown!in!nucleotideSdeficient!‘minimum!essential!medium’!(Invitrogen)!containing!0.25!μM!methotrexate.!When!resistant!colonies!appeared,!they!were!expanded,!aliquots!frozen,!and!the!remaining!cells!subjected!to!2!to!3Sfold!higher!concentration!of!methotrexate.!This!process!was!repeated!for!a!total!of!6! cycles,! reaching! a! final! maximum!methotrexate! concentration! of! 30! μM,! after!which! higher! enzyme! production!was! not! achieved.! The! final! cell! line! produced!was!named!CHOShPPT1.!The!resulting!clones!secreted!from!200!S!250!µg!of!PPT1!enzyme!per!ml!of!culture!medium.!
!
To! purify! rhPPT1,! the! CHOShPPT1! cells!were!maintained! in! nucleosideSdeficient!minimum!essential!medium!(MEM)! (Gibco®! [Thermo!Fischer!Scientific! Inc,!Vista,!CA,! USA]:! Cat.! 32561)! containing! 30! μM!methotrexate,! and! were! supplemented!with!10%!dialyzed!FBS! (Gemini!Bio!Products,!West!Sacramento,!CA,!USA),!100!–106)!containing!100!units/ml!penicillin,!100!μg/ml!streptomycin,!and!0.25!μg/ml!
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amphotericin!B.!Subsequently,!confluent!adherent!CHOShPPT1!cells!were!split!1:2!and! grown! in! FS12! medium! (Invitrogen)! supplemented! with! 10%! FBS! to!confluence.! Cells! were! then! washed! with! phosphateSbuffered! saline! (PBS,!ingredients! in!Appendices(2.4)! three! times! and! cultured! in! serum! free!medium!(HyClone™) CDM4CHO™! Media,! GE! Healthcare:! Cat.! SH30557)! for! 14! days,! with!medium!collected!and!replenished!with! fresh!medium!every! two!days.!Typically,!30! dishes! each! containing! 5! ml! of! medium! were! used.! Collected! medium! was!centrifuged!at!400!x!g,!filtered!through!a!0.2!mm!filter!unit!to!remove!debris!and!floating! cells,! then! concentrated! approximately! 20Sfold! using! a! stirred! cell!equipped!with!a!YMS10!membrane!(Millipore,!Billerica,!MA,!USA)!at!4°C!and!snapSfrozen!until!further!use.!!
!





4.3! Administration(of(AAV/ERT(The!outline!of!the!therapeutic!approach!in!this!study!are!summarized!in!Figure(15(below! but! will! be! described! further! in! Chapter( 5.! ! All! treatments! were!administered!at!Washington!University!Medical!School,!by!members!of!Professor!Mark! Sands! laboratory! under! approved! Institutional! Animal! Care! and! Use!Committee!(IACUC)!protocols!and!did!not!require!any!specific!aftercare.!!On!postSnatal!day! (PND)!1,!pups! receiving!ERT! treatment!were! removed! from! their! cage!and!placed!gently!onto!a!paper!towel!and!bedding!underneath!a!ventilated!!hood.!Using!a!Hamilton®!syringe!and!30Sgauge!needle!(BD,!Franklin!Lakes,!NJ,!USA),!an!injection!of!rhPPT1!enzyme!(concentrated!at!1.5!mg/ml)!in!a!volume!of!100!μl!(for!a! total! dose! of! 0.15! mg! enzyme)! was! injected! into! the! pup! via! the! superficial!temporal!(facial)!vein.!!
!
On! the! second! day! (PND! 2)! pups! receiving! rAAV2/9SPPT1!were! again! removed!from!their!cage!and!placed!carefully!onto!a!paper!towel!and!bedding!underneath!a!ventilated!hood.!At!this!age,!it!is!not!necessary!to!shave!the!skin,!make!an!incision!or! drill! a! hole! as! the! skin! and! skull! are! thin! enough! for! direct! injection.!Using! a!
Hamilton®!syringe!and!30Sgauge!needle!(BD)!as!described!previously!(Macauley!et)
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al.,!2012),!2!µl!of!virus!(1!x1011!vg/ml)!was!bilaterally!injected!into!6!sites,!directly!through! the! skull! without! the! use! of! stereotactic! apparatus:! the! anterior! cortex!(estimated! 1! mm! rostral! to! bregma,! 2mm! medial/lateral! of! midline! and! 2! mm!ventral! to! the!skull’s! surface),!hippocampus/thalamus! (estimated!3.5!mm!rostral!to! bregma,! 2! mm!medial/lateral! of! midline! and! 2! mm! ventral)! and! cerebellum!(estimated! 6! mm! caudal! to! bregma,! 1! mm!medial/lateral! of! midline! and! 2! mm!ventral!to!the!skull’s!surface)!(Figure(14).!On!each!of!PND!7,!14,!and!21,!pups!also!received!a!further!100!μl!of!enzyme!(for!a!total!dose!of!0.15!mg!enzyme)!this!time!via!intraperiotoneal!injection.!!
!!
Beginning!on!PND!30!and! recurring!every!7!days!until! 5!or!7!months,!mice! that!were! given! ERT! continued! to! receive! hrPPT1! injections! via! the! tail! vain.! The!animal!was!placed!into!a!clean!cage!and!then!loaded!into!a!brass!mouse!restrainer!(preSheated! on! a! heating! pad! to! allow! for! vasodilation)! for! tail! vain! injection!(Harvard!Apparatus,!Hollison,!MA,!USA).! !The!tail!was!held! taught! to! identify! the!tail!vein!running!on!each!side!of! the! tail.!Next,! the!needle! tip! (Hamilton®! syringe!and!30Sgauge!needle,!ESS!Laboratory)!was!inserted!into!the!vein!superficially!and!250!μl!(for!a!total!dose!of!0.375!mg!enzyme)!of!hrPPT1!was!administered.!!
!
4.4! Behavioural(testing(












Figure'15.' Schematic' representation'of' treatment' groups'used' to' investigate' adeno8associated' virus'
(AAV)8mediated' gene' therapy' and' enzyme' replacement' therapy' (ERT)' (AAV'+' ERT)' in' combination.'The!diagram!represents!mice!treated!at!5!and!7!months!of!age!with!the!exception!of!ERT!at!5!months!of!age,!which!was!not!included!in!this!study.!In!total,!9!cohorts!of!mice!were!used!and!included;!1)'wildBtype!mice!at!5!and!7!months!of!age!(n!=!4,!n!=!5,!respectively),!2)!untreated!Ppt1Bdeficient!(Ppt1%/%)!!mice!at!5!months!of!age!(n!=!4,!n!=!5,!respectively),!3)!Ppt1%/%!mice!treated!with!intravenous!ERT!alone!at!7!months!(n!=!4),!4)'Ppt1%/%!mice!treated!with!AAV2/9BPPT1!alone!at!5!months!(n!=!4,!n!=!4,!respectively)!and!5)'Ppt1%/%!mice!treated!with!a!combination!of!AAV2/5BPPT1!and!ERT!at!5!months!of!age!(n!=!4,!n!=!3,!respectively).!Abbreviations:!PND!=!postnatal!day;!ERT!=!enzyme!replacement!therapy.!B/B!=!Ppt1%/%!mice.'
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!
rotarod!was!carried!out!together!with!activity!wheel!tests!as!described!previously!(Macauley! et' al.,'2012! and! Dearborn! et' al.,'2015).! Treated! mice! and! untreated!controls!were!tested!on!the!constant!speed!rotarod!(Ugo!Basile!Srl,!Varese,!Italy)!at!3,!5!and!7!months!of!age.!At!each!age,!mice!received!3! test! sessions,!where!each!session!included!a!preBtest!trial!on!a!stationary!rod,!followed!by!2!test!trials.!On!a!given! test!day,! the! time!between! trials! for!a! single!mouse!was!approximately!20!minutes! and! tests! were! conducted! over! 3! consecutive! days.! The! rod! rotated!unidirectionally!at!3!rpm!for!60!seconds!and!the!dependent!variable!for!each!trial!was!the!number!of!seconds!the!mouse!was!able!to!remain!on!the!rod.!On!separate!days,! all!mice! also! underwent! normal! and! complex! activity!wheel! tests.! ! To! test!baseline!voluntary!wheel!running!activity!and!acclimate!the!mice!to!the!chamber!and!running!apparatus!prior!to!the!complex!wheel!test,!mice!(3!month!time!point!only)! were! initially! tested! on! a! normal! running! wheel! (Mouse! Motor! Skill!Sequences!Activity!Wheel,!Lafayette!Instrument,!Lafayette,!IN,!USA)!for!1!hour!on!2!consecutive! days! (1! trial/day).! The! normal! activity! wheel! contained! 38!consecutive! rungs! (0.4! cm! in! diameter)! that! were! spaced! 0.614! cm! apart.! Mice!were! allowed! to! explore! the! wheel! and! activity! chamber! for! 1! hour! on! 2!consecutive!days.!To!test!fine!motor!control!and!integration!between!the!forelimbs!and!hind!limbs,!the!complex!running!wheel!was!created!by!removing!some!of!the!wheel!rungs!thus!creating!unequal!spaces!between!the!rungs!of!the!wheel!(0.614!cm,! 1.6! cm,! or! 2.6! cm).! The! mice! received! 5! consecutive! days! of! performance!testing!on!the!complex!wheel.!Dependent!variables!for!both!tests!included!average!speed,!maximum!speed,!time!spent!running!on!the!wheel,!distance!and!time!spent!not!running!on!the!wheel.!All!behavioural!tests!were!conducted!under!the!IACUC!
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protocol!from!Washington!University!School!of!Medicine.!
4.5! Post8treatment'assessment'of'survival'Mice!were!assessed!once!a!week!for!body!weight!and!more!frequently!for!general!health.!Mice!were!sacrificed!when!a!loss!of!greater!than!10%!of!the!highest!weight!recorded! was! noted! for! two! consecutive! weeks,! when! animals! could! not! right!themselves!or!were!moribund!(unresponsive!to!tactile!stimulation).!The!observer!conducting! these! studies!was! blinded! to! treatment! groups.! A! Kaplan–Meier! logBrank! test! was! used! to! determine! whether! there! was! an! overall! significant!difference!among!these!groups!and!pairBwise!comparisons!were!performed!using!a!Bonferroni! correction! to! alpha! (0.05! divided! by! the! number! of! comparisons).! A!significance!level!of!0.05!was!used!for!the!overall!test!and!0.05/4!=!0.0125!for!the!pairBwise!group!comparisons.!
!
5! Echocardiography'Although! the! NCLs! are! primarily! neuropathic! diseases,! the! mutated! genes! that!cause! them! are! present! in! all! cells! of! the! body! and! clinical! and! morphological!cardiac!abnormalities!have!been!reported!in!patients!with!CLN1!and!CLN3!disease!as!well!as! in!various!animal!models!(Staropoli!et'al.,'2012;!Galvin!et'al.,'2008).!As!treatments! that! target! the! CNS! become! more! effective! in! extending! lifespan,!visceral! phenotypes! such! as! cardiac! pathology! may! become! more! relevant.! To!investigate! the!presence!of! functional!cardiac!pathology! in!Ppt1%/%'mice!at! the!end!stage! of! disease! and!Cln3%/%!at! the!middle! and! towards! the! end! stages! of! disease,!transthoracic! echocardiography!was! performed! on! each!mouse!model! and! their!corresponding! ageBmatched! controls! as! they! became! available.! Ppt1%/%'mice! and!
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their!wildBtype!controls!were!tested!at!6!months!of!age!and!Cln3%/%!mice!and!their!wildBtype!controls!were!tested!at!12!and!18!months!of!age.!Echocardiography!was!performed! using! the! Vevo®' 2100! ultrasound! system! (Visualsonics,! Toronto,!Canada)! and! carried! out! by! Dr! Bin! Yu! and! Norman! Catibog! within! the!Cardiovascular! Division! at! King's! College! London.! The! entire! procedure! was!conducted! in! accordance! with! the! Guidance! on! the! Operation! of! the! Animals!(Scientific!Procedures)!Act,!1986!(UK!Home!Office).  
!
5.1! Preparing'for'cardiac'imaging'and'image'acquisition'Echocardiography! and! ultrasound! imaging! was! carried! out! using! standard!procedures! that! have! been! described! previously! (Ram! et' al.,' 2011)! and!demonstrated! nicely! in! a! comprehensive! video! made! by! Pistner! et' al.,! 2010,!available! on! the! Jove! website! (http://www.jove.com/video/2100/murine%
echocardiography%and%ultrasound%imaging).! In! summary,! the! isofluraneBanaesthetized!mouse!was!placed!supine!on!an!electrical!heating!pad!at!37°C!and!fitted!with!a!nose!cone!(over!mouth!and!nose)!to!deliver!0.5!B!1.5%!isoflurane!to!99.5! B! 98.5%! oxygen! to! maintain! anaesthesia.! Ultrasound! transmission! gel!(Aquasonic©'100,!Parker!Lab,!Fairfield,!New!Jersey,!USA)!was!applied!to!the!paws,!which! were! then! secured! to! the! electrode! pads! with! 3M™'Transpore™' surgical'
tape! (3M,! Loughbrough,! UK)! and! an! anal! probe! inserted! to! allow! for! continual!electrocardiogram!(ECG)!and!body!temperature!monitoring.!Depilatory!cream!was!applied!to! the!chest!and!abdomen!(Veet®,!Bershire,!UK)! for!2!minutes! to!remove!fur.!We!waited! for! 5!minutes! before! any!measurements!were! recorded! to! allow!heart!rate!to!stabilize.!Heart!rates!were!>450!beats/min!(bpm)!for!the!duration!of!the! study! (maintained!with! adjustment!of! level! of! anesthesia).!The!normal!heart!
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rate!in!a!conscious!healthy!mouse!is!600!B!650!bpm,!this!is!reduced!by!anaesthetics!allowing! for! improved! image! visualization! and!measurements,! however,! if! heart!rate! falls! below! 450! bpm,! the! assessment! of! the! physiological! question! being!investigated! will! be! compromised! as! image! acquisition! becomes! more! difficult!(reviewed!in!Collins!et'al.,'2003!and!Chen!et'al.,'2012).!Any!images!obtained!with!suboptimal! physiological! parameters! (ECG,! respiratory! rate,! body! temperature)!were!considered!unreliable!data!and!excluded!from!analysis.!
'!!!!
Figure'16.'Echocardiography:'General'procedure'for'image'acquisition.'a'–'d)!shows!still! images!taken! from! a! demonstration! video! (Pistner! et' al.,! 2010)! on! the! Jove! website!(http://www.jove.com/video/2100/murine%echocardiography%and%ultrasound%imaging),! outlining!preparation!necessary!for! image!acquisition.!e)'Brightness!mode'(BBMode)! image.!Abbreviations:!LV!=!left!ventricular!trace;!HR!=!heart!rate;!A!=!area;!A;s!=!systolic!area;!A;d!=!diastolic!area;!V!=!volume;!Vol;s!=! systolic! volume;! Vol;d! =!diastolic! volume;! SV! =! stroke! volume;!EF! =! ejection! fraction;! CO! =! cardiac!output.! f)' Motion! mode! (MBMode)! image.! Abbreviations:! LVAW;d! =! endBdiastolic! left! ventricular!anterior!wall;!LVAW;s!=!endBsystolic!left!ventricular!anterior!wall!(not!measured!in!our!study);!LVID;d!=!endBdiastolic! left! ventricular! internal! dimension;! LVID;s! =! endBsystolic! left! ventricular! internal!dimension;! LVPW;d! =! endBdiastolic! left! ventricular! posterior! wall;! LVPW;s,! =! endBsystolic! left!ventricular!posterior!wall.!
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5.2! Cardiac'functional'parameters'measured'Image!acquisition!was!carried!out!as!described!by!Pistner!et'al.,!(2010)!and!Chen!et'
al.,! (2012).! In! short,! a! conventional! realBtime! 2D! echocardiographic! study! was!performed! in! parasternal! longBaxis! and! midBpapillary! shortBaxis! views! and! two!image! modes! were! employed,! as! pictured! in! Figure' 16.! The! first! was! the!brightness!mode!(BBmode),!which!allows!the!anatomical!structures!of!the!heart!to!be!visualized!and!quantified!by!producing!a!fourBchamber!image!including!left!and!right! atria! and! ventricles! (Figure'16.' e).! The! second!was! the!motion!mode! (MBmode),!which!provides!a! temporal! image!of! cardiac!wall!motion!and!enables! the!quantification!of!wall!thickness!and!cavity!dimensions!as!well!as!the!movement!of!myocardium,!valves!and!vessel!walls! (Figure'16.'f).!A!number!of!measurements,!specifically!pertaining!to!systolic!and!diastolic!function,!can!be!obtained!by!using!a!combination!of!BBMode!and!MBmode!images.'!However,!it!should!be!noted!that!for!complete!assessment!of!diastolic!performance,!pulsed!Doppler!imaging!and!tissue!Doppler! imaging!(TDI)!should!be!used! in!combination!with!BBmode!and!MBmode!image! acquisition! as! explained! in! detail! in! section' 4.2' of! Chapter' 4! (Ho! et'al.,!2002;!Collins!et'al.,!2003)!and!this!was!not!done!in!this!study.!The!purpose!of!these!experiments! was! to! serve! as! a! pilot! study! in! order! to! investigate! whether!functional! abnormalities! accompany! the! neurological! phenotypes! displayed! in!
Ppt1%/%'mice!at!6!months!of!age!and!Cln3%/%!at!12!and!18!months!of!age.!Therefore,!a!narrow!set!of! standard! readBouts!was! collected! in!order! to! first! identify!obvious!functional!abnormalities,!as!outlined!in!Table'8.''
' '
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Parameter' Mode' Units' Parameter' Mode' Units'Weight! B! g! IVS;d! MBMode! mm!Heart!weight! B! mg! IVS;s! MBMode! mm!Heart!rate!(HR)! BBMode! BPM! LVID;d! MBMode! mm!Area! BBMode! mm2! LVID;s! MBMode! mm!Area;s! BBMode! mm2! LVPW;d! MBMode! mm!Area;d! BBMode! mm2! LVPW;s! MBMode! mm!
Volume! BBMode! μl! Ejection!fraction!(EF)! MBMode! %!
Volume;s! BBMode! μl! Fractional!shortening!(FS)! MBMode! %!Volume;d! BBMode! μl! LV!mass! MBMode! mg!Stroke!volume!(SV)! BBMode! μl! LV!Vol;d! MBMode! μl!Ejection!fraction!(EF)! BBMode! %! LV!Vol;s! MBMode! μl!Fractional!shortening!(FS)! BBMode! %! ! ! !Cardiac!output!(CO)! BBMode! ml/min! ! ! !
'
Table' 8.' Parameters' used' during' echocardiography' to' investigate' cardiac' function' in' this' thesis.'Abbreviations:!d!=!diastolic;!s!=!systolic;!IVS;d!=!endBdiastolic!interventricular!septum!thickness;!IVS;s!=!endBsystolic!interventricular!septum!thickness;!LVID;d!=!endBdiastolic!left!ventricular!internal!dimension;!LVID;s!=!endBsystolic! left! ventricular! internal! dimension;! LVPW;d! =! endBdiastolic! left! ventricular! posterior! wall!thickness;!LVPW;s!=!endBsystolic!left!ventricular!posterior!wall!thickness;!LV!mass!=!left!ventricular!mass;!LV!Vol;d!=!endBdiastolic!left!ventricular!volume;!LV!Vol;s!=!endBsystolic!left!ventricular!volume.!The!overall!body!weight! of! each!mouse!was!measured!prior! to! echocardiography!using! a! scale! (g)! and! the!heart!weight!was!measured!subsequent!to!echocardiography!using!a!fine!balance!(mg).!!! !
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5.3! Analysis'of'echocardiographs'Analysis! was! performed! offBline! on! a! workstation! installed! with! Vevo®' 2100!software! (version! 1.4.0)! by! myself! under! the! supervision! and! guidance! of! ! an!experienced!cardiologists,!blinded!to!the!genotype.!!
!
6! Histological'analysis'of'experimental'tissue'So!far,!we!have!discussed!the!methods!carried!out!in!live!animals!and!cells.!In!the!next!part! of! this! chapter,! all! the!methods!used!once! animals!had!been! sacrificed!will! be! described,! from! harvesting! tissue,! carrying! out! staining! protocols! and!molecular!biology!techniques!employed.!
!
6.1! Processing'and'sectioning'of'brain'tissue'All! mice! were! terminally! anesthetized! with! “Euthatal”! (200! mg! sodium!pentobarbital/ml,! Merial! Animal! Health! Ltd,! Surrey,! UK)! and! transcardially!perfused!with!25!ml!of!phosphate!buffered! saline! (PBS:!50!mM,!with!MgCl2!and!CaCl2,! pH! 7.4,! Sigma:! Cat.! D8662),! followed! by! 50! ml! of! freshly! prepared! and!filtered!4%!paraformaldehyde!(PFA)!in!0.1!M!sodium!phosphate!buffer,!pH!7.4.!To!do! this,! toeBpinch! response! (Collier! et'al.,'1961)!was! confirmed! before! lying! the!animal! supine!with! the!head!pointing!away!and!pinning!out!all! four! limbs!at! the!feet.!Using!blunt!end!forceps!(F.S.T,!Heidelberg,!Germany),!the!skin!and!body!wall!was!lifted!up!at!the!point!of!the!lower!rib!cage!to!create!a!“tent”!shape!and!cut.!The!opening!was!then!extended!laterally!and!along!the!side!of!the!body!with!two!long!cuts!being!careful! to!avoid!puncturing!the!organs.!An! incision!was!made!through!
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the! rib! cage! adjacent! to! the! lungs! and! then! another! cut! was! made! through! the!diaphragm! by! lifting! the! sternum.! The! rib! cage! and! surrounding! loose! skin!was!pinned!back!to!expose!the!heart!and!the!perfusion!needle!was!placed!into!the!left!ventricle! to! allow! for! perfusion.! All! brains! were! carefully! dissected! from! the!cranium! and! immersion! fixed! for! 48! hours! in! 4%! PFA! then! subsequently!cryoprotected! in! a! solution! of! 30%! sucrose! in! trisBbuffered! saline! (TBS:! 50!mM!Tris,! pH! 7.6,! 150!mM!NaCl)! (Bible! et'al.,! 2004;! Pontikis! et'al.,! 2004;! Kühl! et'al.,!2013).!!
!
This!thesis!concentrates!upon!wellBdefined!pathological!changes!that!occur!within!the! forebrain! of! the! mouse! models! used! (Mitchison! et' al.,'1999;! Cotman! et' al.,'2002;!Pontikis!et'al.,'2004,!2005;!Kielar!et'al.,'2007);!therefore,!the!cerebellum!was!removed! by! making! a! single! coronal! cut! using! a! clean,! singleBedge! razorblade!(Fisher! Scientific! [Thermo! Fisher! Scientific],! Loughbrough,! UK)! to! separate! the!forebrain! and! cerebellum,! which! was! retained! for! future! analysis.! Next,! all!forebrains!were!cut!coronally! into!40!μm!thick!sections!on!a!Leitz!1321! freezing!microtome! (Microm!HM! 430,! Carl! Zeiss! Ltd,! Cambridge,! UK)! (Bible! et'al.,! 2004;!Pontikis!et'al.,!2004;!Kielar!et'al.,!2007)!and!stored!in!96Bwell!plates!containing!an!antiBfreeze! cryoprotectant! solution! (TBS! containing! 30%! ethylene! glycol,! 15%!sucrose,!0.05%!sodium!azide)!at!4oC.!
!
6.2! Processing'and'sectioning'of'heart'tissue'It! was! necessary! to! process! heart! tissue! in! a! different! way! to! brain! tissue! for!histological! analysis! a)! due! to! its!more! fibrous! properties! b)! due! to! the! type! of!
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analysis!required.!A!potassium!chloride!(KCl)!perfusion!method!was!used!in!order!to!induce!diastole,!thus!ensuring!that!all!hearts!were!in!a!consistent!relaxed!state.!Mice! were! terminally! anaesthetised! with! “Euthatal”! (200! mg! sodium!pentobarbital/ml,! Merial! Animal! Health! Ltd)! immediately! following!echocardiography.! The! sternum! was! opened! as! for! a! transcardial! perfusion!(section'6.1)!and!0.5!–!1!ml!of!5%!KCl!dissolved!in!0.9%!saline!(sodium!chloride,!NaCl)! solution! was! injected! slowly! into! the! left! ventricle.! The! heart! was! then!dissected! out,! keeping! the! aorta! intact.!Hearts!were! immediately!washed! in! PBS!and!weighed!on!a!fine!balance.!!
!
Primarily,! the! hearts! were! intended! for! histological! analysis! but! for! analysis!beyond! this! project,! heart! tissue! was! also! retained! for! qualitative! reverse!transcription!polymerase!chain!reaction!(RTBqPCR)!and!western!blot!analysis.!As!such,! the! heart! was! carefully! dissected! into! three! parts;! the! aorta! and! upper!segment! for! histology! and! the! middle! and! apical! segments! for! RTBqPCR! and!western!blot!analysis.!For!histological!analysis,!the!upper!segment!was!fixed!in!4%!paraformaldehyde!for!4!hours,!rinsed!in!PBS!and!stored!in!70%!ethanol!(biological!grade! absolute! ethanol,! SigmaBAldrich:! Cat.! E7023)! before! processing! in! paraffin!wax.!This!was!done!by!dehydrating!the!tissue!through!a!series!of!graded!ethanol!baths! to! displace! the! water! and! then! infiltrating! the! tissue! with! wax! using! a!Shandon! Hypercenter! XP! (Fisher! Scientific)! before! embedded! them! into! wax!blocks! ready! for! sectioning. The!middle! and!apical! segments!were! transferred! to!separate! cryogenic! vials! (Corning®,! SigmaBAldrich)! and! flash! frozen! in! liquid!nitrogen!then!stored!at!B80°C.!
!
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Fixed!heart! tissue!was! cut! transversely! into!6!μm! thick! sections!on! a! Leica!base!sledge!microtome!(Leica!Microsystems!(UK)!Ltd,!Milton!Keynes,!UK).!The!resulting!wax!ribbons!containing!the!heart!sections!were!stretched!out!to!remove!wrinkles!by!placing!them!in!a!water!bath!(Raymond!Lamb,!Thermo!Scientific![from!Fisher!Scientific])! containing! demineralized! water! at! 45! B! 50°C! and! collected! onto!
Superfrost™! Plus! slides! (Fischer! Scientific)! and! dried! over! night! in! the! upright!position!on!a!hot!plate!(Leica)!set!to!37°C.!
!
6.3! Immunohistochemistry''Immunohistochemistry! allows! us! to! gather! information! about!what! proteins! are!expressed!and!where!they!are!expressed!by!providing!a!way!to!selectively!visualise!the!protein!of!interest.!For!this!study,!we!were!interested!in!a!number!of!different!proteins!and!therefore!the!specific!details!of!each!staining!procedure!varied!with!regards! to! tissue! treatment,! specific! antibodies! used! and! incubation! times.! For!simplicity,! an! overview! of! all! antibodies! used! for! immunohistochemistry! is!included!in!Table'9'and!further!differences! in!general!staining!procedure!will!be!outlined!in!the!text.!
!
Currently,!there!are!no!specific!antibodies!against!endogenous!CLN3!or!its!murine!homologue! Cln3,! although! antibodies! exist! that! detect! overBexpressed! protein!(Järvelä! et' al.,! 1998,! 1999;! Luiro! et' al.,! 2001;! Kyttälä! et' al.,! 2004),! we! have!previously! been! unable! to! obtain! reliable! histological! staining! when! we! tested!them!(Cooper,!personal!communication).!To!more!reliably!determine!the!level!and!location! vectorBderived! Cln3/CLN3! expression! (Chapter' 3),! a! 1! in! 6! series! of!
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sections! were! stained! using! antibodies! against! eGFP! (1:10,000,! Thermo! Fischer!Scientific)!as!a!surrogate!marker!for!CLN3!and!Cln3!expression.!To!determine!the!degree! of! astrocytosis! and!microglial! activation! (Chapters'3,'5),! 1! in! 6! series! of!sections!were! stained! for!glial! fibrillary!associated!protein! (GFAP,!1:8,000,!Dako,!Ely,! UK)! or! the! microglial! marker! cluster! of! differentiation! 68! (CD68,! 1:2,000,!Serotec,!Oxford,!UK).!To!assess!the!impact!of!AAV!+!ERT!combination!therapy!on!astrocytosis! and! microglial! activation! (Chapter' 5),! GFAP! and! CD68! were! used!again.!!
!
Sections! were! first! incubated! in! 1%! H2O2! in! TBS! for! 30! minutes! to! quench!endogenous! peroxidase! activity,! subsequently! rinsed! in! TBS,! and! then! blocked!with!15%!normal!serum!in!TBSBT!(TBS!containing!0.3%!Triton!XB100)!for!2!hours.!Next,!sections!were!incubated!overnight!at!4°C!with!the!appropriate!concentration!of! primary! antibody!diluted! in!TBSBT! and!10%!normal! serum! (Table'9).! On! the!following! day,! sections! were! rinsed! in! TBS! and! incubated! in! TBSBT! and! 10%!normal! serum! for! 2! hours! at! room! temperature! containing! the! appropriate!concentration! of! biotinylated! secondary! antisera! (1:1,000,! Vector! Laboratories,!Peterborough,!UK).!After!washing,!sections!were!incubated!for!2!hours!in!TBS!with!avidinBbiotin!peroxidase!complex!(Vestastain®'Elite®!ABC!(AvidinBBiotinBComplex)!kit,!Vector!Laboratories),!prepared!at! least!30!minutes!before!use.!Sections!were!rinsed! in!TBS! and! immunoreactivity!was! visualised! by! incubation! in! 0.05%!3,3–diaminobenzidine! tetrahydrochloride! (DAB,! SigmaBAldrich)! and! 0.001%! H2O2! in!TBS!(filtered!before!use)!for!a!precise!predetermined!time!(between!7B15!minutes,!depending! on! antigen)! that! represents! saturation! for! this! reaction.! Staining!was!terminated!by!adding!iceBcold!TBS!and!rinsed!several!times,!before!sections!were!
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mounted!onto!preBprepared!gelatinBchrome!alum!coated!Superfrost™!microscope!slides!(Fisher!Scientific),!airBdried!overnight,!rinsed!in!100%!industrial!methylated!spirits! (I.M.S.! Fischer! Scientific)! and! cleared! in! xylene! (Fischer! Scientific)! for! at!least! 30! minutes,! before! being! coverslipped! with! DPX! [pBxyleneBbis(pyridinium!bromine)]!(VWR,!Lutterworth,!UK)!using!22!x!60!mm!Borosilicate!glass!coverslips!(VWR).!To!ensure!reproducible!and!quantitative!results,!particular!care!was!taken!to! fully!saturate! the!staining!reaction!and!sections! from!each! treatment!group!at!each!time!point!were!stained!simultaneously!as!one!batch!for!each!antigen.!!
























1:10,!000! Goat!α!rabbit!! Vector!A10259! 1:1000!
Astrocytes! Rabbit!α!GFAP! Dako!!Z0334! 1:!8,!000! Swine!α!rabbit!! Dako!Z0334! 1:1000!Microglia! Rat!α!CD68! Serotec!!MCA1957! 1:!2,!000! Rabbit!α!rat!! Vector!MA1957! 1:1000!Leukocytes! Mouse!!α!CD45! BD!Pharmingen!!550566!
1:500! Goat!!α!rabbit! Vector!BAB1000! 1:300!
Cardiac!gap!junctions! Rabbit!!α!Cx43! Abcam!Ab62689! 1:3000! Horse!!α!goat! Vector!BAB9500! 1:300!SA!node! Rabbit!!α!HCN4! Abcam!Ab69054! 1:7000! Horse!!α!goat! Vector!BAB9500! 1:300!
Table' 9.' Overview' of' antibodies' used' for' immunohistochemistry.! Abbreviations:! eGFP! =! enhanced!green!fluorescent!protein;!GFAP!=!glial!fibrillary!acidic!protein;!CD68!=!cluster!of!differentiation!68;!CD45!=!cluster! of! differentiation! 45;! Cx43! =! connexin! 43;'HCN4! =' hyperpolarizationBactivated! cyclic! nucleotideBgated! channel! 4;!Dil.! =!dilution.!Companies:!Fisher! Scientific! [Thermo!Fisher! Scientific],!Loughbrough,!UK,!Dako;! Dako,! Ely,! UK;! Serotec,! Oxford,! UK;! BD! Pharmigen,! Oxford,! UK;! Abcam,! Cambridge,! UK;! Vector!Laboratories,!Peterborough,!UK.!*The!humanized!recombinant!E.'Coli%derived!GFP!(hrGFP)!gene!was!used!in!
section'3.3'of!Chapter'3.!
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6.4! Nissl'staining'To!visualise!neuronal!cytoarchitechture!and!permit!stereological!analyses!of!brain!tissue! collected! for! the!CLN3!gene! therapy! and!AAV!+!ERT! combination! therapy!studies,!a!1!in!6!series!of!40!μm!coronal!sections!from!each!forebrain!(Figure'17)'was! mounted! onto! gelatinBchrome! alum! coated! Superfrost™! microscope! slides!(Fisher!Scientific)!and!airBdried!overnight.!All!sections!were!then!incubated!for!at!least! 45! min! at! 60°C! in! 0.05%! cresyl! fast! violet! and! 0.05%! acetic! acid! (VWR).!Sections!were!then!rinsed!in!distilled!water!and!differentiated!through!a!series!of!graded! alcohols! (70%,! 80%,! 90%,! 95%,! 100%! I.M.S.)! before! clearing! in! 50:50!xylene:I.M.S.,! followed! by! 100%! xylene! for! at! least! 1! hour! and! then! finally!coverslipped!with!DPX!(VWR).!
!
6.5! Isolectin'B4/wheatgerm'agglutin'staining'To! assess! the! presence! of! myocyte! hypertrophy! and! the! consequent! angiogenic!response! in!Ppt1%/%!and!Cln3'%/%!mice!and!their!corresponding!wildBtype!controls! in!






BB1205).! Prior! to! staining,! paraffin! wax! embedded! sections! were! deparafinized!with! two! changes! of! 100%! xylene! and! 100%! I.M.S! for! at! least! 5! minutes! and!rehydrated! through! a! series! of! graded! alcohols! (96%,! 70%,! 50%,! 25%! I.M.S.).!Sections!were!rinsed!in!PBS!for!5!minutes!and!then!placed!in!a!solution!of!citrateBbased!antigen!unmasking!solution!(Vector:!Cat.!HB3300)!then!steamed!over!a!food!steamer! for!20!minutes! (Russell!Hobbs,!Manchester,!UK)!and! left! to! cool!until! at!room!temperature!(RT).!Sections!were!rinsed!in!PBS!(3!x!5!minutes),!outlined!with!a!grease!pen!(PAPBpen,!Dako)!and!then!blocked!with!10%!goat!serum!(Vector)!in!PBS!for!1!hour!at!RT.!Sections!were!incubated!in!isolectin!B4!(1:200,!Vector:!Cat.!BB1205)! at! 4°C! overnight.! On! the! following! day,! sections! were! rinsed! in! three!changes!of!PBS.!To!visualize!the!myocyte!and!epithelial!cell!borders,!sections!were!further!incubated!in!Fluorescein!Avidin!D!(Alexa!Fluor!568,!1:150,!Vector:!Cat.!AB2001)!and!WGABRho!AB!(1:50,!Vector:!Cat.!RLB1022)!for!2!hours!at!RT!in!the!dark.!
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After! three! washes! in! PBS,! sections! were! then! coverslipped! using! ProLong®'
Diamond'Antifade'Mountant'(Life!Technologies:!Cat.!P36961).!
!
6.6! Picrosirius'red'staining'To!determine! the!presence!of!cardiac! fibrosis! in!Ppt1%/%!and!Cln3%/%!mice!and!their!corresponding! wildBtype! controls! in! Chapter' 4,! sections! were! stained! with!picrosirius! red.! In!brightBfield!microscopy! collagen!appears! red!on! a!pale! yellow!background!(Puchtler!et'al.,'1973;!Junqueira!et'al.,!1979).!Prior!to!staining,!paraffin!wax!embedded!sections!were!deparafinized!with!two!changes!of!100%!xylene!and!100%! I.M.S! for! at! least! 5! minutes! and! rehydrated! through! a! series! of! graded!alcohols!(96%,!70%,!50%,!25%!I.M.S.)!and!finally!rinsed!twice!with!distilled!water.!!Sections! were! blocked! in! 0.2%! phosphomolybdic! acid! (Fluka:! Cat.! 79560)! to!reduce!the!staining!of!other!tissue!components!for!2!minutes!and!then!rinsed!with!distilled!water.!Sections!were!subsequently!stained!for!2!hours!in!0.1%!picrosirus!red!(0.4!g!Direct!Red!80,!SigmaBAldrich:!Cat.!365548!in!400ml!saturated!picric!acid!solution,!Fluka:!Cat.!80456,!13!g!in!1!L!water).!To!facilitate!stain!retention,!sections!were!washed! in! two!changes!of!acidified!water! (0.5%!acetic!acid)! for!5!minutes.!Sections!were!then!dehydrated!through!a!series!of!graded!alcohol!solutions!(25%,!50%,!75%,!100%!I.M.S.)!and!cleared!in!100%!xylene!for!at! least!1!hour!and!then!finally!coverslipped!with!DPX!(VWR).!
!
6.7! Haematoxylin/Van'Gieson'(HVG)''staining'In! Chapter' 4,! haematoxylin/Van! Gieson! (HVG)! was! used! to! stain! Ppt1%/%'heart!sections! in! the! region! of! the! SA! node! (as! identified! by! HCN4/Cx43! staining! in!
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consecutive! sections)! to! permit! the! qualitative! analysis! of! tissue! structure! and!identification! of! pathological! features.! Briefly,! sections! were! deparaffinized! as!described! in! section' 6.2' and! transferred! to! deionized! water! for! 5! minutes.!Sections!were!then!stained!in!0.7%!Harris’s!haematoxylin!(SigmaBAldrich)!for!10!B!30!seconds,!rinsed!in!tap!water!followed!by!distilled!water!and!then!stained!in!van!Gieson! (7.5! ml! 1%! acid! fuchsin! (SigmaBAldrich),! 92.5! ml! saturated! picric! acid!(SigmaBAldrich)! and! 100! ml! distilled! water)! for! 10! –! 30! seconds! followed! by!differentiation! in! 0.5%! hydrochloric! acid! (HCl)! containing! 70%! I.M.S! for! 5! B! 10!seconds.!The!stain!was!then!allowed!to!develop!by!leaving!sections!in!running!tap!water,!before!dehydration!in!graded!concentrations!of!I.M.S,!clearing!in!xylene,!and!then! coverslipped! with! DPX! (VWR).! Haematoxylin! staining! was! also! used! to!counterstain!Ppt1%/%,!Cln3%/%!and!wildBtype!heart!sections!following!immunostaining!for! CD45! to! provide! a! contrasting! colour! that! makes! it! easier! to! identify! the!location!of!any!CD45!positive!cells.!'
!
6.8! Live/dead'staining'and'immunocytochemistry'As!described!in!section'2,!neuronal!cultures!were!grown!on!coverslips!to!evaluate!their! response! to! each! of! the! viral! vectors! designed! for! CLN3! gene! therapy!treatment! in!Chapter'3.!To! identify!cells!undergoing!cell!death!and!whether! this!correlated! with! the! level! of! vector! transduction! following! infection,! fluorescent!reactive! LIVE/DEAD®' Fixable' Red' Stain! (excited! with! 488! nm! laser,!excitation/emission!595/615,! Invitrogen:!Cat.!L23102,)!was!used! in! combination!with! eGFP! (Alexa! Fluor®' 488! conjugate,! excitation/emission! 495/519,! Thermo!Fisher! Scientific:! Cat.! A21311)! and! 4’,! 6BDiamidinoB2Bphenylindole!dihydrochloride! (DAPI,! 0.5B1μg/ml,! SigmaBAldrich,! Cat.! D9542).! DAPI! is! a!
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fluorescent! stain! that!binds! strongly! to!ABT! rich! regions!of!DNA! in!both! live! and!dead!cell!bodies!allowing!all!cells!to!be!visualized!(Kapuscinski,!1995).!Within!the!bicistronic! vectors! used! in! Chapter' 3,! eGFP! acts! as! a! reporter! gene! for! Cln3'expression.! Therefore,! the! eGFP! antibody! will! detect! vectorBtransduced! cells!expressing!both!eGFP! and!Cln3'genes.!The! fluorescent! reactive! red!dye! is!able! to!permeate! the! compromised! membranes! of! necrotic! cells! and! react! with! free!amines!within! the! cell! and! on! the! cell! surface,! giving! rise! to! intense! fluorescent!staining.!In!contrast,!only!the!cellBsurface!amines!of!live!cells!are!available!to!react!with!the!dye!and!therefore,!only!a!dim!staining!is!detected!(Invitrogen!protol).!As!such,! transduced! cells! that! are! dead/alive! can! be! distinguished! within! the! cell!culture.!On!the!day!of!analysis!(3!days!after!viral!infection),!the!LIVE/DEAD®'dye!(1!μl/well)!was!added!to!the!culture!medium!and!incubated!for!30!minutes!at!37°C!to!allow!damaged/dying!cells!to!take!up!this!amineBreactive!fluorescent!dye.!Cultures!were!then!washed!three!times!with!PBS!prior!to!fixing!with!4%!PFA!for!10!minutes!at!RT.!To!determine!the!proportion!of!cells!that!were!transduced!and!to!ascertain!whether!these!cells!were!dead!or!alive,!immunocytochemistry!was!carried!out!on!the! LIVE/DEAD®'dye! stained! cells! (in! the! dark).! Following! three! washes! in! PBS!cells! were! incubated!with! eGFP! diluted! in! 10%! normal! goat! serum! (NGS)! for! 1!hour!at! room!temperature.!Coverslips!were! then!washed! three! times! in!PBS!and!incubated! for!30!minutes!at! room!temperature.!Nuclei!were!counterstained!with!DAPI! (1:2000,! SigmaBAldrich).! Coverslips! were! mounted! onto! slides! using!Fluoromout!G!(Southern!Biotech,!Cambridge,!UK).!!
7! Vector8driven'gene'expression'VectorBdriven! gene! expression! was! assessed! in! Chapter' 3.' In! E15B17! striatal!neuronal! cultures! that! were! infected! with! AAV2/9.mCln3.eGFP! and!
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AAV2/9.hCLN3.eGFP! bicistronic! vectors,! eGFP! was! undetectable! by!immunocytochemistry! even! at! the! greatest! MOI! (section' 3.1' in! Chapter' 3).! In!contrast,! cells! infected! with! AAV2/9.eGFP! showed! clear! eGFP! expression.! One!explanation! for! this! finding! is! that! gene! expression! downstream! of! IRES! is!expressed! at! a! lower! level! compared! to! genes! upstream! of! IRES! (Davies! and!Kaufman!et'al.,! 1992;!Houdebine! 1999,!Attal!et'al.,! 1999;!Hennecke!et'al.,! 2001).!Therefore,! to! confirm! and! compare! the! expression! of! eGFP! at! the! mRNA! level!following!transfection!with!each!viral!vector,!we!carried!out!quantitative!PCR!using!injected!brain!tissue.!It!was!not!possible!to!directly!compare!Cln3/CLN3!expression!between!all! three!vectors!as!primers! for!mouse!Cln3'cannot!distinguish!between!
Cln3! expression! driven! by! the! AAV2/9.mCln3.eGFP! vector! and! endogenous!Cln3.!Therefore,! only! primers! against! eGFP! or! the! IRES! portion! can! be! used! as! a!surrogate! marker! of! vector! expression,! while! primers! for! human! CLN3! would!allow!for!direct!detection.!!!
!
7.1! CNS'tissue'lysis'for'analysis'of'gene'expression'A! subset! of! mice! that! received! intracranial! injections! of! each! viral! vector! (as!described! in! section' 3.2)! were! then! sacrificed! 2! weeks! later.! To! obtain! higher!yields! of!RNA,! brains!were!not! perfusion! fixed! for!RNA!extraction.! Instead,!mice!were! injected! with! a! lethal! dose! of! “Euthatal”! (1.5! ml! of! 200! mg! sodium!pentobarbital/ml,!Merial! Animal! Health! Ltd.).! The! sternum!was! opened! as! for! a!transcardial! perfusion! (section' 6.1)' and! 0.1! ml! (1.000! I.U./ml)! heparin!(Wockhardt,!Wrexham,!UK)!was! injected! into! the! left! ventricle! to! prevent! blood!coagulation! followed! by! 1!ml! PBS! (PBS:! 50!mM!Phosphate! buffered! Saline,!with!MgCl2!and!CaCl2! ,!pH!7.4,! SigmaBAldrich:!Cat.!D8662)! twice! to! flush! the!brain!of!
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blood.!The!fresh!brains!were!extracted!and!placed!into!a!coronal!brain!slicer!(Zivic!Instruments,!Pittsburgh,!PA).!The!brain!was!hemisected!and!further!divided!into!6!mm! coronal! segments! using! brain! matrix! razor! blades! (Fisher! Scientific).! Each!segment! was! placed! in! a! labeled! cryogenic! vial! (Corning®,! SigmaBAldrich)!containing! 400! µl! TriReagent®! (Ambion®! (Invitrogen)! and! snap! frozen! in! liquid!nitrogen!and!then!stored!at!B80°C.!
!
On!the!day!of!RNA!extraction,!the!area!used!for!RNA!extraction!was!cleaned!with!a!generous!amount!of!RNAase'Zap®!(Ambion®,!Invitrogen)!before!the!samples!were!defrosted! at! room! temperature! and! left! for! 5!minutes! after! they! had! completely!thawed.! They!were! then!manually! homogenized! using! a! hand! held! homogenizer!preBtreated! with! 70%! I.M.S! and! RNAase' Zap®! (Ambion®,! Invitrogen)! between!samples.!Samples!were!then!sonicated! for!2Bsecond!pulses!x!10!cycles!(Bandelin,!Berlin,!Germany)!whilst!on!ice!and!kept!on!ice!ready!for!RNA!extraction.!
!
7.2! RNA'extraction'from'brain'slices'Total!RNA!was!purified!from!each!homogenized!coronal!brain!slice.!The!lysate!was!transferred! to! a! 1.5! ml! nucleaseBfree! microcentrifuge! tube! together! with! a! 5:1!mixture!of!Trizol:Choloroform!Isoamyl!alcohol!(Fluka![SigmaBAldrich]:!Cat.!25666)!and!pipetted!up!and!down!for!15!seconds.!The!mixture!was!then!transferred!to!a!preBspun!2!ml!heavy!phase!lock!tube!(5!Prime,!Hamburg,!Germany:!Cat.!2302830)!and!left!to!settle!on!ice!for!18!minutes!before!centrifugation!at!14000!rpm!for!10!mins! at! 4°C! using! a! Hettich! EBA! 12! R! centrifuge! with! a! 1412! rotor! (HettichiBZentrifugen,!Tuttlingen,!Germany).!!
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!
The! supernatant! was! transferred! to! clean! 1.5! ml! nucleaseBfree! microcentrifuge!tubes!containing!isopropanol!(PropanB2Bol,!SigmaBAldrich:!Cat.!19516)!at!a!ratio!of!2:1!(Trizol!+!Chloroform!Isoamyl!alcohol):PropanB2Bol.!The!mixture!was!inverted!x!4!and!left!to!sit!at!room!temperature!for!10!minutes!before!centrifuging!at!14000!rpm! for! 15!minutes! at! 4°C! (Centrifuge! 5804! R,! Eppendorf,! Hamburg,! Germany).!The!supernatant!was!removed!whilst! taking!care!not! to!disturb! the!pellet,!which!was!washed!in!75%!ethanol!(biological!grade!absolute!ethanol,!SigmaBAldrich:!Cat.!E7023)! and! nucleaseBfree! water! (Ambion®' (Invitrogen):! Cat.! AM9916)! and!centrifuged! at! 14,000! rpm! for! 5!minutes! at! 4°C! (Centrifuge! 5804!R,! Eppendorf).!The!ethanol!supernatant!was!removed!and!the!pellet!left!to!airBdry!until!clear.!The!pellet!was!then!reBsuspended!in!20!µl!nucleaseBfree!water!and!the!resulting!RNA!was! quantified! using! a! NanoDrop! Spectrophotometer! (NDB1000! Spectrometer,!LabTech,!East!Sussex,!UK)!to!determine!RNA!concentration!and!purity.!!
!
7.3! First'strand'cDNA'synthesis''cDNA!was!generated!using!SuperScriptIII®'Reverse'Transcriptase'(RT)! (Invitrogen:!Cat.!18080B044)! in!keeping!with!their!own!published!protocols.!Briefly,!1.5!μg!of!sample!RNA!template!was!mixed!with!2!μl!of!50!μM!random!decamers!(Ambion®'(Invitrogen):!Cat.!AM5722G),!1!μl!of!40!mM!dNTP!mix!(10!mM!each!of!dATP,!dGTP,!dCTP!and!dTTP!at! neutral! pH! (Solis!Biodyne,!Tartu,! Estonia:! Cat.! 02L21L00100)!and! nucleaseBfree! water! up! to! 13! μl.! The! mixture! was! incubated! at! 65°C! for! 5!minutes!before!leaving!on!ice!for!1!minute.!The!contents!of!the!tube!were!collected!by!brief!centrifugation!and!mixed!with!4!μl!of!5x!FirstBStrand!Buffer,!1!μl!0.1MDTT,!1!μl!of!SuperScript®III'RT!(200!units/μl)!and!1!μl!of!nucleaseBfree!water!by!gentle!
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trituration.! Samples! were! then! incubated! at! 25°C! for! 5! minutes,! 42°C! for! 60!minutes,!50°C!for!30!minutes,!then!55°C!for!30!minutes!before!an!inactivation!step!at! 70°C! for! 15! minutes! using! a! GS4! thermal! cycler! (GLStorm,! Byfleet,! UK).!Reactions!were!diluted!1! in!7!with!nucleaseBfree!H2O! to!a! final!volume!of!140!μl!and!stored!at!B20°C!prior!to!use!as!template!for!RTBqPCR.!
!
7.4! RT8qPCR'design'
FastStart'TaqMan®! assays! (Roche,! Welwyn! Garden! City,! UK)! using! primers! and!probes! for! eGFP,'IRES! and!CLN3! and! three! house! keeping! genes! (RPL13a,!Atb5b!and!β%actin)!were!performed! for!each!sample! in! triplicates!using!a!DNA!Engine®!Peltier! Thermal! Cycler! (BIOBRAD,! Hemel! Hemstead,! UK).! ! In! short,! 1! μl! of! each!cDNA! sample!was!mixed!with! 10! μl! of!FastStart'TaqMan®!Master!mix,! 0.2! μl! of!probe!(100!nm),!0.2!μl!of!forward!primer!(200!nm),!0.2!μl!of!reverse!primer!(100!nm)! made! up! to! 20! μl! with! nucleaseBfree! water! in! a! (special)! 96Bwell! plate!(Thermo!Scientific).!Samples!were!then!incubated!at!95°C!for!10!minutes,!95°C!for!10!seconds,!72°C!for!1!second,!40°C!for!30!seconds!and!60°C!for!30!seconds!for!45!cycles,!50°C!for!30!minutes,!then!55°C!for!30!minutes.!
!
Primers!were!designed!using!published!RefSeq!sequences!sourced!from!the!UCSC!Genome! Browser! website! (http://genome.ucse.EDU).' Primers! were! designed! to!span! intronic! regions! of! the! selected! genes! to! ensure! specific! amplification! of!mRNA!using!Integrated!DNA!Technologies!(https://www.idtdna.com).!Probes!were!selected! using! the! Roche! Universal! ProbeLibrary! Assay! Design! Centre!(https://lifescience.roche.com/shop/en/us/overviews/brand/universal%probe%
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library).!Primer!pairs!were!tested!to!ensure!amplicon!specificity!using!the!online!NCBI! Primer' Blast! tool! (http://www.ncbi.nih.gov/toos/primerLblast).! All! primers!and!probes!used!are!detailed!in!Appendices'2.5.!!
8! Stereology'Stereology! provides! a! means! to! make! quantitative! estimates! about! the! 3D!properties!of!an!object!from!2D!histological!sections!(Weibel,!1979,!1980).!In!this!way,! it! is! possible! to! accurately! assess! both! obvious! and! subtler! changes! in! the!brain! as! a! result! of! lysosomal! dysfunction.! In! this! study,! we! used! stereology! to!estimate!the!number!of!neurons!in!selected!nuclei!for!both!the!CLN3!gene!therapy!(Chapter'3)!and!the!AAV!+!ERT!combination!therapy!studies!(Chapter'5).!When!making! quantitative! estimations,! a! number! of! important! points! must! be!considered.!Firstly,!in!the!diseased!brain,!a!number!of!morphological!changes!may!occur! including! neuronal! atrophy! or! hypertrophy,! together! with! changes! in!regional! volume.! Therefore,! if! two! populations! of! neurons! are! to! be! compared!between!treatment!groups!or!different!genotypes,!it!is!crucial!to!choose!a!method!that! is!unbiased! towards! the!size!and!shape!of! the!neurons!or! the!volume!of! the!brain!they!are!within.!Secondly,!it!would!be!unfeasible!to!count!every!neuron!in!the!brain!considering!the!thousands!of!neurons!in!even!the!smallest!nuclei.!Therefore,!a!reliable!sampling!method!that!allows!an!estimate!to!be!made!based!on!a!known!fraction!of!the!whole!structure!is!required.!!!
!




As!a!prerequisite!to!stereology,!brain!sections!of!known!thickness!must!be!taken!at!a!known!interval!and!stained.!In!this!thesis,!we!have!used!a!1!in!6!series!of!40!µm!Nissl!stained!sections!as!show!in!Figure'17.'!Although,!stereology!offers!a!way!to!attain!a!methodically!unbiased!estimate,!a!system!must!be!put! in!place!to!ensure!that!objects!to!be!measured!are!identified!in!an!accurate!and!consistent!way.!This!is!achieved!in!three!ways.!First,!the!CNS!cytoarchitecture!is!visualized!by!carefully!differentiating!Nissl! stained! sections! so! that!boundaries!between!white!and!grey!matter! become! well! defined! and! different! neuronal! nuclei! can! be! readily!delineated.!Secondly,!to!mark!the!boundaries!of!each!region!of!interest!(ROI)!‘The'
mouse' brain' in' stereotactic' coordinates’! is! used! as! a! reference! of! the! relevant!neurological! landmarks!so!that!the!rostralBcaudal!extent!of!each!structure!can!be!identified! (Paxinos! and! Franklin,! 2001),! see! Figure' 18.! Finally,! an! optical!fractionator!probe!is!used!to!count!a!known!fraction!of!neurons!(see!section'8.1'below).!
!








8.1! Optical'fractionator'probe'for'cell'number'estimation'As!described! above,! the! optical! fractionator! technique! (West!et'al.,! 2002)! allows!for!an!estimate!of!the!total!number!of!objects!in!an!area!of!interest!to!be!acquired!based!on!a!subsample!of!these!objects!in!a!known!fraction!of!the!region.!Once!the!
Figure' 18.' Representation' of' neurological' landmarks.' Example!of!a!Nissl!stained!section! in! the!midBregion!of! the!brain! (a)!and! its!corresponding! stereotactic! coordinates! (b),! with! the! the! ventral!posteromedial! and! ventral! posterolateral! (VPM/VPL)! nuclei! of! the!thalamus! highlighted! as! a! hypothetical! region! of! interest.! Adapted!from!(Paxinos!and!Franklin,!2001).!
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area! of! interest! has! been! identified! and! a! line! traced! around! the! area! at! low!magnification!(x2.5!objective),!the!counting!parameters!can!be!defined!as!follows.!A!sampling!grid! that!will!be!superimposed!onto! the!area!of! interest! to!provide!a!succession!of!systematic!sampling!sites!and!a!dissector!frame,!which!incorporates!optical! section!planes!by!moving! the! focal!plane!up!and!down,!are!chosen.! !Both!the!sampling!grid!and!the!dissector!frame!are!defined!based!on!the!size!of!the!ROI!and!the!number!of!sections!needed!to!produce!a!coefficient!of!error!(CE)!between!0.05! and! 0.1.! Counting! is! carried! out! at! x100! objective! using! strict!inclusion/exclusion!criteria.!Only!cells!within!the!counting!frame!that!meet!defined!morphological! criteria! are! counted.! This! is! defined! as! those!within! the! frame! or!touching! the! green! boundary,! while! cells! touching! the! red! line! are! excluded,!depicted! in! Figure' 19.' d.! When! counting! cells,! it! is! important! to! employ! strict!morphologicallyBbased!counting!rules!to!maintain!consistency.!Cells!were!counted!as! neurons! if! they! had! a! clearly! identifiable! nucleus,! a! large! cell! body! and!Nissl!staining!within! the! cytoplasm.! In! contrast,! astrocytes!and!microglia! (small! soma,!darkly!stained,!granular!cytoplasm)!or!cells!with!ambiguous!morphology!were!not!counted,!see!Figure'19.'d.!
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'
Figure'19.''Stereology'counting'method.'a)!Example!of!grid!size!chosen!for!the!analysis!of!primary!somatosensory!barrelfield!cortex!(S1BF).!b)'A!tracing!delineating!laminae!V!of!S1BF!cortical!region!at!x2.5.!c)!Dissector!frame!measurements.!d)'Example!of!a!counting!frame!at!x100!showing!a!number!of!neuronal!objects:!Objects!that!have!a!pink!star!represent!legitimate!neurons.!Objects!indicated!to!by!the!blue!arrows!are!microglia.!Objects!touching!the!green!line!are!neurons!that!qualify!as!within!the!frame! (pointed! out! by! the! green! arrow).! Objects! touching! the! red! line! are! neurons! that! count! as!outside!the!counting!frame!and!would!not!be!counted!(pointed!to!out!by!the!red!arrows).!!Viral!vectors!were!injected!into!the!middle!of!the!striatum.!In!order!to!assess!the!impact! of! vectorBmediated! Cln3/CLN3'expression! on! the! survival! of! transduced!striatal! cells! (Chapter'3),! neuron! counts!were! conducted!within! the! striatum! of!three!consecutive!sections;!the!section!corresponding!to!the!eGFPBstained!section!showing!the!greatest!amount!of!eGFP!immunoreactivity,!the!sections!immediately!before!and!the!section!after.!The!neurons!in!the!striatum!were!counted!in!a!1!in!6!series!of! sections!using!a!425!μm!x!425!μm!sampling!grid!and!a!70!μm!x!40!μm!dissector! frame! ensuring! a! CE! of! 0.05! –! 0.1,! indicating! adequate! sampling!efficiency.!!
!
The! thalamus! displays! significant! and! localised! glial! activation! as! well! as!pronounced!and!significant!neuronal!loss!by!5!months!of!age!in!Ppt1%/%!mice!(Kielar!
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et'al.,!2007).!By!5!months,! localised!glial!activation! is!also!present! in! lamina!V!of!the! cortex,!but!neuron! loss! in! this! region! is!not! significant!until!7!months!of! age!(Kielar!et'al.,!2007).!In!order!to!compare!neuron!loss!between!wildBtype!mice!and!each!treatment!group!(no!treatment,!AAV,!ERT!or!AAV!+!ERT!combination!therapy,!
Chapter'5)!the!regions!of!interest!chosen!to!examine!neuronal!survival!at!5!and!7!months!were!VPM/VPL!and!laminae!V!of!S1BF!(7!months!only).!The!neurons!in!the!VPM/VPL!and!S1BF!were!both!counted!in!a!1!in!6!series!of!sections!using!a!175!μm!x!175!μm!sampling!grid!and!a!70!μm!x!40!μm!dissector!frame!and!a!225!μm!x!225!μm! sampling! grid! and! a! 70! μm! x! 40! μm! dissector! frame,! respectively.! These!measurements!resulted!in!CE!values!of!0.05!–!0.1!and!as!for!the!striatum,!ensuring!adequate!sampling!efficiency.!
9! Measuring'cortical'thickness'To!assess!the! impact!of!AAV!+!ERT!combination!therapy!on!cortical!atrophy! in!5!and!7!month!old!Ppt1%/%!mice! (Chapter'5),! cortical! thickness!was!assessed! in! the!S1BF,!the!most!severely!affected!cortical!region!in!this!mouse!model!of!NCL!(Kielar!
et' al.,'2007).! Ten! perpendicular! lines! were! drawn! from! the! pial! surface! of! the!cortex!to!the!dorsal!boundary!of!the!corpus!callosum,!and!the!mean!length!of!these!lines! was! used! to! calculate! cortical! thickness! of! the! S1BF.! This! procedure! was!performed! on! three! consecutive! sections! from! 1! in! 6! mounted! Nissl! stained!sections! (the!middle! section! of! the! cortical! region! and! the! sections! immediately!before! and! after)! (Bible! et' al.,! 2004;! Cooper! et' al.,! 2007,! Pontikis! et' al.,! 2004,!Pontikis!et'al.,!2005).!Cortical!thickness!(μm)!for!each!animal!was!collected!and!the!mean!thickness!was!calculated!for!each!treatment!group!or!genotype.!
!
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10!Thresholding'analysis'The!density!of!some!immunostaining!makes! it!difficult! to!accurately!discriminate!between! individual! objects! and! therefore,! counting! these! objects! by! stereology!would!be!unfeasible.!SemiBautomated!thresholding!image!analysis!provides!a!way!to!obtain!quantitative!data!from!the!optical!density!of!immunoreactivity!visualized!through!DAB!staining!as!described!in!earlier!studies!(Bible!et'al.,!2004;!Pontikis!et'
al.,! 2004;! Pontikis! et'al.,! 2005;! Kielar! et'al.,! 2007).! This! technique! was! used! to!compare!the!relative!levels!of!GFAP!and!CD68!immune!reactivity!between!different!groups! in! both! the! CLN3! gene! therapy! (Chapter' 3)! and! the! AAV! +! ERT!combination! therapy! studies! (Chapter' 5).! Although! the! basic! technique! is! the!same,! the!sections!selected! for!analysis!depend!on! the!study! in!question.!For! the!CLN3!gene!therapy!study!(Chapter'3),!analysis!was!carried!out!in!the!striatum!and!the!sections!were!selected!in!the!same!way!as!for!stereological!analysis;!the!section!corresponding! to! the! eGFPBstained! section! showing! the! greatest! amount! of!immunoreactivity,! the! sections! immediately!before!and! the! section!after.! For! the!AAV!+!ERT!combination!therapy!study,!the!middle!of!the!nucleus!of!interest!(S1BF!or! VPM/VPL)! was! identified! using! defined! anatomical! landmarks! (Paxinos! and!Franklin,! 2001)! and! the! section! immediately! before! and! the! section! after! were!selected.! As! standard,! 30! nonBoverlapping! images! representing! the! whole! ROI!were!taken!from!3!consecutive!sections.!
!
These! images! were! captured! using! a! live! video! camera! (JVC,! 3CCD,! KYBF55B,!London,! UK),! mounted! onto! a! Zeiss! Axioplan! microscope! (Zeiss)! with! a! x40!objective! (Lambda! Photometrics! Ltd.,! Harpenden,! UK).! Lamp! intensity,! video!
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Figure' 20.' Screen' grab' of' Image' Pro' Plus' 5.0' software' during' threshold' set8up.' a)'Tissue!stained!for!glial!fibrillary!protein!(GFAP)!b)'Histogram:!red!green!blue!(RGB)! is!set!manually!to!pick!up!GFAP!staining,!this!provides!a!threshold!value!that!can!be!applied!to!all!images!of!tissue!stained!for!GFAP!at!the!same!time.!!
camera!setup!and!microscope!calibration!were!recorded!and!kept!constant!during!the!analysis!to!minimize!variability!in!the!images.!!















All!images!were!analyzed!using!ImageJ!1.49v.!This!image!processing!program!uses!a! variety! of! Java™' plugins! and! recordable! macros! to! measure! numerous!parameters! in! images! (Girish! and! Vijayalakshmi,! 2004).! For! the! purpose! of! this!study,! ROI!within! each! image!were! traced! in! colour! using! a! variety! of! selection!tools! and! applied! as! an! overlay.! Prior! to! analysis,! all! images! were! blinded! to!
Figure' 21.' ' IsolectinB4' (IsoB4)' and' wheat' germ' agglutin' (WGA)' measurement'
acquisition' using' the' Image' J' programme.' a)! IsoB4! positively! stained! endothelial! cell!membranes!within!one!region!of! interest! (ROI)!(total!4),!which!can!be!marked!and!counted!using! the! paintbrush! tool.! b)' WGA! positively! stained! myocyte! membranes,! with! one!membrane!(total!30)!traced!using!the!freehand!selection!tool.'
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prevent!experimenter!bias.!To!determine!differences!in!the!number!of!endothelial!cells!within!the!left!ventricular!wall!between!wildBtype!and!Cln3%/%!and!Ppt1B/B!mice!at! the! different! time! points,! 4! frames! measuring! 300! pixel! width! by! 300! pixel!height! were! randomly! constructed! over! each! image.! The! number! of! endothelial!cells! in! each! frame!were! counted!manually! (Figure'21.'a)! and! recorded!and! the!average! value! of! the! 4! frames!was! calculated.! This! process!was! repeated! for! all!images.! To! identify! differences! in! myocyte! size,! 30! myocytes! were! selected! at!random! and! their! cell!membrane! borders!were! traced!manually! (Figure'21.' b).!Using! the! “ROI!manager”,! the! area!of! each!myocyte! outlined!was! calculated,! and!the!average!myocyte!size!for!each!image!was!calculated.!This!process!was!repeated!for!all!images.!!
12!Fibrosis'analysis'The! dye! picrosirus! red! stains! collagen! and! is! considered! a! marker! of! cardiac!fibrosis!(Puchtler!et'al.,'1973;!Junqueira!et'al.,!1979).!SemiBautomated!thresholding!analysis! was! used! to! quantify! the! area! of! staining! as! a! measure! of! the! relative!amount! of! fibrosis! present! in! both!wildBtype! and!Cln3%/%! and!Ppt1B/B!mouse!heart!tissue!at!different!ages! in!Chapter'4.!The!same!basic! technique!used!to!compare!the! relative! levels!of!GFAP!and!CD68! immune! reactivity!described! in!section'10!was!used!with!the!following!adjustments:!4!consecutive!sections!at!the!level!of!the!right!and!left!ventricle!were!analysed.!However,!the!precise!strategy!for!collecting!images! for! analysis!differed!between! the!6!month!old!Ppt1B/B!vs.!wildBtype!group!and!the!12!and!18!month!old!Cln3%/%!vs.!wildBtype!groups.!Ppt1%/'vs.!wildBtype!mice!were!analyzed!early!on!in!the!study!using!thresholding!analysis!on!a!single!image!of! the! whole! heart! section! at! x5! magnification,! obtained! using! an! automatic!panoramic!“stitching”!feature!available!with!the!microscope!software!used!(Image'
! 188!
Pro'Plus).! In!contrast,!12!and!18!month!old!Cln3%/%'vs.! control!mice!were!analyzed!later! on! in! our! investigation! and! at! this! time,! it! was! not! possible! to! carry! out!analysis! using! the! same! method! due! to! issues! with! the! microscope! software.!Instead,! the! level! of! fibrosis! in! these!mice! was! evaluated! by! taking! 30! abutting!images! throughout! the! myocardium! of! the! whole! heart! section! at! x40!magnification.!Both!approaches!were!carried!out!using!a! live!video!camera!(JVC),!mounted! onto! a! Zeiss!Axioplan!microscope!with! x5! and! x40! objectives! (Lambda!Photometrics! Ltd.)! and! subsequent! thresholding! analysis! was! carried! out! as!described!in!section'10.!
!
13!Qualitative'analysis'Some!staining!was!able!to!provide!useful!qualitative!information!without!the!need!for!quantification.!For!example,! staining! for!SA!node!markers! in!Ppt1%/%!mice!and!the! presence! of! CD45! positive! cells! in! the! hearts! of! 18! month! old! Cln3%/%! mice!(Chapter' 4).! In! these! cases,! samples! were! blinded! to! genotype! and! an! initial!assessment!of!the!stained!section!was!carried!out!first!to!identify!positive!staining!and!then!to!establish!whether!the!staining!was!interesting!in!terms!of!quantity!or!morphology! of! the! stained! objects.! If! so,! representative! pictures! were! taken!throughout! the! tissue! using! an! appropriate! objective! (x5,! x10,! x20,! x40! or! x63!depending!on!the!region!and!size!of!stained!objects!of! interest)!on!a!Leica!DMRB!microscope!(Leica!Mikroskopie!&!Systeme!GmbH,!Wetzlar)!with!a!Zeiss!AxioCam!HRc!Rev!2!digital!camera!and!processed!using!AxioVision!(version!4.7.2)!software.!Images!were!then!examined!to!observe!the!morphology!of!objects!of!interest!and!distribution!of!staining.!
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al.,! 2010).! It! affects! 1! E! 5! in! 100! 000! children! worldwide! but! has! a! higher!prevalence! in! Northen! Europe! (Lerner! et# al.,! 2001).! Most! children! develop!symptoms!at!around!7!years!of!age!and!finally!succumb!to!the!disease!after!two!to!three! decades! of! poorly! treated! symptoms! including! blindness,! cognitive! and!motor!impairment!and!epilepsy!(Munroe!et#al.,!1997;!Hofman!et#al.,!1999;!Lerner,!2001).!CLN3!disease!patients!also!display!a!number!of!psychiatric!symptoms!e.g.!aggression,!depression!and!sleep!disturbances!(Williams!et#al.,#2006).!Although!the!causative! gene! CLN3,! was! one! of! the! first! genes! underlying! a! human! NCL! to! be!cloned! (The! International! Batten! Disease! Consortium,! 1995)! and! more! than! 40!mutations! in! the! gene! have! been! identified,! the! normal! function! of! the! CLN3!protein! and! how! these! mutations! lead! to! disease! is! still! unclear!(http://www.ucl.ac.uk/ncl;!Cooper,!2008;!Getty!and!Pearce,!2011).!This! is!at! least!partly!due! to! the! lack!of!specific!antisera! that!recognize!endogenously!expressed!CLN3!making!it!difficult!to!arrive!at!a!consensus!as!to!its!intracellular!location!and!topography!(Haskell!et#al.,!2000;!Mao!et#al.,!2003).!As!long!as!these!blind!spots!in!our! knowledge! exist,! finding! specific! mechanistically! focused! treatments! will!remain! a! challenge.! Furthermore,! CLN3! is! a! hydrophobic,! integral! membrane!protein!and! is!not! secreted! in!a!precursor! form! that!enables!uptake!via! the!MP6!receptor!(Janes!et#al,!1996,!Michalewski!et#al.,!1999;!Kaczmarski!et#al.,!2003;!Mayo!
et#al.,!2003;!Rakheja!et#al.,!2008;!Getty!and!Pearce,!2011).!Therefore,!unlike!NCLs!that!are!caused!by!an!enzyme!deficiency,!therapeutic!approaches!such!as!enzyme!replacement! and! gene! therapy! cannot! take! advantage! of! “crossEcorrection”!
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(Fratantoni!et#al.,!1968,!1970;!Kornfeld,!1992;!Haskell!et#al.,!1999;!Mao!et#al.,!2003;!Phillips!et#al.,!2005;!Kyttälä!et#al.,!2005;!Sands!and!Davidson,!2006).!!
1.2! Gene(therapy(–(a(novel(approach(for(treating(CLN3(disease(As! discussed! in! section( 5.7( of! Chapter( 1,! most! of! the! progress! made! towards!developing!a!therapy!for!CLN3!disease!has!been!in!blocking!various!aspects!of!its!pathology.! This! has! involved! the! use! of! glutamate! receptor! antagonists! (Kovacs!and!Pearce,!2008,!Kovacs!et#al.,!2011),!or!inhibiting!the!autoimmune!response!with!immunosuppressant! drugs! (Chattopadhyay! et# al.,! 2002a,! Seehafer! et# al.,! 2011),!which! is! currently! being! tested! in! a! phase!2! trial! at! the!University! of!Rochester,!USA! (https://www.clinicaltrials.gov/ct2/show/NCT01399047).! However,! these!therapies!do!not!halt! or! reverse! the!primary! cause!of!CLN3!disease! and!provide!relatively! limited!therapeutic!efficacy.!Approaches!that!directly!target!the!genetic!defect!that!underlie!CLN3!disease!are!far! less!established.!Since!the!effects!of!the!CLN3!protein!deficiency!are!widespread,!such!a!treatment!approach!would!ideally!restore!CLN3!protein! in!a! large!portion!of!the!brain.!AAVEmediated!gene!transfer!potentially! provides! a! delivery! system! that! can! achieve! this! kind! of! distribution,!importantly,!without!the!integration!of!the!vector!DNA!into!the!host!genome.!Over!the! past! decade,! various! naturally! occurring! and! laboratory! designed! AAV!serotypes!have!become!popular!vectors!for!experimental!gene!therapy!approaches!for!neurological!disease!(Weinberg!et#al.,#2013).!Their!growing!popularity!is!owed!to!a!number!of!factors,!which!make!them!valuable!vehicles!for!gene!delivery!to!the!CNS!(Weinberg!et#al.,#2013).!Namely,!AAV!is!capable!of!infecting!both!dividing!and!quiescent!cells,!can!successfully!infect!and!transduce!a!wide!variety!of!different!cell!types,!facilitates!longElasting!expression!from!a!single!delivery!(over!1.5!years)!and!
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exhibits!no!pathogenicity!(Choi!et#al.,#2005).!!Such!AAV!vectors!have!already!been!used!to!treat!the!neurological!defects!in!mouse!models!of!other!LSDs,!as!well!as!in!clinical! trials! (Janson! et#al.,! 2002;! Griffey! et#al.,! 2004,! 2005,! 2006;! Crystal! et#al.,!2004;! Taupin,! 2006;! Fisch! et# al.,! 2005;! Sladek! et# al.,# 2005;! Sands! et# al.,! 2006;!Passini!et#al.,!2006;!Sands!and!Davidson,!2006;!Shihabuddin!et#al.,!2006;!Crystal!et#
al.,! 2006;! Sondhi! et#al.,! 2007;! Greenwald! et#al.,! 2008;!Worgall! et#al.,! 2008;! Gritti,!2011;!Mingozzi!and!High,!2011,!Leone!et#al.,!2012;!Rafi#et#al.,!2012,!Tomanin!et#al.,!2012;!Crystal!et#al.,!2014).!!
!
Up!until!recently,!AAVEmediated!gene!transfer!was!almost!exclusively!considered!as!a!treatment!for!enzymeEdeficient!LSDs!and!overElooked!as!a!worthwhile!option!for! CLN3!disease! because! of! the! lack! of! “crossEcorrection”.!However,! this! is! now!changing! as! recent! studies! have! begun! to! challenge! this! dogma! (Hughes! et# al.,!2011;! Crystal! et#al.,! 2014).! Only! cells! that! are! directly! transduced! by! wildEtype!CLN3!expressing!AAV!vectors!are!likely!to!be!corrected!and!therefore,!widespread!transduction!is!preferable.!However,!these!corrected!cells!might!also!influence!the!secretion! of! other! factors! that! are! normally! regulated! by! CLN3,! thus! offering! an!alternative!way!to!correct!neighbouring!cells!(Sondhi!et#al.,!2014).!!!
!
1.3! Aims(and(hypotheses(Originally,!the!overall!aim!of!this!study!was!to!assess!the!safety!of!using!AAV2/9Emediated!CLN3! gene! transfer! in! a!mouse!model! of! CLN3!disease.! To!do! this,!we!used!a!series!of!bicisitronic!vectors!expressing!either!mouse!or!human!Cln3/CLN3!together! with! eGFP! as! a! surrogate! marker! for! Cln3/CLN3! expression! and! an!
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AAV2/9! vector! expressing! eGFP! alone! as! a! control.! Each! of! the! vectors! were!administered!to!the!right!caudate!putamen!(CPu),!or!striatum!as!it!will!be!referred!to!in!the!main!text!of!this!chapter,!of!3!and!7.5!month!old!Cln3G/G!mice!together!with!ageEmatched!wildEtype!control!mice!and!then!sacrificed!2!and!6!months! later! for!evaluation.!!!However,!due!to!unforeseen!and!fundamental!errors! in!procedures! in!the!animal!facility!during! the! initial!breeding!of!our!Cln3G/G!mice,!a! large!proportion!of! these!mice!were!subsequently! found!to!have! incorrect!genotype!(i.e.!were!wildEtype!or!heterozygous!instead).!This!was!beyond!our!control!and!occurred!before!the!start!of!this!project,!but!in!part!due!to!the!slowly!progressive!phenotype!of!these!mice!did!not!become!apparent! for!some!time.!By! the! time! the!problem!was! identified,!the! surgery!and!survival!was!already!complete!and! the!histological! analysis!well!underway.!As!such,!we!had!to!reEgenotype!all!the!mice!in!this!study!from!the!tissue!that!had!been!harvested!from!them!and!the!smaller!number!of!mice,!which!had!the!correct! genotype! and!were! therefore! still! suitable! for! analysis,! was! determined.!The!original!experimental!plan!and!the!adaptions!made!after!the!procedural!errors!in!the!animal!facility!were!discovered!are!outlined!in!the!section!below.!!We!hypothesised!that!gene!therapy!may!be!a!possible!treatment!for!CLN3!disease,!but! that! responses! to! the! vector! and! CLN3! overEexpression! may! represent! a!challenge,!that!would!have!to!be!overcome.!!
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2! Experimental(plan(and(methods(
2.1! Why(mice?(As!discussed!in!Chapter(1,!section(3.1.a,(the!conservation!of!genes!between!many!different! species! has! allowed!us! to! use! a! number! of! animal!models! to! study! the!NCLs,!from!yeast!(Pearce!and!Sherman,!1998;!Pearce,!2001;!Gachet!et#al.,!2005)!to!larger!animals!such!as!sheep!(Broom!et#al.,!1998;!Tammen!et#al.,!2001;!Frugier!et#
al.,!2008),!cow!(Houweling!et#al.,!2006)!and!pig!(Cesta!et#al.,#2006).!These!models!have! been! instrumental! in! shedding! light! on! different! aspects! of! NCL! pathology!(Phillips! et# al.,! 2006;! Pears! et# al.,! 2006,! Bond! et# al.,#2013).! However,! the! most!widely! used! strategy! for! modelling! these! diseases! is! the! use! of! mice.! This! is!because!unlike!smaller!models!like!yeast!or!flies,!which!provide!useful!information!about! the! molecular! mechanisms! of! disease,! mice! offer! a! biological! system!somewhat! akin! to! ours! in! which! genes! can! be! manipulated! and! the! resulting!phenotypes! characterized! (Palmer! et# al.,! 2013,! Shacka,! 2012;! Perrin,! 2014).!Furthermore,!although!larger!animals!like!sheep!more!closely!recapitulate!human!disease!due! to! their!greater! level!of!biological!complexity,!mice!can!be!bred!on!a!larger! scale! within! a! short! period! of! time! and! have! a! relatively! short! life!expectancy.!As!a!result!of!mouse!studies,!we!now!have!a!better!understanding!of!the!mechanism!of!disease,!have!established!landmarks!of!disease!progression!and!have!also!been!able!to!identify!therapeutic!targets!such!as!gene!therapy!(Cooper!et#
al.,#2015).!!!To!evaluate!the!feasibility!of!using!AAV2/9Emediated!CLN3!gene!therapy!in!CLN3!patients,! it! is! fundamental! that!we! first! establish!whether! a)! it! is! safe,! as! is! the!focus!of!this!study!and!b)!whether!it!is!therapeutically!effective.!Through!the!use!of!
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mouse!models,!we!can!address!these!questions!systematically!by!a)!assessing!the!glial!and!neuronal!response!to!CLN3!gene!transfer!within!the!disease!environment!at!various!stages!and!b)!measuring!its!impact!on!wellEdefined!disease!phenotypes!(Cooper!et#al.,!2006).!!!As! discussed! in! Chapter( 2,! section( 1.1( and! 1.2,! homologous! recombination!techniques!have!led!to!the!creation!of!Cln3Δex7/8!and!Cln3G/G!mouse!models!of!CLN3!disease! (Mitchison! et#al.,! 1999! and! Cotman! et#al.,! 2002).! Ideally,! Cln3Δex7/8! mice!could! be! considered! preferable! for! this! study! as! they!more! precisely!mimic! the!human!1!kb!deletion!and!are!therefore!plausibly!the!most!accurate!model!to!test!CLN3!gene!transfer!(Cotman!et#al.,!2002;!Brakebusch,!2010;!Staropoli!et#al.,#2012).!However,! because! they!needed! to!be! rederived! these!mice!were!not! available! in!sufficient!quantity!at!the!start!of!this!project,!and!therefore!Cln3G/G!mice!were!used.!Relatively! few! differences! in! the! phenotypes! of! Cln3Δex7/8! and! Cln3G/G! mice! have!been! reported! and! these! may! be! largely! due! to! differing! strain! backgrounds.!Nonetheless,!as!the!objective!of!the!study!was!not!to!investigate!the!mechanism!of!disease!resulting!from!the!genetic!mutation!but!rather!the!effects!of!gene!therapy!within! a! pathological! environment,! Cln3G/G! mice! provide! an! adequate! model! for!assessing!safety!as! they!display!effectively! the!same!pathology!as!Cln3Δex7/8!mice.!When! they! became! available! a! small! cohort! of! Cln3Δex7/8! mice! was! originally!included! to! compare! to! the! corresponding! Cln3G/G! mice! (see! Figure( 23),( but!following!the!genotyping!issues,!these!mice!became!a!more!important!part!of!this!study!as!shown!in!Figure(25.!!
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2.2! Experimental(vectors(Three!vectors!were!produced!as!described!in!section(3.1(and!illustrated!in!Figure(
11(of!Chapter(2.(Each! vector! served! a! specific! purpose.!The!CLN3!experimental!vectors! AAV2/9.CMV.mCln3EIRESEeGFP! (AAV2/9.mCln3.eGFP 1 )# and!AAV2/9.CMV.hCLN3EIRESEeGFP! (AAV2/9.hCLN3.eGFP)#were! created! to! assess! the!effects! of! Cln3/CLN3# expression! while! AAV2/9.CMV.eGFP! (AAV2/9.eGFP)# was!created!as!a!control!to!discern!which!if!any!of!these!changes!were!associated!with!the!vector!itself!or!expression!of!the!reporter!gene.!We!used!two!different!versions!of!Cln3,! one! expressing! the! human! form!of!CLN3! and! another! expressing!mouse!
Cln3! to! reflect! the! allogeneic! scenario! in! which! gene! therapy! would! be!administered.!!
2.3! Experimental(design(The!location!of!the!injections,!age!of!the!mice!at!the!time!of!injection!and!the!stage!at!which!the!mice!are!sacrificed!are!important!considerations!in!order!to!properly!judge! the! effects! of! CLN3! gene! therapy.! The! striatum!was! chosen! as! the! site! of!injection!because!of!its!large!size!and!relative!homogeneity,!which!allow!the!effects!of! the! vector! to! be! easily! measured! at! the! injection! site! and! at! a! increasing!distances! from! it.! Studies! have! shown! that! early! administration! of! gene! therapy!might!confer!a!better!therapeutic!outcome!(Waddington!et#al.,!2012).!However,!in!this!study!mice!were!injected!at!3!and!7.5!months!of!age!in!order!to!compare!how!the! response! of! the! brain! to! gene! therapy! differs! at! different! stages! of! disease!progression.!To!assess!the!shortE!and!longEterm!effects!of!each!vector!in!terms!of!protein! expression! and! the! glial! and! neuronal! response! to! this! expression! over!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!The!gene!eGFP!is!represented!as!eGFP!in!the!bicistronic!vectors.!
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time,!mice!were!sacrificed!at!2!and!6!months!after!injection.!As!such,!by!injecting!the!vectors!and!sacrificing!mice!at!these!survival!times,!the!resulting!brain!tissue!was!harvested!at!between!5!and!13.5!months!of!age.!As!pathology!in!the!striatum!is! relatively! limited!until!much! later! in! the!disease,! this! circumvents! any!glial! or!neuronal!changes!as!a!result!of! the!gene! therapy!treatment!being!masked!by! the!immune!and!neuronal!responses!that!occur!in!the!striatum!as!part!of!the!disease!cascade.!An!overall!summary!of!the!experimental!plan!is!outlined!in!Figure(22.!!
2.4! Control(groups(to(assess(vector(and(injection(related(effects(To!assess!how!the!vectors!behave!specifically!within!a!diseased!brain!compared!to!a!wildEtype!brain!and!how!this!changes!over!time,!it!was!important!that!each!Cln3Edeficient!mouse!had!a! corresponding!wildEtype!control! (see(Figure(22).!We!also!included!three!additional!control!groups!as!a!result!of!our!pilot!studies,!described!in!section(3.3(of! this! chapter.!Firstly,!by! injecting! the! right! striatum!and! leaving!the!left!striatum!uninjected,!we!were!able!to!create!an!internal!control!to!allow!a!direct! comparison! to! be! made! between! injected! and! uninjected! hemispheres.!Secondly,! in! order! to! discriminate! between! changes! caused! by! either! a)! the!mechanical! trauma!created!by! the!needle!during!vector! administration!or!b)! the!pressure!imposed!upon!the!brain!as!a!result!of!injecting!a!relatively!large!volume!(1!µl)!into!it,!we!carried!out!a!number!of!shamEoperated!and!vehicle!only!injections!for!each!of!the!two!survival!points!(see(Figure(24).!!As! mentioned! in! the! Introduction( to! this! chapter,! the! unexpected! genotyping!issues!we!encountered!had!devastating!effects!on!the!original!experimental!design!and!forced!us!to!change!the!direction!of!the!project.!After!reEgenotying!the!Cln3G/G! !
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Cln3Δex7/8#mice!were! injected!with!each!of! the!vectors! at!7.5!months!of! age!and! sacrificed!after!2!months! to!compare!to!Cln3G/G!mice!injected!at!7.5!months,!sacrificed!after!2!months.!n!=!4!per!group.!!
!
Figure( 24.( Schematic( representation( of( control( groups( used.(WildEtype! mice! received! either! a! shamEoperated! injection! or! an! injection! of! 1! µl! of! endotoxinEfree! phosphate! buffered! saline! (PBS)! and! were!sacrificed!after!2!or!6!months.!Mice!that!were!sacrificed!2!months!after!injection!were!used!as!controls!for!1)!WildEtype! and!Cln3G/G##mice! injected! at! 3!months,! sacrificed! after! 2!months! and!2)!WildEtype! and!Cln3G/G#mice!injected!at!7.5!months,!sacrificed!after!2!months.!While!mice!that!were!sacrificed!after!6!months!were!used!as!controls!for!3)!WildEtype!and!Cln3G/G#mice#injected!at!3!months,!sacrificed!after!6!months!and!4)!WildEtype!and!
Cln3G/G#mice#injected!at!7.5!months,!sacrificed!after!6!months.!n!=!6!per!group.!!of! wildEtype!mice,! which!were! unaffected! by! the! genotyping! discrepancies.! This!was!still!informative!as!it!provided!us!with!information!about!how!the!response!to!each! of! the! vectors! changes! over! time.! Fortunately,! two! mouse! populations!remained!partly!intact!for!analysis!although!with!a!reduced!number!of!2!E!4!mice!per!treatment!group.!These!were!the!Cln3G/G!mice#injected!at!3!months!of!age!and!sacrificed!after!2!months!and!the!Cln3Δex7/8!mice! included!as!a!comparison!to! the!





Figure( 25.( Schematic( representation( of( mice( excluded( from( the( study( following( discrepancies( in(
genotype.(The! red! numbers! indicate! the!mice! that!were! confirmed! as! true!Cln3G/G!mice! after! reEgenotyping.!The!dark!boxes!outlined!with!a!red!border!represent!the!groups!of!mice!that!were!so!severely!affected!by!the!genotyping!issue!they!had!to!be!excluded!with!the!exception!of!those!highlighted!in!the!yellow!boxes.!!
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3! Results(
Prior! to! carrying! out! any! experiments!within! the! brain,! a! series! of! in#vitro#pilot!studies! were! conducted! to! assess! the! properties! of! our! experimental! AAV2/9Emediated! viral! vectors! in! neuronal! cultures,! in! terms! of! their! transduction!efficiency! and! potential! for! being! toxic.! As! discussed! in!Chapter( 2,! section(3.1,(AAV2/9Emediated!viral!vectors!are!efficient!at!delivering!a!transgene!to!the!brain!(reviewed!in!Dayton!et#al,#2012;!Aschauer!et#al.,#2013),!making!them!ideally!suited!for! the! study! of! experimental! gene! therapy! treatments! of! monogenic! brain!diseases.! Before! AVV2/9Emediated! gene! therapy! treatments!might! be! tested! for!their! therapeutic! efficacy! in! CLN3! disease,! we! considered! that! a! thorough!evaluation!of!their!transduction!efficiency,!the!resulting!transgene!distribution!and!any!associated!adverse!response!to!either!the!vector!itself!or!the!expression!of!the!gene! of! interest! (in! this! case! either! mouse! (Cln3)#of! human! (CLN3)! should! be!established! in#vivo.!To!answer!these!questions!we!investigated!the!distribution!of!immunoreactivity! for! the! eGFP! reporter! gene! expressed! by! AAV2/9.eGFP,!AAV2/9.mCln3.eGFP#and#AAV2/9.hCLN3.eGFP!and!in!areas!corresponding!to!eGFP!positivity,!analysed!astrocytosis,!microglial!activation!and!neuron!loss.!!!
3.1! Vector(transduction(in(E15N17(striatal(neuronal(cultures(Before! carrying! out! an! in#vivo! study! to! test! the! feasibility! of!AAVEmediated! gene!therapy!for!CLN3!disease,!we!first!conducted!a!series!of!in#vitro#pilot!studies!to!test!the! MOI! necessary! to! achieve! vector! transduction,! whether! there! was! any! cell!death! associated!with! vectorEdriven! gene! expression! and!which! cell! types! these!vectors!were!capable!of!transducing.!!
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a)! Determining(an(appropriate(MOI(for(vector(transduction(in(wildNtype(
E15N17(striatal(cultures(As! a! transmembrane! protein,! CLN3! cannot! be! released! to! “crossEcorrect”!neighboring! cells.! Therefore! to! have! any! significant! therapeutic! effect! the! vector!chosen! for! gene! therapy! in! CLN3! disease! must! be! capable! of! widespread!transduction.! Having! been! shown! to! achieve! robust! expression! in! the! CNS!following! intracranial! injection! compared! to! other! AAV! serotypes,! AAV2/9Emediated!viral! vectors! are! especially! good! candidates! for! this! sort!of! application!(Cearley!and!Wolfe,!2006).!However,!there!is!a!caveat!that!makes!the!transduction!capability! of! these! vectors,! like! any! system! in! which! Cln3! is! overEexpressed,!potentially! undesirable.! Studies! in! Drosophila! have! shown! toxic! effects! of! Cln3!overEexpression,!causing!pronounced!neurodegeneration!(Tuxworth!et#al.,!2009).!Therefore,! the! level! of! Cln3! expression! that! might! confer! therapeutic! benefit!should!be!carefully!balanced!before! reaching!a! level!at!which!a!neurotoxic!effect!might!manifest.!As!such,!the!first!pilot!experiment!was!carried!out!to!determine!a!suitable! MOI! at! which! to! infect! wildEtype! E15E17! striatal! neuronal! cells! with!AAV2/9.eGFP!and!to!determine!whether!there!was!any!associated!neuron!toxicity.!Once! the! cultures! had! been! prepared! as! described! in! Chapter( 2,( section( 2,(neurons! and! glia! were! infected! with! varying! concentrations! of! AAV2/9.eGFP!corresponding!to!an!MOI!of!10,!100!(data!not!shown),!1,000,!10,000!and!100,000!for!3!days,!using!4!technical!replicates.!Subsequently,!cells!were!treated!with!a!red!
LIVE/DEAD®#dye,!fixed!and!stained!for!the!reporter!gene!eGFP!in!order!to!identify!transduced! cells.!We! assessed! the! level! of! vector! transduction! in! cells! following!infection!and!looked!for!any!associated!cell!death!by!surveying!the!cultures!for!coElocalisation! between! eGFP! immunoreactivity! and! red! dye! that! marks! dying!neurons!(see(Figure(26).!
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Qualitative!analysis!of!each!coverslip!revealed!that!above!an!MOI!of!1,000!the!level!of! vector! transduction! with! AAV2/9.eGFP! treatment! increases! as! the! MOI!increases,!but!even!at!an!MOI!of!100,000,!complete!transduction!of!these!cultures!was!not!evident!(Figure(26.(c).!By!including!a!‘No!virus’!control,!we!were!able!to!examine!the!amount!of!cell!death!in!these!cultures!independent!of!treatment!with!AAV2/9.eGFP!and!found!that!although!more!cell!death!occurred!than!expected,!the!level!did!not!differ!between!untreated!and!treated!cells!or!change!with!increasing!MOI!(Figure(26.(d,(h,(l,(p).!Therefore,!within!the!chosen!range,!an!MOI!of!100,000!appeared!most! suitable! for! achieving! the! greatest! level! of! transduction! without!causing!appreciable!cell!death.!!
b)! WildNtype(and(Cln3Ndeficient(E15N17(neuronal(cultures(are(both(















































Interestingly,! we! were! unable! to! detect! any! eGFP! protein! expression! in! cells!infected!with!the!AAV2/9.mCln3.eGFP'or!AAV2/9.hCLN3.eGFP!vectors!at!the!same!concentration,!even!at!increased!exposure,!see!Figure'28.'c'and'g.!In!wildEtype!and!Cln3+deficient!cells!that!were!infected!with!AAV2/9.eGFP,!we!were!able!to!assess!the! ability! of! the! vector! to! transduce! cells! and! determine! whether! this! had! a!neurotoxic! effect.! ! By! assessing! the! expression! of! eGFP! after! infecting! cells!with!AAV2/9.mCln3.eGFP!and!AAV2/9.hCLN3.eGFP,!we!wanted!to!detect!the!amount!of!vectorEdriven! Cln3/CLN3! expression! and! assess! whether! overEexpression! of!






























associated! with! the! vector! up! to! an! MOI! of! 100,000.! We! also! concluded! that!following! infection!with! the!Cln3/CLN3>expressing!vectors,! it!was!not!possible! to!detect!eGFP!expression!in)vitro.!As!will!be!discussed!in!the!Discussion((section(6)!of!this!chapter,!we!tried!a!number!of!different!Cln3/CLN3!antibodies!with!limited!success! so! we! were! unable! to! stain! for! Cln3/CLN3! expression! directly.! As!mentioned!in!Chapter(2,(section(7,(one!potential!explanation!for!these!findings!is!that! the!second!signal! from!bicistronic! IRES!vectors! is! sometimes!expressed!at!a!lower! level! compared! to! the! first! (reviewed! in! Ngoi! et) al.,)2004;! Martin! et) al.,)2006).!Therefore,! to!confirm!the!expression!of!eGFP! at! the!mRNA! level! following!transfection! with! each! viral! vector,! we! carried! out! TaqMan®! RT>qPCR! and! GFP!immunohistochemistry!using!brain!tissue.!!!
3.2! Detecting(AAV2/9:driven(Cln3/CLN3(expression(in)vivo(Two!pilot!experiments!were!conducted!to!confirm!and!compare!the!vector>driven!expression!of!Cln3!from!AAV2/9.mCln3.eGFP)and!CLN3!from!AAV2/9.hCLN3.eGFP.!In! the! first! experiment,! two! independent! methods,! TaqMan®! RT>qPCR! and!immunohistochemistry,!were! used! to! detect! the! expression! of!Cln3/CLN3)on! the!mRNA!and!protein!level.!For!the!second!experiment,!TaqMan®!RT>qPCR!alone!was!used! to! compare! vector! expression! across! all! three! vectors! in! wild>type! mice.!Because!the!purpose!of!these!experiments!was!not!to!investigate!the!impact!of!the!vectors!on!the!brain,!both!pilot!studies!were!carried!out!in!wild>type!mice!only.)!
a)! Detection(of(Cln3/CLN3(expression(Three!wild>type!mice!received!bilateral!injections!into!the!striatum!(one!to!the!left!and! one! to! the! right,! injection! sites! as! per! section( 3.2( of! Chapter( 2)! with!
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AAV2/9.eGFP,)AAV2/9.mCln3.eGFP)and!AAV2/9.hCLN3.eGFP.!After! 2!weeks,!mice!were!euthanized!for!analysis!of!transgene!and!protein!expression.!Each!brain!was!bisected!and!one!side!was!divided!into!three!equal!coronal!parts!and!flash!frozen!in!liquid!nitrogen!for!RNA!extraction,!while!the!other!half!was!immersion!fixed!in!4%!PFA!for!histological!analysis.!!!Whilst! it! was! possible! to! directly! detect! the! expression! of! human! CLN3) from!AAV2/9.hCLN3,! AAV2/9.eGFP! does! not! express! Cln3) at! all! and! AAV2/9.mCln3!expresses! mouse! Cln3,)which! is! indistinguishable! from! endogenous! mouse)Cln3.!One!way! to! resolve! this!would!be! to!establish! the!baseline!of!Cln3)expression!by!including!untreated!wild>type!mice!of! the! same!age!or! the! left!hemisphere!as!an!internal!control!or!using!the!expression!of!IRES.!As!such,!primers!were!designed!to!detect! eGFP! expressed! by! AAV2/9.eGFP,! the! IRES! portion! expressed! by!AAV2/9.mCln3.eGFP! and! human! CLN3! expressed! by! AAV2/9.hCLN3.eGFP.! This!enabled!us!to!detect!gene>expression!driven!by!each!of!the!vectors!but!as!different!primers! were! used,! the! level! of! gene! expression! between! the! vectors! could! not!accurately!be!compared.!!!




















(!!As! a! result,! the! site!of! injection!may!have! fallen! inconsistently!between! region!1!and!2.!!Therefore,!the!region!with!the!highest!cycle!threshold!(Ct)!value!was!used!to!determine!the!actual!region!within!which!the!injection!was!contained.(!The! AAV2/9.eGFP>treated! wild>type! mouse! had! very! similar! levels! of! eGFP!expression!along! the! rostral>caudal! axis!of! the! injected!brain,!with! expression!of!this!gene!equal!in!regions!2!and!3,!and!only!slightly!lower!in!region!1!(Figure(29).(This! suggests! that! AAV2/9.eGFP! has! broad! transduction! capability! and! drives!expression! equally! throughout! the! brain.( Conversely,! the! AAV2/9.mCln3.eGFP>treated!mouse!had!higher!levels!of!IRES!expression!in!region!1!where!the!injection!
Figure( 29.( Vector:driven( transgene( expression.( TaqMan®! RT>qPCR!assessment! of! mRNA! levels! of! AAV2/9.eGFP>driven! eGFP,!AAV2/9.mCln3.eGFP>driven! mouse! Cln3) and! AAV2/9.hCLN3.eGFP>driven!human!CLN3.!The!right!vector>injected!hemisphere!(striatum)!of!each!wild>type!mouse!was!cut!into!3!pieces!(rostral,!middle,!caudal).!1,!2,!3!represent!each! brain! region! (rostral! –! caudal).! TaqMan®! RT>qPCR! with! relative!quantitation!(house! keeping!genes!were!β>Actin,!ATP5b! and!RPL13a)!was!used! to! assess! the! expression! level! of! eGFP! driven! by! AAV2/9.eGFP,! the!IRES!portion!driven!by!AAV2/9.mCln3.eGFP!(mCln3.eGFP)!and!human!CLN3!driven!by!AAV2/9.hCLN3.eGFP!(hCLN3).!n!=!1!for!each!vector.!
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had! been! directed,! but! there!was! a! gradual! reduction! in! the! level! of! expression!along!the!rostral>caudal!axis,!with!only!half!the!amount!of!expression!in!region!3!compared! to! region! 1! (Figure( 29).! Wild>type! mice! that! were! injected! with!AAV2/9.hCLN3.eGFP!appeared! to!have! the!most!variable!expression.!The!highest!amount! of! hCLN3! expression! was! in! region! 2! (where! the! injection! was! placed).!However,! unlike! AAV2/9.mCln3.eGFP! which! showed! a! steady! reduction! in!expression! levels! towards! the! caudal! part! of! the! brain,! the! lowest! level! of! gene!expression!was!found!in!region!1!at!half!the!level!of!expression!compared!to!region!3,!which! in! turn! showed!half! the! amount! of! expression! as! region!2! (Figure(29).!There! are! three! potential! explanations! for! the! difference! in! the! pattern! of! gene!expression!between!the!three!vectors.!The!first!explanation!is!that!AAV2/9!vector>driven!gene!expression!is!dependent!on!location!within!the!brain.!Although!this!is!consistent! with! previous! findings! showing! that! the! ability! of! AAV9! to! drive!transgene! expression! (GFP! only)! varies! between! brain! regions,! there! is! no!evidence! to! suggest! that! this! is! further! dependent! on! the! transgene! being!expressed! (Aschauer! et) al.,) 2013).! The! second! explanation! is! that! the!administration!of!vector!or!the!spread!of!the!vector!after!infusion!is!variable.!The!most!likely!explanation!is!that!the!brains!were!not!dissected!equally.!In!the!mouse!brain! injected! with! AAV2/9.eGFP,! the! expression! of! eGFP! was! detected!proportionately!between!regions!1,!2!and!3!suggesting!that!the!brain!was!divided!into! three! equal!parts! and! the! injection! site! (striatum)!was! captured! in! region!2!allowing!for!equal!distribution!of!vector!along!the!rostral>caudal!axis!of!the!brain.!However,! in! the! mouse! brain! injected! with! AAV2/9.mCln3.eGFP! where! the!expression!level!of!IRES!was!not!detected!equally!along!the!rostral>caudal!axis,!it!is!possible!that!region!1!was!larger!than!region!2!and!region!2!larger!than!region!3,!leading!to!a!gradient!of!vector!distribution!(Figure(29).!The!same!reasoning!could!
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also! explain! the! expression! pattern! in! the! mouse! injected! with!AAV2/9.hCLN3.eGFP.! Inconsistency! in! the!precise!dissection!performed,!or! in! the!placement! of! injection! sites,! might! explain! the! different! patterns! of! expression!shown!in!Figure(29.(!This!small!pilot!study!was!carried!out!to!confirm!vector>driven!gene!expression!at!the! mRNA! level,! which! this! study! did.! In! order! to! clarify! why! there! was! such!variability! in! vector>driven! gene! expression! along! the! rostral>caudal! axis! of! the!brain! for! AAV2/9.mCln3.eGFP! and! AAV2/9.hCLN3.eGFP,! and! to! determine! the!relative! level!of!gene!expression!between!each!vector,!we!carried!out! the!second!pilot! experiment,! this! time! incorporating! additional! controls! to! account! for!variables! which! may! have! resulted! from! the! experimental! design! or! dissection!procedure.!!!










Figure( 30.( Relative( expression( of( vector:driven( (enhanced( green( fluorescent( protein)(
eGFP( by( AAV2/9.eGFP,( AAV2/9.mCln3.eGFP( and( AAV2/9.hCLN3.eGFP.( a)! Injection! loci!(indicated!by!red!arrow!and!red!dot)!shown!by!sagittal!and!coronal!schematic!diagrams!modified!from!Paxinos!and!Franklin!atlas,!2001.!The!right!injected!hemisphere!(striatum)!of!3!wild>type!mice!was!cut! into!6!regions!as!represented!(not! to!scale)!below!the!atlas! image.)TaqMan®!RT>qPCR! with! relative! quantitation! (house! keeping! genes! were! β<Actin,! ATP5b! and! RPL13a)! was!used!to!assess!the!expression!level!of!eGFP!expressed!by!AAV2/9.eGFP!(b),!AAV2/9.mCln3.eGFP!(c)!and!AAV2/9.hCLN3.eGFP!(d)!in!each!of!the!6!regions.!e)(The!relative!level!of!eGFP!expression!in!the!6!regions,!driven!by!each!vector!were!compared!(eGFP!expressed!by!AAV2/9.eGFP![eGFP],!AAV2/9.mCln3.eGFP![mCln3.eGFP]!and!AAV2/9.hCLN3.eGFP![hCLN3])!and!revealed!a!significant!difference! between! region! 5! of! the! AAV2/9.eGFP>injected! and! AAV2/9.mCln3.eGFP>injected!striatum! (p*! =! 0.0253),! and! regions! 3! and! 5! of! the! AAV2/9.mCln3.eGFP>injected! and!AAV2/9.hCLN3.eGFP>injected! striatum! (p*! =! 0.0304! and!p**)=)0.0050).! This! data! suggests! that!AAV2/9.mCln3.eGFP!drove!the!most!transgene!expression!while!AAV2/9.hCLN3.eGFP!expressed!the!least.!The!data!is!presented!as!mean!±SEM.!p)values!were!calculated!using!a!two>way!ANOVA!with!Bonferroni!correction.)
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vectors!since!AAV2/9.eGFP!does!not!express!this!gene,!and!the!background!from!endogenous)Cln3!would!make! it!difficult! to!detect!expression!exclusively!derived!from! AAV2/9.mCln3.eGFP.) Therefore,) in! order! to! accurately! compare! relative!vector>driven!expression!between!each!of! the!vectors,!we!used!eGFP!primers! for!all!three!vectors.!!When!using!a!brain!matrix!to!divide!the!brain!into!6!parts,!the!striatum!falls!within!region!4!(Figure(30.(a).!Comparing!eGFP!mRNA!level!within!this!region!4!(where!the! injection!was!administered),!AAV2/9.mCln3.eGFP>injected!mice!had!twice!the!level!of!eGFP!expression!compared!to!AAV2/9.eGFP>injected!mice,!and!5!times!the!level!compared!to!mice!injected!with!AAV2/9.hCLN3.eGFP!(Figure(30.(b,(c(and(d).!
eGFP!expression!could!be!detected!along!the!entire!rostral>caudal!axis!of!the!brain!following! injection! with! all! three! vectors,! however,! the! pattern! of! distribution!varied.!Expression!of!eGFP! in!the!AAV2/9.eGFP>injected!mice!was!greatest!within!region! 4! with! a! gradual! decrease! between! regions! 3! –! 1.! Conversely,! between!regions! 4! and! regions! 5! and! 6,! eGFP! expression! dropped! by! about! a! third!suggesting!that!the!vector!transduces!the!rostral!regions!more!readily!(Figure(30.(
b).! In! comparison,! eGFP! expression! in! AAV2/9.mCln3.eGFP<injected! mice! was!consistently! at! its! highest! between! regions! 3! –! 5.! As! for! AAV2/9.eGFP>injected!mice,!the!reduction!in!expression!followed!a!similar!gradual!decrease!from!region!3! >! 1! but! a! more! sudden! decrease! in! region! 6,! again,! indicating! that!AAV2/9.mCln3.eGFP)preferentially) transduces! more! rostral! regions! of! the! brain!(Figure(30.(c).!In!contrast!to!both!AAV2/9.eGFP!and!AAV2/9.mCln3.eGFP<injected!mice,! AAV2/9.hCLN3.eGFP>injected! mice! showed! a! more! dramatically! different!pattern!of!distribution.!The!greatest!level!of!eGFP!expression!was!in!region!4,!with!slightly!lower!levels!in!region!3.!Between!regions!2!>!1!and!5!>!6!however,!the!levels!
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of!eGFP! expression!dropped! to! almost! zero,! suggesting! that!AAV2/9.hCLN3.eGFP!driven!eGFP!expression!is! largely!confined!to!the!region!within!which!this!vector!was!injected!and!did!not!spread!far!from!the!site!of!injection!(Figure(30.(d).!!!The! data! collected! from! this! pilot! experiment! confirmed! that! each! vector! drives!transgene!expression!at!the!mRNA!level,!and!is!distributed!along!the!rostral>caudal!axis! of! the! brain,! but! also! suggests! that! the! pattern! of! expression! and/or!distribution!may!be!specific!to!the!vector.!Figure(30.(e(shows!that!within!region!3,!eGFP! is! expressed! at! a! significantly! higher! level! when! driven! by!AAV2/9.mCln3.eGFP) compared! to! AAV2/9.hCLN3.eGFP! (p) value! 0.0304),) and!within! region! 5! there! is! significantly! more! eGFP! expression! following! injection!with! AAV2/9.mCln3.eGFP)compared! to! both! AAV2/9.eGFP! (p)value! 0.0253)! and!AAV2/9.hCLN3.eGFP!(p)value!0.050).!(
(These! in)vivo! pilot! experiments! confirmed! the! expression! of! eGFP! at! the!mRNA!level,!but!our!data!also!showed!that!eGFP!expression!at!the!protein!level!could!not!be! detected! in) vitro) (Figure( 28).! This! indicates! that! although! there! is! mRNA!expression!of!eGFP,! it! is!either!not!translated!into!protein,!or!the!protein!is!being!degraded,!or!that!another!unexplained!mechanism!operates!in)vitro.!Therefore,!to!check! if! eGFP! could!be!detected!using! immunohistochemistry! in)vivo,!we! carried!out!a!further!set!of!pilot!experiments.!!
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3.3! Detecting(GFP(protein(expression(in)vivo)and(assessing(the(glial(
response(Although!AAV2/9.eGFP!was!utilized!for!the!main!experiment,!this!vector!was!not!available! at! the! time! of! these! pilot! experiments! so! instead! AAV2/9.hrGFP!comprising! the! humanized! recombinant! E.) Coli<derived! GFP! (hrGFP)! gene! was!used.! This! gene! is! not! used! as! extensively! as! eGFP! derived! from! the! jellyfish!
Aequorea) victoria,) but! for! this! experiment! served! as! a! suitable! alternative.!AAV2/9.hrGFP,) AAV2/9.mCln3.eGFP) and! AAV2/9.hCLN3.eGFP! vectors! were!injected! into! the! striatum! of! three! wild>type! mice! each! (injection! sites! as! per!
section(3.2(of!Chapter(2).!After!two!weeks,!mice!were!euthanized!for!analysis!of!GFP! protein! expression.! Each! brain! was! harvested! and! fixed! in! 4%! PFA! for!histological!analysis.!A!1! in!6!series!of!sections!was!stained!using!an!antibody! to!hrGFP!as!described! in!Chapter(2,(section(6.3.(The!staining!revealed!widespread!hrGFP!immunostaining!along!the!rostral>caudal!axis!of!the!brain!(Figure(31.(a(and(












































































Figure! 32.! AAV2/9.mCln3.eGFP! and! AAV2/9.hCLN3.eGFP4driven! enhanced! green!
fluorescent! protein! (eGFP)! protein! expression! in!wild4type!mice! after! 2!weeks! and!
the! effects! upon! astrocytosis! and! microglial! activation.! a! –! b)! Immunohistological!staining! for! eGFP! protein! resulting! from! the! AAV2/9.mCln3.eGFP! and! e! –! g)!AAV2/9.hCLN3.eGFP!vectorAdriven!expression!of!eGFP!as!a!surrogate!marker!for!Cln3/CLN3*expression,!within!the!region!of!the!striatum!where!the! injection!was!administered,!shown!at! low!magnification! to!demonstrate! the! extent! of! protein! expression!within! the! injection!tract! and! at! high! magnification! to! emphasise! the! transduction! of! neurons! in! this! region.!eGFP! positive! cells! were! detected! only! within! the! site! of! injection! and! at! low! levels! as!highlighted!in!a!and!b!and!e! A!g)!showing!a!series!of!sections!along!the!rostralAcaudal!axis!captured! at! low! magnification.! c! and! h)! Immunohistological! staining! for! the! astrocyte!marker! glial! fibrillary! acidic! protein! (GFAP)! in! the! region!of! the! injection! tract! revealed! a!concentration!of!GFAP!immunoreactive!cells!in!the!cortex!especially!around!the!entry!site!of!the!needle!and!the!underlying!corpus!callosum,!and!fewer!within!the!region!of!the!striatum!where! eGFP! is! expressed.!d! and! i)! Immunohistological! staining! for! the!microglial!marker!cluster!of!differentiation!68!(CD68)!showed!that!CD68!immunoreactive!cells!predominantly!clustered!around!the!site!of!injection!within!the!cortex!and!underlying!corpus!callosum,!but!was!limited!in!areas!overlapping!with!eGFP!expression.!Scale!bars! in!x1.6! images!of!a!–!i!=!1000µm,!in!x20! images!of!a,!c,!d,! f,!h!and!i!=!200!µm.!!n!=!3,!representative!images!shown!here!where!vector!spread!was!greatest.!
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When! the! first! pilot! RTAqPCR! experiment!was! conducted,! the! corresponding! left!hemispheres!were!reserved!for!histological!analysis.!As!further!confirmation!of!the!distribution!of! eGFP!protein! expression,!we! cut! the! left! hemisphere! into! coronal!sections! and! used! a! 1! in! 6! series! of! sections! to! repeat! the! GFP! immunostaining!experiment! and! investigate! whether! the! level! of! protein! expression! was! also!limited! in! these! sections.! Interestingly,! although! the! spread! of! the!AAV2/9.mCln3.eGFP*and! AAV2/9.hCLN3.eGFP! vectors! (Figure! 33)! did! not! reach!the! same! level! as! for! AAV2/9.eGFP! (data! not! shown),! there!was! relatively!more!eGFP! immunoreactivity! in! these! sections! compared! to! the! previous!immunostaining!experiment!(Figure!32).!!The!discrepancy!in!the!relative!levels!of!eGFP! protein! expression! between! AAV2/9.eGFP* and* AAV2/9.mCln3.eGFP* and!AAV2/9.hCLN3.eGFP!vectors!raises!an!important!question!about!the!variability!of!vector!spread!and/or!expression.!It!would!appear!that!the!vectors!do!not!behave!consistently! when! injected! into! different! brains! and! therefore,! a! large! sample!number! for! each! vector! would! be! necessary! to! determine! the! extent! of! this!variability.!!!




















vivo$ using! immunohistochemistry! to! survey! which! cells! were! transduced! by!assessing! the!morphology!of!eGFP;positive!cells.!Based!on! this!analysis,! all! three!vectors!predominantly!transduced!neurons!within!the!cortex!and!striatum!(Figure'
34)'but!there!were!some!GFP!positive!cells!present!with!glial!morphology!(Figure'
34.'b).!This!is!consistent!with!other!studies!showing!that!AAV2/9;mediated!gene!transfer! preferentially! targets! neurons! (Cearley! and! Wolfe,! 2005;! Bartlett! et$ al,!2008;!White!et$al,!2011;!Ellis!et$al,!2013).!!!The!second!purpose!of!this!small!pilot!study!was!to!evaluate!the!short;term!impact!of!the!injection,!vector!and/or!Cln3/CLN3!expression!on!glial!activation!within!the!injected!striatum.!A!series!of!sections!were!stained!for!eGFP!(Figure'32.'a!–!b'and!
e' ;!g)! to! determine! the! spread! of! the! vector! (described! above)! together!with! an!additional!set!of!sections!for!the!astrocyte!marker!GFAP!and!the!microglial!marker!CD68!(Figure'32.'c'and'h'and'd'and' i,'respectively).! !For!all! three!vectors,!GFAP!and! CD68! immunoreactivity! was! mostly! confined! to! the! site! of! injection.! At! a!distance!(along!the!rostral;caudal!axis)!to!the!injection!tract,!immunoreactivity!for!these!glial!markers!was!detected!at!a!much!lower!level!suggesting!that!astrocytosis!and! microglial! activation! was! largely! associated! with! the! injection! itself,! as!opposed! to! responding! to! the! vector! or! expression! driven! by! it.! For!AAV2/9.mCln3.eGFP2! and! AAV2/9.hCLN3.eGFP2injected! mice! in! which! vector!spread!was!limited!to!regions!around!the!injection!tract,!we!detected!limited!GFAP!and! CD68! immunoreactivity! in! areas! lateral! or! medial! to! the! injection! tract,!suggesting!that!astrocytosis!and!microglial!activation!was!mainly!associated!with!the! injection;associated! trauma!and! importantly,!not!with!Cln3/CLN3$expression.!This! set! of! data! emphasised! the! need! for! sham;operated! and! vehicle;injected!controls!in!order!to!properly!investigate!the!impact!of!Cln3/CLN3!expression.!!
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!
Figure'34.'Morphology'of'cell'types'transduced'by'AAV2/9'vectors'in'wildAtype'brain.'Photomicrographs!taken! of! immunohistological! staining! for! humanized! recombinant! (hr)! or! enhanced! (e)! green! fluorescent!protein! (GFP)! resulting! from! AAV2/9.hrGFP;,! AAV2/9.mCln3.eGFP;! and! AAV2/9.hCLN3.eGFPAdriven!expression! of! GFP,! reveal! the! preferential! transduction! of! neurons! (black! arrows)! and! occasional! astrocyte!(white!arrow)!within!the!cortex!(broken!arrow)!(a)!and!striatum!(solid!arrow)!(b'and!c)!at!high!magnification.!Scale!bar!=!100!µm.!!
















These!pilot!experiments!were!integral!to!the!planning!of!the!main!experiment.!By!infecting!striatal!neuronal!cultures!in#vitro!we!were!able!to!test!the!concentration!of!vector!needed!to!achieve!cell!transduction,!and!to!determine!whether!there!was!any! associated! neuronal! toxicity.! We! found! that! a! high! concentration! of! vector!(MOI!of!at! least!1000)! is!needed!to!achieve! transduction!and!consistent!with! the!literature,!there!were!no!neurotoxic!effects!associated!with!AAV2/9!(Howard!et#al.,#2008).!These!experiments!also!revealed!that!there!may!be!a!discrepancy!between!the!levels!of!mRNA!and!protein!expression.!By!carrying!out!an!RTNqPCR!pilot!study!on! brain! tissue! that! had! been! injected! with! each! of! the! vectors,! we! found! that!vectorNdriven! gene! expression! occurred! at! varying! levels! and! spread! along! the!rostralNcaudal!axis!to!varying!degrees.!By!staining!in#vivo,!we!were!able!to!confirm!that!protein!is!expressed!(which!we!were!not!able!to!show!in!neuronal!cultures),!and!these!studies!also!revealed!variation!in!the!distribution!of!eGFP!independent!of!the!vector,!thus!highlighting!the!need!for!a!high!sample!number.!Our!in#vivo!pilot!work!also!showed!that!glial!activation!was!associated!with!the!injection!tract!but!this! was! reduced! by! 1!month! after! the! vector! had! been! injected! into! the! brain,!underlining! the! need! for! additional! controls! and! suggesting! that!mice! should! be!sacrificed!at!least!2!months!after!vector!administration.!!
4! Assessment(of(AAV2/9(viral(vector5mediated(gene(
transfer(
To!determine!the!transduction!efficiency!of!the!AAV2/9Nmediated!viral!vectors!in!this!study!and!the!resulting!transgene!distribution,!we!assessed!immunoreactivity!for! the! eGFP! reporter! gene! expressed! by! AAV2/9.eGFP,! AAV2/9.mCln3.eGFP#and!AAV2/9.hCLN3.eGFP.! This! was! initially! carried! out! in! the! three! pilot! studies!
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described!in!section(3.3,(but!as!the!survival!times!were!only!2!weeks!to!3!months,!this! did! not! address! the! question! of! longNterm! transgene! expression.! Therefore,!transduction! efficiency! of! AVV2/9.eGFP,! AAV2/9.mCln3.eGFP! and!AAV2/9.hCN3.eGFP! was! next! compared! at! 2! and! 6! months! after! injection.! We!found! that! eGFP!expression!persists! at! 6!months!post! injection! (Figure(36.(g( N! i(and( j( 5( l),! consistent! with! other! studies! that! have! demonstrated! longNterm!transgene! expression! using! the! CMV! promoter! (Peel! and! Klein! et# al.,# 2000).!However,! although! transgene! expression! did! not! vary! with! survival! time,! our!findings!showed!variable!degrees!of!viral!transduction!throughout!all!the!groups,!as!previously!indicated!by!our!pilot!data.!For!each!sample,!the!number!of!sections!that!were!positive!for!eGFP!were!counted!and!are!summarised!in!Appendices(3.1.(In!some!cases,!the!AAV2/9.eGFP!vector!had!a!wide!distribution!with!eGFP!detected!in!brain!structures!at!a!considerable!distance!from!the!injection!site!including!the!globus! pallidus,! subthalamic! nuclei,! thalamus,! hippocampus,! cortex,! substantia!nigra,!and!in!some!instances!even!the!olfactory!bulb!and!brainstem,!(Figure(36.(d,(
g(and!j(and(Figure(37.(b(5(f).(However,!in!other!cases,!independent!of!vectorNtype,!age,!genotype!or!vector!used,!eGFP!expression!was!limited!to!the!site!of!injection,!see( Figure( 36.( a( 5( b( and! Figure( 37.( a.! Ideally,! at! least! 3! sections! are! used! for!thresholding! analysis! and! stereology,! therefore! where! eGFP! expression! was!confined!to!less!than!3!sections!the!sample!was!excluded!from!subsequent!analysis!(with!the!exception!of!Cln36/6#mice!injected!with!AAV2/9.mCln3.eGFP!at!3!months!and! sacrificed! after! 2! months,! n! =! 2).! Unfortunately,! of! the! 6! wildNtype! mice!injected!with! AAV2/9.eGFP! at! 3!months! and! sacrificed! after! 2!months,! only! one!showed!eGFP!staining!in!a!limited!number!of!sections,!see!Figure(36.(a.!This!was!also! the! case! for! mice! of! the! same! cohort! that! had! been! injected! with!AAV2/9.mCln3.eGFP!(Figure(36.(b),( leaving!only! the!mice! that!had!been! injected!
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with!AAV2/9.hCLN3.eGFP!for!analysis.!Therefore,! this!entire!group!was!excluded.!Similarly,! of! the! 6! mice! injected! with! AAV2/9.mCln3.eGFP! at! 3! months! and!sacrificed! 6! months! later,! only! one! showed! eGFP! positivity! and! therefore,! only!AAV2/9.eGFP! and! AAV2/9.hCLN3.eGFPNtreated! mice! were! included! at! this! time!point.! One! obvious! explanation! for! the! variation! in! eGFP! distribution! is! that! the!injections!themselves!were!variable.!However,!all!injections!were!carried!out!using!the!same!standardised!procedure!(the!syringe!was!fitted!to!a!pump!attached!to!a!micro! syringe! controller,! the! settings! of! which! were! kept! the! same)! and!importantly,! separate! syringes! and!needles!were!used! to! administer! each! vector!and!kept!consistent!throughout!the!experiment!(see!section(3.2(of!Chapter(2).!(
!
Another! possible! explanation! is! the! presence! of! preNexisting! antibodies! against!AAV.!Although!AAVs!are!not!considered!to!be!particularly!immunogenic,!they!can!cause! a! humoral! immune! response,! as! is! evident! in! that! mice! obtained! directly!from! commercial! vendors! have! been! shown! to! often! harbor! neutralizing!antibodies!(Rapti!et#al,!2012).!As!a!result,!a!significant! fraction!of!mice!have!preNexisting!antibodies!against!AAVs,!and!even!at!very!low!levels,!these!antibodies!can!prevent! successful! transduction! (Jeune! et#al,! 2013).! In! this! respect! it! would! be!important!to!investigate!our!mouse!colonies!for!the!presence!of!such!antibodies.!!
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transgene! expressing! astrocytes! (McCrown! et# al.,# 1996;! Davidson! et# al.,! 1999;!Bartlett! et# al.,! 2008,! Ellis! et# al.,#2013).! Our! pilot! studies! revealed! that! all! three!AVV2/9!vectors!preferentially!transduce!neurons!when!injected!into!the!CNS,!and!we!found!this!to!be!the!case!for!all!cohorts!with!the!occasional!astrocyte!positively!stained!for!eGFP!(Figure'34).!!
4.1! The'short1term'impact'of'Cln3/CLN3(expressing'AAV2/9'vectors'
on'glia'One! of! the! challenges! to! successful! gene! therapy! is! the! generation! of! acute! host!immune! responses! directed! against! vector! encoded! transgene! products! or! the!vector! itself! (Wong! et#al.,#2003).! AAVTmediated! viral! vectors! have! relatively! low!intrinsic! immunogenicity! and! have! therefore! been! shown! to! induce! little! or! no!innate!immune!response,!which!is!one!of!the!reasons!why!they!are!so!appealing!for!therapeutic!use!(Boissier!et#al.,!2004).!However,!this!is!not!always!the!case!for!the!transgenes! expressed! by! AAVTmediated! viral! vectors! (Kohn! et# al.,# 1999).!Therefore,! to! investigate! the! shortTterm! impact! of! AAV2/9.eGFP,!AAV2/9.mCln3.eGFP! and! AAV2/9.hCLN3.eGFP! on! astrocytosis! and! microglial!activation!in!mouse!models!of!CLN3!disease,!we!stained!sections!for!the!astrocyte!marker! GFAP! and! the! microglial! marker! CD68! and! compared! the! injected!hemisphere!(n!=!2!T!6)!to!the!uninjected!hemisphere!(n!=!2!T!6)!of!the!same!mouse!brain!as!an!internal!control.!To!separate!the!effect!of!the!transgene!and!the!effect!of! the!mechanical! and! volume! obstruction! associated!with! the! administration! of!the!vectors,!we! included!a!shamToperated!group!(where! the!needle!was! inserted!into! the!brain,!but!no! fluid! injected)! (n!=!6)!and!a!vehicleTinjected!group!(where!the!same!volume!of!PBS!vehicle!was!injected!into!the!brain)!(n!=!6),!that!were!also!
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sacrificed! after! 2! months.! The! extent! of! GFAP! and! CD68! immunoreactivity! was!determined! following! the! administration! of! all! three! vectors! into! wildTtype! and!
Cln3///! mice! injected! at! 3! and! 7.5! months! of! age! (with! an! additional! group! of!
Cln3Δex7/8!mice!which!were!also! injected!at!7.5!months)! then!sacrificed!2!months!later.!By!comparing!wildTtype!mice!to!Cln3Tdeficient!mice,!we!wanted!to!determine!how! the!glial! response! in! the!brain!of!Cln3///!or!Cln3Δex7/8!mice!differs! to! the!glial!response!in!a!healthy!control!brain.!This!is!important!because!pronounced!gliosis!is!a!common!feature!of!the!NCLs!(Bible#et#al.,!2004;!Oswald!et#al.,#2005;!Kielar!et#al.,#2007;!Chang!et#al.,!2008;!Kuronen!et#al.,#2012),!and!is!antecedent!to!neuron!loss!in!mouse!models!of!CLN3!disease!(Pontikis!et#al.,#2004,!2005).!Although!gliosis!does!not! appear! in! the! striatum! of! diseased! mice! until! around! 16! months! of! age!(Pontikis!et#al.,#2005),!a!vectorTprovoked!immune!response!may!be!more!sensitive!within! the!CLN3!disease!milieu.!Furthermore,!by! injecting!mice!at!3!months,! just!after!the!onset!of!the!disease!and!7.5!months,!once!the!disease!is!established,!we!were!able! to!compare!how!the!response!of!Cln3///!or!Cln3Δex7/8!mice!changes!with!disease!progression.!However,!due!to! the!genotyping! issues!encountered!and!the!confounding! issue!of!vector!spread!described!above,! the!cohorts!of!mice! injected!were!incomplete!at!the!stage!of!analysis!(Figure'25).!Therefore,!we!were!only!able!to!analyse!Cln3///!mice!injected!at!3!months,!Cln3Δex7/8!mice!injected!at!7.5!months!and!wildTtype!mice!injected!at!7.5!months.!!!!To! quantify! the! intensity! of! GFAP! and! CD68! immunoreactivity! in! the! striatum,!thresholding! analysis! was! performed! on! the! GFAPT! and! CD68Tstained! sections!corresponding! to!GFP!positivity! in! a!defined! striatal! region!at! close!proximity! to!the!site!of!injection.!!
'
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a)! Vector'administration'in'Cln3(/('mice'injected'at'3'months'of'age'A! significant! increase! in! astrocytosis!was! observed! in! the! AAV2/9.eGFPTinjected!striatum! of# Cln3///!mice! compared! to! the! contralateral! uninjected! side! (p! value!0.0038)!(Figure'38.'d),'but!no!significant!differences!were!detected!between!the!vectorTinjected! striatum!and! the! shamToperated!or! vehicleTinjected! control!mice.'
Cln3///!mice! that! had! been! injected!with! AAV2/9.mCln3.eGFP! however,! showed! a!significant! increase! in!astrocytosis! compared! to! the! contralateral!uninjected! side!(p!value!<!0.0001)!that!was!almost!three!times!greater!than!in!mice!injected!with!AAV2/9.eGFP! (Figure'38.' e).! This!was! also! significantly! greater! than! the! shamToperated!or!vehicleTinjected!control!mice!(p!value!<!0.0001!for!both)!(Figure'38.'


































operated! (p! value! 0.0044)! and! vehicle8injected! control! mice! (p! value! 0.0005)!(Figure' 38.' g).! However,! while! we! also! observed! significantly! more! microglial!activation! in! the! AAV2/9.mCln3.eGFP8injected! striatum! compared! to! the!uninjected! striatum! (p( value! 0.0254)! and! vehicle8injected! striatum! (p( value!0.0034),! this! was! not! greater! than! the! microglial! activation! detected! following!AAV2/9.eGFP!injection!(Figure'38.'h).!We!also!did!not!see!any!further!significant!difference!in!microglial!activation!between!AAV2/9.mCln3.eGFP8injected!mice!and!sham8operated! or! vehicle8injected! mice.! Compared! to! AAV2/9.eGFP! and!AAV2/9.mCln3.eGFP! treated! mice,! the! striatum! of! AAV2/9.hCLN3.eGFP8injected!mice! showed! a! significant! difference! in! microglial! activation! compared! to! the!uninjected! contralateral! side,! ! sham8operated! and! vehicle8injected!mice! (p(value!<0.0001! for!all)! that!was!almost!5! times!greater! than!had!been!observed! for! the!first! two!vectors!(Figure'38.'i).!This!suggests! that! the!microglial!response!to! the!administration! of! all! three! vectors! is! more! restricted! than! the! corresponding!astrocytosis,!but!that!human!CLN3!induces!a!more!pronounced!effect.!!!Generally,! for! all! three! vectors,! there! was! an! increase! in! GFAP! and! CD68!immunoreactivity! present! within! the! injected! striatum,! compared! to! the!contralateral! unininjected! side! and! to! a! lesser! extent,! the! sham8! and! vehicle8injected!controls.!We!were!unable!to!identify!a!consistent!trend!in!terms!of!which!of! the! three! vectors! elicited! the! greatest! overall! glial! response.! The! fact! that! the!highest!amount!of!astrocytosis!was!associated!with!the!expression!of!mouse!Cln3(driven(by! AAV2/9.mCln3.eGFP! and! the! greatest! amount! of! microglial! activation!was! associated! with! human! CLN3! expression! driven! by! AAV2/9.hCLN3.eGFP,!indicates! that! there! is! a! specific! glial! response! to! Cln3/CLN3.! Unfortunately,!inadequate! vector! spread! in! wild8type! mice! injected! at! 3! months! of! age! and!
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sacrificed! 2! months! later! meant! that! we! are! only! able! to! comment! on! the! glial!response! within! Cln3,/,!mice,! and! cannot! conclude! how! any! responses! to! vector!administration!are!different!to!those!of!a!healthy!brain!at!3!months!of!age.!!!

































there!is!a!much!greater!response!to!AAV2/96mediated!mouse!Cln3%expression!and!an!even!more!pronounced!response!to!AAV2/96mediated!human!CLN3!expression.!!When! we! analysed! the! CD686stained! tissue! to! assess! microglial! activation,! the!microglial! response! to! each! of! the! vectors! followed! a! consistent! trend! with! the!astrocyte!response! to! these! three!vectors.!We!observed!an! increase! in!microglial!activation! in! the!AAV2/9.eGFP6injected!striatum!of%wild6type!mice! injected!at!7.5!months! compared! to! the! contralateral! uninjected! side! (p! value! 0.0464)! and! also!sham6operated!(p!value!0.0025)!and!vehicle6injected!control!mice!(p%value!0.0006)!(Figure' 39.' g).! Although! we! did! not! see! a! significant! difference! in! microglial!activation! between! the! AAV2/9.mCln3.eGFP6injected! striatum! of! wild6type! mice!compared! to! the! contralateral! uninjected! side,! we! did! observe! a! similar! trend!(Figure' 39.' h).! The! most! consistent! finding! with! the! astrocytosis! data! was! a!significant! increase! in! microglial! activation! in! the! AAV2/9.hCLN3.eGFP6injected!striatum!compared!to!the!contralateral!uninjected!side!(p!value!<0.0001)!that!was!approximately! three! times! greater! than! the! microglial! response! seen! for! the!AAV2/9.mCln3.eGFP6injected! and! AAV2/9.eGFP6injected! striatum! compared! to!their! contralateral! uninjected! sides! (Figure' 39.' i).! There! were! also! significant!differences!between!the!injected!striatum!and!sham6operated!and!vehicle6injected!controls!(p%value%<0.0001!for!both).!!!Overall,!all!three!vectors!elicited!an!increase!in!GFAP!and!CD68!immunoreactivity!within! the! striatum! ipsilateral! to! the! site! of! vector! injection,! compared! to! the!contralateral! unininjected! side,! and! to! a! lesser! extent,! the! sham6operated! and!vehicle6injected!controls.!The!greatest!overall! glial! response!was!associated!with!human!CLN3! expression!while!mouse!Cln3! expression!had!a! significant! effect! on!
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astrocytosis! but! not! microglial! activation.! These! findings! were! consistent! with!what!we!observed!within! the!Cln3,/,!mice! injected! at! 3!months! of! age! in!section'
4.1.a.'!To!assess!how!Cln3,deficient!mice!respond!later!in!disease!progression!(compared!to! at! the! start! of! disease! onset),! and! to! determine! how! this! is! different! to! the!response!within! age!matched!wild6type!mice,!we! analysed!Cln3Δex7/8!mice! at! 7.5!months!of!age.!It!is!important!to!note!that!the!original!experimental!plan!included!a!set!of!Cln3,/,!mice!at!7.5!months!of!age!that!were!stained!at!the!same!time!as!the!wild6type! control! mice! discussed! above! for! direct! comparison,! but! as! already!discussed! in! section' 2.4,'because! of! genotyping! issues! they! had! to! be! excluded!from! the! study.! Therefore,! the! set! of! Cln3Δex7/8! mice! that! have! been! analysed!instead! should! be! treated! with! caution! as! they! were! stained! separately! to! the!control!wild6type!mice!injected!at!7.5!months!of!age,!and!are!genetically!different!to!the!Cln3,/,!mice!injected!at!3!months!of!age.!!














































Cln3!/!!! 3! 2! *mCln3!>!
hCLN3!>!*AAV2/9.eGFP! *!hCLN3>!*mCln3!=!*AAV2/9.eGFP!Wild5type! 7.5! 2! *!hCLN3>!*mCln3!>!*AAV2/9.eGFP! *!hCLN3>!*mCln3$=!*AAV2/9.eGFP!
Cln3Δex7/8!! 7.5! 2! *!hCLN3>!AAV2/9.eGFP>!!mCln3!>! *hCLN3>!AAV2/9.eGFP!>!mCln3!>!
$
Table'10.'Summary'of'glial'response'to'vectors'in'mice'sacrificed'2'months'after'injection.'The!pattern!of! astrocytosis! (GFAP)!and!microglial! activation! (CD68)! in! response! to!each!vector!2!months!after! injection!varied! between! Cln3!/!$mice,! wild5type! and! Cln3Δex7/8$mice$ that! were! ! injected! at! different! ages.! The! overall!outcome! of! these! experiments! is! summarised! here.! mCln3$ =$ AAV2/9.mCln3.eGFP,! hCLN3! =!AAV2/9.hCLN3.eGFP,$‘*’!=!significant!difference!between!vector5injected!and!uninjected!sides!(Alpha!0.05),!‘>’!=!!greater!than!and!‘=’!=!equal!to.$
'was!detected!in!the!wild5type!mice,!this!does!not!explain!why!within!the!Cln3Δex7/8!group! we! did! not! detect! any! differences! between! AAV2/9.eGFP5injected! or!AAV2/9.mCln3.eGFP5injected! striatum! compared! to! the! contralateral! uninjected!side!at!all.!!It!would!appear!that!there!is!an!overall!glial!response!to!vector!driven!transgene!expression! that! is! generally! more! pronounced! for! human! CLN3,! although!responses!to!mouse!Cln3!were!also!observed.!Evidently,!these!acute!responses!are!independent! of! genotype! but!we! cannot! reliably! comment! on! how! the! situation!changes!with!age.!See!summary!Table'10'above.!!
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4.2! The'longKterm'impact'of'Cln3/CLN3'expressing'AAV2/9'vectors'on'
glia'It!is!plausible!that!therapeutically!beneficial!affects!of!viral5mediated!gene!transfer!might! emerge! once! the! acute! response! to! the! vector! or! vector! driven5transgene!expression!has!subsided.!Therefore,!to!determine!how!the!glial!response!changes!over! time,! we! analysed! the! impact! of! AAV2/9.eGFP,! AAV2/9.mCln3.eGFP! and!AAV2/9.hCLN3.eGFP! on! astrocytosis! and!microglial! activation! at! 6!months! after!injection.!!Unfortunately,!all!the!Cln3!/!!mice!that!were!sacrificed!at!this!time!point!had! to! be! excluded! from! the! study! due! to! the! previously!mentioned! genotyping!issue!(section'2.4).!Therefore,!the!extent!of!GFAP!and!CD68!immunoreactivity!at!6!months! after! vector! administration!was! determined! in!wild5type!mice! only.! ! All!three! vectors! were! injected! at! 3! and! 7.5! months! of! age,! and! then! mice! were!sacrificed! 6! months! later.! ! Sections! were! stained! for! GFAP! and! CD68,! and! the!injected!hemisphere!(n!=!3!5!6)!was!compared!to!the!uninjected!hemisphere!(n!=!3!5!6)!of!the!same!mouse!brain!as!an!internal!control,!together!with!sham5operated!and!vehicle5injected!mice,!also!sacrificed!after!6!months!post5injection!(n!=!6).!To!quantify! the! intensity! of! GFAP! and! CD68! immunoreactivity! in! the! striatum,!thresholding! analysis! was! performed! on! the! GFAP5! and! CD685stained! sections!corresponding!to!a!defined!striatal!region!of!GFP!positivity!as!described!in!section'
4.1.'!!




sacrificed'6'months' later.' a' 5' c)! Representative! images! taken! of! immunohistological! staining! for! enhance!green! fluorescent! protein! (eGFP)! (transgene),! green! fibrillary! protein! (GFAP)! (astrocytes)! and! cluster! of!differentiation! 68! (CD68)! (microglia)! showing! vector5driven! (AAV2/9.eGFP,! AAV2/9.mCln3.eGFP,$AAV2/9.hCLN3.eGFP)$ ! transgene! expression! and! ! associated! astocytosis! and! microglial! activation! in! the!striatum.! d' K' f)! Histograms! showing! percentage! GFAP! staining! in! the! injected! striatum! compared! to! the!contralateral! uninjected! striatum! (n! =! 4,! n! =! 5)! for! injections!with! AAV2/9.eGFP! and! AAV2/9.hCLN3.eGFP,!respectively),! sham5operated!wild5type! controls! (n! =! 6)! and! vehicle5injected!wild5type! controls! (n! =! 6).! No!significant! differences! were! found! between! the! level! of! astrocytosis! in! the! AAV2/9.eGFP5injected! or!AAV2/9.hCLN3.eGFP5injected!striatum!compared!to!the!uninjected!side,!and!in!fact!were!lower!than!the!level!of!astrocytosis!in!response!to!sham5!or!vehicle5injection.$!g'K'i)!Histograms!showing!percentage!CD68!staining!in!the!injected!striatum!compared!to!the!contralateral!uninjected!striatum,!sham5operated!wild5type!controls!and! vehicle5injected! wild5type! controls! (n! =! as! above).! ! Again,! no! significant! differences! were! detected!between!the!vector5injected!striatum!and!the!uninjected!side!with!levels!falling!below!the!level!of!microglial!activation!in!sham5operated!and!vehicle5injected!mice.!This!data!suggests!that!the!glial!response!in!wild5type!mice!to!the!three!vectors!reported!2!months!after!vector!administration!is!reduced!over!time.!Abbreviations:!I!=!Injection!only,!UI!=!Uninjected,!S!=!Sham5operated!and!V!=!Vehicle5injected.!The!data!is!presented!as!mean!±SEM.!p$values!were!calculated!using!a!one5way!ANOVA!with!Bonferroni!correction.$Scale!bars!in!x1.6!images!=!1000!µm!
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injected! control! mice! (Figure' 41.' c).! The! same! trend! was! observed! in!AAV2/9.hCLN3.eGFP5injected! mice,! with! even! lower! levels! of! astrocytosis!observed! in! the! injected! vs.! uninjected! striatum! (Figure'41.'d).! Unfortunately,'a!lack! of! vector! spread! in$ the! wild5type! mice! injected! with! AAV2/9.mCln3.eGFP!meant!that!we!could!not!analyse!this!tissue.!When!compared!to!the!Cln3!deficient!mice! injected!at!3!months!and!sacrificed!2!months! later,! the! level!of!astrocytosis!decreased! by! 38%! in! the! AAV2/9.eGFP5injected! striatum! and! 73%! in! the!AAV2/9.hCLN3.eGFP5injected!striatum!(Figure'38.'d'and!f).!These!findings!suggest!that!by!6!months,!the!astrocytic!response!to!the!vector!or!vector5driven!transgene!is!markedly! reduced!and!no!greater! than! that! caused!by! the! injection!procedure!itself.!!Analysis! of! CD68! stained! tissue! revealed! a! similar! reduction! in! microglial!activation.! Microglial! activation! was! almost! at! the! same! level! between! the!AAV2/9.eGFP5injected! striatum! or! AAV2/9.hCLN3.eGFP5injected! mice! and! the!contralateral!uninjected!sides,!with!no!significant!differences!between!these!values!observed! (Figure' 41.' e' and! f).! Interestingly,! the! level! of! astrocytosis! in! sham5operated! and! vehicle5injected! mice! was! significantly! greater! than! the! vector5injected!and!uninjected!side!for!both!vectors.!In!the!AAV2/9.eGFP5injected!group,!vehicle5injected!mice!had!significantly!more!microglial!activation!than!the!injected!striatum!(p$value$0.0337)!and!the!uninjected!striatum!(p$value$0.0013)!(Figure'41.'
e).! Similarly! in! the!AAV2/9.hCLN3.eGFP5injected!group,! the!vehicle5injected!mice!had! significantly! more! microglial! activation! than! the! injected! striatum! (p$value!0.0006)!and!the!uninjected!striatum!(p$value!<0.0001)!but!also!between!the!sham5operated! mice! and! the! uninjected! side! (p$ value! 0.0108)! (Figure' 41.' f).! Again,!compared! to!Cln3!deficient!mice! that!were! injected!at!3!months!and!sacrificed!2!
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months!after! injection,! there!was!generally! less!microglial!activation! for!all! three!vectors.! The! level! of! microglial! activation! differed! by! 38%! between! the!AAV2/9.eGFP5injected! striatum! of! Cln3!/!! and! wild5type! mice! (Figure' 38.' g).!Strikingly,! the! level! of! microglial! activation! in! the! AAV2/9.hCLN3.eGFP5injected!striatum!of!the!same!wild5type!and!Cln3!/!!mice!differed!by!over!90%!(Figure'38.'
i).!These!findings!suggest!that!by!6!months,!the!astrocytic!response!to!the!vector!or!vector5driven!transgene!is!markedly!lower!and!no!greater!than!that!caused!by!the!injection!procedure! itself.!Furthermore,! it!would!appear! that!microglial! response!might!be!more!likely!to!subside!over!time.!!
b)! Vector'administration'in'wildKtype'mice'injected'at'7.5'months'of'age'!When! we! analysed! GFAP5stained! tissue! from! older! mice! that! were! sacrificed! 6!months!after! injection,!we!observed!the!same!pattern!for!all! three!vectors,!as! for!mice! injected! at! 3!months! of! age! and! sacrificed! 6!months,! described! in! section!




























and! vehicle.injected!mice,! but! this!was! also! not! significant! (Figure'42.' f).!When!compared! to! the!wild.type!mice! injected! at! 7.5!months! and! sacrificed! 2!months!later,! the! level! of! astrocytosis! in! the! AAV2/9.eGFP.injected! striatum! was! very!similar! (Figure' 39.' d).! However,! the! level! of! astrocytosis! in! the!AAV2/9.mCln3.eGFP.injected! and! AAV2/9.hCLN3.eGFP.injected! striatum! was!markedly! lower,! by!57%!and!71%!respectively! (Figure'39.'e'and! f).!As!was! the!case!for!the!younger!mice,!these!findings!suggest!that!at!6!months,!the!astrocytic!response! to! the!vector!or! vector.driven! transgene! is! considerably! lower!and!not!significantly! greater! than! in! the! uninjected! side! or! with! the! exception! of!AAV2/9.hCLN3.eGFP!treated!mice,!no!greater!than!the!astrocytic!response!caused!by!the!injection!procedure!itself.!!When!we!analysed!CD68! immunoreactivity!between! the!vector.injected!side!and!uninjected!side,!we!saw!that!for!all!three!vectors,!microglial!activation!was!similar!to!the!uninjected!side!and!below!or!at!the!same!level!as!sham.operated!and!vehicle!only!controls,!with!no!significant!differences!observed.!In!fact,!as!was!the!case!for!wild.type! mice! injected! at! 3! months! and! sacrificed! at! 6! months,! significant!differences!were!only!detected!between!both!the!injected!and!uninjected!sides!and!the! sham.operated! and! vehicle.injected! controls.! In! the! AAV2/9.mCln3.eGFP.injected!group,!microglial!activation!was!in!fact!significantly!higher!in!the!vehicle.injected!mice!compared!to!the!AAV2/9.mCln3.eGFP.injected!side!(p+value!0.0022)!and! the! uninjected! side! (p+ value! 0.0006)! (Figure' 42.' h).! Similarly,! in! the!AAV2/9.hCLN3.eGFP.injected! group,! microglial! activation! was! also! significantly!higher!in!the!vehicle.injected!mice!compared!to!the!AAV2/9.hCLN3.eGFP.injected!side!(p+value!0.0038)!and!the!uninjected!side!(p+value!<0.0001)!but!also!greater!in!the!sham.operated!mice!compared!to!the!uninjected!side!(p+value!0.0117)!(Figure'
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42.'i).!Compared!to!the!wild.type!mice!of!the!same!age!that!were!sacrificed!earlier,!the! microglial! response! was! lower! for! all! the! vectors! than! the! corresponding!astrocyte! response.! There! was! 51%! less! microglial! activation! following!AAV2/9.eGFP! administration! at! 6!months! after! injection! compared! to! 2!months,!62%! less!microglial! activation! following!AAV2/9.mCln3.eGFP! administration! and!most! dramatically,! 85%! less!microglial! activation! following! AAV2/9.hCLN3.eGFP!(Figure'39.'g,'h'and!i).!Consistent!with!data!from!younger!mice!(Figure'39.'a!–!c'and!g'.!i),!this!data!indicates!that!at!6!months!after!injection!with!the!vectors,!the!microglial! response! to! the! vector! or! vector.driven! transgene! is!markedly! lower,!and!no!greater!than!that!caused!by!the!injection!procedure!itself.!It!is!also!apparent!that!microglial!response!might!be!more!susceptible!to!change!over!time.!!
4.3! Overall'acute'and'chronic'effects'of'AAV2/9'mediated'transgene'
expression'on'glia''Collectively,! it! is! clear! that! the! overall! glial! response! to! all! three! vectors,!particularly!those!expressing!Cln3/CLN3,!is!more!pronounced!at!2!months!than!at!6!months!post.injection.!To!better!determine!how!the!glial!response!changes!with!time,! we! compared! GFAP! and! CD68! immunoreactivity! in! the! vector.injected!striatum!of!wild.type!mice! that!were!sacrificed!at!2!and!6!months!post.injection,!irrespective!of! age! (in!wild.type!mice,! there! is! no! reason! to! expect! that! the! glial!response!will!be!different!in!mice!injected!at!3!vs.!7.5!months!of!age![Kielar!et+al.,+2007).!!!A!significant!increase!in!astrocytosis!was!observed!in!the!vector.injected!striatum!of!all!wild.type!mice!sacrificed!2!months!after!injection!compared!to!the!uninjected!
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side.! Clearly,! there! was! a! strong! relationship! between! the! magnitude! of!astrocytosis!and!the!type!of!vector!administered.! !When!mice!were! injected!with!AAV2/9.eGFP,! there! was! significantly! more! astrocytosis! compared! to! the!uninjected!side,!sham.operated!and!vehicle.injected!mice!(p+value!0.0497,!p+value!0.0080!and!p+value!0.0117,!respectively)!(Figure'43.'a).!!When!mice!were!injected!with!AAV2/9.mCln3.eGFP!however,!there!was!also!significantly!more!astrocytosis!compared!to!the!uninjected!side,!sham.operated!and!vehicle.injected!mice!(p+value!<0.0001! for! all)! but! this!was! about! two.folds! greater! than! in!mice! injected!with!AAV2/9.eGFP! (Figure' 43.' b).! ! The! most! striking! astrocytic! response! was! to!AAV2/9.hCLN3.eGFP!which!induced!significantly!more!astrocytosis!in!the!injected!striatum! compared! to! the! uninjected! side,! sham.operated! and! vehicle.injected!mice!(p+value!<0.0001!for!all)!and!was!over!two.folds!greater!than!in!mice!injected!with!AAV2/9.mCln3.eGFP!and!almost!four.folds!greater!than!in!mice!injected!with!AAV2/9.eGFP!(Figure'43.'c).!!!The!microglial! response! to! AAV2/9.eGFP!was! similar! to! the! astrocytic! response!with!significantly!more!microglial!activation!in!the!injected!striatum!compared!to!the! uninjected! side,! sham.operated! and! vehicle.injected! mice! (p+value! <0.0001)!(Figure'43.'d).!Interestingly,!the!microglial!response!was!not!as!pronounced!to!the!AAV2/9.mCln3.eGFP!vector,!with!microglial!activation!being!no!greater!than!in!the!AAV2/9.eGFP.injected! striatum,! and! there!was!no! significant! difference! between!the!AAV2/9.mCln3.eGFP.injected!striatum!and!the!uninjected!side!(Figure'43.'e).!!However,! consistent! with! the! astrocyte! response,! the! most! obvious! microglial!response!was!to!AAV2/9.hCLN3.eGFP!which!induced!significantly!more!microglial!activation!in!the!injected!striatum!compared!to!the!uninjected!side,!sham.operated!
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and! vehicle.injected! mice,! again! p+ value! <0.0001,! and! was! over! double! the!response!than!to!AAV2/9.eGFP!and!AAV2/9.mCln3.eGFP!!(Figure'43.'f).!!Despite!the!discrepancies!between!the!astrocytic!and!microglial!responses!to!each!vector,!these!findings!suggest!that!2!months!after!injection,!there!is!a!pronounced!glial! response! to! AAV2/9.hCLN3.eGFP.driven! CLN3! expression! and! a! specific!astrocytic! response! to! AAV2/9.mCln3.eGFP.driven! Cln3+expression! compared! to!AAV2/9.eGFP!and!overall,! astrocytes! are!more! reactive! to! vector! administration.!After!6!months,!all!glial!activity!returns!to!the!same!level!of!the!uninjected!side!and!is! indistinguishable! from! the! injection! itself! suggesting! that! any! reaction! to+Cln3/CLN3! protein! expression! or! the! vector! is! attenuated! (Figure' 44.).! A!summary!of!the!trends!is!given!in!Figure'45.!!!
a)!The'shortDterm'impact'of'Cln3/CLN3'expressing'AAV2/9'vectors'on'










































































!In! the! striatum! of! Cln3%/%!mice! that! were! injected! at! 3! months! and! sacrificed! 2!months! later,! we! observed! a! trend! towards! a! reduced! neuron! number! in! the!AAV2/9.eGFP4injected!side!compared!to!the!contralateral!uninjected!side!(Figure'




















neuron&number&As!explained!previously! (section&2&and&Figure&47),!only! the!wild:type!mice! that!were!injected!at!3!and!7.5!months!and!sacrificed!6!months!later!were!suitable!for!analysis.! Wild:type! mice! that! were! injected! at! 3! months! and! sacrificed! after! 2!months!were!not!available!to!count,!so! it!cannot!be!concluded!if!any!neuron! loss!would! have! been! apparent! in! this! group.! However,! we! did! not! observe! any!significant! differences! in! the! number! of! neurons! in! the! AAV2/9.eGFP! or!AAV2/9.hCLN3.eGFP:injected! striatum! compared! to! the! uninjected! side! in! wild:type!mice!injected!at!3!months!and!sacrificed!6!months!later!(Figure&47.&a&and!b).!Unfortunately,!as!for!the!thresholding!analysis,!AAV2/9.mCln3.eGFP:injected!mice!were!excluded!from!the!study!due!to!a!lack!of!vector!spread.!As!expected,!when!the!AAV2/9.eGFP:injected! and! AAV2/9.mCln3.eGFP! injected! striatum! of! wild:type!mice!that!were!injected!at!7.5!months!and!sacrificed!at!6!months!were!analysed,!no!difference! in! the! number! of! neurons! compared! to! the! uninjected! side! were!detected,! consistent!with!what!was!observed!at!2!months!post:injection! (Figure&











































neurons!following!injection!with!AAV2/9.hCLN3.eGFP!2!months!after!injection,!but!not!6!months!post@injection!(Figure'48.'c).!One!explanation! for! this! is! that! there!was! slightly!more! variation! in! the!mice! sacrificed! at! 2!months! compared! to! the!mice!analysed!at!6!months.!Nonetheless,!in!terms!of!clinical!relevance,!the!fact!that!no! such! differences! are! observed! following! AAV2/9.mCln3.eGFP! administration!suggests! that! if!hCLN3! is! transferred! to!human!patients,!not!only!might! there!be!less!of!a!glial!response!as!our!data!suggests!but!also,!the!loss!of!neurons!may!not!be!observed.!!
5! Limitations'of'the'study'!The! most! obvious! limitation! to! this! study! is! the! fact! that! our! analysis! was!conducted!with!fewer!mice!than!originally!intended,!thus!reducing!its!power.!This!has! also! left! key! questions! unresolved! including! how! the! vector! effects!we! have!documented!differ!between!Cln3)/)!mice!injected!at!different!stages!of!the!disease,!and!how!this!changes!with!long@term!exposure!to!these!vectors,!and!with!disease!progression.! Nonetheless,! we! have! attempted! to! extrapolate! some! conclusions!based!on!the!data!obtained!from!the!remaining!wild@type!and!Cln3)deficient!mice.!!Although! the! significant! genotyping! issue!was! unforeseeable! and!was! caused! by!procedural!failures!beyond!our!control,!the!matter!of!variable!vector!spread!needs!to!be!understood.!One!explanation!already!mentioned!at! the! start!of! this! section'was! the! possible! presence! of! neutralizing! antibodies! against! AAVs! (Rapti! et-al.,-2012;!Jeune!et-al.,-2013),!which!may!hamper!transduction.!To!determine!whether!this! had! an! impact! on! vector! spread! in! this! study,! blood! samples!would!need! to!have! been! collected! during! the! survival! period! after! vector! administration.!Unfortunately,! this! issue! only! came! to! light! once! all! the! animals! had! been!
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sacrificed,! so! this! analysis! was! not! possible.! Two! difficulties! were! encountered!during! the! surgical! procedure,! which! could! also! explain! the! variation! in! the!amount!of!eGFP!detected!between!brains;!in!some!cases,!there!was!bleeding!upon!withdrawal!of! the!needle!after! infusion!of! the!vector!and!on!a! few!occasions,! the!needle! became! blocked.! However,! these! complications! were! recorded! and! upon!review!did!not!correlate!with!instances!when!the!spread!of!the!vector!was!poor!so!technical!failure!of!our!injections!seems!unlikely.!!!These! studies! are! also! limited! by! the! lack! of! a! reliably! specific! antibody! against!Cln3/CLN3! for! histological! analysis.! This! study! was! designed! to! overcome! this!problem! by! using! bicistronic! vectors,! which! incorporate! an! eGFP! reporter! gene.!The! assumption! here! is! that! eGFP! protein! expression! would! correlate! with!Cln3/CLN3!expression,!as! the!expression!of!both!genes! is!driven!under! the!same!CMV! promoter.! However,! the! relative! expression! of! eGFP! and! Cln3/CLN3! at! the!mRNA!and!protein!levels,!and!whether!it!is!equal!cannot!be!determined!precisely,!and!as!a!result!the!exact!amount!of!Cln3/CLN3!expression!is!unknown.!However,!
Cln3/CLN3! is! the! first! message! and! the! eGFP! is! the! second! message! within! the!vector,! therefore! if! eGFP! is! expressed! at! a! lower! level! as! has! been! reported! for!bicistronic!vectors!(Ngoi!et-al.,-2004;!Martin!et-al.,-2006),!then!we!can!assume!that!there! is! at! least! the! same! or! more! Cln3/CLN3! expression! based! on! the! protein!expression!of!eGFP.!!!Another! important! limitation! of! the! study! is! that,! as! noted! in! section' 3.1' of!
Chapter'2,'two!batches!of!vector!were!provided!by!UCL,!the!yields!of!which!varied!slightly.!Although!all!vectors!were!diluted! to! the!same! final! concentration!before!being! injected,! this! was! retrospectively! inaccurate! as! the! initial! quantification!
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procedure! for! the! first! batch! of! vector! was! imprecise.! When! the! first! batch! of!vector!was! re@measured!at!a! later!date! (once! the!surgeries!had!been!completed)!using! a! more! reliable! method,! we! discovered! small! discrepancies! between! the!initially!reported!and!actual!concentration!of!vectors,!that!meant!that!slightly!more!vector! had! been! injected! than! planned.! Therefore,! it! is! important! to! note!which!mice!were!injected!with!which!batch!of!vector!when!making!comparisons!between!groups.!Wild@type!mice!injected!at!7.5!months!of!age!and!sacrificed!after!2!months!were! injected!with!a!different!batch!of!vector! to! the!wild@type!mice! injected!at!3!and!7.5!months!and!sacrificed!6!months!later.!The!same!batch!of!virus!was!used!for!wild@type!and!Cln3Δex7/8!mice!injected!at!7.5!months!and!sacrificed!2!months!later.!Nevertheless,! the! tissue! from! these! two! groups! were! stained! at! different! times,!which!may!have! impacted!on! the!reliability!of!comparisons!made!between!them,!although!this!can!be!minimised!by!carefully!controlling!the!staining!reaction!as!we!always! do.! Finally,! both! Cln3)/)!and! Cln3-Δex7/8! mice! were! injected! with! the! same!batch!of!virus,!but!again!these!two!groups!were!not!stained!at!the!same!time!and!furthermore,!were!injected!at!different!ages,!both!of!which!are!more!of!a!concern.!Realistically,! the! differences! in! concentration! are! negligible! and! unlikely! to! have!impacted! on! the! trends! reported,! but! may! have! resulted! in! slightly! more! glial!activity!than!at!the!intended!concentration!of!12!x!1012!µl/ml.!!
6! Discussion'
The!aim!of! this!study!was! to!evaluate! the!safety!of!using!AAV2/9@mediated!gene!therapy! for! the! treatment!of!CLN3!disease!using!a! combination!of!wild@type!and!mutant! mice.! Other! viral! vectors! including! lentivirus,! alphavirus! and! herpes!simplex! can! also! be! engineered! to! create! vector! systems! for! the! delivery! of!
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therapeutic!genes!and!have!been!comprehensively!reviewed!elsewhere!(reviewed!in!Walther!and!Stein,!2000;!Kootstra!and!Verma,!2003;!Sands!and!Davidson,!2006).!While!all!viral!vectors!have!their!own!specific!advantages!and!disadvantages,! the!efficiency! with! which! they! can! carry! out! this! function! depends! on! the! precise!application!in!question.!For!example,!lentiviral!vectors!have!been!used!extensively!as!a!gene!transfer!tool!for!the!CNS,!as!they!are!capable!of!transducing!a!variety!of!brain!cells,!resulting!in!high@level,!stable!and!long@lasting!transgene!expression!and!as!such,!have!shown!therapeutic!efficacy!for!the!treatment!of!other!LSDs!(reviewed!in! Jakobsson! and! Lundberg,! 2006).! ! However,! the! integrative! properties! of!lentiviral!vectors!have!always!raised!safety!and!ethical!concerns!about!undesirable!integration! limiting! transgene! expression! and/or! interfering! with! the! normal!function! of! adjacent! genes,! which,! is! particularly! important! given! the! unknown!function!of!CLN3-(reviewed!in!Sands!and!Davidson,!2006;!Connolly,!2002;!Persons,!2010).! AAV! vectors! are! a! popular! candidate! for! gene! therapy! because! of! their!desirable! properties,! including! their! relative! safety,! efficacy! of! transduction,!stability,!and!ability!to!confer!long@term,!stable!transgene!expression!with!little!or!no! associated! inflammation! or! toxicity! and! without! altering! the! host! genome!(reviewed! in! Xiao! et- al.,- 1997;! Büeler,! 1999;!Carter,! 2005;! Mueller! and! Flotte,!2008;! Goncalves,! 2005! and! Hastie! and! Samulski,! 2015;! Laughlin! et- al.,- 1983;!Hermonat! and!Muzyczka,! 1984;! Xiao! and! Samulski,! 1996;-McCown! et-al.,-1996).!!However,! we! have! shown! that! there! is! an! acute! glial! response! to! vector@driven!Cln3/CLN3!expression,!but!that!this!is!not!exclusive!to!protein!expression!as!there!is! also! a! glial! response,! albeit! limited,! to! the! AAV2/9@vector! itself.! This! glial!response!is!not!specific!to!the!age!at!which!the!vector!is!injected!in!wild@type!mice,!but!we!cannot!conclude!if!this!is!also!the!case!in!Cln3@deficient!mice!as!the!disease!progresses.!Most! likely!owing!to!the!species!difference!between!the!human!CLN3-
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transgene! and! the! mouse! model! in! which! it! is! expressed,! AAV2/9.hCLN3.eGFP!generally! elicits! the! greatest! overall! astrocytic! and! microglial! response,! but!AAV2/9.mCln3.eGFP! also! induces! a! similar! response,! albeit! generally! to! a! lower!degree.!This!is!relevant!to!the!clinical!scenario!in!which!vectors!expressing!human!transgenes!would!be!administered!to!patients.!!Interestingly,!the!glial!response!in!wild@type!mice!detected!at!2!months!following!injection!was!completely!resolved!by!6!months! suggesting! that!despite! its! immunogenicity,!AAV2/9@mediated!gene!transfer!could!still!be!a!useful!treatment!in!combination!with!a!short@term!course!of! immunosuppressant! drugs! (Cooper,! personal! communication).! However,! this!finding!was! shown! in!wild@type!mice! and!must! be! repeated! in!mouse!models! of!CLN3!disease!to!ensure!that!genotype!and!disease!progression!does!not!influence!how!glia!respond!to!the!vector!over!time.!!
!
Despite! the! promise! that! any! glial! response! goes! away! over! time,! the! adverse!effects! associated! with! such! a! response! in! the! short@term,! as! well! as! any! other!long@term! effects! of! vector! transduction! must! be! considered.! For! this! reason,!analysis! of! neuronal! number! was! essential! for! determining! any! impact! of! the!vector! administration!upon!neuronal! survival.! It! appears! that! there! is! a!possible!neurotoxic!effect!of! the!vectors!on!neurons,! especially!with!AAV2/9.hCLN3.eGFP.!However,!this!was!not!consistent!between!genotypes!or!ages!and!most!confusingly,!at!6!months,!no!such!differences!in!neuron!number!were!observed!for!any!of!the!vectors.!!Whether!AAV2/9@driven!gene!expression!actually!has!a!neurotoxic!effect!is! an! important! question! to! resolve,! especially! in! Cln3@deficient! mice! in! which!neuron! loss! occurs! in! many! brain! regions! that! will! need! to! be! targeted!therapeutically.! Encouragingly! though,! the! only! significant! difference! in! neuron!
! 271!
number!we!saw!was!in!the!AAV2/9.hCLN3.eGFP@injected!striatum,!which!may!have!had! a! greater! impact! on! the! brain! due! to! the! species! difference! inherent! in!expressing!a!human!protein!in!the!mouse!brain.!Nevertheless,!this!negative!impact!on!neuron!number!raises!some!doubts!on!whether! these!vectors!are!suitable! for!therapeutic! use! in! children.! It! is! not! clear! if! one! of! the! results! of! short@term!inflammation! associated! with! Cln3/CLN3! protein! expression! is! to! cause! neuron!loss,!or!whether!the!Cln3/CLN3-over@expression!has!a!direct!neurotoxic!effect!or!a!combination! of! these! events.! In! the! case! of! the! former,! the! administration! of!immune! suppressant! or! anti@inflammatory! drugs! may! alleviate! these! adverse!effects,! but! if! it! is! the! later! the! choice! of! CMV! promoter! may! need! to! be! re@evaluated.! Interestingly,! our! collaborators! at! UCL! found! that! AAV2/9! vectors!expressing!CLN6!under!the!CMV!promoter!were!neurotoxic!to!the!retinae!of!CLN6!(nclf)!mice!(kleine@Holthaus,!personal!communication).!!!There! is! currently! no! effective! therapy! for! the! treatment! of! CLN3! disease,!therefore,! treatment! approaches! that! show! potential! for! therapeutic! efficacy!should!be!fully!explored.!!In!this!particular!study,!we!have!shown!that!Cln3/CLN3@mediated! gene! therapy!using!AAV2/9!has! the!potential! for!widespread! and! long!lasting! transduction! within! the! CNS! of! wild@type! and! Cln3)/)- mice- leading! to!transient! neuroinflammation! lasting! no! longer! than! 6! months! and! significant!neuron! loss! only! specific! to! human! CLN3! over@expression,! warranting! further!investigation! into! safety! and! therapeutic! efficacy.! Indeed,! studies! using!AAVrh.10hCLN3! have! shown! a! significant! effect! on! astrocytosis! and! a! mild!neurprotective! effect! in! Cln3Δex7/8-mice! with! no! indication! of! toxicity! or! local!inflammation!(Sondhi!et-al.,-2012).!Given!the!evidence!from!this!study!and!our!own!that! Cln3/CLN3! over@expression! does! not! have! adverse! affects! in- vivo,! the! next!
! 272!







1.1! Why(are(neurons(lost(and(somatic(cells(spared?(The! genes! that! cause! the!NCLs! are! ubiquitously! expressed! throughout! the! body,!coding!for!various!proteins!involved!in!secretory!and!or!endo/lysosomal!pathways!within!the!lysosomal!system!(reviewed!in!Mole!and!Cotman,!2015).!The!resulting!accumulation!of!autofluorescent!storage!material! that!characterizes! this!group!of!disorders! is!present! to!varying!degrees! in!all! cell! types! in! the!body! (reviewed! in!Hofmann! and! Peltonen,! 2001).! While! the! level! of! storage! burden! does! not!generally!predict!the!cellular!consequences!of!NCL!mutations!(reviewed!in!Palmer!
et# al.,# 2013),! the! underlying! pathological! mechanisms! involved! appear! to!predominantly!affect!the!brain!leading!to!progressive!neurodegeneration!and!the!devastating! symptoms! that! typify! the! NCLs! including! blindness,! psychomotor!deterioration,! seizures! and! premature! death! (reviewed! in! Zhong,! 2000;! Haltia,!2003).! As! such,! the! majority! of! pathological! studies! have! focused! almost!exclusively! upon! the! CNS! under! the! assumption! that! the! effects! of! disease! are!restricted! to! the! brain! (Mitchison! et#al.,#2004).! Interestingly! though,! the! normal!physiological!level!of!CLN!protein!expression!within!the!brain!compared!to!the!rest!of!the!body!does!not!correlate!with!the!severity!of!disease!observed!in!its!absence,!and!this!is!confounded!by!the!fact!that!for!most!NCLs!the!normal!function!of!these!proteins! is! not! fully! understood! (reviewed! in! Mole! and! Cotman,! 2015).! The!presence! of! mutated! CLN1,! CLN2! and! CLN3! genes! for! example! has! serious!degenerative!effects!within!the!CNS,!but!there!is!little!evidence!to!suggest!that!the!normal! function! of! nonSneuronal! cells! is! disrupted! by! these! mutations! despite!their! relatively! high! level! of! normal! protein! expression! (reviewed! in!Chattopadhyay! and! Pearce,! 2000).! While! mRNA! levels! of! CLN1# and# CLN2! are!
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comparable!in!all!tissues,!the!distribution!of!translated!protein!differs!(reviewed!in!Chattopadhyay! and! Pearce,! 2000;! Margraf! et# al.,# 1999;! Koike! et# al.,# 2002).! An!immunohistochemical!survey!of!human!tissue!has!shown!that!CLN1.encoded!PPT1!protein!is!detected!mostly! in!the!brain,! lungs,!bowel!and!liver!compared!to!other!tissues,!yet!only!the!brain!is!preferentially!targeted!in!CLN1!disease!(Margraf!et#al.,#1999).!Similarly,!high!levels!of!CLN2.encoded!TTPS1!protein!have!been!specifically!detected!in!the!brain,!stomach,!kidney!and!testis!of!the!mouse,!but!again!only!the!brain! is! obviously! affected! as! a! result! of! TTPS1! deficiency! ! (Koike! et#al.,#2002).!Conversely,!mRNA!levels!of!CLN3!varies!between!tissues!with!considerably!higher!expression! in! the! gastrointestinal! tract! and! glandular/secretory! tissue! like! the!liver!compared!to!the!CNS!(Chattopadhyay!and!Pearce,!2000),!yet!no!evidence!of!liver! dysfunction! has! been! reported! in! CLN3! disease! patients! or! Cln3.deficient!mouse!models,!whilst!retinal!cells!expressing!very!little!CLN3!protein!are!seriously!affected!(Cotman!et#al.,#2002).!!
!
It! is! important!to!note,!that!defining!the!level!of!normal!endogenous!CLN!protein!expression!in!humans!and!animal!models,!is!challenging!because!of!the!limitation!of! available! antibodies! and! detection! methods! and! therefore,! there! are!discrepancies!in!reported!protein!levels!between!different!studies.!Nevertheless,!it!is!clear!that!neurons!are!particularly!sensitive!to!mutations!in!the!CLN!genes.!!
!
There!are!a!number!of!possible!explanations!for!why!the!deleterious!effects!of!CLN!gene!mutations!manifest!preferentially!within!the!CNS.!One!of!the!most!obvious!is!that! neurons,! unlike! most! somatic! cells,! are! postSmitotic! and! therefore,!
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dysfunctional! or! dying! neurons! are! not! readily! replaced! (Mitchison! et#al.,#2004).!!Another!explanation! is! that!CLN! genes!may!have!certain!neuronSspecific! roles!or!are! involved! in! processes! which! are! critical! for! neuron! survival,! but! are! less!important! for! cells! outside! the! CNS! (Mitchison! et# al.,# 2004).! For! example,! the!localization!and!functional!activity!of!CLN1Sencoded!PPTS1!protein!is!not!limited!to!lysosomes! in! the! CNS,! but! has! also! been! located! in! the! presynaptic! region! of!neurons!suggesting!a!specific!role!in!synaptic!function!(Gumps!et#al.,#2013;!Kim!et#
al.,#2008;! Ahtiainen! et# al.,#2003;! Lehtovirta! et# al.,#2001;! Heinonen! et# al.,#2000).!Similarly,! whilst! the! exact! functional! role! of! CLN3! protein! is! unknown,! its!involvement!in!a!number!of!cellular!processes!including!endocytosis,!implicates!it!in!neuronSspecific!processes!such!as!neurotransmitter!release!(Pearce,!2000;!Luiro!
et#al.,#2001;!Fossale!et#al.,#2004;!Kama!et#al.,#2007;!Pears!et#al.,#2005).!To!date,!the!majority!of!CLN!proteins!have!been!at!least!indirectly!linked!to!processes!that!are!particularly! important! for! neuronal! function! (reviewed! in! CarcelSTrullols! et# al.,#2015).! Furthermore,! as! neurons! are! generally! highly! polarized,! abnormal!trafficking! of! CLN! proteins! or! of! other! proteins! as! a! result! of! mutations! in! CLN!genes,! are! likely! to! have!more! severe! consequences! in! neurons! than! in! somatic!cells!(Pearce,!2000;!Luiro!et#al.,#2001).!!
!
It! has! also! been! suggested! that! there! are! other! proteins! present!within! somatic!cells! outside! of! the! CNS,! which! are! capable! of! compensating! for! defective! or!missing!CLN!proteins.!For!example,!the!lysosomal!protease!dipeptidyl!peptidase!I!(DPP1)! (also! known!as! cathepsin!C,! CTSC),! expressed!only! outside! of! the!CNS! is!thought! to!carry!out!a!similar! function! to!TPP1!protein,!which! is!absent! in!CLN2!disease!as!a!result!of!mutations! in! the!TPP1! gene!and! therefore,! can!compensate!
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for! TPP1! deficiency!within! the! viscera! (Bernardini! and!Warburton,! 2002).! Even!though! targeting! the!neurological!defects! is! a! therapeutic!priority,! it! is! logical! to!assume! that! CLN! genetic! mutations! have! some! impact! on! the! biochemistry! of!somatic! cells,! leading! to! pathological! changes! in! the! normal! structure! and/or!function! of! the! organs! which! they! respectively! constitute,! that! perhaps! do! not!become! apparent! as! children! succumb! to! the! neurological! disease! early! on!(Chattopadhyay!and!Pearce,!2000;!Mitchison!et#al.,#2004).!Interestingly,!as!will!be!discussed! in! section( 1.3,! best! clinical! evidence! for! cardiac! dysfunction! or!pathology! for! example,! comes! from!CLN3!patients!who! live! longer! than!patients!with!other!forms!of!NCL!that!have!an!earlier!onset!and!more!rapidly!progressing!disease!course!(Østergaard!and!Mølgaard,!2011;!Hofman!et#al.,#2001;!Dilaveries!et#
al.,!2014;#Williams!and!Mole,!2012).!!
!
1.2! Visceral(pathology(–(what(we(already(know(Some! effort! has! been! made! to! characterize! visceral! pathology! in! human! tissue!from! NCL! patients! and! several! mouse! models! of! NCL.! The! bestSdescribed! nonSneuronal!or!somatic!pathological!phenotype!is!the!presence!of!storage!material!in!most!organs!(Kida!et#al.,#2001;!Anderson!et#al.,#2013;!Pallis!et#al.,#1967;!Goebel!et#
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Heart(Endothelial!and!valve!cells! ! NE! ! NE! ! NE! ! 1+!!
Table(11.(Progressive(accumulation(of(lysosomal(storage(in(Ppt1Mdeficient((Ppt1%/%)'mice(taken(from(
Galvin'et'al.,'2008.(Abbreviations:(NS(=(no(storage,(NE(=(not(examined.(!Similarly,! electronSmicroscopic! examination! of! tissue! from! the! Cln3Δex7/8! mouse!model!has! revealed!peripheral!membranous! subunit! cSpositiveSdeposits!with! the!‘fingerprint’! inclusion! profile! typical! of! CLN3! disease,! in! the! liver! (Cotman! et#al.,#2002),!and!subunit!cSpositiveSdeposits!in!the!liver,!spleen,!bone!marrow!and!heart!(Staropoli!et#al.,#2012).!Beyond! the!presence!and!appearance!of! storage!material,!very! few! studies! have! set! out! to! define! extraneuronal! pathology! in! patients! or!animal! models! in! much! detail.! However,! as! visceral! pathology! starts! to! become!more! relevant,! clinical! and! experimental! evidence! is! beginning! to! mount.! For!example,! a! number! of! metabolic! defects,! abnormalities! in! haematopoiesis! and!vacuolation! of! peripheral! blood! lymphocytes! and! epidermal! cells! have! been!observed!in!Cln3Δex7/8!mice!(Staropoli!et#al.,#2012).!In!particular,!cardiac!pathology!
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has! been! reported! in! a! number! of! clinical! case! studies! (Tomiyasu! et# al.,! 2000;!Fealey!et#al.,#2009;!Hofman!et#al.,#1990,!2001),!in!the!Ppt1#./.#model!of!CLN1!disease!(Galvin!et#al.,#2008)!and! to!a! lesser!extent! in! the!Cln3Δex7/8!mouse!model!of!CLN3!disease!(Staropoli!et#al.,#2012),!as!will!be!discussed!in!section(1.3!below.!!
!
1.3! Cardiac(pathology(in(NCL(patients((The!most!obvious!reason!for!why!neurons!are!preferentially!targeted!by!CLN!gene!dysfunction! is! that! they! are! postSmitotic! as!mentioned! already! in! section(1.1(of!this! chapter.! Therefore,! it! is! logical! to! expect! that! the! heart,! which! is! also!considered!to!be!largely!postSmitotic,!to!display!the!most!obvious!signs!of!visceral!pathology! (Bernardo! et# al.,# 2003).! Few! studies! have! focused! specifically! on!functional! and! morphological! changes! in! the! heart! of! NCL! patients! or! animal!models! and! as! such! no! clear! pattern! of! typical! cardiac! manifestations! has! been!established.! Most! evidence! for! heart! dysfunction! comes! from! studies! in! CLN3!patients!who!live!longer!and!are!more!likely!to!develop!cardiac!symptoms!(Galvin!
et#al.,#2008;!Cooper!et#al.,#2015).!As!summarized!in(Table(12,!the!most!commonly!reported! cardiovascular! symptoms! in! these! patients! have! been! ventricular!hypertrophy,! repolarizing! disturbances! and! arrhythmia! (irregular! heart! beat)!often! involving! severe! bradycardias! (slow! heart! rate),! indicating! abnormal!parasympathetic! activity! and/or! sinus! node! dysfunction! (sometimes! with!complete!sinus!node!arrest),!with!some!patients!dying!of!heart!failure!(Hofman!et#
al.,# 1990,! 2001,! Østergaard! and! Mølgaard,! 2011).! Examination! of! the! heart! at!autopsy! has! frequently! revealed!myocyte! hypertrophy,! ventricular! hypertrophy,!ventricular! dilation! and! accumulation! of! lipopigments! in! the! myocardium! and!conduction! system,! fibrosis! and! infiltration!of! adipose! cells! (Hofman!et#al.,#2001;!
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12),!which! develops! in! adulthood! (Mole! and! Cotman,! 2015).! Like! CLN3! disease,!Kufs!disease!has!a!more!protracted!disease!course!compared!to!other!forms!of!NCL!and! therefore! cardiac! symptoms! are! more! likely! to! manifest.! However,! as! Kufs!disease! is!one!of! the! rarest! forms!of!NCL!and! is!particularly!difficult! to!diagnose!given! the! fact! that! there! is!no!visual! loss! (a!distinguishing! feature!of!most!NCLs)!and!accumulation!of! storage!material! is! a!normal!part!of! the!aging!process,! thus!limiting! the!diagnostic!power!of! its! detection!via!biopsy,! there! are! fewer! clinical!reports!available!(Lewandowska!et#al.,#2009;!Pasquinelli!et#al.,#2004).!A!case!study!of!two!patients!with!Kufs!disease,!in!which!one!patient!died!of!cardiac!arrest!while!the! other! suffered! a! nonSfatal! cardiac! arrest,! reported! clear! evidence! for! heart!disease!prior! to! these!events! (Sakajiri!et#al.,#1995).!Mild!ventricular!hypertrophy!and! dilation! and! a! number! of! abnormalities! within! the! conduction! system!including!right!bundle!branch!block!in!which!the!right!ventricle!is!not!activated!by!impulses! travelling! through! it,! hypokenesia! (abnormal!muscle!movement! due! to!disruption! in! the! basal! ganglia)! of! the! ventricular! walls! and! cardiac! arrhythmia!
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involving! ventricular! tachycardia!were!described! in! both!patients! (Sakajiri!et#al.,#1995).! Furthermore,! autopsy! findings! showed! severe! fibrosis,! infiltration! of! fat!cells! into! the! myocardium! and! varying! amounts! of! lipopigment! in! myocardial!fibres! and! the! conduction! system! (Sakajiri! et#al.,#1995).! In! another! clinical! case!report! of! a! patient! with! Kufs! disease,! conduction! abnormalities! appeared! to! be!absent!and!the!only!cardiac!symptoms! identified!were!biventricular!heart! failure!and! biartial! enlargement! with! impaired! ventricular! filling,! storage! accumulation!and!only!mild!myocyte!hypertrophy!and!fibrosis!(Fealy!et#al.,#2009).!!
!
These! findings,! like! those! described! for! CLN3! disease,! emphasise! the! lack! of!specific! cardiac! symptoms! among! not! only! the! NCLs! as! a! group,! but! between!patients!with! the! same! form! of! NCL.! Interestingly,! similar! conduction! defects! to!those! described! in! CLN3! and! Kufs! disease! cases! have! been! shown! to! develop!progressively!in!a!case!of!CLN2!disease!in!which,!intensive!management!involving!longSterm! artificial! ventilation! led! to! prolonged! survival! of! 28! years! of! age!(Fukumura!et#al.,#2011).!Intriguingly,!the!progressive!conduction!defects!were!not!accompanied!by!signs!of!cardiomyopathy,!perhaps!due!to!the!preferential!storage!of! lipopigment! in! the! conduction! system! rather! than! the!myocardium!as! seen! in!other! cases! of! CLN3! disease! (Fukumura! et# al.,# 2011).! This! is! an! important!consideration! as,! unlike! neurodegeneration!within! the! CNS,! the! accumulation! of!storage! materials! is! currently! thought! to! play! an! important! role! in! the!development!of!the!cardiac!pathology!identified!in!CLN3!and!Kufs!disease!(GilbertSBarness!et#al.,#2004;!ReskeSNielsen!et#al.,#1981;!Michielsen!et#al.,#1984;!Sakajiri!et#
al.,#1995;!Toyiyasu!et#al.,#2000;!Hofman!et#al.,#2001).! !While! little!characterisation!of! corresponding!mouse!models! of! CLN3! or!Kufs! disease! has! been! conducted! to!
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investigate! the! basis! of! the! clinical! findings! described! above,! some! progress! has!been!made!to!define!the!microscopic!and!macroscopic!involvement!of!the!heart!in!the!Ppt1./.!mouse!model!of!CLN1!disease,!in!which!clinical!and!pathological!cardiac!dysfunction! has! been! poorly! characterized.! Indeed,! no! systematic! studies! of!cardiac!complications!in!CLN1!disease!have!been!published,!but!an!increased!risk!of!bradycardia!during!anesthesia!has!been!reported!(Miao!et#al.,#2009).!Abundant!GRODs!have!been!identified!in!the!lysosomes!of!smooth!muscle!cells!in!the!media!of! the! aortic! arch! and! to! a! lesser! extent! in! myocardial! cells,! while!echocardiographic! examination! revealed! ventricular! hypertrophy! and! aortic!dilation,! but! mostly! normal! cardiac! function! in! Ppt1./.#mice! at! 7! months! of! age!(Galvin!et#al.,!2008).!Although!cardiac!pathology!has!been!investigated!in!5!month!old! Cln3Δex7/8# mice,! no! overt! evidence! was! found! for! cardiovascular! defects!(Staropoli!et#al.,#2012).!
!



















































































































































These% studies% highlight% three% important% considerations% for% the% treatment% of%NCL%disease.% Firstly,% as% long% as% the% neurological% defects% present% in% the% NCLs% go%uncorrected% they% will% naturally% take% clinical% precedence% over% any% visceral%symptoms.% However,% it% is% likely% that% if% CNS% pathology% is% ultimately% successfully%targeted,%cardiac%complications%are%likely%to%emerge,%similar%to%those%reported%for%CLN3%and%Kufs%disease%patients%with%a% longer%lifespan%and%the%longBterm%survival%of%the%CLN2%disease%patient%described%above%(ReskeBNielsen%et#al.,#1981;%Hofman%et#
al.,#1990,%2000;%Østergaard%and%Mølgaard,%2011;%Dilaveris%et#al.,#2014;% Sakajiri%et#
al.,#1995;%Fealey%et#al.,#2009;%Fukumura%et#al.,#2011).%This%is%of%particular%relevance%for% CLN2% disease,% given% the% fact% that% there% is% currently% a% phase% II% clinical% trial%underway%(https://clinicaltrials.gov/ct2/show/NCT01907087),%but%this%only%targets%therapy%to%the%brain.%Secondly,%characterizing%and%treating%cardiac%pathology%might%have%an%overall%beneficial%effect%on%neurological%symptoms.%Evidence% for% this%has%already%been%provided%from%a%clinical%case%in%which,%a%21ByearBold%male%with%CLN3%disease%was% given% a% pacemaker% and% experienced% a% general% improvement% in%NCL%symptoms%and%increased%life%expectancy%(Østergaard%and%Mølgaard,%2011).%Finally,%it% should% be% appreciated% that% the%mechanisms% responsible% for% cardiac% pathology%may% well% differ% from% those% that% underlie% neurological% pathology.% For% example,%while%no%direct% link%has%been%made%between%storage%material%and%neuron% loss% in%the% CNS,% the% accumulation% of% storage%material% in% cardiac% tissue%may% be% directly%responsible% for% cardiomyopathic% complications% and% conduction% system%abnormalities%in%the%heart%as%mentioned%above%(Fukumura%et#al.,#2011).%Therefore,%treatments% such% as% small% substrate% reduction% therapy% that% have% shown% little%success%in%treating%the%brain,%may%be%more%effective%in%treating%the%heart%and%could%provide% another% way% to% improve% the% overall% prognosis% of% disease% if% used% in%combination%with%CNSBdirected%therapies%as%discussed%in%section(5.1(of%Chapter(6.%%(
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1.4! Aims(and(hypotheses(While%we% continue% to% gather% clinical% information% from%NCL% patient% case% studies,%cardiac%data%from%mouse%models%of%these%diseases%is%either%very%limited,%or%has%not%been% gathered.% The% overall% aim% of% this% thesis% was% to% evaluate% the% use% of% gene%therapy% approaches% for% the% treatment% of% CLN1% and% CLN3% diseases.% Because% the%presence%of%visceral%pathology%may%be%an% important%consideration% for% improving%the%therapeutic%efficacy%of%gene%therapy%approaches%as%explored%in%Chapter(5,%the%aim% of% this% study% was% to% systematically% define% the% presence% of% functional% and%histological%cardiac%pathology%in%the%Ppt1?/?#and%Cln3?/?%mouse%models%of%CLN1%and%CLN3% disease,% respectively.% This% was% done% using% wellBestablished% methods% of%functional% and% histological% analysis% in% collaboration% with% KCL’s% Cardiovascular%Division%in%order%to%identify%robust%phenotypes,%as%will%be%described%in%section(2.%%
%






2.1! Mice(As% described% in% section(1.3(of%Chapter(2,% the%Ppt1?/?#mouse%model% recapitulates%the% rapidly%progressing%disease% course%of%CLN1%disease%with% a% life% expectancy%of%approximately%8.5%months%(Kielar%et#al.,#2007).%As%such,%5%B%8.5%months%of%age%is%a%period% towards% the% end% stage% of% disease% in% these% mice% when% neuropathology% is%considered%to%be%severe.%Therefore,%we%analysed%the%presence%of%cardiac%pathology%in%mice% at% 6%months% of% age% as% a% logical% first% step% to% identifying% the% presence% of%cardiac%phenotypes%in%this%mouse%model%(if%there%is%no%cardiac%pathology%towards%disease%end%stage,%there%is%unlikely%to%be%any%cardiac%pathology%at%earlier%stages%in%disease).% In%contrast,%CLN3%disease%is%more%slowly%progressing,%and%therefore,%we%used%Cln3Δex1?6% (Cln3?/?)%mouse%models% of% CLN3%disease% (Mitchison%et#al.,% 1999)% to%explore%the%presence%and%progression%of%cardiac%pathology%at%12%and%18%months%of%age.% As% described% in% section( 1.1(of%Chapter( 2,% 12%month% old% Cln3?/?% mice% show%moderate%neurological%symptoms%and%neuropathology%(Mitchison%et#al.,%1999),%and%represent%animals%at%the%middle%stage%of%disease,%while%18%month%old%Cln3?/?%mice%show% moderate% to% severe% neurological% symptoms% and% neuropathology% and%represent%mice%approaching% the%end%stage%of%disease%(21%months).%Therefore,%we%wanted%to%assess%whether%these%neuropathological%changes%were%accompanied%by%any% cardiac% defects.% Homologous% recombination% techniques% have% also% led% to% the%creation% of% genetically% more% accurate% Cln3Δex7/8% mice% (Cotman% et# al.,# 2002)% as%described% in% section( 1.2( of% Chapter( 2.% However,% because% they% needed% to% be%rederived% these%mice%were%not%available% in% sufficient%quantity%at% the% start%of% this%project,% and% therefore% Cln3?/?% mice% were% used.% Relatively% few% differences% in% the%phenotypes% of% Cln3Δex7/8% and% Cln3?/?% mice% have% been% reported% and% these% may% be%
!
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largely% due% to% differing% strain% backgrounds.% The% mice% used% in% this% study% are%summarized%in%Figure(49(in(section(2.3.%
%
2.2! Parameters(investigated(No%systematic% studies%have%been%carried%out% in% the%heart%of% any%mouse%model%of%NCL%beyond%the%identification%and%classification%of%storage%material.%Therefore,%we%wanted% to% establish% the% degree% to%which#Ppt1?/?#and%Cln3?/?%mice% exhibit% basic% yet%robust,% echocardiographic% and%histological% phenotypes% that% are% easy% to%measure.%This% included% the% analysis% of% cardiac% myocyte% size% as% a% measure% of% myocyte%hypertrophy,% endothelial% cell% count% to% investigate% any% compensatory% vascular%response% to% cardiac% hypertrophy% and% levels% of% fibrosis% as% an% indicator% of% cardiac%disease.%We%also%carried%out%CD45%(pan%marker%of%hematopoietic%cells)%staining%to%identify%the%presence%of%inflammatory%cells%in%the%myocardium.%To%examine%cardiac%pathology% specifically% within% the% conduction% system,% we% also% used%hyperpolarization% activated% cyclic%nucleotide% gated%potassium%channel%4% % (HCN4,%expressed%by%specialised%myocytes%within%the%SA%node)%and%connexin%43%(Cx43,%a%cell% surface% marker% on% cardiomyocytes% not% expressed% within% the% SA% node)% to%delineate% the%SA%node% together%with%haematoxylin/Van%Gieson% (HVG)% staining% to%qualitatively% assess% the% presence% of% characteristic% features% of% cardiac% pathology%including;%inflammation,%cloudy%cell%swelling,%vacuolization,%myocytolysis,%necrosis%and%loose%connective%tissue%(described%in%Rowland%et#al.,#1992).%To%determine%the%presence%of%functional%pathology%in%6%month%old%Ppt1?/?%mice%and%Cln3?/?%mice%at%12%and% 18% months% of% age,% we% also% carried% out% basic% echocardiographic% analysis% to%investigate%any%morphological%changes,%and%the%ability%of%the%heart%to%pump%blood%around%the%body,%as%outlined%in%Table(8(in%Chapter(2.%%
!
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2.3! Experimental(designs(To% gather% a% broad% range% of% information% about% cardiac% pathology% in% 6%month% old%
Ppt1?/?#mice% and% Cln3?/?% mice% at% 12% and% 18% months% of% age,% mice% underwent%echocardiography%and%their%hearts%were%subsequently%harvested%and%divided%into%3% parts% for% histological% analysis% (as% described% in% section( 2.2)% and% molecular%analysis% (RTBqPCR% and% western% blot).% The% experimental% design% of% this% study% is%summarised%in%Table(49(below:%
%
Figure(49.(Schematic(representation(of(the(experimental(plan(for(cardiac(studies.%This%study%included%66%mice%of%different%genotypes%and%ages:%1)%11%wildBtype%mice%and%113%Ppt1Bdeficient%(Ppt1?/?)%mice%at%6%months%of%age%2)%12%wildBtype%mice%and%10%Cln3%deficient%(Cln3?/?)%mice%at%12%months%of%age%and%3)%10%wildBtype%mice%and%212%Cln3?/?%mice%at%18%months%of%age.%All%mice%underwent%an%echocardiogram%then%immediately%given%a%dose%of%lethal% anaesthesia%and%hearts%were%harvested% (following%KCl%perfusion).%Heart% tissue%was%divided% into% three%equal%parts:%the%upper%segment%was%fixed%in%4%%PFA%and%embedded%in%paraffin%wax%for%histological%analysis,%the%middle%and%apical%segments%were%frozen%in%liquid%nitrogen%and%stored%at%B80°C%for%RTBqPCR%and%western%blot%analysis,% respectively.%Histological%analysis%of%wildBtype%and%Ppt1?/?#mice%at%6%months%and%wildBtype%and%
Cln3?/?#mice%at%12%and%18%months%of%age%included%measuring%the%size%of%wheat%germ%agglutinin%(WGA)Bstained%myocytes%in%the%left%ventricle%(LV)%myocardium%to%detect%myocyte%hypertrophy,%counting%isolectin%B4%(IsoB4)Bstained%endothelial%cells%in%the%LV%myocardium%to%identify%any%increase%in%angiogenesis%in%response%to%cardiac%hypertrophy% and% thresholding% analysis% of% the% area% of% picrosirus% redBstained% collagen% fibres% in% the% LV%myocardium% as% a% measure% of% fibrosis.% Specific% histological% analysis% of% the% (sinoatrial)% SA% node% using%hyperpolarization% activated% cyclic% nucleotide% gated% potassium% channel% 4% (HCN4)% and% connexin% 43% (Cx43)%together% with% haematoxylin/Van% Gieson% (HVG)% staining% was% carried% out% in% wildBtype% and% Ppt1?/?#mice% at% 6%month%to%qualitative%assess%cardiac%pathology%in%the%region%of%the%SA%node,%whilst%wildBtype%and%Cln3?/?#mice%at%12%and%18%months%of%age%underwent%histological%analysis%of%cluster%of%differentiation%45%(CD45)Bpositive%cells%to%qualitatively%assess%the%presence%of%inflammatory%cells%within%the%myocardium.%%
1% These% numbers% represent% the% absolute% number% of% mice% that% underwent% echocardiography% in% this% study.%However,%the%actual%n%number%for%the%different%parameters%measured%varies.%Two%batches%of%6%month%old%Ppt1?
/?#and%wildBtype%mice%underwent%echocardiography.%Data%from%the%first%batch%of%6%month%old%Ppt1?/?#and%wildBtype%mice%(n%=%7%and%n%=%5,%respectively)%that%underwent%echocardiography%was%analysed%on%our%behalf%as%part%of%a%small%initial%pilot%study.%Analysis%was%limited%to:%HR%(n%=%6%and%7),%IVS;d,%LVID;s,%LVID;d,%LV%Vol;s,%LV%Vol;d,%EF,% SV% and% CO% and% additional% strain% and% strain% rate% analysis,%which% subsequently,%was% not% included% in% this%study%as%explained% in%section(4.2(but%can%be% found% in%Appendices(4.1).% In% the%main%experiment,%12%and%18%month% old% Cln3?/?#and% wildBtype% mice% underwent% echocardiography% as% depicted% in% the% schematic% above,%together%with%a%second%batch%of%6%additional%Ppt1?/?%and%wildBtype%mice%and%this%time%the%full%set%of%BB%and%MBMode%parameters%were%measured%(see%Table(8,%Chapter(2).%During%the%final%analysis,%the%data%from%the%first%batch%of%6%month%old%Ppt1?/?#and%wildBtype%mice% (n%=%7%and%n%=%5,% respectively)%was%pooled%with% the% second%batch%of%Ppt1?/?#and%wildBtype%mice%to%increase%the%statistical%power%of%the%experiment.%Therefore,%for%HR,%n=%12%and%11%for%Ppt1?/?%and%wildBtype%mice,%respectively%and%for%Area;s,%IVS;d,%LVID;s,%LVID;d,%LV%Vol;s,%LV%Vol;d,%EF,%SV%and%CO,%n%=%13%and%n=%11%for%Ppt1?/?%and%wildBtype%mice,%respectively.%All%other%parameters,%n%=%6%for%both%








3.1! Functional(cardiac(pathology(in(NCL((Echocardiography% is% used% extensively% in%murine%models% of% cardiac% disease,% as% a%nonBinvasive% method% for% visualizing% cardiovascular% structures% and% assessing%cardiac%function%in#vivo.#Over%the%past%20%years,%developments%in%echocardiography%instrumentation% have% improved% spatial% and% temporal% resolution% for% imaging,%allowing% for%more%accurate% assessments% to%be% conducted% (reviewed% in%Gao%et#al.,#2011).% As% described% briefly% in% Chapter( 2,% section( 5.2,% three% commonly% used%techniques% include%oneBdimensional%MBmode%echocardiography,% twoBdimensional%BBmode%echocardiography%and%Doppler%echocardiography%(Stypmann%et#al.,#2009).%BBMode%provides%a%real%time%4Bchamber%image%of%the%heart,%from%which%anatomical%heart%structures%can%be%visualized%and%measured,%while%MBMode%offers%a%temporal%image%of%cardiac%wall%motion,%which%allows%wall%thickness%and%cavity%dimensions%to%be%measured%as%well%as%the%movement%of%the%myocardium,%valves%and%vessel%walls%(Chen%et#al.,#2012).%While% there% is% some%overlap% in% the% functionality%of%BB%and%MBMode,% Doppler% echocardiology% is% unique% in% its% ability% to% measure% blood% flow%through%valves%and%blood%vessels,% thus%providing% information%about%the%direction%and% velocity% of% blood% flow,% but% like% the% MBMode,% it% can% also% be% used% to% provide%information% about% tissue%movement% e.g.% valves% (Chen%et#al.,#2012).%Using% various%measurements% and% calculations,% it% is% possible% to% obtain% a% number% of% useful%cardiovascular%readBouts%for%identifying%cardiac%dysfunction%(Gao%et#al.,#2011).%The%different% applications% and% advancements% in% various% mouse% cardiomyopathy%models% have% been% previously% summarized% (reviewed% in% Rottman% et# al.,# 2007;%ScherrerBCrosbie%and%Thibault,%2008).%%
!
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In%this%study,%we%used%MB%and%BBmode%echocardiography%techniques%to%investigate%well% established% parameters% of% cardiac% function% in% severely% affected% Ppt1?/?#and%moderately% and% severely% affected% Cln3B/B% mice% compared% to% their% ageBmatched%control%wildBtype%mice,% and% correlated% these% findings%with% available% clinical% case%reports.%The%relevant%MB%and%BBMode%measurements%and%calculations%used%in%this%study% will% be% described% in% the% context% of% the% results% presented,% but% are% also%summarized%in%Table(8(of%Chapter(2.(The%full%extent%of%possible%Vevo#770®%MB%and%BBMode% standard% measurements% and% calculations% can% be% downloaded% as% a% PDF%(https://urresearch.rochester.edu/fileDownloadForInstitutionalItem.action?itemId=




moderately(or(severely(diseased(Cln3%/%'mice((The%number%of%times%the%heart%contracts%or%beats%per%minute%is%referred%to%as%the%heart% rate% (bpm)% and% at% rest,% the% heart% rate% of% a% normal% individual% is% between%approximately%65%–%75%bpm%(Davies,%et#al.,%2001).%Each%heartbeat%(or%cardiac%cycle)%is%initiated%within%specialized%cardiomyocytes%of%the%SA%node%(pacemaker),%located%in%the%wall%of%the%right%atrium,%and%propagated%throughout%the%atria%and%ventricles%via%the%conduction%system%(Csepe%et#al.,#2015).%Electrical%impulses%generated%by%the%SA% node% travel% across% the% atria% causing% the% atria%muscles% to% contract% and% pump%blood% into% the% ventricles% (Levick,% 2003;% Davies% et# al.,% 2001).% Subsequently,% the%
!
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electrical% impulses% arrive% at% the% atrioventricular% (AV)% node% located% between% the%atria%and%ventricles%of%the%heart,%which%slows%down%the%electrical%signal,%producing%a% slight% delay% to% allow% the% ventricles% to% fill% with% blood% (Levick,% 2003;% Davies,%Blakeley% and% Kidd,% 2001).% The% electrical% signal% then% leaves% the% AV% node% via% the%bundle%of%His,%and%travels%along%its%various%branches%to%the%Purkinje%fibres,%which%innovate% the% ventricles,% causing% them% to% contract% and% pump% blood% to% the% lungs%(right)% and% the% rest% of% the% body% (left)% (Levick,% 2003;% Davies,% Blakeley% and% Kidd,%2001).% % Although% the% automaticity% of% the% SA% node% produces% each% heart% beat,% the%rate% at%which% these% electrical% impulses% are% produced,% and% thus% the% heart% rate,% is%influenced%by%parasympathetic% and% sympathetic% nerve% fibres%which% innovate% the%SA% node% from% the% cardiovascular% centres% within% the% CNS% (Jordan% and% Marshall,%1995).% A% disruption% to% any% part% of% the% cardiac% conduction% system%may% result% in%arrhythmias,% in% which% the% heart% beats% too% fast% (tachycardia)% or% too% slow%(bradycardia),%or%with%an%irregular%rhythm%(Awtry,%et#al.,%2006;%Goerke%and%Mines,%1988).% As% described% in% section( 1.3,% cardiac% arrhythmias,% have% been% reported% in%several% NCL% clinical% case% reports% (ReskeBNielsen% et#al.,#1981;%Michielsen% et#al.,#1984;%Hofman%et#al.,#1990,%2001;%Østergaard%and%Mølgaard,%2011;%Dilaveris%et#al.,#2014;%Sakajiri%
et#al.,#1995;%Fukumura%et#al.,#2011),% including%bradycardia%with%periods% of% complete%sinus% arrest% and% tachycardia,% involving% atrial% fibrillation% and% atrial% flutter.%Therefore,%we%assessed%the%heart%rate%of%6%month%old%Ppt1?/?#and%Cln3B/B%mice%at%12%and% 18% months% of% age% compared% to% wildBtype% controls.% Heart% rate% is% easily%determined%from%cardiac%cycles%recorded%on%MB%and%BBmode%tracings%using%at%least%3% consecutive% beats% (Rottman% et# al.,# 2007).% An% important% consideration% when%interpreting%this%data%is%that%these%MB%and%BBmode%tracings%were%taken%while%mice%were% under% anaesthesia.% Anesthetic% agents% are% necessary% to% prevent% movement%and% sedate% mice% for% better% image% acquisition% during% echocardiographic% imaging%
!
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and% this% involves% a% reduction% in% heart% rate.% Heart% rates% in% conscious% unaffected%mice%are%between%600%B%650%beats/min%(reviewed%in%Collins%et#al,#2003;%Chen%et#al.,#2010;%Ho%et#al.,#2011).%The%variable%effects%of%anesthetics%on%murine%heart%rate%and%other% measures% of% cardiac% function% during% echocardiographic% recordings% have%been% previously% documented% and% were% carefully% considered% before% choosing% an%anaesthetic%agent%for%this%study%(Rulicke%et#al.,%2001;%Bauer%et#al.,%2001;%Redfield%et#
al.,%2001;%Ross%et#al.,%2002).%According% to% these%studies,%when%compared% to%other%anesthetics,% isoflurane% resulted% in% the% most% reproducible% measurements% and% as%such,% was% used% to% anaesthetize% the% animals% in% this% study.% Heart% rate% was%maintained%above%>%450%beats/minutes,%below%which% image%acquisition%becomes%more% difficult% (Catibog,% personal% communication).% Therefore,% it% is% the% heart% rate%under% anesthesia% rather% than% the% resting%heart% rate% that%was% compared%between%each%group%of%transgenic%mice%and%their%corresponding%wildBtype%controls.%%%
%
The%heart%rate%of%6%month%old%Ppt1?/?#mice%was%significantly%higher%than%wildBtype%mice% of% the% same% age% (p#value%0.0066)% indicating%possible% tachycardia% at% normal%resting%heart%rate%(Figure(50.(a).%%In%humans,%there%are%a%number%of%different%types%of% tachycardia,% which% are% classified% using% electrocardiogram% (ECG)% recordings%(Motté% et# al.% 1993;% Jastrzebski% et# al.,# 2015;% Oreto% et# al.,# 2009).% Etiologically,%tachycardias% can% occur% as% a% result% of% underlying% structural% heart% disease%(cardiomyopathy)% including% cardiac% hypertrophy,% which% may% disrupt% electrical%signals%within% the%heart,% by%dysregularity%within% the% conduction% system% itself,% or%circulatory%problems%such%as%high%blood%pressure%(Awtry%et#al.,%2006).%One%of%the%main%consequences%of%tachycardia%is%a%reduction%in%cardiac%output%(CO)%as%a%result%of%decreased%ventricular%filling%time,%thus%compromising%the%ability%of%the%heart%to%
!
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effectively%supply%organs%and%tissues%with%oxygen%(Awtry%et#al.,%2006).%The%clinical%consequences%of%this%varies%in%severity%and%depends%on%the%type%of%tachycardia,%but%may% include% mild% symptoms% such% as% dizziness,% heart% palpitations,% angina% and%shortness%of%breath%or% in%more%extreme%cases,%unconsciousness%or% cardiac%arrest%(Awtry%et#al.,%2006).%As%described%in%section(1.3,(progressive%conduction%defects%in%a% case% of% CLN2% disease%manifested% in% a% number% of% arrhythmias% (see%Table( 12),%eventually% leading% to% cardiac%death% (Fukumura%et#al.,#2011).% Interestingly,% severe%supraventricular% tachycardias%during%anaesthesia%were%also%reported% in%a%patient%with% variant% CLN3% disease% with% otherwise% no% other% clinical% cardiac% symptoms%(Hofman%et#al.,#2001),%while%conversely%frequent%episodes%of%bradycardia%have%also%been% reported% during% anaesthesia% in% children% with% CLN1% disease% (Miao% et# al.,#2009).% These% findings% should% be% noted% in% the% context% of% this% study% as% murine%echocardiography%was%carried%out%under%anaesthesia.%%
%


























Cln3%/%'mice' display' robust' neurological' features,' the' lack' of' cardiac' arrhythmias'might'be'a'limitation'for'their'use'in'exploring'cardiac'pathology'in'CLN3'disease.'
'
While'changes'in'heart'rate'during'echocardiography'might'indicate'the'presence'of'cardiac'arrhythmias,'a'much'more'accurate'and'informative'method'would'be'to'use' ECG' analysis,' as' has' been' carried' out' in' other'murine' disease'models' with'cardiac' pathology.' For' example,' as' patients' with' Duchenne'muscular' dystrophy'(DMD)'often'die'of'cardiac'failure,'a'murine'specific'ECG'method'was'developed'to'identify' whether' the' mdx' mouse' model' of' DMD' exhibited' clinically' relevant'cardiac'phenotypes'(Chu'et'al.,'2002).'Given'the'occurrence'of'sinus'bradycardia,'artrial' fibrillation' and' superventricular' and' ventricular' tachycardia' in' several'forms'of'NCL'as'summarised'in'Table&12,'further'studies'to'confirm'the'presence'or'absence'of'this'phenotype'would'certainly'be'warranted.''
'
b)! Left&ventricular&size&and&function&is&compromised&in&Ppt1%/%&and&Cln3%/%+
mice&with&severe&neurological&defects&&Murine'echocardiography'is'widely'used'for'the'assessment'of'LV'size'and'function'using'the'MOmode,'which'represents'the'motion'of'the'heart'over'time.'As'the'MOmode'has'good'temporal'resolution'(more'than'1000'Hz),'it'is'especially'useful'for'detecting' rapid' movement' and' therefore' is' particularly' appropriate' for' use' in'mice,'which'have'a'fast'heart'rate'as'discussed'in'section&3.1.a&above'(reviewed'in'ScherrerOCrosbie'and'Thibault,'2008).'MOmode'echocardiography'is'performed'on'
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the'LV'and'results' in'a'1D'highOresolution'temporal'course'of'any'changes' in'the'diameter' of' the' LV' lumen' and' both' anterior' and' posterior' LV' wall' thickness,'during'systole'and'diastole'(Pistner'et'al.,'2010).'The'2D'BOmode'offers'additional'possibilities' in' estimating' LV' size' and' function' by' allowing' the' LV' lumen' to' be'visualized' and' its' area' measured' (Pistner' et' al.,' 2010;' Ram' et' al.,' 2011).' By'capturing' multiple' frames' from' the' moving' picture,' it' is' possible' to' obtain' an'illusion'of'movement'to'account'for'diastole'and'systole'and'the'phases'in'between'(Pistner'et'al.,'2010;'Ram'et'al.,'2011).'Left'ventricular'disorders'may'manifest'as:'i)' systolic' dysfunction,' which' is' characterized' by' a' decrease' in' myocardial'contractility' resulting' in' a' decrease' in' the' pumping' power' of' the' heart' and/or'impairment'in'filling'of'the'cardiac'chambers'and'often'leads'to'heart'failure;'ii)'LV'hypertrophy,'an'enlargement'and'thickening'of'the'left'ventricular'walls'and'iii)'LV'dilation,'in'which'the'left'ventricle'stretches'and'the'muscle'walls'become'thinner'and'weaker'(Parfrey'et'al.,'1996).'One'paradigm'linking'these'conditions'together'is' that' when' systolic' dysfunction' occurs,' cardiac' output' is' maintained' via' a'compensatory' response' resulting' in' LV' hypertrophy,' but' as' systolic' dysfunction'continues,' the'LV'cannot'pump'with'enough'force'to'expel'a'sufficient'amount'of'blood' into' the' systemic' circulation' leading' to' LV' dilation.' Although' cardiac'hypertrophy' initially' develops' as' an' adaptive' response,' it' is' simultaneously'associated' with' increased' risk' of' additional' cardiovascular' conditions' e.g.' heart'failure'and'arrhythmia'(Frey'et'al.,'2004;'Artham'et'al.,'2009).'Systolic'dysfunction,'LV'hypertrophy'and'LV'dilation'can'all'be'assessed'using'a'combination'of'MO'and'BOmode'echocardiography'as'described'below.'
'
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The' hallmark' of' cardiac' dysfunction' in' many' diseases' of' the' heart' is' systolic'dysfunction'of'the'LV'and'the'most'basic'measures'of'this'are'fractional'shortening'(FS%)' and' ejection' fraction' (EF%),' which' are' usually' related' (reviewed' in'Rottman'et'al.,'2007).'The'EF' is' the'percentage'of' the'volume'of'blood' in' the'LV'during' diastole' that' is' ejected' out' of' the' LV' during' systole,' while' fractional'shortening'refers'to'the'percentage'change'in'the'dimensions'of'the'left'ventricle'between' diastole' and' systole' (Rottman' et' al.,' 2007;' Stypmann' et' al.,' 2009).'Together,'these'measurements'can'be'used'to'indirectly'assess'the'contractility'of'the' LV.' To' achieve' these' measurements,' the' wall' thickness' and' chamber'dimension'of' the'LV'are'obtained' from'MOmode' tracings'as'described' in'section&
5.2&of'Chapter& 2.' LV'wall' thickness' is'measured' in' the' interventricular' septum'(IVS)' and' the' posterior' wall' (LVPW)' during' diastole' (d)' and' systole' (s).' EndOdiastolic' measurements' (IVSd,' LVPWd,' and' left' ventricular' internal' dimension,'diastolic' [LVIDd])' are' obtained' at' the' point' of'maximum'LV' diastolic' dimension'(Rottman'et'al.,'2007;'Gardin'et'al.,'1995).'Conversely,'LV'endOsystolic'dimensions'(IVSs,' LVPWs,' and' LVIDs)' are' obtained' at' the' time' of' maximum' LV' systolic'excursion'of'the'LVPW'when'the'LV'chamber'dimension'is'at'its'smallest'(Rottman'




As' described' above,' ventricular' hypertrophy' describes' the' thickening' of' the'ventricle' walls' (usually' the' left)' and' often' results' in' the' narrowing' of' the'ventricular' lumen,'while' ventricular' dilation' is' the' expansion' of' the' lumen' as' a'result' of' stretching' and' thinning' of' the' ventricular'muscles' (Davies'et'al.,' 2001)'Therefore,' ventricular' hypertrophy' and' dilation' will' usually' be' reflected' in' the'measurements' described' above,' pertaining' to' systolic' function.' ' As' described' in'
section& 1.3,' ventricular' hypertrophy' and' dilation' has' been' observed' in' several'cases'of'CLN3'and'Kufs'disease'and'LV'hypertrophy'has'been'reported'previously'in' Ppt1%/%'mice' (Galvin' et'al.,'2008).' Therefore,' to' determine' the' presence' of' LV'hypertrophy,'LV'dilation'and'systolic'dysfunction'in'6'month'old'Ppt1%/%'mice,'and'
Cln3%/%'mice'at'12'and'18'months'of'age'compared' to'wildOtype'controls,'we'also'carried'out'MO'and'BOmode'echocardiography.''
'






















that$there$was$more$variation$in$the$Ppt1%/%'mouse$group.$In$contrast,$the$thickness$of$ the$ IVS$ remained$ largely$ unchanged$ suggesting$ that$ hypertrophy$ was$ not$widespread$(Figure'51.'b).$In$relation$to$the$LV$hypertrophy$observed,$the$LVID;d$and$LVID;s$(Figure'51.'c'and$g),$showed$no$reduction$in$size$and$interestingly,$the$overall$LV$area$during$systole$and$diastole$calculated$from$BDMode$measurements$showed$ no$ differences$ between$ 6$monthDold$Ppt1%/%''and$wildDtype$mice$ (Figure'






























wild%type*controls*(Galvin*et#al.,#2008).*Furthermore,*impaired*ventricular*systolic*function* with* an* EF* of* 40%* has* been* reported* in* a* patient* with* CLN3* disease*during* the* third* decade* of* life* and* this* was* associated* with* only* moderately*increased*left*ventricular*wall*thickness*in*the*posterior*wall*and*interventricular*septum* (Galvin* et#al.,#2008;* Dilaveris* et#al.,#2014).* Hence,* while* LV* hypertrophy*hints* at* underlying* cardiac* pathology,* it* is* not* a* robust* indicator* or* systolic*dysfunction.*
!We*compared*the*same*parameters*for*LV*thickness*and*function*in*Cln3+/+*mice*at*12*months*of*age*to*wild%type*age*matched*controls.*Interestingly,*we*did*not*find*any*significant*differences*or*convincing*trends*in*LVPW,*LVS,*LVID,*LV*volume*or*area*during*systole*or*diastole*and*no*difference*in*LV*mass,*EF*or*FS*compared*to*12*month*old*wild%type*mice*(Figure'53.'a'–'h,*Figure'52.'b,'Figure'55.'b'and*e).**
*

























a).!To!explore!the!presence!of!LV!dilation,!we!compared!LVID,!LV!Vol,!and!LV!area!in! 18!month! old! Cln3%/%! mice! to! age2matched! wild2type!mice! during! systole! and!diastole.!Unexpectedly,!we!observed!a!significant!reduction!in!the!LVID;d!of!Cln3%/%!mice! compared! to!wild2type! controls! at! this! age! (p(value(0.0065)! (Figure'54.'g),!while!LVID;s!showed!only!a!slight!trend!towards!being!smaller!(Figure'54.'c).!This!was! a! surprising! result! as! there! was! only! a! modest! increase! in! LVPW! and! no!increase! in! IVS! thickness! during! diastole! and! systole! (Figure' 54.' a,' e,' b' and! f).!While,!it!is!difficult!to!explain!the!diastole2specific!reduction!in!LVID!in!relation!to!LVPW;d! and! IVS;d,! this! finding!was! consistent!with! the! LV!Vol;d.!We! detected! a!significant!reduction!in!LV!Vol;d!(p(value!0.0033)!and!a!slightly!lower!LV!Vol;s!that!was!comparable!to!the!reduction!in!LVID;s!(Figure'54.'d'and!h).!Additionally,!B2Mode!analysis!revealed!a!significant!reduction!in!LV!area;d!(Figure'56.'f)!and!LV!Vol;d!(Figure'57.'f)!in!18!month2old!Cln3%/%!mice!compared!to!wild2type!controls!of!the! same! age! (p( value! 0.0072! and! 0.0007,! respectively)! and! a! modest! trend!towards!a! reduction! in!LV!area;s! and!a! significant! reduction! in!LV!Vol;s! (p(value!0.0149)!in!Cln3%/%!mice!compared!to!wild2type!controls!at!18!months!of!age!(Figure'
56.'c'and!Figure'57.'c).!!
!
CLN3! patients! commonly! present!with! cardiac! hypertrophy! (see!Table'12),! and!therefore!it!is!plausible!that!the!same!pathology!could!manifest!in!Cln3%/%!mice,!but!this!was!not!the!case.!Similarly,!there!was!also!no!evidence!for!LV!dilation,!which!has!also!been!reported!(although!not!as!commonly!as!hypertrophy)!in!some!cases!of!CLN3!(Hofman!et(al.,(2001)!and!Kufs!disease!(Sakajiri!et(al.,(1995).!Furthermore,!
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c)! Global( cardiac( function( is( compromised( in( Ppt1%/%( and(Cln3%/%+mice( with(
severe(neurological(defects((While&M(&and&B(Mode&are&useful&for&measuring&LV&dimensions&(IVS;d/s,&LVID;d/s,&LVPW;d/s&and&Area;d/s),& and&calculating&LV&volumes& (LV&mass&and&Vol;d/s)&and&function& (EF& and& FS)& (as& described& in& section&3.1.b),& B(mode& echocardiographic&measurements&can&also&be&used& to&calculate&other& functional&parameters& such&as&cardiac&output&(CO)&and&stroke&volume&(SV)&(see&Appendices(4.2).&Stroke&volume&is& defined& as& the& amount& of& blood& pumped& out& of& the& ventricles& (ml& per& beat)&during&each&contraction,&but&is&most&associated&with&the&LV&and&is&calculated&using&measurements&of&LV&volumes&(LV&Vol;d&[pre(load]&–&LV&Vol;s&[after(load])&(Davies&






































Consistent(with(the(EF(data,(SV(and(CO(were(also(unchanged(in(69month(old(Ppt1%/%mice( compared( to( wild9type( control( mice( (Figure' 58.' a' and( d)( despite( the(reduction(in(LV(Vol;s(and(HR(observed(previously((section'3.1.a'and(b).(Similarly,(no(differences(in(SV(or(CO(were(detected(in(12(month(old(Cln39/9(mice(compared(to(wild9type(mice(at(12(months(of(age((Figure'58.'b'and(e).(This(was(expected(given(the( lack( of( differences( in( LV( Vol;s/d( and( HR( between( genotypes( reported( in(
section' 3.1.a' and( b.( Interestingly( however,( SV( and( CO( were( both( significantly(different( in(Cln39/9(mice(at(18(months(of(age(compared( to(age(matched(wild9type(controls((Figure'58.'c'and(f).(
(
SV(was( considerably( lower( in( 18(month9old( Cln39/9( mice( compared( to(wild9type(age9matched( controls( (p+value( 0.0053)( (Figure' 58.' c).( This( was( not( surprising(given(the(reduction(in(LV(Vol;d(((see(Figure'54.'h).(As(mentioned(in(section'3.1.b,(the(reduction(in(LV(Vol;d(may(have(been(due(to(a(reduction(in(LV(filling(as(a(result(of(diastolic(dysfunction.(Diastolic(dysfunction(can(be(caused(by(a(number(of(factors(e.g.( valvular( regurgitation( (http://www.mayoclinic.org).( Indeed,( second( degree(regurgitation(of( the(pulmonary( valve( and( tricuspid( valve(has(been( reported( in( a(patient(with(Kufs(disease((Sakajiri(et+al.,+1995).'As(LV(Vol;s(was(relatively(normal(and(there(was(no(change(in(EF(or(FS,(it(is(unlikely(that(the(reduction(in(SV(was(due(to(systolic(dysfunction.(Instead,(another(explanation(for(the(reduction(in(SV,(could(be( that( there( was( a( reduction( in( contractility,( the( third( determinant( of( SV( and(another( contributing( factor( to( diastolic( function( that(will( therefore( influence( LV(Vol;d.((Both(valve(function(and(contractility,(as(well(as(a(number(of(other(indices(of(systolic( and( diastolic( function,( can( be( assessed( by( Doppler( echocardiography,(which(provides(an(accurate(haemodyanamic(evaluation(of(the(heart((reviewed(in(
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Anavekar( et+al.,+2009;( Abraham( and(Nishimura,( 2001;( Dandel( and(Hetzer,( 2009;(Gorcsan(and(Tanaka,(2011).(However,(although(this(data(was(collected,(it(is(not(yet(available(due(to(limitations(in(our(ability(to(analyse(it(as(explained(in(section'4.(CO(as(a(function(of(SV(and(HR,(was(also(significantly(reduced(in(18(month9old(Cln39/9(mice(compared(to(wild9type(age9matched(controls((p+value(0.0068)((Figure'58.'f).(As(HR(was(not(altered(in(18(month(old(Cln39/9(mice((Figure'50.'c),(this(reduction(is(most( likely( to( be( associated(with( the( reduction( in( SV.( Reductions( in( SV( and( CO(usually(accompany(heart(failure(and(are(therefore(robust(predictors(of(underlying(cardiac( disease.( Heart( failure( usually( results( in( a( number( of( uncomfortable( yet(manageable(symptoms(such(as(fatigue,(shortness(of(breath,(swelling(of(extremities,(heart( palpitations( and( nausea( (Klabunde,( 1999;( https://www.bhf.org.uk;+
www.mayoclinic.org).( However( in( NCL,( heart( failure( has( led( to( fatal( cardiac(complications((Sakajiri(et+al.,+1995).(As(such,(18(month(old(Cln39/9(mice(displaying(an(SV(and(CO(phenotype(are(valuable(for(investigating(cardiac(dysfunction(in(CLN3(disease,( although,( their( usefulness( will( also( depend( on( whether( the( underlying(cause(of(these(defects(can(be(clearly(and(reproducibly(identified.((
(
3.2! Histological'assessment'of'cardiac'pathology'Our( echocardiographic( analysis( revealed( a( number( of( structural( and( functional(differences( between( mouse( models( and( their( wild9type( counterparts( (Section'
3.1).( These( changes( are( usually( associated( with( structural( rearrangement( of(normal( chamber( wall( components,( and( are( described( as( ‘cardiac( remodelling’((reviewed(in(Oka(et+al.,+2014(and(Kehat(et+al.,+2010).(Indeed,(the(heart(consists(not(only(of(cardiomyocytes(but(also(of(other(cell(types(including(endothelial(cells(and(fibroblasts( (reviewed( in( Zhang( and( Shah,( 2014).( Communication( between( these(
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cell(types(is(important(for(normal(cardiac(function(and(plays(a(key(role(in(disease(pathophysiology( (Tian( and(Morrisey;( Zhang( and( Shah,( 2014;( Tirziu( et+al.,+2010;(Burgoyne( et+ al.,+ 2012).( Through( various( signalling( pathways,( these( cell( types(influence( a( number( of( processes( including( cardiomyocyte( hypertrophy,(angiogenesis,( and( fibrosis,( all( of( which( contribute( to( cardiac( remodelling( in(response( to( disease( (Zhang( and( Shah,( 2014).( Therefore,( to( explore(whether( the(gross( structural( and( functional( changes( observed( were( accompanied( by( cardiac(remodelling(on(the(cellular(level,(we(carried(out(a(series(of(histological(analyses(in(6(month(old(Ppt1%/%(and(12(and(18(month(old(Cln3%/%(mice(vs.(age(matched(wild9type(control( mice.( While( histological( assessment( of( structural( remodelling( in( NCL(patient( heart( tissue( is( limited( to( fibrosis( (see( Table' 12),( we( concentrated( our(analysis(on(myocyte(size,(endothelial(cell(count(as(well(as(fibrosis.(
(
The( cardiac( endothelium( comprises( the( endocardial( (EC)( lining( the( chambers( of(the( heart( and( the( vascular( EC( lining( the( coronary( microvasculature.( Cross9talk(between(cardiomyocytes(and(cardiac(EC(is(strongly(governed(by(redox(signalling,(involving( oxidation/reduction( modification( of( reactive( species,( and( has( been(comprehensively( reviewed( elsewhere( (reviewed( in( Zhang( and( Shah,( 2014;(Burgoyne(et+al.,+2012;(Hafstad(et+al.,+2013(and(Santos(et+al.,+2011).(Through(these(signalling( pathways,( angiogenesis( is( tightly( coupled( to( cardiomyocyte( growth(during( cardiac( development( so( that( cardiomyocytes( have( an( adequate( supply( of(blood( and( oxygen( in( order( to( function( (Giordano( et+al.,+2001).( The( same( redox9signalling( pathways( regulate( angiogenesis( to( maintain( myocardial( capillary(density( in( response( to( disease9causing( stresses( that( stimulate( hypertrophy( of(cardiomyocytes( (Shiojima( et+ al.,+2005;( Izumiya( et+ al.,+2006;( Hsieh( et+ al.,+2006).(
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Therefore,(measuring(myocyte(size(together(with(endothelial(cell(count(in(6(month(old(Ppt1%/%(and(12(and(18(month(old(Cln3%/%(mice(and(their(controls(provides(a(way(to(evaluate(the(presence(of(pathological(stimuli((Ware(and(Simons,(1999).(Fibrosis(is(also(an( integral(part(of( the(process(of( cardiac( remodelling( that(occurs( in(most(cardiac(pathologies.(Cardiac(fibroblasts(make(up(the(largest(population(of(cells(in(the(myocardium(and(their(primary(function(is(to(produce(structural(proteins(that(form( the( extracellular( matrix( (ECM)( (Fan+ et+ al.,+ 2012).( In( disease,( cardiac(fibroblasts(participate(in(the(repair(process(by(differentiating(into(myofibroblasts,(which( have( a( greater( capacity( to( produce( ECM( proteins( as( well( as( mediating(inflammatory( responses( via( the( production( of( cytokines( (Fan( et+al.,+2012;( Baum(and( Duffy,( 2011).( However,( this( adaptive( healing( process( becomes( maladaptive(when( the(conversion(of( cardiac( fibroblast( to(myofibroblasts(eventually( shifts( the(equilibrium(in(ECM(turnover(and(leads(to(the(excess(production(and(deposition(of(ECM(proteins(in(the(myocardium,(referred(to(as(fibrosis((Fan+et+al.,+2012;(Kania(et+





a)! Possible'myocyte'hypertrophy'and'vascular'response'in'Cln3%/%'mice'Surprisingly,(we(did(not(observe(any( increase( in(myocyte(size( in(Ppt1%/%!mice!at(6(months( of( age( in( comparison( to( wild9type( mice( (Figure' 59.' a),( despite( the(increased( thickness( observed( in( the( left( ventricular( posterior( wall( via(echocardiogram( recording( (Figure' 51.' a).( Consistent( with( these( findings( and(literature( suggesting( an( increase( in( capillary( density( is( necessary( for( cardiac(hypertrophy( (Shiojima( et+ al.,+ 2005;( Izumiya( et+ al.,+ 2006;( Tomanek( and( Busch,(1998;( Tomanek( et+al.,+1998;( Tirziu( et+al.,+2007),( no( difference( in( the( number( of(endothelial( cells(was( observed( between(Ppt1%/%+and(wild9type(mouse( heart( tissue((Figure'59.'d).(Measurements(were( taken( in( the(region(of( the( left(posterior(wall(and( there(was( little( variation(within( the( groups.( The( predominant( form(of( post9natal(growth(of(cardiomyocytes( is(an( increase( in( their(size(and(not( their(number((Ahunja(et+al.,+2007).(Therefore,( it( is( likely( that( the(hypertrophy(detected(on( the(macroscopic(level(resulted(from(other(cellular(changes(such(as(an(increase(in(the(ECM.(In(contrast,(we(observed(a(slight(increase(in(myocyte(size(in(Cln3%/%(mice(at(12(months(of(age(compared(to(wild9type(mice,(which(was(not(significant((Figure'59.'
b).(When(we(counted(the(number(of(endothelial(cells(in(Cln3%/%(mice(at(12(months(of( age( and( wild9type( mice,( we( found( that( the( modest( increase( in( myocyte( size(observed( in( the(Cln3%/%(mice(did(not(correspond( to(any(change( in(endothelial( cell(number,(which(remained(the(same(as(in(wild9type(mice((Figure'59.'e).(This(trend(was( fairly( surprising( as( myocyte( hypertrophy( is( thought( to( be( directly( co9
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left#ventricle#The$ amount$ of$ fibrosis,$ as$ assessed$ by$ the$ area$ of$ picrosirius$ red$ staining,$ was$significantly$ greater$ in$ Ppt1%/%$ mice$ at$ 6$ months$ of$ age$ compared$ to$ wild9type$controls$(p'value$0.0039)$with$more$than$a$two9fold$increase$(Figure#60.#a).$This$is$consistent$with$clinical$data$showing$LV$hypertrophy$(also$detected$in$our$mice,$
section#3.1.a,$Figure#51.#a)$and$fibrosis$in$patients$with$NCL$(Hofman$et'al.,'2001;$Tomiyasu$ et' al.,'2000).$ As$ expected$ in$ light$ of$ their$ normal$ heart$ function,$ no$difference$in$fibrosis$was$detected$between$Cln3%/%$mice$and$wild9type$mice$at$12$months$of$age$(Figure#60.#b).$Conversely,$only$a$very$modest$increase$in$fibrosis$was$ observed$ in$ Cln3%/%'mice$ at$ 18$ months$ of$ age,$ and$ this$ was$ not$ significant$(Figure#60.#c).$However,$there$was$a$lot$of$variation$within$both$the$189month$old$
Cln3%/%'and$wild9type$mice,$which$may$explain$why$no$differences$were$observed$(see$ section# 4).$ Nonetheless,$ this$ finding$ was$ surprising,$ considering$ the$significant$ decrease$ in$ SV$ and$ CO$ detected$ from$ echocardiographic$ analysis$ of$



































c)! There'is'SA'node'pathology'in'Ppt1%/%'mice'at'6'months'of'age'Heart& rate& is& controlled& by& the& SA& node& as& described& in& section' 3.1.a.& To&investigate&SA&node& function& in&relation& to& the& increase& in&heart&rate&observed& in&
Ppt1%/%&mice& at& 6&months& of& age,& it&would& have& been& preferable& to& carry& out&ECG&analysis.&Echocardiology&allows&for&HR&to&be&calculated&from&the&number&of&cycles&of&cardiac&contractions&in&a&given&time&(Gao&et(al.,(2011).&Therefore,&only&changes&in&the&cycle& length&of&successful&cardiac&contractions&can&be&detected,&and&abnormal&ectopic&beats&cannot&be&distinguished&from&normal&sinus&beats&(reviewed&in&Ho&et(















shown& to& exhibit& increased& expression& in& a& variety& of& LSDs,& thus& making& them&useful&surrogate&markers&for&storage&accumulation&(Meikle&et#al.,#1997a).&&
&
We&observed&several&striking&structural&differences&within&the&SA&node&of&6&month&old& Ppt1+/+#mice& compared& to& age& matched& controls.& There& appeared& to& be& more&interstitial& fibrosis& and& fatty& infiltration& in& 6&month& old&Ppt1+/+#mice& compared& to&ageHmatched&controls& (Figure'59.'c'and&d),&which&has&been&described&within& the&myocardium&of&NCL&autopsy& tissue&previously& (see&Table'12).& In&addition,&when&we&investigated&the&presence&of&typical&cardiomyopathic&characteristics&(Rowland&
et# al.,# 1992),& we& observed& clear& degeneration& of& myocardial& fibres& with& loose&connective& tissue,&vacuolization&and& immune&cell& infiltration& (Figure'62).&As&will&be& discussed& in& section' 5,& identifying& cardiac& pathology& within& the& SA& node& is&fundamental& to& understanding& the& likely& cause& of& increased& HR& in& 6& month& old&
Ppt1+/+#mice.&While& the& SA&node&pathology& observed&may&disrupt& the& initiation& of&cardiac& impulses& by& the& SA& node& and& alter& heart& rate& (Waller& et# al.,# 1993),&neurodegeneration& within& brainstem& nuclei& that& are& involved& in& the& autonomic&control& of& the& heart& such& as& the& area& postrema& (Xue& et#al.,#2003),& dorsal& motor&nucleus&of&the&vagus&(Cheng&et#al.,#1999)&and&nucleus&of&the&solitary&tract&(Caro&et#




















































our$ lab$ (Nelvagal,$ Cooper$ personal$ communication,$ see$Appendices) 4.3),$might$also$affect$heart$rate.$
$
d)! Inflammatory)responses)in)the)heart)of)Cln3%/%)mice)at)18)months)of)age)Inflammation$ is$ one$ of$ the$ earliest$ responses$ to$ stress$ situations$ in$ the$ heart,$which$ occur$ as$ a$ result$ of$ cardiac$ dysfunction$ and$ involves$ the$ release$ of$inflammatory$ cytokines$ and$ chemokines,$ which$ promote$ the$ infiltration$ of$activated$inflammatory$cells$into$the$myocardium$(reviewed$in$Glezeva$and$Baugh,$2014).$As$such,$cardiac$inflammation$(not$to$be$confused$with$myocarditis$due$to$infection),$is$associated$with$many$different$forms$of$heart$disease.$Paradoxically,$although$ inflammation$ is$a$natural$and$necessary$part$of$ the$healing$response$to$injury,$ it$ can$ also$ increase$ myocardial$ damage$ if$ prolonged$ (Tarzami,$ 2011;$Frangogiannis$ and$ Entman,$ 2004).$ The$ adaptive/maladaptive$ mechanisms$involved$in$inflammation$vary$between$cardiovascular$diseases,$however,$many$of$these$ inflammatory$ processes$ relate$ to$ cardiac$ hypertrophy$ and$ remodelling,$ a$pathological$ feature$of$most$diseases$(reviewed$ in$Frieler$and$Mortensen,$2015).$Cardiac$ hypertrophy$ and$ remodelling$ (involving$ fibrosis)$ are$ features$ of$numerous$ cardiovascular$ diseases,$ with$ various$ underlying$ causes$ including$serious$ events$ like$myocardial$ infarction$ and$more$ insidious$ conditions$ such$ as$cardiomyopathy$and$valvular$dysfunction,$which$may$occur$in$some$forms$of$NCL$(reviewed$ in$ Frieler$ and$ Mortensen,$ 2015;$ Sakajiri$ et# al.,# 1995).$ Despite$ the$various$ number$ of$ pathological$ stimuli$ in$ different$ cardiac$ diseases,$ there$ are$several$ common$ features$ in$ the$ hypertrophic$ response$ including$ inflammatory$signalling$and$immune$cell$activation$(Frieler$and$Mortensen,$2015).$$As$discussed$in$the$previous$section$(section)3.1.c),'Cln3+/+$mice$at$18$months$of$age$exhibited$a$
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4.1! Echocardiographic*image*acquisition*One$of$the$greatest$advantages$of$murine$echocardiography$is$that$it$uses$techniques$and$indices$that$are$easily$translated$from$the$human$to$the$mouse,$allowing$relevant$cardiac$phenotypes$to$be$identified$(reviewed$in$Scherrer<Crosbie$and$Thibault,$2008).$While$the$acquisition$of$murine$echocardiograms$is$relatively$straight–forward,$their$analysis$can$be$challenging$due$to$the$mouse’s$small$size,$rapid$contractions$and$orientation$of$the$mouse$heart$(Scherrer<Crosbie$and$Thibault,$2008).$The$extent$ to$which$these$ factors$ impacted$our$study$will$be$discussed$in$the$following$sections.$
$
a)! Anaesthesia**As$ discussed$ in$ section*3.1.a,$ the$ small$ heart$ size$ and$ rapid$ heart$ rate$ of$mice$necessitates$that$echocardiography$to$be$performed$under$anaesthesia$(Scherrer<Crosbie$ and$ Thibault,$ 2008).$ However,$ the$ mouse$ circulatory$ system$ is$ very$sensitive$ and$ is$ easily$ altered$ by$ interventions$ such$ as$ anaesthesia$ (Scherrer<Crosbie$ and$Thibault,$ 2008;$ Collins$ et#al.,#2003;$ Chen$ et#al.,#2010).$ The$ extent$ to$which$anaesthesia$might$confound$echocardiographic$analysis$varies$according$to$the$ type$ of$ anaesthetic$ agent$ used$ and$ the$ dose$ at$ which$ it$ is$ administered,$therefore$this$was$carefully$considered$when$selecting$the$regimen$of$anaesthesia$(Gardin$ et# al.,# 1995;$ Tanaka$ et# al.,# 1996;$ Collins$ et# al.,# 2003;$ Hoit$ et# al.,# 2001;$Scherrer<Crosbie$ and$Thibault,$ 1999).$As$described$ in$section*5.1*of$Chapter*2,$we$ used$ ~1.5%$ isoflurane$ based$ on$ previous$ studies,$ which$ suggest$ that$echocardiography$ conducted$ under$ isoflurane$ aneasthesia$ provides$ the$ most$reproducible$measurements$(Rulicke$et#al.,$2001;$Bauer$et#al.,$2001;$Redfield$et#al.,$2001;$ Ross$ et#al.,$ 2002;$ Tarin$ et#al.,#1972;$ Hartley$ et#al.,#2008;$ Roth$ et#al.,#2002;$
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Wilkstorm$et#al.,#2008).$Nonetheless,$ the$use$of$ anaesthesia$unavoidably$ reduces$HR$ and$ therefore,$ although$we$were$ able$ to$ detect$ differences$ in$HR$between$6$month$ old$ Ppt1+/+#mice$ vs.$ wild<type$ controls,$ these$ differences$ may$ not$ reflect$actual$ physiological$ differences.$ Alternatively,$ echocardiograms$ could$ have$ been$performed$ on$ conscious$ animals,$ however,$ this$ requires$ training$ of$ the$mice$ by$repeating$echocardiograms$daily$for$7$days$and$this$was$not$feasible$(Yang$et#al.,#1999).$Furthermore,$substantial$variability$in$HR$has$been$identified$between$not$only$different$mouse$strains,$but$within$the$same$mouse$strains$due$to$inevitable$differences$ in$ genetic$ background$ even$ on$ backcrossed$ animals$ (Rottman$ et#al.,#2007;$Roth$et#al.,#2002;$Shusterman$et#al.,#2002).$Therefore,$differences$not$only$in$HR$ but$ all$ the$ parameters$ measured$ should$ be$ considered$ strain<specific$ and$ideally,$mice$should$have$been$compared$with$ littermate$controls.$Unfortunately,$this$ was$ not$ possible$ as$ mice$ were$ not$ bred$ specifically$ for$ the$ purpose$ of$echocardiography.$$
$
b)! Limitation*in*apical*view*image*acquisition*Compared$ to$ the$ human$ heart,$ the$mouse$ heart$ has$ a$more$ vertical$ orientation$(Scherrer<Crosbie$and$Thibault,$2008).$Parasternal$long<$and$short<axis$views$are$therefore$ easily$ obtained$ (Catibog,$ personal$ communication),$ and$ were$ used$ to$collect$ the$ data$ presented$ in$ this$ chapter.$ In$ contrast,$ the$ acquisition$ of$ apical$views$ is$ more$ challenging$ and$ thus$ poorly$ reproducible,$ limiting$ the$ complete$analysis$of$diastolic$function$and$of$the$right$ventricle$(RV)$(Scherrer<Crosbie$and$Thibault,$2008).$Furthermore,$due$to$the$shallow$location,$small$size$and$complex$shape$ of$ the$ RV,$ the$ images$ of$ the$ RV$ tend$ to$ be$ poor$ using$ transthorasic$echocardiograpy$ (Scherrer<Crosbie$ and$Thibault,$ 2008).$As$ such,$ although$ apical$
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view$ images$ were$ recorded,$ they$ could$ not$ be$ analysed$ reliably$ and$ were$therefore$excluded$from$the$study.$
$
4.2! Echocardiographic*measurements*and*analysis*This$study$was$carried$out$in$collaboration$with$KCL’s$Cardiovascular$Division.$All$echocardiograms$were$ carried$ out$ by$ an$ experienced$ echocardiology$ technician$within$ the$department,$ and$ analysis$was$ conducted$by$myself$ following$ training$and$consultation.$This$presented$two$fundamental$limitations$to$the$study.$Firstly,$while$echocardiography$can$be$used$to$measure$a$wide$variety$of$cardiac$features,$the$acquisition$of$the$relevant$images$is$time<intensive.$As$it$is$recommended$that$only$short$durations$of$anaesthesia$are$used$during$echocardiography$(Scherrer<Crosbie$and$Thibault,$2008),$we$had$to$focus$on$taking$a$limited$number$of$images$per$ session$ (sessions$ were$ typically$ 8$ hours,$ in$ which$ B<mode,$ M<mode,$ Pulse$wave$ (PW)$Doppler,$ Colour$M<Mode$Doppler$ and$ Tissue$Doppler$ Imaging$ (TDI)$were$carried$out$on$a$maximum$of$8$animals).$Technically,$ this$ could$have$been$overcome$ by$ ‘echoing’$ the$ mice$ over$ several$ days.$ However,$ as$ the$echocardiograms$were$conducted$by$the$echocardiography$technician$under$their$own$ project$ licence,$ certain$ restrictions$ meant$ that$ the$ animals$ had$ to$ be$sacrificed$immediately$after$the$procedure.$Secondly,$while$some$echocardiogram$measurements$ are$ relatively$ simple$ such$ as$ those$ pertaining$ to$ LV$ systolic$function$ from$ M<mode$ images$ (e.g.$ IVS,$ LVID,$ LVPW,$ EF$ and$ FS$ described$ in$
section* 3.1.b)$ and$ B<Mode$ images$ (e.g.$ area$ and$ volumes$ described$ in$ section*
3.1.b),$ others$ require$more$ skill$ and$ experience$ e.g.$ Pulse$wave$Doppler,$ Tissue$Doppler$Imaging$(TDI)$and$Colour$M<Mode$Doppler$and$TDI$and$strain$rate$(Gao$
et# al.,# 2011).$ Due$ to$ other$ commitments,$ it$ was$ not$ possible$ for$ the$
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echocardiogram$images$to$be$analysed$by$the$technicians$who$carried$them$out1.$Therefore,$ analysis$was$ limited$ to$ the$ training$ available,$ and$what$ I$was$ able$ to$carry$out$confidently$and$accurately.$
$
a)! Use*of*Doppler*imaging*for*analysis*of*diastolic*dysfunction*B<Mode$and$M<mode$ image$analysis$was$carried$out$ in$ the$present$ study,$which$allowed$ us$ to$ determine$ whether$ or$ not$ the$ Ppt1+/+# and$ Cln3+/+# mice$ tested$exhibited$ any$ obvious$ cardiac$ phenotypes,$ that$ might$ warrant$ more$ in$ depth$analysis.$ From$ this$ analysis,$ the$ next$ steps$ in$ our$ investigation$ would$ be$ to$determine$ LV$ diastolic$ function$ and$ LV$ regional$ function$ in$ Cln3+/+#mice$ at$ 18$months$of$age,$as$they$displayed$significant$differences$in$SV$and$CO$in$the$absence$of$ obvious$ LV$ systolic$ dysfunction$ (section*3.2.a).$ Diastolic$ dysfunction$ is$more$difficult$ to$ determine$ than$ systolic$ dysfunction,$ and$ requires$ a$ number$ of$ single$and$combined$Doppler$imaging$techniques$(Rotterman$et#al.,#2007;$Christoffersen$
et#al.,#2003;$Hoit$et#al.,#2003;$Michael$et#al.,#2004;$Semeniuk$et#al.,#2002).$Doppler$echocardiography$combines$echocardiography,$which$uses$high$ frequency$sound$waves$to$create$an$image$of$the$heart$with$Doppler$technology,$which$allows$the$speed$ and$ direction$ of$ blood$ flow$ to$ be$ determined,$ thus$ providing$ an$ accurate$haemodynamic$ evaluation$ of$ the$ heart$ (reviewed$ in$ Anavekar$ et# al.,# 2009).$However,$as$mentioned$above,$although$Doppler$images$were$collected,$it$was$not$possible$ to$ carry$ out$ the$ appropriate$ analysis,$ which$ limited$ the$ study$ in$ the$following$ways.$PW$Doppler$ imaging$is$mainly$used$for$the$quantitative$measure$of$blood$flow$through$valves$and$blood$vessels,$which$provides$information$about$
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1$As$mentioned$in$Figure*49,*an$initial$echocardiogram$pilot$study$using$6$month$old$Ppt1+/+#vs.$wild<type$mice$(n$=$5$and$7,$respectively)$was$carried$out,$for$which$strain$Doppler$analysis$was$kindly$carried$ out$ and$ analysed$ by$ the$ echocardiography$ technician$ in$ the$ department$ at$ the$ time.$ A$significant$difference$in$radial$strain$was$observed$(p*#=#0.0169),$data$in$Appendices*4.1.$
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the$ direction$ and$ velocity$ of$ blood$ flow$ (Chen$ et# al.,#2012).$ Transmitral$ inflow$Doppler$ (TDI)$ obtained$ in$ apical$ 4<chamber$ view$ or$ long<axis$ view$ provides$information$ about$ the$ velocity$ of$ transmitral$ flow$ and$ isovolumetric$ relaxation$and$contraction$of$the$ventricles$(Du$et#al.,#2008).$In$addition,$TDI$can$be$used$to$analyse$ myocardial$ tissue$ motion$ velocity,$ e.g.$ assessing$ the$ movement$ of$ the$mitral$valve$ for$example$will$ reveal$ the$presence$of$mitral$stenosis,$ in$which$ the$valve$ does$ not$ fully$ open,$ thus$ restricting$ blood$ flow.$ Together$ PW$ Doppler$imaging$ and$TDI,$ are$ used$ for$ evaluation$ of$ the$ severity$ of$ diastolic$ dysfunction$(Chen$et#al.,#2012;$Gao$et#al.,#2011).$Combining$PW$Doppler$and$TDI$with$Colour$M<Mode$Doppler$is$even$more$informative$for$assessing$diastolic$dysfunction$(Gao$
et# al.,# 2011).$ Like$ PW$ Doppler,$ it$ provides$ a$ spatiotemporal$ map$ of$ blood$distribution$ within$ the$ heart$ but$ provides$ independent$ information$ about$ LV$filling$pressures$by$capturing$the$transmitral$propagation$velocity,$and$is$therefore$particularly$ useful$ in$ identifying$ valvular$ regurgitation$ (Thomas$ et# al.,# 1997).$Therefore,$ to$ convincingly$ determine$ the$ presence$ of$ diastolic$ dysfunction,$ and$properly$ evaluate$ the$ possible$ mechanisms$ by$ which$ it$ might$ occur,$ it$ will$ be$important$to$analyse$our$PW$Doppler,$TDI$and$Colour$M<Mode$Doppler$data.$
$
b)! Use*of*Doppler*imaging*for*analysis*of*myocardial*contractility*We$used$M<mode$ echocardiology$ to$measure$ several$ regions$ of$ the$ LV$wall$ and$determine$ LV$ systolic$ function.$ However,$ another$ important$ measure$ of$ LV$function$ that$ was$ not$ included$ in$ this$ study$ is$ myocardial$ contraction,$ which$would$ have$ enabled$ us$ to$ better$ explain$ the$ reduction$ in$ SV$ observed$ in$ Cln3+/+#mice$ at$ 18$ months$ of$ age.$ When$ considering$ the$ different$ echocardiographic$modalities$ for$ assessing$ myocardial$ contraction,$ it$ is$ necessary$ to$ distinguish$
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between$myocardial$motion$and$wall$deformation$(reviewed$in$Dandel$and$Hetzer,$2008).$While$displacement$and$velocity$characterize$wall$motion,$strain$and$strain$rate$ represent$ wall$ deformation$ (Dandel$ and$ Hetzer,$ 2008).$ Systolic$ waveform$(Sa)$is$a$measure$of$regional$LV$wall$motion$velocity$obtained$using$TDI$and$thus$provides$useful$information$about$regional$wall$contraction$regardless$of$whether$or$not$it$is$“passive”$(movement$not$accompanied$by$change$in$shape)$or$“active”$(movement$accompanied$by$change$in$shape$i.e$deformation).$TDI<derived$strain$and$strain$rate$imaging$however,$can$be$used$to$assess$how$much$and$at$what$rate$the$myocardium$lengthens$and$shortens$(stretches)$with$each$contraction$(i.e$the$amount$ and$ rate$ of$ deformation)$ (Dandel$ and$ Hetzer,$ 2008).$ While$ strain$ and$strain$rate$are$not$actually$measurements$of$contractility$as$deformation$ is$ load<dependent,$ they$ are$ useful$ for$ estimating$ systolic$ function$ (especially$ regional$contractile$function).$$
$
4.3! Vascular*function*We$did$not$carry$out$any$analysis$of$vascular$function$in$the$Ppt1+/+#or$Cln3+/+$mice$in$this$study.$To$evaluate$aortic$structure$in$Ppt1+/+#mice,$Galvin$et#al.,#used$M<mode$echocardiography$ to$measure$ the$ diameter$ of$ the$ ascending$ aorta$ (Galvin$ et#al.,#2008).$Their$measurements$revealed$significantly$ increased$luminal$diameters$at$three$different$ levels$of$ the$ascending$aorta$ (Galvin$et#al.,#2008).$However,$ given$the$time$constraints$during$echocardiography$sessions,$in$our$study$we$decided$to$concentrate$on$LV$structure$and$function.$Notwithstanding,$vascular$function$will$be$important$parameters$to$analyse$in$the$future.$PW$Doppler$can$also$be$used$to$measure$ blood$ flow$ through$ the$ aorta$ as$well$ as$ the$ carotid$ artery$ and$ provide$general$information$about$myocardial$perfusion$(Williams$et#al.,#2007;$Feintuch$et#
!337!
al.,#2007;$Luo$et#al.,#2007).$These$methods$are$ frequently$used$ to$ investigate$ the$presence$of$atherosclerosis$(Wikstorm$et#al.,#2005),$however,$they$are$also$useful$for$ assessing$ diastolic$ and$ systolic$ dysfunction$ due$ to$ its$ impact$ on$ blood$ flow$within$vessels$(Chen$et#al.,#2012).$
$
4.4! Unexplored*alternative*methods**As$we$have$seen,$echocardiography$and$Doppler$imaging$are$versatile$tools$for$the$assessment$ of$ cardiac$ function$ in$ humans$ and$ also$ in$ murine$ models.$ The$continuous$ improvement$ of$ these$ techniques$ through$ the$ development$ of$ 3D$imaging$ for$ example,$ has$ enhanced$ the$ visualization$ of$ cardiovascular$ anatomy,$facilitating$more$accurate$evaluation$of$LV$systolic,$diastolic,$regional$and$vascular$function$ (Scherrer<Crosbie$ and$ Thibault,$ 2008;$ Gao$ et# al.,#2011;$ Dawson$ et# al.,#2004).$While$echocardiography$must$be$approached$with$caution,$as$discussed$in$a$number$of$reviews$(Collins$et#al.,#2003;$Scherrer<Crosbie$and$Thibault,$2008$and$Stypmann$et#al.,#2009),$echocardiography$and$Doppler$imaging$still$represent$the$mainstay$ of$ non<invasive$ cardiovascular$ assessment.$ Although$ they$ are$ still$ the$most$commonly$used$cardiac$imaging$methods,$a$number$of$other$techniques$have$been$developed$to$visualize$and$assess$cardiac$function,$including$nuclear$imaging$procedures$such$as$micro$CT$(Nahrendorf$et#al.,#2007),$micro$PET$scan$(Kreissl$et#
al.,#2006),$and$contrast$enhanced$cardiac$MRI$(Slawson$et#al.,#1998;$Wiesmann$et#
al.,#2001;$Yang$et#al.,#2004).$These$techniques$rival$echocardiography$and$Doppler$in$ many$ ways,$ for$ example$ PET$ provides$ information$ about$ non<mechanical$aspects$ of$ cardiac$ function$ such$ as$ myocardial$ substrate$ metabolism,$ receptor$binding,$and$gene$expression$(Kreissl$et#al.,#2006),$while$CT$and$MRI$offer$better$spatial$ resolution$ (Nahrendorf$et#al.,#2007;$ Slawson$et#al.,#1998;$Wiesmann$et#al.,#
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2001;$ Yang$ et# al.,# 2004).$ However,$ these$ methods$ are$ less$ accessible,$ more$expensive$and$complex,$unlike$echocardiography$and$Doppler$ imaging$which$are$relatively$cost<effective,$widely$available$and$have$relatively$short$acquisition$time$allowing$for$high$through<put$(Bauer$et#al.,#2011;$Azam$et#al.,#2012;$Rotterman$et#
al.,#2007;$Gao$et#al.,#2011).$
$
4.5! Histological*approach**We$ used$ various$ staining$ techniques$ to$ assess$ myocyte$ size,$ endothelial$ cell$number,$fibrosis,$the$presence$of$CD45<positive$cells$and$SA$node$pathology$in$the$heart$tissue$of$6$month$old$Ppt1+/+#and$12$and$18$month$old$Cln3+/<$mice$and$their$corresponding$wild<type$ controls.$Although,$ these$ staining$approaches$provide$a$relatively$clear$indication$of$several$aspects$of$cardiac$function$at$the$cellular$level,$there$are$a$number$of$limitations$associated$with$these$methods.$
$
a)! Sample*number*One$of$ the$main$ limitations$of$ this$ study$was$ the$ small$ sample$number$used$ for$histological$ analysis$ (n$ =$ 3$ –$ 6).$While$ this$was$ not$ an$ issue$ for$ the$ qualitative$assessment$ of$ CD45$ positive$ cells,$ which$ were$ either$ present$ or$ absent$ in$ low$numbers$ or$ the$ quantitative$ evaluation$ of$ myocyte$ size$ and$ endothelial$ cell$number$that$as$can$be$seen$from$the$small$size$of$the$error$bars$(Figure*59.*a$<$f)$showed$ little$ variability$ within$ each$ group,$ the$ low$ sample$ number$ made$ it$difficult$to$ascertain$with$confidence$whether$or$not$cardiac$fibrosis$represents$a$pathological$ phenotype$ in$ Cln3+/+#mice.# Therefore,$ moving$ forward,$ it$ will$ be$important$ to$ analyse$ further$ samples.$ The$ difference$ in$ variability$ between$ 6$month$ old$ Ppt1+/+#mice$ (little$ variability)$ and$ 12$ and$ 18$ month$ old$ Cln3+/<$ mice$
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(considerably$ more$ variability)$ could$ be$ explained$ by$ differences$ in$ cardiac$pathology$between$these$two$groups$of$mice$or$just$greater$variation$in$the$rate$of$disease$progression$during$the$more$protracted$course$of$CLN3$disease.$Whereas,$the$variability$between$wild<type$mice$at$different$ages$may$be$explained$by$ the$fact$ that$ fibrosis$ is$ a$ feature$ of$ aging$ that$ can$ be$ influenced$ by$ various$ factors$(reviewed$ in$Biernacka$ and$Frangogiannis,$ 2011).$ Therefore$ in$ older$mice$ at$ 12$and$18$months$of$age,$this$may$give$rise$to$variability,$although$this$is$also$true$of$myocyte$hypertrophy$ and$ less$ variation$was$observed.$Another,$ and$more$ likely$explanation$ is$ that$variability$was$due$ to$differences$ in$how$the$data$ for$ fibrosis$was$ collected$as$described$ in$section*12*of$Chapter*2.$ The$ level$of$ fibrosis$ in$6$month$ old$ Ppt1+/+# vs.$ control$ mice$ was$ analyzed$ early$ on$ in$ the$ study$ using$thresholding$ analysis$ on$ single$ images$ of$ the$ whole$ heart$ section$ at$ x5$magnification,$obtained$using$image$“stitching”$technology.$In$contrast,$the$level$of$fibrosis$in$12$and$18$month$old$Cln3+/+#vs.$control$mice$was$analyzed$later$on$in$our$investigation$ once$ the$ heart$ tissue$ was$ available$ and$ at$ this$ time,$ it$ was$ not$possible$to$carry$out$analysis$in$the$same$way$due$to$technical$issues.$Instead,$the$level$of$fibrosis$in$these$mice$was$evaluated$by$taking$abutting$images$throughout$the$myocardium$of$ the$whole$heart$ section$ at$ x40$magnification,$ perhaps$ giving$rise$to$more$variable$results.$
$
b)! Alternative*approaches*Myocyte$ hypertrophy,$ endothelial$ cell$ count$ and$ fibrosis$ were$ chosen$ for$ the$purposes$ of$ this$ study$ as$ they$ are$ distinctive$ features$ of$ commonly$ occurring$cardiac$ pathology$ (Zhang,$ personal$ communication).$ Furthermore,$ these$phenotypes$ are$ related$ to$ the$ process$ of$ cardiac$ remodelling,$ which$ occurs$ in$
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response$ to$ disease$ (reviewed$ in$Harvey$ and$ Leinwand,$ 2011,$ Oka$ et#al.,#2014).$Therefore,$ not$ only$ can$ they$ provide$ strong$ evidence$ for$ cellular$ cardiac$pathology,$but$they$also$provide$clues$for$possible$mechanisms$of$disease$(Harvey$and$Leinwand,$2011;$Oka$et#al.,#2014;$Burlew$and$Weber,$2000,$2002).$In$addition,$technically,$ these$ measures$ provided$ reliable$ and$ reproducible$ read<outs$ of$cardiac$pathology$ for$which$the$necessary$resources$and$guidance$was$available.$However,$ the$ following$ approaches$ could$ certainly$ be$ used$ to$ augment$ the$histological$methods$used$in$this$study$and$provide$additional$confirmation$of$our$findings.$
$
i.*Measuring*cardiac*hypertrophy*Various$other$approaches$besides$WGA,$IsoB4$and$picrosirus$red$staining$exist$to$investigate$myocyte$hypertrophy,$endothelial$cell$counts$and$fibrosis,$respectively.$Pathological$cardiac$hypertrophy$is$often$characterized$by$the$expression$of$atrial$natriuretic$peptide$(ANP)$and$B<Type$peptide$(BNP),$circulating$cardiac$hormones$produced$by$myocytes$ in$ the$heart$ (Cavallero$et#al.,#2007;$Gardner,$2003).$While$ANP$ is$produced$primarily$by$myocytes$within$ the$atria,$BNP$ is$expressed$more$equivalently$ in$ the$ atria$ and$ ventricles$ (reviewed$ in$ Gardner,$ 2003).$ Their$dramatic$ increase$ in$ response$ to$ hypertrophy$make$ them$ good$markers$ for$ the$activation$ of$ the$ hypertrophic$ mechanisms$ employed$ in$ response$ to$ various$cardiac$diseases$(Gardner,$2003).$Antibodies$against$ANP$and$BNP$can$ therefore$be$used$as$an$alternative$to$measuring$myocyte$size.$Another$way$to$detect$cardiac$hypertrophy$is$to$compare$the$ventricular$weight$of$Ppt1+/+#and$Cln3+/+#mice$to$their$wild<type$controls,$however,$due$to$issues$concerning$variable$KCl$perfusion$(how$much$blood$remains$in$the$heart$cannot$be$reliably$controlled),$this$method$is$not$
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as$accurate$as$the$aforementioned$techniques$and$should$not$be$used$in$isolation.$Indeed,$ the$ ventricles$ of$ 6$month$old$Ppt1</<$mice$ and$ their$ corresponding$wild<type$ controls$ were$ weighed$ and$ revealed$ a$ significant$ increase$ in$ ventricular$weight$in$the$Ppt1</<$mice$(p**#=#0.0042),$thus$providing$preliminary$evidence$for$ventricular$hypertrophy$(Appendices*4.1).$However,$although$this$correlates$with$our$echocardiogram$data$ (section*3.1.b,$Figure*51.*a),$no$difference$ in$myocyte$size$was$detected$(section*3.2.a,$Figure*59.*a).$
$
ii.! Measuring*endothelial*cell*number*By$ staining$ heart$ tissue$ with$ IsoB4,$ we$ were$ able$ to$ visualise$ and$ count$ the$number$ of$ endothelial$ cells$ and$ compare$ capillary$ density$ (lined$ by$ endothelial$cells)$ in$ the$ LV$myocardium$of$Ppt1+/+#and$Cln3+/+#mice$ to$wild<type$ age$matched$controls.$ The$ aim$ was$ to$ determine$ whether$ or$ not$ there$ was$ enhanced$angiogenesis$in$these$diseased$mice$as$a$response$to$disease<driven$hypertrophic$changes$ in$ the$heart.$ An$ alternative$way,$ to$measure$ angiogenesis,$which$would$have$ the$ benefit$ of$ directly$ linking$ angiogenesis$ to$ cardiomyocyte$ hypertrophy$might$be$ to$ stain$ for$ vascular$ endothelial$ growth$ factor$ (VEGF).$Cardiomyocytes$produce$ and$ release$ a$ number$ of$ paracrine$ signals$ in$ order$ to$ regulate$ the$vasculature$ of$ the$myocardium$ (Zhang$ and$ Shah,$ 2014).$One$ of$ the$most$ potent$angiogenic$ factors$released$by$cardiomyocytes$ is$VEGF,$which$ is$able$to$signal$ to$neighbouring$ECs$ to$ increase$ capillary$ formation$ (Hsieh$et#al.,#2006;$Giordano$et#
al.,#2001).$ However,$ VEGF$ antibodies$ produce$ an$ interstitial$ pattern$ of$ staining$and$therefore,$unlike$counting$IsoB4<stained$endothelial$cells,$another$method$of$analysis$would$have$to$be$used,$such$as$qualitative$or$thresholding$analysis.$$
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/+#mice$vs.$age<matched$wild<type$control$groups$using$echocardiography,$and$then$explore$the$cellular$basis$of$these$changes$using$histological$techniques.$The$next$step$would$be$to$explore$the$molecular$basis$of$any$cellular$changes$and$as$such,$heart$tissue$was$reserved$for$further$analysis.$However,$we$were$unable$to$carry$out$this$analysis$within$the$time$frame$of$the$project$and$as$such,$this$represents$a$limitation$to$this$study.$We$did$not$observe$any$significant$differences$in$myocyte$hypertrophy$ across$ any$ of$ the$ disease$ groups$ (Figure*59.* a* <$ c)$ and$ qualitative$analysis$of$CD45<positive$cells$and$did$not$show$any$marked$differences$(Figure*
63),$but$we$did$observe$a$33%$significant$increase$in$endothelial$cell$number$in$18$month$ old$ Cln3+/+#mice$ (Figure* 59.* d* <$ f)$ and$more$ than$ a$ two<fold$ increase$ in$fibrosis$ in$ 6$ month$ old$ Ppt1+/+# mice$ (Figure* 60.* a),$ together$ with$ SA$ node$pathology$ (Figure* 62).$ Therefore,$ further$ studies$ which$ target$ relevant$pathological$ changes$at$ a$molecular$ level$using$ techniques$ such$as$RT<qPCR$and$western$ blot$ analysis$ to$ investigate$ changes$ in$ mRNA$ and$ protein$ levels$respectively,$may$reveal$further$significant$phenotypes$within$the$heart.$A$number$of$approaches$have$been$used$ to$ investigate$ the$molecular$pathways$ involved$ in$cardiac$ remodelling$ in$ response$ to$ pathophysiological$ stimulation$ (reviewed$ in$Kehat$ et# al.,#2010).$ Based$ on$ this$ literature,$ one$ possible$ avenue$ that$ could$ be$explored$in$the$future,$might$be$to$investigate$Ca2+/calmodulin<dependent$kinase$II$ (CaMKII)$ expression$ for$ example,$which$ appears$ to$ play$ an$ important$ role$ in$pathological$cardiac$hypertrophy$(reviewed$in$Anderson,$2009).$$
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5! Discussion*In$ addition$ to$ the$ well<characterized$ neurological$ changes$ that$ dominate$ in$ the$NCLs,$cardiac$complications$are$not$uncommon$in$CLN3$patients,$especially$in$the$late$ stages$of$ disease$ (Dilaveris$et#al.,#2014;$Østergaard$ and$Mølgaard,$ 2011).$As$such,$CLN3$plausibly$belongs$ to$ the$Metabolic$Cardiomyopathies,$which$describe$amino$acid,$lipid$and$mitochondrial$disorders,$as$well$as$storage$diseases$that$are$associated$with$both$myopathy$and$cardiomyopathy$(reviewed$ in$Gilbert,$2003).$The$ most$ frequent$ symptoms$ in$ CLN3$ disease$ include$ ventricular$ hypertrophy,$various$ arrhythmias$ e.g.$ bradycardia$ with$ sinus$ arrest$ and$ artrial$ fibrillation$(Dilaveris$ et# al.,# 2014;$ Østergaard$ and$ Mølgaard,$ 2011;$ Hofman$ et# al.,# 2001).$Despite$ this,$ little$attention$has$been$placed$upon$exploring$cardiac$pathology$ in$CLN3$disease,$beyond$occasional$case$reports$and$autopsy$studies$(Hofman$et#al.,$2001).$For$CLN1$disease,$even$clinical$reports$and$post+mortem$studies$are$limited$as$ children$ often$ succumb$ to$ the$ neurological$ disease$ before$ cardiovascular$complications$ have$ the$ opportunity$ to$ manifest.$ However,$ if$ these$ neurological$symptoms$are$effectively$treated$and$lifespan$is$extended,$it$is$probable$that$CLN1$patients$will$manifest$cardiac$features$that$are$similar$to$those$described$in$CLN3$and$Kufs$disease$ (Galvin$et#al.,#2008;$Hofman$et#al.,#2001;$Michielsen$et#al.,#1984;$Reske<Nielsen$et#al.,#1981;$Tomiyasue$et#al.,#2000;$Fealey$et#al.,#2009;$Østergaard$and$Mølgaard,$2011).$Indeed,$in$a$clinical$case$of$protracted$CLN2$disease,$cardiac$symptoms$arose$(Fukumura$et#al.,#2011).$In$terms$of$animal$studies,$little$has$been$achieved$so$far$in$terms$of$systematically$identifying$cardiac$phenotypes$in$Ppt1+/+#and$ Cln3+/+#mice$ (Galvin$ et#al.,#2008;$ Staropoli$ et#al.,#2012).$ Therefore,$ this$ pilot$study$ represents$ the$ first$ step$ towards$ characterizing$ cardiac$ phenotypes$ in$murine$NCL,$providing$evidence$for$the$existence$of$cardiac$features$that$reiterate$the$heart$complications$described$in$human$patients,$see$Table*13.$This$includes$
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LV$ hypertrophy$ (section* 3.1.b),$ potential$ tachycardia$ (section* 3.1.a),$ potential$diastolic$ dysfunction$ and$ heart$ failure$ (section* 3.1.c)$ accompanied$ by$ changes$associated$ with$ cardiac$ remodelling$ such$ as$ increased$ fibrosis,$ mild$ myocyte$hypertrophy$ and$ enhanced$ angiogenesis$ (section* 3.2.a* and$ b),$ and$ histological$signs$ of$ SA$ node$ pathology$ (section* 3.2.c).$ While$ the$ manifestation$ of$ cardiac$phenotypes$ in$ Ppt1+/+#and$ Cln3+/+#mice$ expands$ their$ potential$ as$ disease$models,$determining$ the$cause$of$ cardiac$pathology$ in$ these$mice$ is$of$great$ significance.$The$ main$ question$ pertains$ to$ whether$ the$ cardiac$ pathology$ observed$ in$ this$study$ are$ intrinsic$ to$ the$ heart$ or$ secondary$ to$ pathology$within$ the$ brainstem,$which$plays$an$important$role$ in$the$regulation$of$cardiac$function$(Argiles$et#al.,#2000).$ Mutations$ in$ different$ CLN$ genes$ result$ in$ similar$ neurological$ disease,$explained$in$part$by$the$CNS<sensitive$roles$of$these$proteins$(reviewed$in$Weimer$
et# al.,# 2002;$ Chattopadhyay$ and$ Pearce,$ 2000;$ Mitchison$ et# al.,# 2004;$ Cooper,$2003).$ However,$ cardiac<specific$ roles$ for$ PPT1$ or$ CLN3,$ which$ might$ directly$explain$ the$ development$ of$ cardiac$ pathology$ in$ their$ absence,$ have$ not$ been$identified$ (Weimer$ et# al.,# 2002).$ Like$ all$ LSDs,$ deficiencies$ in$ these$ lysosomal$proteins$lead$to$a$build$up$of$lysosomal$storage$material.$While$there$is$no$direct$link$between$storage$material$and$neurodegeneration$within$the$brain$(Griffey$et#
al.,#2004;$Tyyrelä$et#al.,#2004;$Cooper$et#al.,#2006),$the$cellular$composition$within$the$heart$is$completely$different,$and$therefore$it$is$possible$that$cardiopathology$may$ in$ fact$ be$ driven$ by$ storage$ material$ accumulation.$ It$ has$ already$ been$proposed$ that$ storage$ material$ directly$ interrupts$ the$ conduction$ of$ electrical$impulses$ within$ the$ heart,$ initiating$ a$ pathological$ cascade$ involving$ cardiac$remodelling,$which$ in$ turn$contributes$ to$cardiac$dysfunction$(Gilbert<Barness$et#
al.,#2004;$ Reske<Nielsen$ et#al.,#1981;$Michielsen$ et#al.,#1984;$ Sakajiri$ et#al.,#1995;$Toyiyasu$et#al.,#2000;$Hofman$et#al.,#2001).$ In$addition,$ fatty$ infiltration$may$also$
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Table* 13.* Summary* of* overall* findings* in* 6* month* old* Ppt1Sdeficient* (Ppt1%/%),* 12* month* old* Cln3S
deficient*(Cln3%/%)*and*18*month*old*Cln3%/%*mice*vs.*ageSmatched*controls.**Downward$facing$arrows$denote$a$reduction,$upward$facing$arrows$denote$an$increase$and$hyphen$represents$no$change.**$Until$ recently,$ it$ was$ thought$ that$ it$ was$ forebrain$ and$ cerebellum$ that$ are$primarily$affected$in$the$NCLs$(Cooper$et#al.,#2015).$However,$recently,$significant$brainstem$ and$ spinal$ cord$ pathology$ has$ been$ identified$ in$ NCL$murine$models$(Nelvagal$ and$ Cooper,$ unpublished$ observations).$ The$ brainstem$ contains$ a$number$ of$ nuclei$ within$ the$ medulla$ oblongata,$ which$ are$ involved$ in$ the$parasympathetic$ and$ sympathetic$ regulation$ of$ the$ heart$ (reviewed$ in$ Leslie,$1985;$VanderHorst$and$Ulfhake,$2004).$Therefore,$as$discussed$in$section*3.2.c,$it$is$possible$that$neurodegeneration$within$these$nuclei$or$indeed$pathology$within$the$ spinal$ cord,$ has$ a$ secondary$ effect$ on$ the$ heart.$ Ultimately,$ the$ source$ of$cardiac$ pathology$ needs$ to$ be$ distinguished$ to$ ensure$ efficient$ targeting$ of$ the$correct$therapeutic$approaches$(Cooper$et#al.,#2015).$A$useful$model$to$investigate$this$ would$ be$ to$ use$ a$ working$ ‘heart<brainstem’$ preparation$ (Paton,$ 1995),$ to$investigate$ how$ the$ brainstem$ mechanisms$ regulating$ cardio<respiratory$ motor$activity$is$altered$in$murine$models$of$NCL.$From$a$therapeutic$approach,$targeting$
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therapy$ to$ the$ brainstem$ and$ spinal$ cord$ would$ provide$ information$ about$ the$weighting$of$brainstem/spinal$cord$pathology$ in$NCL$pathogenesis.$ Interestingly,$unpublished$data$ from$Mark$Sands’$ lab$at$Washington$University$Medical$School$suggests$ that$ gene$ therapy$ directed$ to$ the$ forebrain,$ the$ brainstem$ and$ spinal$cord,$or$both$have$different$effects$upon$neurological$disease$suggesting$that$the$efficacy$of$gene$therapy$is$largely$site<specific.$$
$
While$ fitting$ a$ pacemaker$ seems$ to$ improve$ the$ overall$ condition$ in$ some$ NCL$patients,$ this$ is$ a$ treatment$of$ a$ symptom$and$not$ the$underlying$problem$ itself$(Østergaard$ and$ Mølgaard,$ 2011).$ If$ cardiac$ complications$ are$ secondary$ to$brainstem$ pathology,$ as$ has$ been$ shown$ to$ be$ the$ case$ for$ Huntington$ Disease$(HD)$ for$example$(Griffioen$et#al.,#2012),$ then$treating$ the$brainstem/spinal$cord$pathology,$ may$ also$ alleviate$ heart$ symptoms.$ As$ such,$ our$ findings$ are$particularly$ relevant$ and$ the$ availability$ of$ robust$ murine$ cardiac$ phenotypes$would$ serve$ as$ a$ useful$ tool$ for$ understanding$ the$ mechanisms$ involved$ in$therapeutic$ approaches$ such$ as$ brainstem/spinal$ cord<directed$ gene$ therapy.$Notwithstanding,$ brainstem$ nuclei$ project$ to$ regions$ throughout$ the$ brain$ and$viscera$ and$ therefore,$ improvements$ in$ overall$ disease$ outcome$will$most$ likely$result$ from$ the$ combined$ knock<on$ effect$ of$ treating$ several$ aspects$ of$ NCL$pathology.$ If$ the$ cardiac$ pathology$ we$ have$ observed$ is$ intrinsic$ to$ the$ heart$however,$ treatment$ approaches$ that$ directly$ target$ the$ viscera$ such$ as$systemically$ delivered$ ERT,$ combined$with$ CNS<directed$ gene$ therapy$may$ also$give$ rise$ to$ improvements$ in$ overall$ disease$ outcome$ and$ this$will$ be$ discussed$next$in$Chapter*5.$As$a$final$comment,$it$seems$that$the$current$dogma$is$shifting$with$regards$to$the$NCLs$being$considered$a$group$of$purely$‘neuronal’$disorders$
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! Moving(towards(therapies(for(CLN1(disease(As! discussed! in! previous! chapters! (Chapter(1(and!2),!with! the! exception! of! the!much! rarer! congenital! CLN10! disease,! CLN1! disease! is! the! most! rapidly!progressing!form!of!NCL!and!is!caused!by!inactivating!mutations!in!the!CLN1%gene,!resulting! in! a! deficiency! in! PPT1! enzyme! activity! (Vesa! et%al,,%1995;! Mole! et%al.,%1999;!Das!et%al.,%2001;!Hofmann!et%al.,%2001).!Children!with!CLN1!disease!develop!symptoms!at! around!18!months!of! age,! typically! starting!with! clumsiness!before!proceeding!to!loss!of!vision,!motor!and!cognitive!deficits!and!seizures!(Santavouri!
et% al.,% 1973;! Wisniewski! et% al.,% 1992).! Without! the! availability! of! effective!treatments!to!interrupt!or!resolve!the!course!of!disease,!these!children!invariably!die! in! early! to! midTchildhood! (Schulz! et% al.,! 2013,! Santavouri! et% al.,! 1993).!However,!as!discussed!in!section(3.1.a(of!Chapter(1,!the!development!of!potential!treatments!for!this!devastating!disease!have!been!considerably!accelerated!by!the!availability!of!genetically!modified!murine!models!(HawkinsTSalsbury!et%al.,%2013).!These!mouse!models! (Gupta! et%al.,%2001! and! Jalanko! et%al.,%2005),! including! the!
Ppt1./.%mice!used!in!this!study!(Gupta!et%al.,%2001),!exhibit!many!typical!features!of!the!human!disease!including!progressive!neurodegeration,!cortical!thinning,!brain!atrophy,! the! accumulation! of! fluorescent! storage! material,! retinal! dysfunction,!spontaneous! seizures,! motor! deficits! and! shortened! lifeTspan! (~! 8.5! months)!(Gupta! et%al.,%2001;! Bible! et%al.,%2004;! Griffey! et%al.,%2006).! As! such,! they! provide!accurate!diseaseTrelated!phenotypes,!and!have!served!as!valuable!tools!for!better!understanding! the! pathogenesis! of! disease! and! developing! treatment! strategies.!Such!strategies!were!described!in!section(5(of!Chapter(1(and!have!been!reviewed!in! (Hobert! et%al.,%2006;! Platt! and! Lachmann! et%al.,%2009;!HawkinsTSalsbury! et%al.,%
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2013),(but! to!reiterate! the!therapies!most!appropriate! for! the!treatment!of!CLN1!disease! include!ERT,!BMT!gene! therapy,! neuronal! stem! cells! and! small!molecule!drugs! (HawkinsTSalsbury!et%al.,%2013).!While,! progress! is! being!made! for! each!of!these! single! therapeutic! approaches,! they! still! lag! behind! the! advances!made! in!treating!CLN2!disease!mice!(Katz!et%al.,%2014;!Vuillemenot!et%al.,%2011,!2015;!Sodhi!
et%al.,%2005,!2008;!Worgall!et%al.,%2008;!Chang!et%al.,%2008;!Passini!et%al.,%2006;!Xia!et%
al.,%2000).! Emerging! data! from! combination! treatment! approaches! suggest! that!these! treatments! might! be! more! effective! by! synergistically! targeting! multiple!aspects!of!disease!pathology!or!multiple! sites!of!pathology! (HawkinsTSalsbury!et%
al.,%2013).!Such!combinatorial!approaches!have!not!yet!been!tested!clinically,!but!experimental! therapies! in!mice,!are!now!beginning! to!pave! the!way! towards! this!goal!as!discussed! in!detail! in!section(5.6(of!Chapter(1(and!reTvisited! in! the!next!section!below.!
!
! Combination(therapies(–(a(new(approach(As! discussed! in! section( 5.6! of! Chapter( 1,! three! studies! have! been! published,!which!have!attempted!to!improve!the!efficacy!of!gene!therapy!for!CLN1!disease!by!combining! it! with! either! a! bone!marrow! transplant! or!with! two! small!molecule!treatments,!which!on!their!own!have!each!resulted!in!relatively!small!incremental!improvements! in! pathology.! The! first! effort! made! at! gene! therapy! based!combination! therapy! for!CLN1!disease!was! carried!out! in!Ppt1./.!mice!using!BMT!and!CNSTdirected!AAV2/5Tmediated!gene!therapy!(Macauley!et%al.,%2012).!AAV2/5Tmediated! gene! therapy! significantly! improved! cortical! thickness,! decreased!storage! burden! and! glial! activation,! improved! motor! function! and! increased!lifespan!(Macauley!et%al.,%2012).!However,!combining!AAV2/5!with!BMT!resulted!in!
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even! further! improvements! in!neuropathology!and!motor! function!and!a!striking!increase! in! lifespan!(Macauley!et%al.,%2012).!However,! it!remains!unclear!whether!this! dramatic! improvement! in! efficacy! was! due! to! BMT! having! an!immunomodulatory!effect!on!the!neuroinflammatory!component!of!CLN1!disease,!or!a!positive!effect!on!systemic!pathology,!or!was!in!fact!due!to!radiation!induced!increases! in! vector! expression! and! subsequently! the! level! of! PPT1! activity!(Alexander! et% al.,% 1994;! Yalkinoglu! et% al.,% 1988).! Furthermore,! when! this!experiment!was!repeated!with!a!“radiation!only”!control!group,!the!initial!results!could!not!be!replicated!for!reasons!that!are!yet!to!be!elucidated!(Sands,!personal!communication).!!
!
The! first! attempt! to! combine! gene! therapy! with! the! administration! of! a! small!molecule! treatment!was! carried! out! in!Ppt1./.%mice! using! CNSTdirected! AAV2/5Tmediated! gene! therapy! alone,! and! in! combination!with! systemic! delivery! of! the!lysosomotropic! PPT1! mimetic! phosphocsyteamine! (Roberts! et% al.,%2012).! While!CNSTdirected!gene!therapy!alone!decreased!brain!atrophy,!improved!brain!weight,!reduced!the!neuroinflammatory!response,!cleared!storage!material!and!improved!motor!function!and!lifespan!as!expected,!adding!phosphocsyteamine!provided!no!further! benefit,! with! the! exception! of! moderate! improvements! in! motor!performance!(Roberts!et%al.,%2012).!Another!combinatorial!approach!that!has!been!tested!in!Ppt1./.%mice!aimed!to!target!glial!activation!in!PPT1Tdeficient!mice!at!the!same! time!as! the!enzyme!deficit!within! the!CNS!by!combining!AAV2/5Tmediated!gene! therapy! with! an! antiTinflammatory! drug! called!MW151.! As! expected,! CNSTdirected! AAV2/9TPPT1! treatment! alone,! had! a! positive! impact! upon!neuropathological!phenotypes,! and!was!accompanied!by! improvements! in!motor!
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function,! a! reduction! in! seizure! frequency! and! an! extension!of! lifespan! in!Ppt1./.%mice!(Macauley!et%al.,%2014).!!However,!for!the!most!part,!MW151!did!not!have!any!additive! affects,! giving! rise! to! only! modest! additional! improvements! in! motor!performance!and!life!expectancy!(Macauley!et%al.,%2014).!!
!
Taken! together,! these! studies! support! the! concept! of! combination! therapy! as! a!valid!approach!for!treating!CLN1!disease.!Treating!the!primary!enzyme!deficiency!itself!does!not!appear! to!be!entirely!effective,!but! targeting!other! components!of!the! disease! cascade! can! theoretically! provide! additional! benefit.! However,! at!present,!the!right%combination!is!yet!to!be!discovered.!So!far,!the!small!molecules!that!have!been!chosen!have!apparently!not!targeted!the!most!appropriate!parts!of!the! pathological! cascade! that! are! missed! by! gene! therapy,! and! therefore,! other!avenues!must!be!explored.!!
!
! Aims(and(hypotheses(CNSTdirected!AAVTmediated!gene! therapy! is!able! to!alleviate!a! significant!part!of!the! neuropathology! associated! with! CLN1! disease,! but! has! no! impact! on! the!systemic!disease,!which!as!discussed!in!Chapter(4,!is!certainly!relevant!at!least!in!terms! of! cardiac! pathology.! Therefore,! based! on! previous! findings! (Galvin! et%al.,%2007)! we! hypothesized! that! untreated! visceral! pathology! may! be! one! of! the!limitations!to!achieving!better!efficacy.!!To!investigate!whether!the!positive!effects!of! AAVTmediated! gene! therapy! can! be! enhanced! by! also! treating! the! systemic!manifestations! of! disease,! we! combined! CNSTdirected! gene! therapy! with!intravenously! delivered! ERT.! ERT! administered! by! this! route! is! ineffective! at!
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treating! neuropathology,! unless! it! is! administered! before! the! BBB! is! fully!developed!and!becomes!impermeable!to!large!molecules!like!PPT1!enzyme!(Hu!et%
al.,%2012).!As!such,!systemic!delivery!of!ERT!means!that!the!exogenously!supplied!enzyme!will!most! likely! be! largely! confined! to! the! viscera,! where! it! can! correct!pathology,!whilst!CNSTdirected!AAVTmediated!gene!therapy!is!targeted!directly!to!the!brain.!In!this!way,!it!should!be!possible!to!treat!the!CNS!and!viscera!separately!and! assess! the! individual! therapeutic! contribution! of! each! treatment! when!administered!in!combination.!
!
We! hypothesised! that! treating! the! brain! and! body! would! be! important! for!improving! the! efficacy! of! gene! therapy! for! CLN1! disease! and! assessed! whether!adding!ERT!to!AAV!gene!therapy!in!order!to!treat!somatic!pathology!would!achieve!this!objective.!
!
2! Experimental(plan(and(methods(





Figure( 64.( Schematic( representation( of( wildJtype( and( Ppt1Jdeficient( (Ppt1%/%)( mice( used( in( the(
study.! This! study! included! 37! mice! of! different! genotypes:! 9! wildTtype! mice! and! 28! Ppt1./.mice.! Mice!receiving! either! no! treatment! (wildTtype! and! Ppt1./.% controls),! AVV! only,! ERT! only! or! AAV! +! ERT!combination!treatment!were!sacrificed!after!5!or!7!months,!producing!9!cohorts:!1)!Untreated!wildTtype!mice,!sacrificed!after!5!months!(n!=!4);!2)!Untreated!wildTtype!mice,!sacrificed!after!7!months!(n!=!5);!3)!Untreated!Ppt1./.mice,!sacrificed!after!5!months!(n!=!4);!4)!Untreated!Ppt1./.mice,!sacrificed!after!7!months!(n!=!5);!5)!AAV!onlyTtreated!Ppt1./.mice,!sacrificed!after!5!months!(n!=!4);!6)!AAV!onlyTtreated!Ppt1./.mice,!sacrificed!after!7!months!(n!=!4);!7)!ERT!onlyTtreated!Ppt1./.mice,!sacrificed!after!7!months!(n!=!4);!8)!AAV!+! ERT! combinationTtreated! Ppt1./.mice,! sacrificed! after! 5! months! (n! =! 4);! 9)! AAV! +! ERT! combinationTtreated!Ppt1./.mice,!sacrificed!after!7!months!(n!=!3).!It!should!be!noted!here!that!‘AAV!only’!will!be!used!throughout!this!chapter!(unless!inappropriate)!to!describe!mice!treated!with!CNSTdirected!AAV2/9TPPT1!mediated! gene! therapy,! ‘ERT! only’! will! be! used! to! describe! mice! treated! with! systemically! supplied!exogenous!rhPPT1!enzyme!and!‘AAV!+!ERT!combination’!treatment!refers!to!mice!treated!with!both!CNSTdirected! AAV2/9TPPT1! mediated! gene! therapy! and! systemically! supplied! exogenous! rhPPT1! enzyme.!Further!abbreviations!have!been!used!for!histograms,!the!details!of!which!are!described!in!corresponding!figure!legend.(
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! Overview(of(experimental(treatment(groups(As!discussed!in!section(4.3(of!Chapter(2,!two!separate!treatments,!AAV2/9TPPT1!mediated! gene! therapy! and! ERT! (intravenously! supplied! exogenous! rhPPT1!enzyme),!were!utilized!to!target!CNS!and!systemic!pathology!in!Ppt1./.%mice.!Along!side!wildTtype!and!Ppt1./.%mice! receiving!no! treatment,!mice! received!ERT!alone,!AAV! alone! or! a! combination! of! both! treatments! (described! in! section( 2.3.( and!demonstrated!in!Figure(65).!By!including!untreated!wildTtype!mice!and!untreated!
Ppt1./.%we!were!able!to!measure!the!impact!of!ERT!alone,!AAV!alone!and!ERT!+!AAV!together.! Although! the! clinical!manifestations! of! CLN1! disease! present! primarily!with! neurological! symptoms,! pronounced! visceral! storage! also! accumulates!(Galvin!et%al.,%2008).!While!the!accumulation!of!storage!material!is!not!necessarily!the!cause!of!disease!it!is!indicative!of!lysosomal!dysfunction!(Mitchison!et%al.,%2004;!Cooper!et%al.,%2003;!Mole!et%al.,%2005).!Significant!manifestations!of!disease!outside!of!the!CNS!in!CLN1!patients!are!not!widely!reported,!partly!because!these!patients!succumb!to!neurological!disease!before!these!visceral!manifestations!are!clinically!apparent,! however,! as! shown!by!our! findings! in!Chapter(4,(cardiac! pathology! is!present! within! these! mice! and! other! signs! of! visceral! pathology! have! been!reported! previously! (Hofman! et% al.,% 2001;! Galvin! et% al.,% 2008;! Hu! et% al.,% 2012).!Indeed,!during!the!perinatal!period,!lysosomal!enzyme!can!still!cross!the!BBB!and!is!partly!effective!at!treating!CNS!pathology!(Hu!et%al.,%2012).!However,!rather!than!attempting!to!deliver!the!PPT1!enzyme!directly!to!the!brain!in!this!way,!we!used!it!to!exclusively! target! the! systemic!manifestations!of!disease!on! the!basis! that! the!BBB!is!essentially!impenetrable!to!PPT1!enzyme!after!3!weeks!of!age!(Urayama!et%
al.,%2004,!2008).!Any!amelioration!of!neuropathology!by!exogenously!administered!PPT1!enzyme!would!only! slightly!delay! the!development!of! brain!pathology! and!these!effects!would!be!undetectable!by!5!and!7!months!(Hu!et%al.,%2012).!Therefore,!
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treating!mice!with!ERT!alone!enabled!us!to!assess!the!overall!effect!of!systemically!delivered! ERT! treatment.! As! we! know! from! previous! literature! (reviewed! in!Dayton!et%al,%2012;!Aschauer!et%al.,%2013;!Cearley!and!Wolfe,!2006)!and!our!results!from(Chapter(3,(the!hybrid!serotype!AAV2/9!is!able!to!achieve!good!rostralTcaudal!distribution!within! the! CNS! and! specifically! target! neurons! (Cearley! et%al.,%2005;!Sharma!et%al.,%2010).!For!this!reason,!AAV2/9Tmediated!gene!therapy!was!used!to!treat!the!CNS!by!direct!injection!to!the!brain.!Just!as!rhPPT1!is!unable!to!cross!the!BBB! to! access! the! CNS,! CNSTdirected! AAV2/9TPPT1! is! unlikely! to! spread!significantly! beyond! the! CNS,! thus! treatment!was! largely! restricted! to! the! brain,!where!pathology! is!most!severe.!To!evaluate!whether!ERT!had!an!additive!effect!when! combined! with! AAVTmediated! gene! therapy,! we! treated! mice! with! both!therapies.! By! comparing! mice! in! this! “AAV! +! ERT! combination”! group! to! mice!treated!with!single!therapies,!it!was!possible!to!delineate!any!effects!beyond!those!achieved!with! gene! therapy! alone.! Each! of! these! treatments! required! a! different!experimental!approach!as!outlined! in!section(4.3(of!Chapter(2(and!discussed! in!further!detail!below.!!
!
! Experimental(design((The!site!of!injection!for!ERT!and!gene!therapy!treatment,!age!of!mice!at!the!time!of!injection! and! the! stage! at! which! the! mice! are! sacrificed! were! all! important!considerations!for!judging!the!effects!of!AAV!+!ERT!combination!therapy.!AAV2/9Tmediated!gene!therapy!was!administered!to!three!brain!regions,!previously!shown!to! be!particularly! affected! in!Ppt1./.%mice! (Macauley!et%al.,%2012).! These!were! the!anterior! cortex,! hippocampus/thalamus! region! and! the! cerebellum.! In! these!regions,! cortical! thinning! (anterior! cortex),! glial! activation,! neuron! loss! and!
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accumulation!of!storage!material!can!be!easily!detected!at!5!and!7!months!(Kielar!
et% al.,% 2007).! By! specifically! targeting! the! most! severely! affected! areas! (whilst!achieving!good!spread!and!taking!advantage!of! “crossTcorrection”),!we!should!be!able!to!test!the!ability!of!this!method!to!treat!disease!within!the!CNS.!Intravenous!vascular!access!is!technically!challenging!in!the!adult!mouse!and!even!more!so!in!neonatal!mice.! Therefore,! the! routes! of! PPT1! enzyme! administration! in! animals!receiving! ERT!were! carefully! considered.! Referring! to!Figure(65,!mice! receiving!ERT!treatment!were!injected!via!various!routes!(superficial!temporal!(facial)!vein,!peritoneum!and!tail!vein)!at!PND!1,!7,!14!and!21!and!then!once!a!week!for!5!or!7!months! from!PND! 30! as! described! in! section(4.3(of!Chapter(2.! It! is! technically!very! difficult! to! achieve! safe! and! accurate! access! to! intravenous! routes! between!PND!4!and!PND!28.!Traditionally,!the!superficial!temporal!vein!(STV)!is!considered!to!be!the!most!appropriate!route!of!administration!in!mice!at!PND!1!because!it!has!the! unique! advantage! of! being! anchored! in! the! subcutaneous! connective! tissue,!such!that!it!is!not!easily!displaced!by!the!needle!point!and!also!because!it!is!fairly!straight! and! visible! through! the! skin! (Billingham! and! Brent,! 1956;! Sands! et%al.,%1999).! From! PND! 4,! it! is!more! difficult! to! identify! the! STV! as! the! skin! becomes!darker!and!hair!begins!to!grow.!Therefore,!the!second!injection!of!enzyme!(at!PND!7!then!PND!14!and!21)!was!given!via!the!peritoneum!because!of!the!small!size!of!the!tail!vein!until!PND!28.!From!PND!30!to!5!or!7!months!weekly!intravenous!(i.v)!injections!of! hrPPT1!enzyme!were! administered!via! the! tail! vein,! as! it!was! large!enough!by! this! time! to!hit!with! a!30!gauge!needle! and!allows! for!more!accurate!injections!as!it!is!easily!visualised!(as!opposed!to!other!more!fur!covered!regions).!
!
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ERT! and! AAV2/9Tgene! therapy! treatments! were! administered! at! PND! 1! and! 2,!respectively,! as! studies!have! shown! that!early!administration!of!both! treatments!correlates!with!better!disease!outcomes!(Sands!et%al.,%1994;!Hu!et%al.,%2012;!Sands!










As! discussed! extensively! in! section(1.3(of!Chapter( 2,(we! used!mice! at! 5! and! 7!months!of!age!to!investigate!the!impact!of!AAV!+!ERT!combination!therapy!on!the!thalamus! and! cortex! of!Ppt1./.!mice.!Ppt1./.%mice! live! to! about! 8.5!months! in! the!absence!of!treatment!(Gupta!et%al.,%2001).!Ppt1./.%mice!at!5!and!7!months!of!age!are!therefore! towards! the! normal! end! stage! of! disease,! with! increasing! disease!severity!displaying!progressively!more!severe!changes!in!cortical!thickness,!glial!!
!
!
Figure(66.(Schematic( illustration(of(somatosensory(thalamocortical(system.!Representative! subTsample!of! coronal! sections! (rostral! to! caudal! from! top! left! to!bottom! right)! showing! the!boundaries!of! the!primary!somatosensory! barrel! field! cortex! (S1BF)! of! the! cortex! (blue)! and! the! ventral! posteromedial! and! ventral!posterolateral!nuclei!of!the!thalamus!(VPM/VPL)!(red).!Adapted!from!(Paxinos!and!Franklin,!2001)!!
activation,! neuron! loss! and! storage! material! accumulation! (Kielar! et% al.,%2007),!against!which!the!efficacy!of!treatments!can!be!measured.!These!parameters!were!measured!within! the! primary! somatosensory! barrel! field! cortex! (S1BF)! and! the!ventral! posteromedial! and! ventral! posterolateral! (VPM/VPL)! nuclei! of! the!
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thalamus!as!highlighted!in!Figure(66.(Apart!from!storage!material,!the!presence!of!visceral! pathology! has! not! been! extensively! characterized! in! Ppt1./.%mice! and!therefore,!we!did!not!analyse!any!other!organs!in!this!particular!study!at!present!but! this! will! be! done! at! a! later! date! (with! particular! emphasis! on! the! heart)!(Chapter(4).!
!
3! Results(
As!discussed!in!Chapter(1(section(3.1.a,!Ppt1./.%mice!accurately!recapitulate!many!important! pathological! features! of! CLN1! disease! (Bible! et%al.,%2004;! Kielar! et%al.,%2007).!Mice!at!the!end!stage!of!disease!exhibit!regional!cortical!thinning!together!with!successive,!specific!and!severe!neuron!loss!within!the!thalamus!and!cortex!as!well!as!other!brain!regions!(Kielar!et%al.,%2007).!This!neuronal!loss!is!accompanied!(preceded! at! earlier! ages)! by! widespread! astrocytosis! and! localized! microglial!activation! (Bible! et% al.,% 2004),! and! extensive! autofluorescent! storage! material!accumulates!in!the!lysosomes!of!neurons!and!glia!throughout!the!brain,!as!well!as!in! peripheral! organs! (Bible! et% al.,%2004;! Gupta! et% al.,%2001;! Jalanko! et% al.,%2005;!Macauley!et%al.,%2009;!Galvin!et%al.,%2008).!By!measuring!the!impact!of!CNSTdirected!AAV2/9Tmediated!gene!therapy,!systemically!delivered!ERT!and!a!combination!of!both!treatments!on!these!wellTdefined!disease!phenotypes!compared!to!untreated!wildTtype! and! Ppt1./.! mice,! we! were! able! the! evaluate! whether! the! efficacy! of!AAV2/9Tmediated!gene!therapy!can!be!augmented!by!the!addition!of!systemically!delivered! ERT.! To! do! this,! we! carried! out! a! number! of! histological! analyses!including!cortical!thickness!measurements,!thresholding!analysis!of!astrocyte!and!microglial!markers,! neuron! counts! and! thresholding! analysis! of! storage!material!
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burden.! These! mice! also! exhibit! motor! deficits,! myoclonic! jerks,! seizures! and! a!shortened!lifespan!(Gupta!et%al.,%2001).!Prior!to!our!histological!analysis,!the!effects!of!AAV!+!ERT! combination! therapy!were! also!measured!against! these! important!behavioural! phenotypes! by! our! collaborators! at! Washington! University! medical!School!as!will!be!discussed!in!section(4(of!this!chapter.!
!
! The(impact(of(each(treatment(on(cortical(thickness(is(revealed(late(




Figure( 67.( Impact( of( adenoJassociated( virus( (AAV)Jmediated( gene( therapy( and( enzyme( replacement(
therapy((ERT)(on(cortical(thickness(at(5(and(7(months(of(age(in(Ppt1Jdeficient((Ppt1%/%)(mice.(To!assess!the!thickness!of! the!primary!somatosensory!barrel! field!cortex!(S1BF)!across!all! treatment!groups!following!each!treatment!we!carried!out!thickness!measurements!within!the!S1BF!of!Nissl!stained!sections!taken!from!mice! at! 5! and!7!months!of! age.!a)! and!b)!Representative! images! from!Nissl! stained!brain! sections! showing!cortical!thicknesses!of!the!S1BF!in!5!(a)!and!7!(b)!month!old!mice.!These!images!demonstrate!different!extents!of! cortical! atrophy! following! each! treatment! (AAV! alone! (AAV),! ERT! alone! (ERT)! and! AAV! +! ERT! (A+E))!against!untreated!wildTtype!and!untreated!Ppt1./.%control!mice.! !a)!Cortical!thinning!was!most!pronounced!in!untreated!Ppt1./.%mice!at!5!months!of!age,!and!this!was!largely!corrected!by!intracranial!AAV!only!treatment,!but! not! by!AAV!+!ERT! combination! treatment.!However,! to! underline! the! variability!within! the!AAV!+!ERT!combination! treatment! group,! multiple! sections! are! shown! to! demonstrate! the! varying! degrees! of! cortical!thickness.!b)!Cortical!thinning!was!even!more!pronounced!in!Ppt1./.mice!at!7!months!of!age!and!again,!this!was!corrected!by!AAV!treatment!alone.!No!such!correction!is!seen!with!ERT!or!AAV!+!ERT!combination!treatment.!However,!once!again!to!highlight!the!variability!within!the!AAV!+!ERT!combination!treatment!group,!multiple!sections! are! shown! to! illustrate! the! varying!degree! of! cortical! thickness.! c)!Histogram!presenting! the!mean!cortical! thickness! in! each! treatment! group! (untreated!wildTtype!mice! (WT),! untreated!Ppt1./%mice%(Ppt1./.),!
Ppt1./.%mice! treated!with!AAV!only! (AAV),!ERT!only! (ERT)!and!AAV!+!ERT!(A+E),! (n!=!4! for!each!group).!No!significant!effects!were!observed!between!treatments!at!5!months!of!age,!but!a!trend!towards!reduced!cortical!thickness!was! observed! in! untreated!Ppt1./.! and!AAV!+!ERT!onlyTtreated!mice,!whereas!wildTtype! and!AAV!onlyTtreated!mice!were!of! a! similar! greater! thickness.!d)!Histogram!showing! the!mean! cortical! thickness! in!each! treatment!group!(untreated!wildTtype!mice! (WT)!n!=!5,!untreated!Ppt1./%mice%(PPT),!n!=!5,!Ppt1./.%mice!treated!with!AAVTonly!(AAV)!n!=!4,!ERT!only!(ERT)!n!=!4!and!AAV!+!ERT!combination!(A+E)!n!=!3.!Significant!differences!were!observed!between!the!groups.!The!cortical!thicknesses!of!Ppt1./.%and!ERTTonly!treated!mice!were!significantly! lower!than!wildTtype!and!AAV!onlyTtreated!mice!(p**%=%0.0061!and!0.0024!for!wildTtype!vs.!




StereoInvestigator! software! to! measure! the! thickness! of! the! S1BF! across! all! the!treatment! groups! at! 5! and! 7! months! of! age,! having! defined! the! anatomical!boundaries! of! S1BF! in! Nissl! stained! sections! using! the! Paxinos! and! Franklin’s!(2001)!atlas.!
!
a)! There(are(no(differences(in(cortical(thinning(between(the(treatments(
groups(at(5(months(There! were! no! significant! differences! in! cortical! thickness! between! any! of! the!treatment!groups!at!5!months!of!age!(Figure(67.(a(and!c).!As!previously!reported,!the! thinning! of! the! S1BF! that! is! characteristic! of!murine! CLN1! disease! does! not!become! significant! until! 7! months! of! age,! but! is! present! to! a! lesser! extent! at! 5!months! (Kielar!et%al.,%2007;!Bible!et%al.,%2004)! (Figure(67.(a! T!d).!Consistent!with!this,!at!5!months!of!age,!the!S1BF!in!Ppt1./.%mice!was!only!slightly!thinner!than!in!wildTtype! mice! and! no! significant! differences! were! present! between! any! of! the!treatment! groups! (Kielar! et% al.,%2007;! Bible! et% al.,%2004)! (Figure( 67.( a( and! c).!Nevertheless,! despite! this! modest! difference! between! genotypes,! AAV2/9TPPT1Ttreated!mutant!mice!showed!a!trend!towards!improved!S1BF!thickness,!such!that!it!was! very! similar! to! values! in! unaffected!wildTtype!mice.! (Figure(67.(a(and!c).!Although!our!collaborators!are!generating!a!group!of!mice!treated!with!ERT!only!with! a! 5! month! survival! time,! technical! problems! prevented! them! from! being!available!at!the!time!of!study!and!therefore,!as!will!be!the!case!for!all!parameters!tested! in! this! chapter,! the! effects! of! ERT! alone! on! the! Ppt1Tdeficient! CNS! at! 5!months! are! unknown.! Interestingly,! the! cortical! thickness! of! the! S1BF! in! mice!treated! with! a! combination! of! both! AAV2/9TPPT1! and! rhPPT1! was!indistinguishable! from! Ppt1./.%mice,! showing! that! this! treatment! had! no! positive!
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effect! (Figure(67.(a(and!c).! This! suggests! that! although!AAV!+!ERT! combination!therapy!does!not!make!cortical!thickness!worse!in!Ppt1./.mice,!the!positive!effects!of!AAV2/9TPPT1!are!reduced!when!combined!with!ERT!treatment.!
!
b)! AAV2/9Jmediated( gene( therapy( alone,( and( combined( AAV( +( ERT(
treatment(are(effective(at(reversing(cortical( thinning( in(Ppt1%/%'mice(at(7(




To!explore!these!effects!further,!we!set!out!to!investigate!the!cellular!basis!of!these!findings.! The! thalamocortical! system! is! a! particular! focus! of! neuropathological!changes! in! Ppt1Tdeficient! mice.! Successive! waves! of! astrocytosis! and! microglial!activation! precede! neuron! loss! that! occurs! first! within! the! thalamus! and! only!subsequently! in! the!corresponding!cortical! target! regions! (Kielar!et%al.,%2007).!As!such,! this! sequence! of! events! provide! a! wellTdefined! series! of! pathological! land!marks!for!judging!therapeutic!efficacy.!Therefore,!we!stained!sections!from!treated!and!untreated!mice!at!both!5!and!7!months!of!age!for!the!astrocyte!marker!GFAP,!microglial!marker!CD68!and!Nissl! stained!an!adjacent! series!of! sections! to!allow!estimates! of! neuron! number! to! be! made.! This! analysis! focused! on! the!somatosensory! relay! nuclei! (VPM/VPL),! and! its! target! cortical! region! (S1BF)!where!we!had!obtained!thickness!data!from.!
!





et% al.%2007).! In! order! to! investigate! the! effects! of! combining! AAV2/9Tmediated!gene!therapy!with!ERT!on!astrocytosis!and!microglial!activation!in!5!and!7!months!old!Ppt1−/−%mice,!we!immunostained!sections!from!mice!in!all!treatment!groups!for!the!astrocytic!marker!GFAP!and!the!microglial!marker!CD68!and!used!thresholding!image!analysis!to!quantify!the!expression!of!these!markers!within!the!S1BF!of!the!cortex! and! the! VPM/VPL! of! the! thalamus! and! compared! the! extent! of! glial!activation!between!each!treatment!group.!
!
a)! Combining( ERT( treatment(with( AAV2/9(mediated( gene( therapy( negates(
the( positive( effects( of( AAV2/9( treatment( on( GFAP( and( CD68(
immunoreactivity(in(the(S1BF(of(5(month(old(Ppt1−/−'mice.(Examination!of! the!S1BF!in!sections!stained!with!GFAP!and!CD68!at!5!months!of!age,!showed!that!consistent!with!previous!findings!(Macauley!et%al.,%2011;!Kielar!et%
al.,%2007;!Groh!et%al.,%2013),!wildTtype!control!mice!displayed!negligible!amounts!of!GFAP! and! CD68! immunoreactivity,! whereas! Ppt1./.%mice! showed! a! significantly!increased! amount! of! astrocytosis! (p%value!=!0.0238)! and! a! strong! trend! towards!increased!microglial!activation,!with!astrocyte!activation!being!more!pronounced!than!microglial!reactivity!(Figure(68.(a,(e(and(b,(f,(and(i,(j).!The!lack!of!significance!is! due! to! the! high! variability! in! the!AAV!+! ERT! combination! treatment! group! as!running!the!statistical!analysis!without!this!combined!treatment!group!reveals!an!
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expected!significant!increase!in!CD68!staining!in!the!S1BF!of!untreated!Ppt1./.!mice!
vs.!wildTtype!mice!(data!not!shown,!see(Appendices(5.1.!When!comparing!each!of!the! treatment! groups! to! untreated! Ppt1./.%mice,! AAV2/9Tmediated! gene! therapy!appeared! to! reduce! astrocytosis! by! about! half,! while! microglial! activation! was!reduced! by! about! a! third,! although! neither! of! these! changes! were! statistically!significant! (Figure(68.(c,(g(and! i,( j).!Again,! running! the! statistical! analysis! in! the!absence! of! the! AAV! +! ERT! combination! treatment! group! however,! revealed!significant! differences! in! the! level! of! CD68! staining! between! untreated! and!AAV!only! treated!Ppt1./.%mice! and! there!was! also! a! significant,! but! smaller! difference!between!wildTtype!mice! and!AAV! onlyTtreated!Ppt1./.%mice! (data! not! shown,! see!





































































Ppt1−/−&mice)CLN1!is!a!progressive!disease!and!as!such,!neuroinflammation!is!more!pronounced!at!7!months!in!Ppt1%/%'mice!(Kielar!et!al.,!2007),!allowing!us!to!determine!whether!the!effects!of!each!therapy!persisted!within!older,!more!severely!affected!mutant!mice.!To!do!this,!we!examined!the!S1BF!in!sections!stained!for!GFAP!and!CD68!in!mice! at! 7! months! of! age! across! all! treatment! groups.! Importantly,! unlike! the!younger! cohort! of!mice,! a! group! of!Ppt1%/%'mice! treated!with!ERT! alone!was! this!time!available!at!7!months!of!age.!The!addition!of!this!group!allowed!us!to!better!determine! how! individual! effects! following! AAVTmediated! gene! therapy! or! ERT!treatment,!might! interact! to!give! rise! to!any!combinatorial!effects!when! they!are!administered! together.! As! expected,! wildTtype! control! mice! continue! to! display!minimal!amounts!of!GFAP!and!CD68!immunoreactivity!compared!to!Ppt1%/%'mice!at!7!months!of!age,!this!was!significant!for!both!GFAP!and!CD68!immunoreactivity!(p'value!0.0163! and!p'value!<0.0001,! respectively)! and! compared! to! younger!mice,!was!even!more!pronounced!(Figure)69.)a,)f)and)b,)g)and!k,)l).!At!7!months!of!age,!although! astrocytosis! was! still! greater! than!microglial! activation,! this! difference!was! less! pronounced! than! the! change! in! microglial! activation! between! 5! and! 7!months,!which!was!much!greater!than!for!astrocytosis!(already!quite!pronounced!at! 5!month)! (section)3.2.a).! Similar! to! our! findings! at! 5!months!of! age! (section)
3.2.a),! ! AAV2/9Tmediated! gene! therapy! appeared! to! nonTsignificantly! reduce!astrocytosis!by!about!a!third,!while!microglial!activation!was!significantly!reduced!by!about!a!fifth!(p'value!0.0005)!when!compared!to!untreated!Ppt1%/%'mice'(Figure)
69.)b,)g)and!c,)h)and!k,)l).!!
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These! findings! indicate! that! at! both! 5! and! 7! months,! AAV2/9Tmediated! gene!therapy!has!a!greater!impact!on!preventing!microglial!activation!than!astrocytosis,!and! overall! appears! to! slow! disease! progression.! Furthermore,! astrocytosis! and!microglial!activation! in! the!S1BF!at!7!months!of!age!were!no! longer!significantly!different! to! wildTtype! mice! (Figure) 69.) k) and! l).! As! expected,! GFAP! and! CD68!immunoreactivity! in! ERT! onlyTtreated! 7! month! old! mutant! mice! was! almost!indistinguishable!from!the!levels!seen!in!untreated!Ppt1%/%'mice!at!this!age!(Figure)
69.) b,) g) and! d,) i) and! k,) l).! Like! untreated! Ppt1%/%'mice! at! 7! months! of! age,!astrocytosis!and!microglial!activation!was!significantly!higher!in!7!month!old!Ppt1%
/%'that! received! ERT! onlyTtreatment! compared! to! ageTmatched!wildTtype!mice! (p'value!=!0.0193!and!<!0.0001,!respectively)!(Figure)69.)a,)f)and!d,)i)and!k,)l).!Given!the! capacity! of! AAVTmediated! gene! therapy! to! reduce! microglial! activation! to!almost! the!same! level!as! in!wildTtype!mice,!CD68! immunoreactivity! in!ERT!onlyTtreated!Ppt1%/%'mice!was!also!significantly!greater!than!in!AAVTtreated!Ppt1%/%'mice!(p'value!0.0004)!(Figure)69.)l).!These!findings!suggest!that,!ERT!treatment!alone!has!no!effect!on!these!neuropathological!hallmarks!of!disease!in!older!mice.!As!ERT!by! itself!appears! to!have!no!effect!on!astrocyte!activation!or!microglial!reactivity!within! the! brain,! it!might! be! expected! that! combining! ERT! treatment!with!AAVTmediated! gene! therapy! would! have! no! effect! resulting! in! a! similar! reduction! in!GFAP! and! CD68! immunoreactivity! as! was! achieved! with! AAVTmediated! gene!therapy! alone.! Perhaps! it! might! also! be! sensible! to! expect! a! similar! moderate!worsening!of! combined!AAV!+!ERT! treatment!upon! these!markers! as!we! saw! in!combination!treated!animals!at!5!months!of!age!(section)3.2.a,)Figure)68.)d,!h)and!
i,)j).!However,!when!we!analyzed!tissue!from!7!month!old!AAV!+!ERT!combination!treated!mice,!there!was!a!dramatic!increase!in!the!level!of!GFAP!immunoreactivity!in!the!S1BF,!which!was!about!75%!higher!than!in!7!month!old!Ppt1%/%'mice!treated!
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with!AAVTmediated!gene!therapy!alone!(p'value!0.0040)!and!almost!twice!that!of!7!month! old! untreated! Ppt1%/%'or! ERT! onlyTtreated! Ppt1%/%'mice,! with! the! level! of!astrocytosis!compared!to!unaffected!wildTtype!mice,!much!greater!than!these!two!groups!(p'value!0.0003)!(Figure)69.)a)5)e)and!k).!Although!the!effect!of!AAV!+!ERT!combination!therapy!on!microglial!activation!was!not!as!dramatic!as! its!effect!on!astrocytosis,! we! found! that! consistent! with! our! findings! at! 5! months! of! age!(section3.2.a,! Figure) 68.) h) and! j),! CD68! immunoreactivity! in! AAV! +! ERT!combinationTtreated!mice!was!almost!five!times!greater!than!the!level!in!AAV!onlyTtreated!mice,!and!almost!as!high!as!in!7!month!old!untreated!Ppt1%/%'mice,!and!this!increase!was!statistically!significant!(p'value!0.0075)!(Figure)69.)g,)h)and)j)and!l).!Unsurprisingly,!with! this! contrasting!effect!on!microglial! activation! following! the!addition! of! ERT! to! AAVTmediated! gene! therapy,! CD68! immunoreactivity! in!combinationTtreated! animals! at! 7!months! of! age!was! statistically! higher! than! in!wildTtype!mice!(p'value!0.0017)!like!in!7!month!old!untreated!Ppt1%/%'mice!(Figure)













































































c)! Combining* ERT* treatment*with* AAV2/99mediated* gene* therapy* negates*
the* positive* effects* of* AAV2/9* treatment* on* GFAP* and* CD68*
immunoreactivity*in*the*VPM/VPL*of*5*month*old*Ppt1−/−&mice*CLN1!disease!progresses!rapidly,!quickly!incorporating!more!and!more!regions!of!the!brain!with!devastating!consequences!(Haltia!et#al.,#1973a,!1973b;!Santavuori!et#
al.,#1973;!Bible!et#al.,#2004).!In!order!for!a!therapy!to!be!effective,!it!must!be!able!to!correct!or!prevent!pathology!in!the!most!severely!(if!not!all)!affected!areas.!In!Ppt1+
/+#mice,!glial!changes!within!the!cortex!occur!at!approximately!the!same!time!as!the!thalamus,! but! in! contrast,! astrocytosis! and! microglial! activation! within! the!thalamus!are!more!pronounced!and!localized!to!specific!nuclei!(Kielar!et#al.,#2007).!Like!S1BF! in! the!cortex,! its! corresponding!somatosensory! thalamic! relay!nucleus!VPM/VPL!is!one!of!the!most!affected!nuclei!within!the!thalamus!(Bible!et#al.,#2004;!Jalanko! et# al.,# 2005;! Kieler! et# al.,# 2007;! Macauley! et# al.,# 2011).! Therefore,! to!investigate! the! impact! of! each! therapy! within! this! region! and! find! out! whether!these!effects!were!similar!to!those!within!the!S1BF,!we!measured!GFAP!and!CD68!immunoreactivity! within! the! VPM/VPL! across! all! treatment! groups! in! 5! and! 7!month!old!mice.!
!
Analysis!of!the!VPM/VPL!in!sections!stained!with!GFAP!and!CD68!at!5!months!of!age!showed!that,!consistent!with!our!findings!within!the!S1BF!(Figure*68.*a,*e*and!
b,!f*and!i,!j),!wild\type!control!mice!showed!only!very!low!levels!of!GFAP!and!CD68!immunoreactivity! while! in! contrast,! untreated! Ppt1+/+#mice! at! this! age! displayed!markedly!increased!amounts!of!both!astrocytosis!(p#value!0.0013),!and!microglial!activation! (p# value! 0.0076)! with! microglial! reactivity! being! less! pronounced!(Figure*70.*a,!e*and!b,* f*and! i,* j).!Consistent!with!previous! reports! (Kielar!et#al.,#
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(Figure'70.'a,!b!and!d'and!e,!f'and!h'and!i!and!j).!As!mentioned!previously,!no!ERT<treated!Ppt1%/%'mice!were!available! for! comparison!at! this! age,! but! like! the!S1BF,!the! additional! administration! of! ERT! appeared! to! have! a! negative! impact! on! the!ability! of! AAV2/9<mediated! gene! therapy! to! rescue! astrocytosis! and! microglial!activation!within!the!VPM/VPL.!Overall,!the!outcome!of!combination!therapy!was!not! greatly! influenced! by! the! severity! of! the! disease! milieu,! it! was! ineffective!regardless! of! the! amount! of! astrocytosis! or! microglial! activation,! and! AAV<mediated!gene!therapy!was!less!effective!within!the!thalamus.!!
!
d)! Combining'ERT'with'AAV2/9@mediated'gene'therapy'worsens'the'effects'
upon'GFAP'and'CD68' immunoreactivity' in' the'VPM/VPL'of'7'month'old'
Ppt1−/−&mice'Neuroinflammation! is! more! pronounced! in! the! VPM/VPL! than! in! the! S1BF! of!untreated! Ppt1%/%! mice! at! 5! months! of! age! (Kielar! et! al.,! 2007),! and! while! AAV<mediated! gene! therapy! appears! to! be!more! effective! in! the! S1BF! (section3.2.a,!
Figure'68.'b,!f'and!c,'g'and!i,!j),!combination!treatment!is!consistently!ineffective!in!both!brain!regions.!At!7!months!of!age,!astrocytosis!and!microglial!activation!in!the!S1BF! increases,!yet! the!preventative!action!of!AAV<mediated!gene! transfer! is!more!effective!and! combination! treatment! continues! to!be!negative!by! reversing!these!positive!effects!(Section'3.2.b,!Figure'69).!!
!
Therefore,! to! evaluate! how! each! therapy! (including! ERT! alone)! impacts! on!astrocytosis!and!microglial!activation!within!the!more!severely!affected!VPM/VPL!at!a!more!advanced!stage!of!disease,!we!examined!the!VPM/VPL!in!sections!stained!
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for!GFAP!and!CD68!at!7!months!of!age!across!all!treatment!groups.! !As!expected,!wild<type! control! mice! showed! negligible! amounts! of! GFAP! and! CD68!immunoreactivity!at!this!age,!while!7!month!old!Ppt1%/%'mice!displayed!significantly!increased!amounts!of!both!astrocytosis!(p'value!0.0137)!and!microglial!activation!(p'value!<!0.0001)! (Figure'71'a,' f'and!b,'g'and!k,! l).! Interestingly,! the!degree!of!astrocytosis! within! the! VPM/VPL! in! Ppt1%/%'mice! at! 7! months! of! age! was! quite!similar!to!that!seen!at!5!months!of!age,!whereas!the!level!of!microglial!activation!was!approximately!twice!as!much!at!7!months!compared!to!the!level!at!5!months!and!on!par!with!the!amount!of!astrocytosis!(Figure'70.'b,'f'and!i,'j'and!Figure'71.'
b,'g'and!k,'l).!These!data!suggest!that!astrocyte!activation!within!the!thalamus!of!Ppt1<deficient!mice!may! begin! to! plateau! at! 7!months.! Given! these! findings,! the!VPM/VPL! at! 7!months! potentially! represents! the!most! pronounced! pathological!environment,! and! thus! the! most! difficult! therapeutic! challenge! to! prevent! this!pathology!from!developing.!To!find!out!how!the!different!treatments!were!capable!of! meeting! this! challenge,! we! compared! each! treatment! group! to! untreated! 7!month! old! Ppt1%/%' mice.! While! the! amount! of! GFAP! immunoreactivity! in! the!VPM/VPL! of! 7! month! old! AAV! only<treated! mice! was! similar! to! the! level! in!untreated!Ppt1%/%'mice!of!the!same!age,!the!amount!of!CD68!immunoreactivity!was!significantly! lower' (p' value! 0.0002)! (Figure' 71.' b,' g' and! c,' h' and! k,! l).! AAV<mediated!gene!therapy!appeared!to!be!mostly!ineffective!at!reducing!astrocytosis!in! the! thalamus! at! this! age! (Figure' 71.' b,! c' and! k),! but! was! able! to! reduce!microglial!activation!to!about!a! fifth!of! the! level! in!age<matched!untreated!Ppt1%/%'mice,!almost!bringing!it!down!to!the!same!amount!in!unaffected!wild<type!mice!of!the!same!age,!with!no!significant!difference!between!the!two!(Figure'71.'f'<!h'and!
l).!Intriguingly,!this!was!similar!to!the!effect!of!AAV<mediated!gene!therapy!in!the!VPM/VPL! of! 5! month! old! mice,! where! AAV! only! treatment! had! little! effect! on!
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astrocytosis,! but! did! have! a! larger! effect! on!microglial! activation! (section'3.2.c,!
Figure'70.'a,!e'and!c,!g'and!k,! l),!suggesting!that!astrocytosis! in!the!VPM/VPL!at!both! ages! is! especially! difficult! to! prevent.! In! the! S1BF,! AAV2/9<mediated! gene!therapy! appeared! to! be! more! effective! at! 7! months! post<treatment! than! at! 5!months,! and! as! was! evident! in! VPM/VPL,! the! protective! effects! upon!microglial!reactivity! in! the! cortex! were! more! pronounced! later! in! the! disease.! When! we!assessed!the!VPM/VPL!in!ERT!only<treated!mice!of!7!months!of!age,!we!found!that!GFAP!and!CD68! immunoreactivity!was!either! indistinguishable! (CD68),!or!worse!(GFAP)!than!in!untreated!Ppt1%/%'mice,!and!was!also!significantly!greater!than!wild<type!mice!(p'value!0.0006!and!<!0.0001,!respectively)!(Figure'71.'a,!f!and!b,!g!and!
























































































Figure' 72.' Successful' combination' treatment.' Representative' images' of' instances' in' which'
adeno<associated' virus' (AAV)' +' enzyme' replacement' therapy' (ERT)' combination' treatment'
was'able'to'reduce'the'amount'of'glial'fibrillary'protein'(GFAP)'and'cluster'differentiation'68'
(CD68)' immunoreactivity' compared' to' untreated' wild<type' and' untreated' Ppt1<deficient'
(Ppt1%/%)'mice'(greatest'effects'shown'here).!AAV!+!ERT!combination!treatment!was!most!effective!at!reducing!GFAP!and!CD68!immunoreactivity!within!the!primary!somatosensory!barrel!field!cortex!(S1BF)! at! 5! months! of! age,! and! similarly! effective! within! the! ventral! posteromedial/ventral!posterolateral!(VPM/VPL)!nuclei!of!the!thalamus!at!5!months!of!age!and!the!S1BF!at!7!months!of!age.!However,! although! a! reduction! in! GFAP! and! CD68! immunoreactivity! was! also! observed! in! the!VPM/VPL! at! 7! months! of! age,! it! was! comparatively! less! evident! indicating! the! limitations! of! this!therapy!even!in!the!best!case!scenario.!Scale!bar!in!x10!images!(main)!=!100!µm.!
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GFAP! immunoreactivity!was!significantly!greater! than!unaffected!wildVtype!mice,!(p" value! 0.0002),! further! demonstrating! that! combination! treatment! has! no!positive!effect!on!reducing!astrocytosis!(Figure'71.'a,!b!and!e'and!k).!The!amount!of! CD68! immunoreactivity! in!AAV!+!ERT! combinationVtreated!mice! compared! to!untreated!Ppt1&/&"mice!was!only!marginally! lower!and!therefore,!also!significantly!much! higher! than! in! wildVtype! control! mice! (p"value! 0.0003)! and! AAVVtreated!
Ppt1&/&"mice! (p"value! 0.0044)! (Figure' 71.' f,' g' and! j' and! l).! These! findings! were!consistent!with!our!results!in!the!S1BF!at!7!months,!suggesting!that!although!ERT!essentially!has!no!effect!on!glial!activation!when!administered!in!combination!with!AAVVmediated!gene!therapy,!it!not!only!negates!gene!therapy’s!positive!effects!on!neuroinflammation!in!these!regions!but!may!actually!exacerbate!it.!!
!
e)! The'impact'of'the'severity'of'CLN1'disease<associated'neuroinflammation'
on'the'outcome'of'treatment''Consistent! with! previous! studies! (Kielar! et" al.,"2007),! our! data! has! shown! that!neuroinflammation! varies! in! its! severity! depending! on! the! region! and! stage! of!disease.! Based! on! our! observations,! astrocytosis! and! microglial! activation! is!greatest!within!the!VPM/VPL!at!7!months!of!age,!then!the!VPM/VPL!at!5!months!of!age,! the! S1BF! at! 7! months! of! age! and! the! least! amount! of! glial! activation! was!observed! in! the! S1BF! at! 5! months! of! age.! A! summary! of! the! impact! of! each!treatment! on! astrocytosis! and! microglial! activation! is! provided! in! Figure' 73.'Overall,! the! efficacy! of! AAV2/9Vmediated! gene! therapy! varied! depending! on! the!region!and!stage!of!disease,!but!generally!had!a!positive! impact! in! reducing!glial!activation,!consistent!with!previous!findings!using!other!AAV!serotypes!(reviewed!in!Hobert!and!Dawson,!2006;!Platt!and!Lachmann,!2009!and!HawkinsVSalbury!et"
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al.,"2013).! In! contrast,! ERT! treatment! alone!had! largely! no! effect! on! astrocytosis!and!microglial! activation!within! the! S1BF! or! VPM/VPL! at! 5! or! 7!months! of! age.!Most! interestingly,! AAV! +! ERT! combination! therapy! resulted! in! equivalent! or!greater!amounts!of!glial!activation!than! in!untreated!Ppt1&/&"mice,!suggesting! that!the!addition!of!ERT!not!only!has!no!additive!affects,!but! in! some!way!blocks! the!action! of! AAVVmediated! gene! therapy,! or! makes! it! worse! and/or! less! effective.!However,!it!is!extremely!important!to!take!into!account!the!variability!within!this!group.!Indeed,!the!sum!of!our!data!suggests!that!AAV!+!ERT!combination!treatment!is!less!effective!at!attenuating!neuroinflammation!compared!to!AAV2/9Vmediated!gene! therapy! alone.!However,! as! shown! in!Figure'72,! there!were! some! cases! in!which!the!combination!of!AAV2/6Vmediated!gene!therapy!and!ERT!was!in!fact!very!effective!at!reducing!astrocytosis!and!microglial!activation!(Figure'72.'c,'i'and!f,'l),!making! it! difficult! to! clearly! determine! its! overall! effects.! In! the! absence! of! a!consistent! outcome! for! this! combination! treatment! group,! we! cannot! conclude!whether!the!treatment!a)!was!administered!successfully!(without!infection)!or!b)!had!any!deleterious!effect!as!will!be!further!discussed!in!section'4'of!this!chapter.!!
!
! AAV'+'ERT'combination'treatment'has'limited'or'partially'adverse'















al.,"2010,! 2015;! Palmer! et" al.,"2013).! The! loss! of! these! thalamic! relay! neurons!occurs! several! months! before! the! loss! of! their! target! neurons! or! interneurons!within! the! cortex! and! this! is! accompanied! by!microglial! activation! (Kielar! et"al.,"2007),! which! is! considered! to! be! a! sensitive! marker! of! neuronal! dysfunction!(Raivich!et"al.,"1999).!This!loss!of!neurons!contributes!to!brain!atrophy!and!may!be!
Figure'73.'Schematic'representation'of'the'overall'treatment'effects.'Glial'fibrillary'protein'(GFAP)<
positive' astrocytes' and' cluster' of' differentiation' 68' (CD68)<positive' microglia' are' depicted'
pictorially.! The!number!of! astrocytes! and!microglia!within! each! region! at! each! age! (left! and! right! side!panels)!corresponds!to!the!relative!levels!of!astrocytosis!and!microglial!activation!in!untreated!Ppt1&/&"mice.!The! purple,! green! and! yellow! symbols! represent! AAV! only,! ERT! only! and! AAV! +! ERT! combination!treatments,! respectively! (as!depicted! in! the! corresponding! graphs! in!previous! figures).!Arrows!pointing!down! illustrate! a! reduction! in! astrocytosis! or!microglial! activation! and! arrows! pointed! up! represent! a!increase!in!astrocytosis!or!microglial!activation.!The!width!of!the!arrow!symbolises!the!relative!degree!to!which! these! increases! or! decreases! occurred.!Where! a! cross! is! depicted,! the! amount! of! astrocytosis! or!microglial!activation!remained!approximately!the!same.'
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partly! responsible! for! the! neurological! behavioural! phenotypes! displayed! in!human!and!murine!CLN1!disease.!Therefore,!whilst!glial!activation!is!useful!to!our!understanding! of! the! pathological! events! that! lead! to! neuron! loss,! and! therefore!represents!a!potentially!effective! therapeutic! target,! the! loss!of!neurons! is!key!to!disease! and! therefore,! effective! therapies!must! ultimately! be! able! to! circumvent!this! loss.! This! is! challenging,! given! the! near! complete! loss! of! cortical! neurons! at!autopsy!(Haltia!et"al.,"1973a,!b).!Using!cortical!thickness,!silver!staining!and!motor!performance!as! an! indication!of!neuron! loss,! numerous! studies!have! shown! that!AAVVmediated! gene! therapy! in!Ppt1&/&!mice"is! able! to! rescue! the! loss! of! neurons!quite!successfully,!but!ultimately!this!is!unsuccessful!as!mice!still!die!prematurely!(Griffey! et" al.," 2006;! Roberts! et" al.," 2012;! Macauley! et" al.," 2012).! Early!administration! of! ERT! has! been! shown! to! slow! the! progression! of! motor!dysfunction,! indicating! that! it! may! help! conserve! neuronal! populations! if! the!exogenously! supplied! enzyme! can! gain! access! to! the! brain! (Hu! et"al.,"2012).! To!directly! investigate! the! effects! of! combining! these! two! treatments! on! neuronal!survival,!we!used!unbiased! optical! fractionator! estimates! of! the! number! of!Nissl!stained!neurons!within!the!VPM/VPL!and!S1BF!across!all!the!treatment!groups!at!5!and!7!months!of!age.!!
!
The! pattern! of! neuron! loss! within! the! thalamocortical! system! has! been! well!defined!in!relation!to!the!glial!changes!previously!described!(section'3.2)!(Bible!et"
al.,"2004;! Kielar! et" al.,"2007).! Concentrating! on! the! VPM/VPL,! which! we! know!displays!prominent!astrocytosis!relatively!early!on!in!disease!(Kielar!et"al.,"2007),!neuron!loss!becomes!significant!at!5!months!of!age!and!gets!progressively!worse.!This!loss!of!neurons!within!the!VPM/VPL!and!other!thalamic!sensory!relay!nuclei!
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occurs! before! the! loss! of! neurons! in! corresponding! target! regions! within! the!sensory! cortex! (Kielar! el" al.,"2007).! As! such,! these! cortical! regions! are! affected!differently! according! to! when! their! afferent! thalamic! neuron! populations!degenerate,! giving! rise! to! regional! differences.! There! are! also! differences! in! the!order!in!which!specific!types!of!neurons!are!lost!within!each!lamina!(Griffey!et"al.,"2004).! Generally! the! loss! of! thalamic! relay! neurons! precedes! the! loss! of!interneuron! populations! leading! to! the! subsequent! loss! of! their! corresponding!target!granule!neurons,!and!the!eventual!loss!of!other!cortical!neuronal!cell!types!(Kielar!et"al.,"2007).!Focusing!on!the!S1BF,!the!first!signs!of!neuronal!loss!occurs!in!lamina! IV! at! 5! months! with! the! loss! of! parvalbuminVpositive! GABAergic!interneurons,! then!by!7!months!granule!neurons!are! lost! in! lamina! IV!as!well! as!pyramidal! neurons! in! lamina!V! (Kielar!et"al.,"2007).!Given! their! large! cell! bodies!and! distinct! morphology,! we! decided! to! concentrate! on! counting! pyramidal!neurons! in! lamina! V! of! the! S1BF.! However,! at! 5! months! of! age,! there! is! little!difference! between! Ppt1&/&" mice! and! wildVtype! mice! within! this! region! (as!confirmed!by!our!cortical!thickness!data,!section'3.1),!unlike!the!VPM/VPL!which!already!shows!significant!differences.!Therefore,!we!only!counted!neurons! in! the!VPM/VPL!only!at!5!months,!but!also!assessed!neuron!number! in! lamina!V!of! the!S1BF!at!7!months,!in!addition!to!VPM/VPL.!!
!
a)! Neuron'loss'in'the'VPM/VPL'of'5'month'old'Ppt1−/−(mice'is'only'partially'
prevented' by' both' AAV2/9' mediated' gene' therapy' alone' and' in'
combination'with'ERT.'Consistent!with!the!findings!described!in!section'3.2.'c,!this!analysis!showed!that!compared! to! unaffected! wildVtype! control! mice,! there! was! a! dramatic! and!
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significant!reduction!in!the!number!of!VPM/VPL!neurons!in!untreated!Ppt1&/&"mice!at!5!months!of!age!by!58%!(p"value!0.0163)!(Figure'74.'a).!To!find!out!if!any!of!the!treatments!were! effective! in! preventing! this! pathology,!we! analysed! each! of! the!groups!and!compared!them!to!the!untreated!Ppt1&/&"mice!at!this!age.!Upon!analysis!of! AAV! onlyVtreated!Ppt1&/&"mice,!we! found! that! just! AAV! treatment! by! itself!was!only!partly!effective!at!preventing!neuron!loss!in!the!VPM/VPL!at!5!months.!These!mice!had!44%!more!neurons!compared!to!ageVmatched!untreated!Ppt1&/&"mice,!and!this!difference!was!not!significant!(Figure'74.'a).!As!already!mentioned,!a!group!of!mice!treated!with!ERT!only!was!not!available!at!the!time!of!the!study,!however,!to!evaluate! whether! combining! ERT! with! AAV2/9Vmediated! gene! therapy! had! any!impact!on! the!number!of!neurons! rescued!by!AAVVmediated!gene! therapy!alone,!we! analysed! combinationVtreated! Ppt1&/&"mice! at! 5! months! of! age.! Combination!therapy! also! showed! a! trend! towards! being! able! to! rescue! neurons,! however,!compared! to!AAV!onlyVtreated!Ppt1&/&"mice,!AAV!+!ERT!combinationVtreated!mice!had! only! 28%! more! neurons! compared! to! ageVmatched! untreated! Ppt1&/&"mice!(Figure'74.'a).!Therefore,!whilst!ERT!does!not!improve!the!ability!of!AAV!to!rescue!neurons,! both! AAV! and! AAV! +! ERT! combination! treatment! may! be! only! partly!beneficial!in!the!VPM/VPL!at!5!months.'
!
b)! Combining'ERT'with'AAV2/9<mediated'gene'therapy'does'not'improve'its'
ability' to' prevent' neuron' loss' in' the' VPM/VPL' of' 7' month' old' Ppt1−/−(


























































examined!Nissl!stained!sections!from!mice!at!7!months!of!age,!when!neuron!loss!is!markedly! worse! (Kielar! et! al.,! 2007).! Importantly,! an! ERT! only! group! was! also!available! at! this! time! point,! allowing! us! to! better! understand! the!mechanism!by!which!combination!therapy!might!exert! its!effects.!The!number!of!neurons!in!the!VPM/VPL!compared!to!unaffected!wildMtype!control!mice!at!7!months!of!age!was!significantly!lower!(p"value!<!0.0001)!(Figure'74.'b).!Characteristic!of!the!pattern!of!disease!progression!in!CLN1!disease,!this!neuron!loss!was!much!greater!than!at!5!months!of!age,!with!76%!fewer!neurons!in!contrast!to!58%,!fewer!neurons!at!5!months! (Figure' 74.' a).! When! we! analysed! AAV! onlyMtreated! Ppt1&/&"mice! at! 7!months!of! age,!we! found! that! approximately!half! of! these!neurons!were! rescued!with!significantly!more!VPM/VPL!neurons!in!AAV!onlyMtreated!mice!compared!to!untreated!Ppt1&/&"mice!at!this!age!(p"value!0.0465),!but!significantly!fewer!neurons!compared!to!unaffected!wildMtype!mice!(p"value!<!0.0001)!(Figure'74.'b).!This!was!interesting! given! the! modest! effects! of! AAV! only! treatment! at! 5! months! of! age!(section'3.2.'c,!Figure'70.'c,!g'and!i,'j).!When!we!analysed!ERTMonly!treated!mice!we! discovered! that! ERT! had! effectively! no! impact! on! thalamic! neuron! loss,! the!number!of!neurons!in!the!VPM/VPL!of!ERT!onlyMtreated!Ppt1&/&"mice!and!untreated!
Ppt1&/&"mice! was! almost! indistinguishable,! with! similarly! 72%! fewer! neurons!compared! to!wildMtype!mice,!p"value!<!0.0001! (Figure'74.'b).!This!data!was!not!surprising! based! on! previous! studies! which! show! that! neuropathology! in!untreated!Ppt1&/&"mice!is!only!responsive!to!exogenously!administered!PPT1!during!the!first!few!weeks!of!life,!but!that!these!effects!were!diminished!by!7!months!(Hu!
et"al.,"2012).!Interestingly,!when!we!analyzed!the!VPM/VPL!in!combinationMtreated!mice!at!7!months!of!age!we!found!that!there!was!no!significant!difference!between!untreated! Ppt1&/&"mice! and! combinationMtreated! mice! at! this! age! (Figure' 74.' b).!Therefore,! the! ability! of!AAVMmediated! gene! therapy! to!partially! prevent! neuron!
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loss!was!almost!completely!reversed!by!the!addition!of!ERT.!Like!ERT!onlyMtreated!mice,! the! number! of! neurons! in! the! VPM/VPL! of! combinationMtreated!mice! at! 7!months! of! age! was! similar! to! untreated! Ppt1&/&"mice,! with! 67%! fewer! neurons!compared!to!wildMtype!control!mice!(p"value!<!0.0001)!(Figure'74.'b).!!
!
c)! Combining'ERT'with'AAV2/9Cmediated'gene'therapy'does'not'improve'its'
ability'to'prevent'neuron'loss'in'the'S1BF'of'7'month'old'Ppt1−/−&mice.'As!outlined!at!the!beginning!of!this!section,!relay!neurons!are!lost!in!the!VPM/VPL!before!the!loss!of!cortical!neurons!within!S1BF,!but!by!7!months!of!age!this!loss!is!apparent! in! both! regions! (Kielar! et! al.,! 2007).! In! this! way,! analyzing! the! S1BF!served!two!purposes;!first!it!allowed!us!to!evaluate!the!more!subtle!effects!of!each!therapy,!since!pathology!is!not!as!pronounced!as!in!the!VPM/VPL.!Secondly,!it!also!allowed! us! to! collect! evidence! for! any! possible! ‘knockMon’! effects! of! therapeutic!effects! in! the!VPM/VPL!upon! the!S1BF.! In!addition,!by!directly!counting!neurons!within!the!S1BF,!we!were!able!to!determine!if!there!was!a!correlation!between!the!impact!of!each!therapy!on!neuronal!loss!and!cortical!thickness.!As!anticipated,!we!detected!a!significant!difference!between!the!number!of!neurons!within!the!S1BF!of!unaffected!wildMtype!mice!and!untreated!Ppt1&/&"mice,!with!26%!fewer!neurons!in!7!month!old!untreated!Ppt1&/&"mice!compared!to!the!wildMtype!controls!(p"value!0.0483)! (Figure'74.' c).! As! expected,! this! cortical! neuron! loss!was! less! dramatic!than! within! the! VPM/VPL! at! 7! months,! which! showed! a! reduction! of! 76%.!Strikingly,! this!was! almost! completely! reversed! in!AAVMonly! treated!mice! at! this!age! (Figure' 74.' c).! These! mice! had! almost! the! same! number! of! neurons! as!unaffected! wildMtype! mice,! although! no! significant! difference! was! detected!compared!to!untreated!Ppt1&/&"mice!(this!group!had!slightly!less!statistical!power,!n!
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=!4!vs.!n!=!5).!These!results!showed!that!AAV2/9Mmediated!gene!therapy!was!able!to!prevent!proportionally!more!neuron!loss!in!the!S1BF!at!7!months!of!age!than!in!the!more!severely!affected!VPM/VPL!(Figure'74.'b).!This!is!likely!to!have!been!the!combined! result! of! AAV2/9Mmediated! gene! therapy! partially! preventing! neuron!loss!in!the!VPM/VPL!earlier!in!the!disease,!thus!mitigating!the!subsequent!loss!of!neurons! in! the!S1BF,!and!perhaps!directly!preventing!neuron! loss! in! the!S1BF! in!the! later! stages! of! disease.! Predictably,! ERTMtreatment! alone! had! no! such! effect!with!7!month!old!ERT!onlyMtreated!mice!displaying!similar!neuronal! loss! to!ageMmatched!untreated!Ppt1&/&"mice!(Figure'74.'c).!As!was!the!case!in!the!VPM/VPL!at!7!months!of!age,!there!was!little!difference!in!neuron!number!between!ERT!+!AAV!combination!therapy!and!untreated!Ppt1&/&"mice,!at!this!age.!As!such,!the!number!of!neurons!was!significantly!lower!than!in!both!7!month!wildMtype!control!mice,!and!ageMmatched! AAVMtreated! Ppt1&/&"mice! (p"value! 0.0204! and! 0.0470,! respectively)!(Figure' 74.' c).! Therefore,! the! ability! of! AAVMmediated! gene! therapy! to! rescue!neuron!loss!was!almost!completely!reversed!by!the!addition!of!ERT!and!in!fact,!this!may!have!resulted!in!further!neuron!loss.!Overall,!the!data!collected!from!each!of!these! treatment!groups!was!consistent!with! the!corresponding!cortical! thickness!data!at!7!months!of!age!(section'3.1,'Figure'67.'b'and!d).!
!
d)! Understanding'the'relationship'between'neuron'loss'and'glial'activation'Overall,! analysis! of! the! somatosensory! thalamocortical! system! (S1BF! and!VPM/VPL)! following! treatment! with! AAV! only,! ERT! only! or! AAV! +! ERT!combination! treatment! indicate! that!while! AAV! only! treatment!was! consistently!effective! at! preventing! neuron! loss! in! untreated!Ppt1&/&"mice! (section' 3.3' a' C' c),!combining!it!with!ERT!was!hardly!any!more!beneficial!than!leaving!mice!untreated!
! 393!
altogether.! Whether! neuron! loss! is! the! result! of! glial! activation,! or! a! direct!consequence! of! enzyme!deficiency!within! the! neurons! themselves,! and!what! the!mechanism! is! by! which! AAV2/9Mmediated! gene! therapy! was! effective! (either!reducing!glial!activation,! simply!restoring!enzyme!activity,!or!directly!preventing!neuron! loss! in! some! other! way)! is! an! important! consideration.! Furthermore,!whether! the! inability! of! ERT! to! confer! additional! benefits! to! AAVMmediated!neuronal!survival!is!the!result!of!it!having!no!effect!at!all!(due!to!the!limited!ability!to!cross! the!BBB),!or!because! the!effects!are! limited!to!glial!activation! is!another!important!issue!to!resolve.!Therefore,!we!shall!now!consider!how!the!data!in!this!section! relates! to! the! previous! data! on! astrocytosis! and! microglial! activation!(section'3.2).!We!observed!a!correlation!between!the!ability!of!AAV!to!reduce!glial!activation!and!rescue!neurons!in!both!the!S1BF!and!VPM/VPL,!but!in!the!few!cases!where! astrocytosis! was! not! reduced! (e.g.! VPM/VPL! at! 5! month! and! 7! months),!there!were!still!positive,!albeit!relatively!smaller,!effects!on!neuronal!survival.!This!provides! evidence! for! other! mechanisms! that! lead! to! neuron! loss! such! as! early!synaptic! and! axonal! pathology! (Virmani! et" al.," 2005;! Kielar! et" al.," 2009),! and!indicates! that! wider! analysis,! e.g.! staining! sections! for! synaptic! markers! within!these! regions,!may!be! informative! for! considering! the!mechanism!by!which!AAV!exerts! its!positive!effects.!Generally,!AAV!+!ERT!combination! treatment!had! little!positive!effect!on!glial!activation!or!neuron!survival,!but!at!7!months!of!age,!these!combinationMtreated!mice!displayed! a! trend! towards! slightly! increased! astrocyte!activation,! yet! slightly! lower! levels! of!microglia! reactivity! in! both! the! S1BF! and!VPM/VPL,!yet!this!did!not!appear!to!impact!the!survival!of!neurons.!An!important!caveat!to!these!findings!with!regards!to!the!lack!of!efficacy!of!combination!therapy!is!the!high!degree!of!variability!within!this!treatment!group.!Given!the!fact!that!the!additive! affects! of! ERT! may! be! subtle! or! that! technical! issues! surrounding! its!
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repeated! administration! may! add! a! level! of! complexity,! inconsistent! results!between! individual! combinationMtreated! mice! mean! that! these! effects! are! in!danger!of!being!masked!once!analyzed!as!a!group.!The!rational!for!combining!AAVMmediated! gene! therapy!with! ERT!was! to! separately! target! pathology! within! the!brain!via! the!use!of!gene! therapy,!and!pathology! in! the!body!via!ERT.!Therefore,!another! important! point! to! emphasize! is! that! since! CLN1! disease! is! primarily!neuropathic! in!nature,! the!neuropathological!phenotypes!measured! in! this! study!are! useful! predictors! of! disease! outcome! following! CNSMdirected!AAV! treatment,!but! do! not! reflect! the! impact! of! ERT! on! visceral! pathology,! where! systemically!delivered!ERT! is!more! likely! to! confer! additive! affects.! Therefore,! any! additional!benefits!of!combining!ERT!with!AAVMmediated!gene! therapy!eventually! lie! in! the!extension!of!lifespan.!!
!
! Autofluorescent'storage'material'accumulation'is'corrected'by'
combination'therapy'A! characteristic! hallmark! of! the! NCLs! is! the! intralysosomal! accumulation! of!autofluorescent! lipofuscinMlike! storage!material! (ceroid)! as! a! result! of! lysosomal!dysfunction,!as!described!in!section'3.1.'i'of!Chapter'1'(Cooper,!2003;!Mole!et"al.,"2005;!Seehafer!and!Pearce,!2006;!Goebel! and!Wisniewski,!2004;!Mitchison!et"al.,"2004;!Futerman!and!van!Meer,!2004;!Meikle!et"al.,"2006;!Ballabio!and!Gieselmann,!2009;!Vitner!et"al,"2010).'Therefore,! storage!material! serves!as!a!very!useful!and!readily!detectable!marker!of!disease!progression,!and! is!an!especially!useful! tool!for!judging!therapeutic!efficacy!(Xu!et"al.,"2011;!Macauley!et"al.,"2009;!Griffey!et"al.,"2004;!Sondhi!et"al.,"2007;!Cooper!et"al,"2014,!pp.!349!M!356).!To!evaluate!the!ability!of! AAVMmediated! gene! therapy,! ERT! and! AAV! +! ERT! combination! therapy! to!
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address! the! PPT1Mdeficit! in! Ppt1&/&"mice! and! clear! storage! burden,! the! extent! of!autofluorescence! in! the!S1BF!and!VPM/VPL!(as! they!show!significant!gliosis!and!neuron! loss),! was! measured! using! threshold! image! analysis! on! confocal! images!captured!within!these!brain!regions,!across!all!treatment!groups.!
!
a)! AAV2/9Cmediated' gene' therapy' alone,' and' combined' AAV' +' ERT'
treatment'are'effective'at'clearing'storage'material'within'the'S1BF'and'
VPM/VPL'of'5'month'old'Ppt1−/−&mice.'Storage! material! is! found! ubiquitously! throughout! the! CLN1! disease! brain! at!autopsy,!but!accumulates!progressively!from!as!early!as!1!month!of!age!in!Ppt1&/&"mice! (Bible! et" al.," 2007;! Galvin! et" al.," 2007).! The! pattern! of! this! progressive!accumulation! does! not! share! the! spatiotemporal! pattern! of! glial! activation! or!neuron! loss! within! the! thalamocortical! system! (Bible! et" al.," 2004).! Instead,!significant! increases! in! autofluorescent! storage! material! in! the! cortex! and!thalamus!both!occur!at!3!months!of!age,!and!continue!to!increase!dramatically!with!disease!progression!at!a!similar!rate!in!both!brain!regions!(Kielar!et"al.,"2007).!As!such,!in!this!section!storage!material!in!the!SIBF!and!VPM/VPL!will!be!considered!at! the! same! time.! As! expected,! virtually! no! storage! material! was! detected! in! 5!month!old!wildMtype!mice!in!contrast!to!ageMmatched!untreated!Ppt1&/&"mice,!which!showed! a! significant! amount! of! storage!material! accumulation! in! both! the! S1BF!and!VPM/VPL!(both!p"value!<!0.0001)!(Figure'75.'a,!e'and!b,'f'and!i,!j).!Consistent!with! previous! studies,! Ppt1&/&"mice! at! the! same! age! that! had! been! treated! with!AAV2/9Mmediated! gene! therapy! had! significantly! lower! amounts! of!autofluorescent!storage!material! in!the!S1BF!(p"value!<!0.0001)!and!VPM/VPL!(p"value!0.0001)!compared!to!5!month!old!untreated!Ppt1&/&"mice.!This!was!a!dramatic!
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reduction! of! 95%! in! the! S1BF,! and! a! less! pronounced! but! still! considerable!reduction!of!66%!in! the!VPM/VPL!(Figure'75.'b,! f'and!c,'g'and! i,' j).!The!storage!material!burden! in!the!VPM/VPL!of!5!month!old!AAV!onlyMtreated!mice!was!also!significantly! higher! compared! to! ageMmatched! wildMtype! control! mice! (p" value!0.0355)!(Figure'75.'e,!g'and! j),!but! this!could!be!explained! in!part!by! the!higher!levels!of! storage!material! in! the! thalamus! to!begin!with,! although! this!difference!was! marginal.! Interestingly,! thresholding! analysis! of! 5! month! old! AAV! +! ERT!combinationMtreated!mice,! revealed! a! highly! significant! difference! in! the! level! of!storage!material!within!both!the!S1BF!and!VPM/VPL!of!combination!treated!mice!compared! to! ageMmatched! untreated! Ppt1&/&! mice! (p" value! <! 0.0001! for! both)!(Figure'75.'b,'f'and!d,'h'and'i,!j).!Notably,!there!were!no!significant!differences!at!this!age!between!storage!burden! in! the!S1BF!and!VPM/VPL!of! the!AAV!only!and!AAV!+!ERT!treatment!groups,!suggesting!that!at!5!months!of!age,!both!treatments!were!equally!effective!at!preventing!storage!material!accumulation!(Figure'75.'c,'g'and' d,' h' and! i,' j).! Although! there! were! no! significant! differences! between! the!groups,!our!data!showed!conflicting!trends!in!terms!of!whether!or!not!the!addition!of! ERT! conferred! additive! therapeutic! effects.! In! the! S1BF,! combinationMtreated!








































































Regardless,!these!data!suggest!that!therapeutically!delivered!rhPPT1!enzyme!was!able! to! target! the! brain! and! prevent! the! build! up! of! storage! material! to! some!extent,!but!any!additive!effects!as!a!result!of!ERT!treatment!are!clearly!subtle!and!specific! to! the! S1BF.!Unfortunately,! as! for! the! analysis! of! cortical! thickness,! glial!activation!and!neuron!loss,!no!ERT!only!treated!group!was!available!at!5!months!of!age!so!the!levels!of!storage!burden!could!not!be!examined!after!this!treatment.!
!
b)! Combined*AAV*+* ERT* treatment* is* less* effective* than*AAV2/9=mediated*
gene* therapy* alone* at* clearing* storage* material* within* the* S1BF* and*
VPM/VPL*of*7*month*old*Ppt1−/−&mice.*At! 7!months! of! age,! the! accumulation! of! storage!material! in! both! the! S1BF! and!VPM/VPL! of! untreated! Ppt1%/%! mice! is! approximately! 14! times! the! level! in! agePmatched! wildPtype! controls! (Kielar! et( al.,( 2007).! Therefore,! we! wanted! to!investigate! the! extent! to!which! each! treatment!was! also! able! to! prevent! storage!material! at! this! more! advanced! stage! of! disease.! In! the! S1BF,! we! observed! a!significant!clearance!of!storage!material!across!all!treatment!groups!at!7!months!of!age!compared!to!untreated!Ppt1%/%!mice.!However,!compared!to!data!obtained!at!5!months! of! age! (section* 3.4.a,! Figure* 75),! the! effects! of! these! treatments! were!similar! in!S1BF,!but!differed!in!the!VPM/VPL!(Figure*76).! !As!expected,!7!month!old!untreated!Ppt1%/%!mice!had!significantly!more!storage!material!in!both!the!S1BF!(p(value!<!0.0001)!and!VPM/VPL!(p(value!<!0.0001)!compared!to!wildPtype!control!mice,!which!showed!minimal! levels!of! storage!(Figure*76.*a,!b*and! f,!g*and*k,* l).!There!was!19%!more!storage!in!the!S1BF!at!7!months!compared!to!5!months!and!38%!more!storage! in! the!VPM/VPL!at!7!months!compared! to!5!months,!and! this!was! reflected! in! the! larger! difference! in! storage! between! the! two! regions! at! 7!
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months!of!age!(Figure*75.*b,!f*and*i,*j*and!Figure*76.*b,!g*and!k,!l).!Examination!of!the! S1BF! and! VPM/VPL! of! AAV! onlyPtreated! Ppt1%/%(mice! at! 7! months! of! age,!revealed!significantly!lower!amounts!of!storage!material!compared!to!age!matched!untreated!Ppt1%/%(mice! (p(value! 0.0003! and! 0.0096,! respectively)! (Figure*75.*b,! f*and!c,*g*and*k*and* l).!This!was!a! striking! reduction!of!95%! in!storage!burden! in!S1BF,!and!a!smaller!but!still!marked!reduction!of!61%,!in!the!VPM/VPL,!which!had!more! storage! material! to! begin! with! (Figure* 76.* k* and! l).! These! findings! were!almost!exactly!recapitulated!with!our!findings!at!5!months!(95%!in!the!S1BF,!66%!in!the!VPM/VPL)!suggesting!that!AAVPmediated!gene!therapy!was!able!to!maintain!its!efficacy!overPtime.!The!efficacy!of!AVV!treatment!alone!at!7!months!of!age!was!further!demonstrated!by!the! lack!of!significant!difference!between!the!AAV!onlyPtreated!mice!and!the!wildPtype!mice!in!the!S1BF!(Figure*76.*a,!c*and*k).!An!ERTPonly!treated!group!was!also!available!at!7!months,!providing!insight!for!the!actions!displayed!by!AAV!+!ERT!combination!treatment.!However,!we!found!that!ERT!had!different!effects!in!the!S1BF!and!VPM/VPL!at!7!months!of!age.!Mutant!mice!treated!with!just!ERT!had!a!significant!59%!reduction!in!storage!material!in!the!S1BF!at!7!months!of!age,!compared!to!Ppt1%/%(mice!(p(value!0.0381)!(Figure*76.*b*and!d*and*
k).! In!comparison,!ERT!had!only!a!small!effect!on!reducing!storage!burden!in!the!VPM/VPL! of! mutant! mice! at! 7! months! of! age,! with! only! an! 18%! reduction! in!storage!material,!compared!to!Ppt1%/%(mice,!and!this!was!not!significant.!
!
As!suggested!by!our!5!month!data,!which!showed!that!combination!therapy!tended!to! have! beneficial! effects! upon! storage! burden! in! the! VPM/VPL! beyond! those!conferred! by! AAV! alone! (Figure* 76.* g,* h* and! j),! this! finding! indicated! that!intravenously!supplied!rhPPT1!enzyme!was!partially!able!to!access!the!brain!and!
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towards! less! storage! material! in! combination4treated! mice! compared! to! AAV4treated!mice!whereas!in!the!VPM/VPL!of!combination4treated!mice!at!7!months!of!age,!this!was!reversed!(Figure'76.'f,!j'and'l).!
!
Taken! together,! these! data! indicate! that! storage! material! accumulation! is!prevented! fairly! well! within! the! S1BF! at! early! (5! months)! and! late! (7! month)!stages! of! disease,! across! all! treatment! groups.! However,! in! the! more! severely!affected!VPM/VPL,!only!intracranial!gene!therapy!was!able!to!significantly!prevent!the! increase! in! storage! burden.! Although,! these! data! hint! at! potentially! positive!affects!on!storage!material!as!a!result!of!combining!AAV!+!ERT!treatment,!this!data!does! not! correlate! with! neuron! loss,! further! highlighting! the! ambiguous! link!between! storage!material! and!neuron! loss.!As! such,! additional! read4outs! such!as!astrocytosis!and!microglial!activation!appear!to!be!more!informative.!
!
4! Limitations'of'the'study'
The!main!limitation!of!this!study!was!the!high!degree!of!variability!within!the!AAV!+!ERT!combination!group!at!both!ages!examined!(Figure'72).!Only!n!=!4!or!n!=!3!mice!were!available!for!analysis!at!5!months!and!7!months!of!age,!respectively!in!following! AAV! +! ERT! combination! therapy.! !Within! these! treatment! groups,! the!ability!of!AAV!+!ERT!combination!treatment!to!reduce!cortical!thickness,!decrease!neuroinflammation,! rescue! neuron! loss! and! clear! storage! material! was!inconsistent!as!highlighted!in!Figure'67'and!Figure'72.'Although!ERT!was!largely!ineffective!when!administered!alone,!and!the!overall!effect!on!these!parameters!of!combined!ERT!and!AAV4mediated!gene!therapy!appeared!to!reduce!the!efficacy!of!
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AAV!only!treatment,!closer!examination!of!individual!sample!revealed!that!in!some!cases!AAV!+!ERT!combination!treatment!had!a!detrimental!effect!on!existing!CLN1!disease!pathology,!but!in!others,!had!subtle!additive!effects.!Therefore,!it!would!be!informative! to! determine! the! origin! of! this! variability.! One! obvious! potential!explanation!for!the!worsening!effects!observed!within!the!AAV!+!ERT!combination!group! is! that! an! infection! or! other! adverse! influence!may! have! been! introduced!during! the! administration! of! AAV4mediated! gene! therapy! and! ERT.! The! risk! of!infection! is! increased! in! combination! treated!mice! since!multiple! injections! and!experimental! procedures! are! required! for! AAV4mediated! gene! therapy!(intracranial! injection)! and! ERT! (repeated! injections! to! the! superficial! temporal!vein,! peritoneum! and! tail! vein).! To! determine! the! presence! of! any! possible!infection4related! neuroinflammation! (above! the! existing! low! level! within! Ppt1%/%'mice,! Groh! et'al.,'2013),!we!will! stain! sections! for! CD4! and! CD8,!which!mark! T4helper! cells! and! cytotoxic! T4cells,! respectively,! and! serve! as! indicators! of!inflammatory!processes!within!the!CNS!in!response!to!microbial!products!(Baba!et'
al.,'2006).! Although! it! appears! that! these! cells!may! have! a! small! contribution! to!pathogenesis!in!CLN1!disease!(Groh!et'al.,'2013),!there!is!evidence!to!support!the!entry! of! lymphocytes! into! the! brain! in! response! to! infection,! as! a! result! of!disruptions!to!the!BBB!due!to!persistent!glial4mediated!neuroinflammation!(Amor!
et' al.,' 2009;! Saha! et' al.,' 2012).! These! changes! to! the! permeability! of! the! BBB!involve!pericytes,!which!play!a!pivotal!role!in!the!maintenance!of!the!BBB!(Saha!et'
al.,' 2012).! Therefore,! we! will! also! stain! for! the! pericyte! marker! cluster! of!differentiation! 140a! (CD140a)! to! evaluate! their! activation! state.! Pericyte!abnormalities! resulting! from! pathological! events! within! the! CLN1! disease! brain!compromise! the! integrity! of! the! BBB,! facilitating! susceptibility! to! T4helper! cells!and!cytotoxic!T4cell! infiltration!(Saha!et'al.,'2012).!Therefore,!the!presence!of!any!
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infection!would!be! likely! to!exacerbate! the!“vicious!cycle”!of!neuroinflammatory4led! neurovascular! dysfunction! associated! with! further! neuroinflammation! and!neurodegeneration! beyond! CLN1! disease! pathology! (Zlokovic! et' al.,' 2008).!Evidence!of!different!levels!of!CD4,!CD8!or!CD140a!immunoreactivity!may!explain!the!variability!within!the!AAV!+!ERT!combination!group!and!justify!replicating!this!study! under! optimised! conditions! that! better! limit! infectious! risk! factors.!Furthermore,!repeating!this!study!with!the!addition!of!sham!operated!and!vehicle!only!groups!will!help!control!for!any!neuroinflammation!introduced!as!a!result!of!the!experimental!procedures!involved!in!the!administration!of!AAV4mediated!gene!therapy! and! ERT.! Other! studies! have! not! provided! any! evidence! for! injection4associated! neuroinflammation,! but! it! is! still! important! to! rule! this! out! in! this!particular!study!(Macauley!et!al.,!2014;!Lu!et'al.,'2010,!15).!
!
The! issue! of! introducing! infections! as! a! result! of! multiple! injection! procedures!would!be!eliminated!by!instead!administering!a!single!treatment,!which!was!able!to!target!the!whole!body!with!one!application!as!opposed!to!two!treatments!which!target!the!CNS!and!viscera!separately!and!require!repeated!applications!(i.e.!AAV!and!ERT).!If!viral!vectors!could!be!developed,!which!are!better!able!to!diffuse!the!BBB,! transduce! a! wider! range! of! cell! types! and! maintain! long4term! expression,!gene!therapy!could!be!used!alone!to!treat!both!the!CNS!and!the!viscera!to!provide!more! substantial! improvements! in! overall! disease! outcome.! The! dawn! of! such!“super!vectors”!may!be!slowly!approaching!as!research!into!the!early!intravenous!administration!of!existing!vectors!(AAV2/9)!to!foetal!and!neonatal!mice!(Rahim!et'
al.,' 2011)! and! the! development! of! newer! generations! of! vectors! continue! to!emerge!(Cearley!et'al.,'2006;!Klein!et'al.,'2008).!!
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!
Another! limitation! to! this! study! is! that! we! have! not! yet! assessed! the! impact! of!intravenously! supplied! ERT! on! systemic! disease,! and! therefore,! cannot! fully!measure! the! extent! to! which! ERT!may! exert! synergistic! effects! when! combined!with!AAV4mediated!gene!therapy.!However,!perhaps!owing!to!the!issues!regarding!variability! described! above,! lifespan! data! collected! from! our! collaborators! at!Washington!University!Medical!School!suggest!that!any!improvements!in!visceral!pathology!do!not!lead!to!improved!rotarod!performance!or!a!further!extension!in!lifespan!(Sands,!personal!communication).!
!
5! Discussion'
The! aim! of! this! study!was! to! evaluate!whether! systemically! supplied! ERT! could!enhance!the!beneficial!effects!of!AAV4mediated!gene!therapy,!on!well4established!neurological! disease! phenotypes.! AAV4mediated! gene! therapy! is! already! very!efficient!at!reducing!storage!load!(Griffey!et'al.,'2004,!2006),!leaving!little!room!for!further! improvement.! Nonetheless,! our! findings! suggest! that! AAV! +! ERT!combination! treatment! is! also! capable! of! further! preventing! storage! material!accumulation,!but!these!effects!do!not!extend!to!neuron!survival!or!a!reduction!in!neuroinflammation.!Overall,!ERT!only!and!AAV!+!ERT!combination!treatments!had!no! significant! impact! on! cortical! thickness,! neuroinflammation! or! neuron! loss! in!
Ppt1'%/%'mice.! However,! when! directly! compared! to! AVV! only! treated! mice,! the!addition!of!ERT!to!AAV4mediated!gene!therapy!appeared!to!reverse!the!beneficial!effects! of! gene! therapy.! Furthermore,! combination! therapy! showed! concerning!trends!towards!increasing!the!levels!of!neuroinflammation!and!neuron!loss!above!
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their! already! severe! level! in!Ppt1'%/%'mice.! Therefore,! it!would! appear! that! in! this!particular!study,!this!combination!of!AAV2/94mediated!gene!therapy!and!ERT!was!not! successful! compared! to! previous! combination! therapy! approaches! for! CLN1!disease.! As! described! in!section'5.6'of!Chapter'1,! combining!AAV! gene! therapy!with! BMT! greatly! enhanced! the! therapeutic! efficacy! of! AAV2/5,! with! a! marked!improvement!in!motor!function!and!lifespan,!(Macauley!et'al.,'2012),!although!this!has! not! been! replicated.! Combining! AAV4mediated! gene! therapy! with! the!lysosomotrophic!PPT!mimetic!phosphocysteamine!or! the!anti4inflammatory!drug!MW151! both! gave! rise! to!modest! improvements! in!motor! function! above! those!obtained!with!AAV!gene!therapy!alone!(Roberts!et'al.,'2012;!Macauley!et'al.,'2014).!Examined! alongside! these! combination! therapies,! AAV! +! ERT! combination!treatment! has! less! of! a! positive! effect! on! histological! responses,!motor! function!and! lifespan! in! Ppt1%/%'mice! and! in! fact! raises! safety! concerns.! However,! further!studies! using! i)! a! larger! sample! number! of! AAV! +! ERT! treated! animals;! and! ii)!ruling! out! the! potential! presence! of! infection! as! a! result! of! the! experimental!procedures! as! discussed! in! section' 4,! are! essential! before! eliminating! this!approach!as!a!viable!option.!Furthermore,!it!is!important!to!underline!the!fact!that!CNS4directed!AAV4mediated!gene! therapy! is!not!optimal.!Emerging!data!suggests!that!neuropathology!within! the!brainstem!and!spinal!cord!(Nelvagal!and!Cooper,!personal! communication)! cannot! be! reached! by! current! intracranial!administration! of! gene! therapy! and! may! play! a! significant! role! in! disease!pathogenesis.!In!contrast,!these!regions!can!be!accessed!by!ERT!via!delivery!to!the!CSF!using! intrathecal!administration!(Lu!et'al.,'2015).!This!approach!has!resulted!in! improvements! in! motor! function! and! decreased! microglial! reactivity! in! the!spinal!cord!and!cortex!and!improved!motor!function!and!prolonged!lifespan!(Lu!et'
al.,' 2015).! These! findings! suggest! that! ERT! treatment! has! further! potential! in!
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1! Introduction(The'aim'of'this'thesis'was'to'explore'gene'therapy'as'a'potential'treatment'for'two'different' forms'of'NCL'disease,'CLN1'disease,'which' is'caused'by'a'mutation'of'a'soluble' lysosomal' enzyme' (PPT1)' and' CLN3' disease,' which' results' from' a'mutation' of' a' transmembrane'protein' (CLN3)' (Cooper'et#al.,#2010;'Kyttälä'et#al.,#2006).' Like' the' rest' of' the' NCLs,' CLN1' and' CLN3' diseases' share' a' number' of'pathological'and'clinical'features'(Cooper'et#al.,#2010).'However,'below'the'surface'of'these'shared'features,'there'are'marked'subtypeMspecific'differences'in'how'and'why'they'manifest'(Cooper'et#al.,#2010).'The'gene'products'of'CLN1#and'CLN3'are'likely' to' carry' out' different' functions'within' the' lysosomal' system' (Jalanko' and'Braulke,'2009),'as'described'in'section(4.1(and'4.2(of'Chapter(1.(Therefore,' it' is'not' surprising' that' there' are' differences' in' the' pathology' (section( 3.1.d.ii( of'
Chapter(1)'that'occurs'as'a'result'of'these'mutations'(Cooper'et#al.,#2015).'Indeed,'in' order' to' better' treat' CLN1' and' CLN3' disease,' therapeutic' approaches' should'really' regard' these'diseases' as'unique'entities' (Cooper'et#al.,#2015).'Moreover,' a'better' understanding' of' the' specific' pathological' cascades' that' operate' in' each'form' of' NCL' (Neverman' et#al.,#2015)' would' allow' for'more' precise' targeting' of'therapy.' Although' a' complete' understanding' of' normal' protein' function' and' the'pathological'consequences'of' their'disruption'may'become' less' important' if' they'can' be' circumvented' by' directly' targeting' the' gene' defect' (gene' therapy)' or' the'protein'deficiency' (stem' cells' and'ERT),' CLN1'and'CLN3'disease' still' need' to'be'considered' individually' when' attempting' these' strategies.' For' soluble' enzyme'deficient'forms'of'NCL'like'CLN1'disease'for'example,'the'phenomenon'of'“crossMcorrection”'makes'it'easier'to'directly'target'the'gene'defect'or'protein'deficiency'and'move'towards'an'effective'therapy,'despite'the'holes'in'our'knowledge'of'the'normal' function' of' this' protein' and' its' usual' substrate' (Cooper' et# al.,# 2015).'
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However,' for' transmembrane' proteinMdeficient' forms' of' NCL' like' CLN3,' directly'targeting' the' gene' defect' presents' more' obstacles' and' replacing' the' missing'protein'exogenously' is'virtually' impossible.'Therefore,'a'greater'consideration'of'the'key'events'that'result'from'mutations'in'CLN3' is'necessary'in'order'to'devise'much' needed' alternative' (or' indeed' combinatorial)' mechanismMbased' therapies'(Kovacs'et#al.,#2011,'2012;'Seehafer'et#al.,#2011).'
'
A' detailed' knowledge' of' neuropathology' provides' a' way' to' carefully' target' and'judge' the' effects' of' therapy' on' different' aspects' of' disease' pathogenesis.' The'specific' staging' of' glial' activation' and' neuron' loss' for' CLN1' and' CLN3' disease,'exemplifies'the'differences'that'exist'between'these'forms'of'NCL.'In'CLN1'disease,'glial'activation,'followed'by'neuron'loss'predominantly'starts'within'select'nuclei'(e.g.'VPM/VPL)'and'subMregions'(e.g.'S1BF)'of' the'thalamocortical'system'from'3'months' of' age,' becoming' more' pronounced' and' less' compartmental' with'increasing'age'(Kielar'et#al.,#2007).'The'thalamus'is'more'severely'affected'than'the'cortex,'and'astrocytosis'is'more'obvious'and'widespread'than'microglial'activation'(Kielar'et#al.,#2007).'In'Chapter(5,'the'effects'of'combining'AAV'gene'therapy'with'ERT' in'Ppt1///'mice' (starting'at'birth,'before' the'onset'of'disease'pathology)'was'measured' within' the' thalamocortical' system' at' two' different' ages' (5' and' 7'months)' to' determine' its' effect' upon' the' course' of' pathology' in' terms' of' its'severity' at' the' end' stage' of' disease.' In' CLN3' disease,' pathology' is' much' more'protracted,'and'not'as'specific'to'the'thalamocortical'system'(Pontikis'et#al.,#2004;'Tyynelä' et#al.,#2004).' Although' the' thalamocortical' system' is' a' significant' site' of'early' pathology' (Weimer' et# al.,# 2006),' other' important' areas' include' the'hippocampus' and' the' cerebellum' (Pontikis' et# al.,#2004).' Neuron' loss' does' not'
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occur' until' 14'months,'whilst' subtle' glial' changes' can' be' detected' as' early' as' 5'months,' which' progressively' worsens' over' time,' but' remain' relatively' subtle'(Pontikis'et#al.,#2004).'In'Chapter(3,'the'impact'of'AAV'gene'therapy'at'the'site'of'injection'in'Cln3Mdeficient'mice'was'assessed'following'injection'of'the'striatum'at'two'different'stages'of'disease'(3'and'7.5'months)'and'two'different'survival'times'(2' and' 6' months).' At' this' point' in' disease' progression,' glial' activation' is' not'pronounced'and'neuron'loss'is'limited'within'the'striatum'and'therefore,'we'were'able'to'more'clearly'assess'the'impact'of'the'experimental'vectors'(AAV2/9.eGFP,'AAV2/9.mCln3.eGFP'and'AAV2/9.hCLN3.eGFP)'upon'the'brains'of'injected'mice.'In'this' way,' a' knowledge' of' disease' pathology' allowed' us' to' inject' a' relatively'unaffected'brain' region' to' study' the' impact'of'Cln3'overMexpression,' rather' than'simply'ascertaining'the'effect'of'AAV'gene'therapy'upon'disease'pathology'within'this'region.'
'
As'described'in'Chapter(3,'gene'therapy'for'the'treatment'of'lysosomal'membrane'forms'of'NCL' is' a' reasonably'novel' concept,' stifled'by' the' fact' that'CLN3' cannot'“crossMcorrect”'neighbouring'cells'(Cooper'et#al.,#2008;'Sands'and'Davidson,'2006)'and' overMexpression' of' CLN3' may' be' toxic' (Tuxworth' et# al.,' 2009).' This' thesis'aimed'to'test'the'feasibility'of'gene'therapy'for'the'treatment'of'CLN3'disease'and'revealed' that'Cln3/CLN3' can'be' successfully'delivered' to' the'murine'brain'using'AAV2/9Mmediated'gene'transfer'and'achieve'widespread'transduction'of'neurons'and' longMlasting' transgene' expression' without' any' obvious' longMterm' adverse'effects' (Chapter( 3).' ' Although' the' NCLs' are' primarily' neuropathic,' pathology'outside'of'the'CNS'has'not'been'well'defined'(Cooper'et#al.,#2015).'Clinically,'CLN3'is' known' to' have' a' cardiac' involvement' (Hofman' et#al.,#2001;' Østergaard' et#al.,#
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2011;' Tomiyasu' et# al.,# 2000)' but' heart' pathology' is' yet' to' be' systematically'investigated' functionally' or' histologically' in' either' CLN3' or' CLN1' disease.'Therefore,' one'of' the' objectives' of' this' thesis'was' to' investigate' the'presence'of'cardiac'abnormalities'in'these'forms'of'NCL'using'echocardiography'and'histology.'This' analysis' revealed' that' both' CLN1' and'CLN3'disease' display' both' functional'and' histological' cardiac' pathology' in' mice' (Chapter( 4).' Pathology' within' the'viscera' has' important' implications' for' attempting' to' treat' both' forms' of' the'disease,'as' it'may' limit' the'efficacy'of'CNSMdirected'therapeutic'approaches,'such'as' intracranial' gene' therapy.' In' contrast' to' gene' therapy' for' CLN3' disease,' this'strategy' is'at'a'more'advanced'stage'of'development' for'CLN1'disease.'However,'its'success'is'limited'by'the'fact'that'aspects'of'NCL'pathology,'whether'within'the'brain' or' elsewhere' in' the' body,' still' appear' to' remain' untreated' (HawkinsMSalsbury,'2013).'By'combining'CNSMdirected'AAV2/9Mmediated'gene'therapy'with'systemically' administered' ERT,' this' thesis' (Chapter( 5)' aimed' to' investigate'whether' treating' both' neurological' and' visceral' aspects' of' CLN1' disease' would'boost' the'efficacy'of'AAV'gene'therapy.'Surprisingly,'our'results'showed'that' the'positive'effects'of'AAV'gene'therapy'where'diminished'when'combined'with'ERT'but'why' this' should' be' the' case' is' unclear' and' further' investigation' is' certainly'needed.' In' this' final' chapter,' the' significance' of' these' findings' in' relation' to'previous'and'current'research'will'be'discussed.''
'
2! Gene(therapy(is(a(valid(treatment(for(CLN3(disease(after(all(To' test' the' distribution' and' safety' of' AAV2/9Mmediated' gene' transfer' of' human'mouse' and' human' Cln3/CLN3,' we' targeted' the' striatum' of' wildMtype' and' Cln3/deficient' mice' at' 3' and' 7.5' months' of' age' as' described' in' Chapter( 1.' Our' data'
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revealed' that' variable,' but' at' best' widespread' transgene' expression' could' be'achieved'via' intracranial'AAV2/9Mmediated'gene'therapy'and'this'was'associated'with'an'astrocytic'and'microglial'response,'which'was'generally'most'pronounced'for'AAV2/9.CLN3h.eGFP,'suggesting'that'the'expression'of'human'CLN3#causes'the'greatest'inflammatory'response'(section(4(of'Chapter(3).'However,'inflammation'in'response'to'all' three'vectors'was'acute'(significant'only'at'2'months)'and'was'resolved'6'months'after'injection'(section(4.1(and'4.2(of'Chapter(3,'respectively).'Whether' these' vectors' caused' neuron' loss,' either' through' inducing' an' acute'inflammatory'response'or'through'some'other'mechanism,'could'not'be'concluded'from'our'results'due'to'a'discrepancy'between'neuron'loss'data'at'2'and'6'months'of'age'(section(4.3.a(and'4.3.b'of'Chapter(3).'However,'overall,'we'were'able'to'show' that' AAV2/9Mmediated' gene' therapy' is' potentially' a' feasible' approach' for'treating' CLN3' disease' in' that' it' does' not' have' any' overtly' negative' effects.' This'careful' and' systematic' approach' to' assessing' safety' is' an' important' step' in' the'development' of' novel' therapies.' Naturally,' the' next' step'would' be' to' assess' the'therapeutic'efficacy'of'gene'therapy'for'CLN3'disease.''
'
As' discussed' in' section( 6( of' Chapter( 3,( this' has' already' been' done' by' our'collaborators'using'AAVrh10hCLN3'in'Cln3Δex7/8#mice'(Sondhi'et#al.,#2012),'a'study'that'we'were'also'involved'in.'Taking'a'closer'look'at'this'study'in'context'of'the'neuropathology'described'in'section(1,'AAVrh10hCLN3'was'administered'into'the'striatum,'hippocampus'and'cerebellum'of'2'day'old'Cln3Δex7/8#mice'and'the'impact'of'AAVrh10hCLN3'on'CLN3'neuropathology'was'assessed'within'multiple'regions'(cerebellum,' medulla,' pons,' ventral' midbrain,' dorsal' midbrain,' hypothalamus,'thalamus,' striatum,' olfactory' tubercle,' anterior' cortex,' central' cortex,' posterior'
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cortex,'posterior'cortex'and'hippocampus)'at'16' M'18'months'of'age,'when'CLN3'disease' pathology' would' normally' be' quite' advanced' (Sondhi' et#al.,#2012).' The'widespread' distribution' and' longMterm' expression' of' AAVrh10hCLN3Mderived'CLN3'expression'was'confirmed,'and' this'was'associated'with'several' significant'improvements' in' neuropathology' (Sondhi' et# al.,# 2012).' A' reduction' in'autofluorescent'storage'material' in'all' regions'analysed'was'observed,'especially'within' the' central' cortex,' anterior' cortex,' striatum,' thalamus,' hippocampus' and'pons' (Sondhi' et# al.,#2012).' Furthermore,' astrocytosis' was' significantly' reduced'within' the' primary' motor' (M1)' cortex' and' striatum' compared' to' untreated'
Cln3Δex7/8#mice,'and'there'also'appeared'to'be'a'positive'effect'on'astrocytosis'in'the'hippocampus'and'thalamus'(Sondhi'et#al.,#2012).'In'contrast,'AAVrh10hCLN3'had'very' little'effect'on'microglial'activation'and'in' fact' this'was'slightly' increased'in'the'VPM/VPL' thalamus'of'AAVrh10hCLN3Mtreated'mice.'This' is' interesting'when'considered' in' relation' to' the' data' from' our' CLN3' gene' therapy' study,' which'showed'that'any'inflammatory'effects' induced'by'AAV2/9Mmediated'viral'vectors'(section(4.2(of'Chapter(3),'dampened'down'by'6'months,'and'suggests'that'gene'therapy'is'unable'to'prevent'microglial'activation'in'the'late'stages'of'disease'and'that' this' may' be' further' exasperated' by' CLN3' expression.' In' terms' of' neuron'survival,' AAVrh10hCLN3' treatment' had' no' significant' impact' on' neuron' and'interneuron'number,'however'neurons'in'specific'subMregions'of'the'hippocampus'were'to'an'extent'protected'in'AAVrh10hCLN3Mtreated'mice,'as'well'as'in'the'M1'cortex' but' in' other' regions' such' as' the' striatum' and' nucleus' of' the' thalamus'(LGNd),'AAVrh10hCLN3'had'little'effect'(Sondhi'et#al.,#2012).''Taken'together,'this'study' showed' that' the' treatment' of' Cln3Δex7/8#mice' by' neonatal' CNSMdirected'AAVrh10hCLN3'leads'to'long'term'expression'of'CLN3#gene'and'is'able'to'reduce'storage' burden' and' astrocytosis,' and' is' not' associated' with' any' neurotoxic' or'
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significant'inflammatory'effects.'However,'as'AAVrh10hCLN3'treatment'had'little'impact'on'microglial'activation'and'neuron'survival'(Sondhi'et#al.,#2012),'it'is'clear'that'despite'widespread'transduction,'gene'therapy'for'CLN3'using'this'particular'vector' is' not' optimal.' Furthermore,' it' demonstrates' that' even' if' astrocytosis' is'prevented,'neurodegeneration'still'occurs,'perhaps'owing'to'the'lack'of'any'impact'of'AAVrh10hCLN3'upon'microglial'activation.'Nonetheless,'given'the'present'lack'of'any'alternative' therapeutic'strategies' these'data,' together'with' the' findings' in'this' thesis,' potentially' elevate' gene' therapy' as' being' worthy' of' further'consideration'as'a'new'experimental'therapy'for'CLN3'disease.'
'
2.1! A(clinical(trial(for(CLN3(gene(therapy(is(already(being(planned(Surprisingly,'given' the' lack'of'any'published'preMclinical'data,'a' research' team' is'already' working' towards' a' phase' I' clinical' trial' for' CLN3' gene' therapy.' This'research' was' initiated' by' Professor' Tammy' Kielian' at' the' University' Nebraska'Medical' Centre' in' collaboration' with' Abeona' Therapeutics' (Cooper,' personal'communication).' PreMclinical' experiments' in' 1' month' old' mice' using' AAV' gene'therapy'was'carried'out'by'Professor'Kielians’'research'group'and'showed'striking'improvements'in'a'number'of'disease'outcomes'compared'to'mice'that'received'a'control'virus'without'the'CLN3'transgene.'Motor'activity'was'apparently'restored'to' almost' the' same' level' as' wildMtype' mice' and' neuroinflammation' was'significantly' reduced' (http://www.raredr.com/publications/Rare/Disease/




CLN3(pathogenesis(As'discussed'in'section(5.7.a(and'5.7.b(of'Chapter(1,'therapies'for'treating'CLN3'disease' have' been' traditionally' focused' on' trying' to' identify' and' block'downstream'effects'of'mutations'in'the'CLN3'gene'using'animal'models'(Cooper'et#
al.,# 2008).' For' example,' counteracting' autoimmunity' using' immunosupressant'drugs'(Lim,'2006,'2007;'Seehafer'et#al.,'2011;'Finn'et#al.,#2011;'Kovacs'et#al.,#2006;'Herrmann' et#al.,#2008;' Chattopadhyay,' 2002a,b)' or' blocking' excitotoxicity' using'glutamate' receptor' antagonists' e.g.' memantine' or' EGISM8332' ' (Chattopadhyay,'2002a;'Pears,'2005;'Kovács'et#al.,#2006,'2011,'2012).'For'now,'it'would'appear'that'autoimmunity'is'a'more'promising'therapeutic'target'than'excitotoxicity,'with'the'immunosuppressant'drug'Mycophenolate'mofetil'already'in'a'phase'II'clinical'trial'(https://www.clinicaltrials.gov/ct2/show/NCT01399047),' and' new' antiMinflammatory' drugs' being' currently' tested,' which' show' positive' effects' upon'behavioural' and' histological' measures,' especially' in' combination' with'neuroprotective'drugs'(Tarczyluk'and'Cooper,'personal'communication).'
'
Sadly,'beyond'these'two'therapies,'little'progress'has'been'made'for'treating'other'aspects' of' CLN3' disease' pathology.' While' there' are' many' suggestions' for' the'various' functions' of' CLN3,' and' how' its' dysfunction' might' lead' to' disease'(described' in' section( 4.2( of' Chapter( 1),' few' therapeutic' interventions' have'followed'as'it' is'difficult'to'pick'out'the'most'primary'functions'to'target'(CárcelMTrullols' et#al.,#2015;' Getty' and' Pearce).' An' important' aspect' of' CLN3' pathology'
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that'has'until'now'been' largely'overMlooked,' is' the'presence'of'cardiac'pathology'(Østergaard' and' Mølgaard,' 2011;' Hofman' et# al.,# 2001;' Dilaveries' et# al.,' 2014).'Clinically,' cardiac' symptoms' in' CLN3' disease' have' been' treated' by' pacemakers'with' some' overall' improvement' (Østergaard' and'Mølgaard,' 2011)' but' no' other'cardiac' specific' treatments' have' been' explored.' Given' the' dominance' of'neuropathology' however,' treating' the' heart' is' likely' to' only' be' beneficial' in'synergy'with'CNSMspecific'treatments'and'thus,'neurological'treatments'will'most'likely' remain' the' primary' focus,' further' highlighting' the' importance' of' gene'therapy'as'an'emerging'therapy'for'CLN3'disease.'
'
3! Is(thalamocortical(pathology(in(CLN1(disease(prevented,(
delayed(or(changed(by(AAV(gene(therapy?(Previous'studies'using'a'rAAV2/5MPPT1'vector'(Macauley'et#al.,#2012),'delivered'to'the'same'brain'regions'of'neonatal'Ppt1///#mice'as'in'our'study,'showed'that'gene'therapy'was'able'to'increase'lifespan'from'8'to'about'13'months,'maintain'motor'performance' to' the' same' level' as' in' wildMtype' mice' up' to' 8' months' and'significantly' reduced' cortical' thinning,' astrocytosis,' microglial' activation' and'storage' burden' at' 12' months' (Macauley' et# al.,#2012).' Consistent' with' our' data'(section(3.2(and'3.3(of'Chapter(5),'AAV'gene'therapy'treatment'alone,'was'unable'to' prevent' glial' activation' and' neuron' loss' completely,' but' does' appear' to'significantly'delay'these'events'(Macauley'et#al.,#2012).'In'this'previous'study,'the'brains' of' treated'mice'were' only' analysed' at' 12'months' of' age' (Macauley' et#al.,#2012),'whereas'in'our'study,'we'analysed'mice'at'5'and'7'months'of'age'providing'an'insight'into'the'effects'of'gene'therapy'upon'disease'progression.'We'found'that'
! 418!
AAV2/9Mmediated'gene'therapy'was'relatively'effective'at'preventing'astrocytosis'at'both'5'and'7'months' in'S1BF'and'this'was'also'true'of'microglial'activation'in'the'VPM/VPL'at'5'and'7'months'of'age'(section(3.2.a,'3.2.b(and'3.2.c(of'Chapter(
5).' However,' AAV2/9Mmediated' gene' therapy' was' mostly' unsuccessful' at'preventing' astrocytosis' in' the' VPM/VPL' at' 5' and' 7' months' (section( 3.2.c( and'
3.2.d( of' Chapter( 5).' Consistent' with' the' effect' of' AAV' gene' therapy' on' glial'activation' within' the' S1BF,' AAV' gene' therapy' was' also' quite' effective' at'preventing' neuron' loss' in' the' SIBF,' and' very' effective' at' preventing' cortical'atrophy,'but'was'not' as' effective'at'preventing'neuron' loss'within' the'VPM/VPL'(section'3.3.c,'3.1(and'3.3.a(and'3.3.b(of'Chapter(5).' Based' on'what'we' know'about' the' spatiotemporal' pattern' of' glial' activation' and' neuron' loss' within' the'thalamocortical' system' (Kielar' et# al.,# 2007),' it' would' appear' that' overall,' the'pattern' of' thalamocortical' pathology' remains' the' same' following' AAV' gene'therapy,' with' the' thalamus' being' affected' more' severely' than' the' S1BF,' where'pathology' is' less' severe.' This' suggests' that' AAV' gene' therapy' is' not' sufficiently'effective' to' prevent' glial' activation' and' neuron' loss'within' the' VPM/VPL'where'pathology' first' originates,' but' is' able' to' keep' pathology' at' bay'within' the' S1BF,'perhaps' as' a' knockMon' effect' of' partially' (although' not' completely)' treating' the'VPM/VPL.''
'
There' are' two'obvious' explanations' for'why'AAV'gene' therapy'was'not' entirely'effective;' firstly,' transgene' expression'may'have' declined' over' time' or' secondly,'important' regions' of' the' brain' may' have' been' missed' by' AAV' mediated' gene'therapy,' which' are' beyond' the' reach' of' “crossMcorrection”' and' which' left'untreated,'may'have'impacted'on'the'thalmocortical'system.'In'terms'of'transgene'
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expression,' as' discussed' in' section( 2.3( of' Chapter( 5,( AAV2/9Mmediated' gene'therapy'confers'good'long'term'expression'(Xu'et#al.,#2001;'Macauley'et#al.,#2012;'Dayton'et#al.,#2012;'Roberts'et#al.,#2012)' and' therefore,' it' is'more' likely' that' key'sites'of'pathology'within'the'brain'were'not'targeted.'
'
In' this' thesis' brains'were' not' assessed' for' PPT1' activity' but' based' on' previous'data' (Macauley' et# al.,# 2012),' it' is' likely' that' AAV2/9Mtreated' mice' had'supraphysiological' levels' of' enzyme' activity' compared' to' wildMtype' littermates,'with' the' highest' enzyme' activity' localized' to' the' sites' of' injection' as' shown'previously' (Griffey'et#al.,#2005).' It'has'been'suggested' that'only'5'–'10%'normal'levels'of'enzyme'are'needed'for'therapeutic'efficacy'(HawkinsMSalsbury'and'Sands,'2011)' and' therefore,' the' thalamus' should' in' theory' have' been' very' effectively'treated.'Indeed,'if'the'thalamus'received'such'high'levels'of'enzyme,'then'why'was'pathology' not' prevented' there?' Perhaps' it' is' simply' too' affected' to' be' rescued,'even' when' treated' early?' Alternatively,' it' is' possible' that' persistent' pathology'within' other' regions' of' the' brain' that'were' not' targeted'may' have' impacted' on'regions'like'the'thalamus'and'cortex,'limiting'the'overall'therapeutic'efficacy'of'the'AAV'gene'therapy'as'described'in'section(5(of'Chapter(5.''
'
3.1! Newly(emerging(sites(of(brain(pathology(are(not(treated(by(AAV(
gene(therapy(One' of' the' biggest' breakthroughs' in' the' study' of' NCL' pathogenesis' was' the'discovery' that' pathology' occurs' in' a' graded' fashion' along' the' interconnected'pathways'of'the'thalamocortical'system'(Cooper'et#al.,#2015).'Following'the'same'
! 420!
line'of'reasoning,' it'has'been'suggested'that'the'brain'stem'nuclei' that'project'to'the'thalamus,'or'even'the'spinal'cord,'may'display'even'earlier'pathology'than'the'thalamus'and'may'be'partly'responsible'for'the'loss'of'thalamic'neurons'(Cooper'
et#al.,#2015).' It' appears' that' this'may' be' the' case,'with' severe' pathology'within'these' regions' occurring' before' the' onset' of' pathology' in' the' thalamus' (Nelvagal'and'Cooper,'personal'communication).'As'such'if'left'untreated,'spinal'cord'and/or'brainstem'pathology'may'well'have'an' impact'on'regions' that'have'been'treated'by'AAV.'Therefore,'failing'to'target'these'regions'may'have'serious'implications'for'the'overall'therapeutic'efficacy'of'CNSMdirected'therapies'like'AAVMmediated'gene'therapy.'
(
3.2! ERT(does(not(augment(the(effects(of(AAV2/9Nmediated(gene(
therapy(The'purpose'of'this'study'was'to'evaluate'whether'ERT'was'better'able'to'augment'AAV' gene' therapy' compared' to' previous' attempts' to' treat' systemic' pathology'using'a'lysosomotropic'PPT1'mimetic'(Roberts'et#al.,#2012),'BMT'(Macauley'et#al.,#2012)'or'an'antiMinflammatory'drug'(Macauley'et#al.,#2014).' Indeed,'using'ERT'to'treat' visceral' pathology' has' proven' effective' in' LSDs' such' as' Fabry' disease'(Linthorst' et#al.,#2004),' mucopolysaccharidosis' (Wraith' et#al.,#2004)' and' Pompe'disease' (Sun'et#al.,#2007)'using'an' intravenous' route'of' administration' that'does'not'provide'access'to'the'CNS.'However,'our'data'showed'that'ERT'does'not'have'an'additive'effect'in'Ppt1Mdeficient'mice'and'to'some'extent'worsens'the'effects'of'AAV2/9Mmediated' gene' therapy.' The' mechanism' by' which' ERT' negates' the'positive'actions'of'AAV2/9Mmediated'gene'therapy'has'not'yet'been'confirmed,'but'one'likely'explanation'is'the'introduction'of'an'infection'in'the'course'of'repeated'
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ERT'treatments,'when'administered' in'combination'with'AAV2/9Mmediated'gene'therapy'as'discussed'in'the'section(4(of'Chapter(5.(Neuroinflammation'is'already'a' characteristic' feature'of'NCL'pathology' ' (Bosch'and'Kielian,'2015;'Kielar'et#al.,#2007;'Kuronen'et#al.,#2012;'Morgan'et#al.,#2013;'Partanen'et#al.,#2008;'Pontikis'et#
al.,#2004,'2005;'Schmiedt'et#al.,#2012;'Thelen'et#al.,#2012;'von'Schantz'et#al.,#2009)'and'is'associated'with'neurodegeration'as'described'in'section(3.1.d(of'Chapter(1.(Although' the' basis' of( neuroinflammation' is' still' not' fully' understood,' this'phenotype'is'treated'to'some'degree'by'AAVMmediated'gene'therapy.'However,'in'the'event'of'an'infection,'the'same'innate'immune'response'would'be'initiated'and'inflammatory'cascades'ensue,'impacting'the'disease'milieu,'perhaps'exacerbating'glial'activation'and'subsequent'neuron'loss,'as'discussed'in'section(4(of'Chapter(5'(Gendelman,' 2002).' Therefore,' we' cannot' rule' out' that' in' the' absence' of' an'infection,'ERT'would'not'be'effective,'especially'in'light'of'confirmation'of'visceral'pathology'within'the'heart'as'will'be'discussed'in'section(5.('However,'it'raises'the'question'whether,'as'discussed'in'section(5(of'Chapter(5,'optimising'gene'therapy'or' ERT' to' directly' treat' both' brain' and' body'may' be'more' effective' than' using'these' therapies' in' combination.' First' a' proof' of' principle' is' needed' and'unfortunately,'we'were'unable'to'show'this'in'this'study.''
'
As' outlined' in' section( 5(of'Chapter( 1,' clinical' studies' using' neuronal' stem' cell'therapy' (https://clinicaltrials.gov/ct2/show/NCT00337936)' and' the' small'molecules' Cystagon®' (https://clinicaltrials.gov/ct2/show/NTCT00028262)' have'already'been'carried'out'for'CLN1'disease'(with'little'success),'while'experimental'therapies'like'ERT'and'AAV'gene'therapy'are'still'at'the'preMclinical'stage'(Sands,'2013).' In' contrast,' for' CLN2' disease,' ERT'
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a)! Progress(for(ERT(treatment(is(at(the(stage(of(clinical(trial(for(CLN2(disease(ERT'is'a'feasible'approach'for'both'CLN1'and'CLN2'disease,'which'are'both'caused'by'deficiencies' in' lysosomal'enzymes'(Jalanko'and'Braulke,'2008).'However,' this'approach' has' been' relatively' much' more' successful' for' CLN2' disease.' Proof' of'principle' in#vitro#experiments' using' CLN2' patientMderived' fibroblasts' exposed' to'human' TPP1' (CLN2)' have' been' shown' to' restore' TPP1' activity' and' reduced'subunit' c' accumulation' (Lobel,' 2001).' Furthermore' hypomorph' CLN2Mdeficient'mice,' mutated' to' express' varying' levels' of' CLN2,' have' shown' that' only' 6%'restoration'is'necessary'for'sufficiently'delaying'disease'onset'(Sleat'and'ElMBanna,'2008).' To' gain' access' to' the' brain,' intraventricular' delivery' of' TPP1' to' Tpp1Mdeficient' mice' has' been' carried' out' and' demonstrated' a' reduction' in' storage'material,'glial'activation'and'resting' tremor'and'since'TPP1'was'also'detected' in'the'periphery,'may'have'also'treated'somatic'pathology'(Chang'et#al.,#2008).'These'findings'led'to'an'investigation'of'the'distribution'and'safety'of'recombinant'TPP1'(rhTPP1.' BMN' 190)' via' intracerebroventricular' (IVC)' delivery' in' the' CLN2'Dachshund' model,' which' showed' reduced' accumulation' of' storage' material'
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together'with'widespread' rhTPP1' activity' throughout' the' brain' and' resulting' in'improvements' in' brain' morphology,' neurological' function' and' histopathology'(Katz' et#al.,#2014,' Vuillememnot' et#al.,' 2014).' Following' these' positive' results,' a'clinical' trial' of' intraventricular' ERT' was' launched' in' 2014,' which' aimed' to'evaluate' safety,' tolerability' and' pharmacokinetics' and' efficacy' of' regular'administration' of' rhTPP1.' BMN' 190' in' human' CLN2' patients'(https://clinicaltrials.gov/ct2/show/NCT01907087).' To' date' interim' positive'results'have'been'announced'that'suggest'the'expected'diseaseMassociated'decline'in'neurological'function'may'be'stabilised'by'ERT'and'the'longerMterm'results'are'awaited'with'great'interest.'
'
Therapeutic'efforts'for'CLN1'disease'clearly'lag'behind'those'for'CLN2'disease,'and'it'may'be'that'a'higher'level'of'PPT1'activity'is'needed'to'be'effective,'or'that'the'diffusion' of' PPT1' through' the' brain' parenchyma' is' limited' (Cooper,' personal'communication).' Indeed,' ERT' has' only' reached' the' preclinical' stage' for' CLN1'disease' and' many' practical' issues' remain' unresolved' regarding' the' delivery' of'PPT1' to' the'brain.'As'discussed' in'section(5.1(of'Chapter(1,(highMdose'ERT'has'been' administered' intravenously' to' Ppt1Mdeficient' mice,' resulting' in' an'attenuation'of'visceral'pathology'and'the'delay'of'neuropathology'if'administered'prior' to' closure' of' the' BBB' (Lu' et#al.,#2010,' Hu' et#al.,#2012)' but' was' unable' to'prevent' CNS' neuropathology' in' the' longMterm' as' mentioned' in' Chapter( 1( and'
Chapter( 5.' However,' a' recent' study' has' bypassed' the' BBB' to' target' the' CNS'directly' (Lu' et#al.,#2015).' In' this' study,'Ppt1///#mice'were' treated' repeatedly'with'purified' recombinant' PPT1' enzyme' via' the' lumbar' intrathecal' space' at' various'concentrations'(Lu'et#al.,#2015).'The'treatment'was'well'tolerated'and'was'able'to'
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extend'lifespan'in'proportion'to'the'concentration'of'enzyme'administered'(Lu'et#
al.,# 2015).' Neuropathology' was' improved,' with' a' reduction' in' autofluorescent'storage'material'in'the'spinal'cord,'reduced'microglial'activation'in'the'cortex'and'spinal'cord'and' improvements' in'motor' function'(Lu'et#al.,#2015).'These' findings'echo'those'reported'for'preclinical'studies'for'other'LSDs'such'as'MPS'I'(Kakkis'et#
al.,#2004)'and'CLN2'disease'(Chang'et#al.,#2008).'Therefore,'is'it'possible'that'ERT'could'ultimately'be'a'valid'approach'for'treating'both'CNS'and#visceral'pathology'in'CLN1'disease?'
'
b)! Progress(for(gene(therapy(is(at(the(clinical(trial(stage(for(CLN2(disease(Like'ERT,'gene'therapy'approaches'for'treating'CLN2'disease'have'advanced'more'quickly' than' in' CLN1' disease,' with' two' clinical' trials' underway'(https://clinicaltrials.gov/ct2/show/NCT01414985' and' NCT01161576).' The'feasibility'of'viralMmediated'gene'therapy'for'CLN2'disease'was'first'tested'in'the'Tpp1Mdeficient' mouse' CNS' using' a' series' of' different' vectors' including'recombinant' Ad,' feline' immunodeficiency' virus' (FIV)' and' AAV5' via' intracranial'injection' (striatum' and' cerebellum)' resulting' in' transduction' of' cells' in' regions'neighbouring'the'injection'site'and'high'expression'of'TPP1'enzyme'(Haskell'et#al.,#2003).' Using' multiple' injection' targets,' the' efficacy' of' AAV2' and' AAV2MCLN2'vectors'was' then' tested' in' Cln2/deficient'mice' and'was' able' to' partially' correct'brain'pathology' (Passini'et#al.,#2006).' Following' the' identification'of'AAVrh10'as'able'to'spread'further'throughout'the'CNS,'it'was'shown'that'AAVrh10MTPP1'was'able' to' further' improve' neuropathology,' as' well' as' behavioural' measures' and'increase' lifespan,' especially' if' given'very'early' in'disease'progression' (Sondhi'et#
al.,#2007).'As'a'result'of'these'findings'in'mice,'studies'were'carried'out' in' larger'
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animal,' nonMhuman' primates' to' establish' dose' and' safety' profiles' for'AAVrh10hCLN2'(Sondhi'et#al.,#2007)'while'dogs'are'still'being'used'to'determine'therapeutic'efficacy'(Tecedor'et#al.,#2014;'Katz'et#al.,#2015).'The'results'from'these'large'animal'studies'have'shown'that'AAVrh10MTPP1'is'safe,'with'the'exception'of'mild/moderate'white'matter'inflammation'around'the'injection'site'and'is'able'to'improve' motor' performance,' cognitive' function' and' extend' lifespan,' providing'grounds'for'the'potential'benefit'of'AAVrh10hCLN2'in'human'patients'(Neverman'
et#al.,#2015).'''
'
As' discussed' in' section( 5.5( of' Chapter( 1( and' as' we' have' seen' in' Chapter( 5,(experimental'gene'therapy'has'proven'only'partly'successful'for'the'treatment'of'CNS'pathology' in'CLN1'disease'mice.'However,' for'both'CLN1'and'CLN2'disease,'treating' the'CNS'and' the'viscera'using'gene' therapy'has'proven'difficult'as'AAVMvectors' do' not' spread'well'within' the' viscera' (Sands,' personal' communication).'However,'recent'studies'have'shown'that'systemic'delivery'of'AAV2/9'to'fetal'and'neonatal'mice'(Rahim'et#al.,#2011)'and'lateMgestation'nonMhuman'primates'(Mattar'
et#al.,#2015)' is' able' to' achieve' widespread' systemic' gene' expression' as' well' as'expression'within' the'CNS.'Whether' this'vector'will'prove'beneficial' for' treating'whole' body' pathology' in' NCL' or' any' other' monogenic' disorder,' is' yet' to' be'determined.' If' possible,' this' approach' may' be' preferable' to' using' ERT,' which'would'require'repeated'administration'to'the'CNS'and'viscera,'perhaps'giving'rise'to'a'number'of'adverse'effects.''
'
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Whether' ERT' or' gene' therapy' is' used' to' treat' the' body' and' brain' separately' or'together,' an' important'question' remains' M'why' is' it' that' efforts' at'ERT'and'AAV'gene' therapy' are'more' advanced' for' CLN2' disease' than' CLN1' disease?' One' key'obstacle'to'furthering'successful'gene'therapy'and'ERT'for'the'treatment'of'CLN1'disease,' as' evident' from' the' review' of' ERT' and' AAV' gene' therapy' studies'discussed'in'this'section,'is'that'a'well'characterised'large'animal'model'exists'for'CLN2'disease'(Awano'et#al.,#2006),'whereas'no'such'model'exists'for'CLN1'disease'(see' discussion' below).' Even' if' theoretically' feasible,' these' therapies' can' only'properly'be'further'developed'in'animal'models'that'mirror'the'complexity'of'the'human'brain,'making'such' large'animal'models'highly'valuable'(Neverman'et#al.,#2015).' Therefore,' without' large' animal' models' for' CLN1' disease,' translating'promising'findings'from'mouse'studies'is'made'more'difficult.'
!
c)! Moving(therapy(forward(for(CLN1(disease(–(the(need(for(large(animal(
models(Whilst'numerous'active'experimental'populations'of'large'animal'models'exist'for'CLN2'and'CLN8'(canine)'and'CLN6'and'CLN5'(sheep)'(Bond'et#al.,#2013),'no'such'experimental'populations'are'available'for'CLN1'disease.'A'mutation'in'PPT1#was'previously' identified' in' a' Miniature' Dachshund' (Sanders' et# al.,# 2010).' The'mutation'reported'was'a'single'base'insertion'in'the'coding'sequence'at'nucleotide'position'c.736_737,'causing'a'frame'shift'and'leading'to'the'loss'of'the'catalytically'active' His289' residue' (Sanders' et# al.,#2010).' Based' on' the' crystal' structure' of'PPT1,'this'frame'shift'mutation'would'be'expected'to'cause'loss'or'modification'of'numerous'residues'that'comprise'the'hydrophobic'core'of'the'protein,'resulting'in'the' complete' loss' of' PPT1' thioesterase' activity' (Bellizzi' et# al.,#2000).' This' was'confirmed' through' enzymatic' activity' assays' and' was' accompanied' by' clinical,'
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ultrastructural,' molecular' and' genetic' features' akin' to' human' CLN1' disease'(Sanders' et# al.,# 2010).' For' instance,' neurological' examination' of' this' minature'Dachshund'during'infancy'(9'months)'by'a'veterinary'specialist'revealed'a'number'of' clinical' signs,' including' kyphosis' (hunching' of' the' back)' and' stiffness' of' gate,'which'progressed' to'uncontrolled' rhythmic'head'movements,' ataxia'and'general'weakness'and'blindness'(Sanders'et#al.,#2010).'This'was'preceded'by'a'protracted'period' of' progressive' neurological' signs' observed' by' the' owners' e.g.' nervous'behaviour,' inability' to' recognize' or' respond' to' commands,' loss' of' ability' to'recognize'owner/people'in'household,'increased'sensitivity'to'loud'noises,'circling'behaviour,' loss' of' coordination,' tremor,' severe' loss' of' vision' and' bumping' into'obstacles' (Sanders' et# al.,#2010).' PostMmortem' microscopic' examination' showed'abundant' accumulation' of' autoflourescent' storage'material' in' neurons' of' retina,'cerebellum'and'cerebral'cortex,'which'upon'ultrastructural'examination'appeared'to' be' contained' in' lysosomeMlike' membrane' bound' inclusions' and' consisted' of'uniform' granularMlike'material,' similar' to' GRODs,' characteristic' of' CLN1' disease'(Tyynelä' et# al.,# 2000).' A' canine' model' like' this,' would' prove' very' useful' for'evaluating' therapeutic' interventions' for' treating' CLN1' disease,' unfortunately'however,'canine'carriers'of'the'c.736_737insC'mutation'that'have'been'identified'to'date'have'been'unable'to'breed'(e.g.'due'to'neutering'or'a'lack'of'sperm'cells'in'seminal' fluid)'and' thus'efforts' to' identify'additional'affected'or' carrier'minature'Dachshunds' for' the' purpose' of' establishing' a' CLN1' research' colony,' continues'(Sanders'et#al.,#2010).'
'
As' discussed' in' section( 5.1( and' 5.5( of' Chapter( 1,' gene' therapy' and' ERT'experiments' in' mice' have' provided' proof' of' principle' for' these' potential'
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treatments,' however,' due' to' differences' in' the' brain' volume' and' morphology'between'mice'and'humans,'mice'are'ultimately'limited'as'a'model'for'human'CLN1'therapies.'For'example,'the'widespread'distribution'of'gene'therapy'(Griffey'et#al.,#2004,'2005)'or'ERTMderived' (Lu'et#al.,#2010,'2015)'PPT1'protein' throughout' the'brain'is'thought'to'be'required'for'optimum'correction'of'NCL'neuropathology'and'this'is'very'much'influenced'by'the'anatomy'of'fluidMfilled'brain'structures,'which'are'vastly'different'between'small'and'larger'animal'species'(Sanders'et#al.,#2010).'Large'animals'are'more'similar' to'humans' in'relation'to'brain'size'and'structure'but' are' also' more' akin' to' humans' in' terms' of' lifespan,' physiology' and' clinical'symptoms'of'disease,'making'them'superior'models'(Bond'et#al.,#2013).'In'order'to'progress'with'current'experimental' therapies' for'CLN1'disease,'efforts'have'now'been'made'to'create'a'large'animal'model'for'CLN1'disease.'A'novel'porcine'model'is' currently' being' generated' by' Dr' Tom' Wishart' and' colleagues' at' the' Roslin'Institute,' University' of' Edinburgh' using' a' method' similar' to' one' that' has'previously'been'used'to'create'a'porcine'model'of'ataxia'telangiectasia'(Beraldi'et#
al.,#2015).' This' involves' the' use' of' CRISPRs' to' engineer' the' R151X'mutation' in'
PPT1' in' stem' cells,' from' which' PPT1/deficient' pigs' will' be' derived.' It' will' be'interesting' to' see' how' closely' this'model' recapitulates' the' human'disease' but' it'should'prove'to'be'a'useful'tool'for'further'evaluating'experimental'therapies.''
'
Similarly,' there' are' also' no' currently' available' experimental' colonies' of' large'animal'models'that'recapitulate'CLN3'disease'(Bond'et#al.,#2013).'For'a'long'time,'the' therapeutic'outlook' for'CLN3'disease'was'considered'to'be'quite'bleak'given'the'nature'of'the'CLN3'protein'and'the'little'that'is'known'about'it'(Cooper'et#al.,#2008).'However,' as'novel' therapies' like'gene' therapy'begin' to'emerge,' the' same'
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argument' regarding' the' need' for' large' animal' models' to' advance' therapeutic'progress'for'CLN1'disease,'also'applies'to'CLN3'disease.'As'such,'efforts'are'being'made'to'create'large'animal'models,'not'only'for'therapeutic'investigation'but'also'to'further'our'understanding'of'disease'pathogenesis'(Palmer'et#al.,#2003).'A'CLN3'porcine' model' of' CLN3' disease' has' been' generated' by' Dr' David' Pearce' and'colleagues'using'the'method'described'above'(Beraldi'et#al.,#2015),'but'has'not'yet'been'published.'
'
4! Is(combination(therapy(a(better(approach(for(all(NCLs?(Therapeutic'progress'for'the'NCLs'is'currently'staggered'having'reached'different'stages'for'different'forms,'but'with'no'viable'therapy'available'for'any'NCL'(Hobert'and'Dawson,'2006;'Wong'et#al.,#2010;'Cooper,'2008).'Whether'progress'is'limited'by'a'lack'of'understanding'of'disease'pathogenesis,'the'logistics'of'enzyme'or'drug'administration,' a' lack' of' large' animal' models' for' testing' potential' therapies,' or'more' specific' issues' such' as' the' development' of' neutralising' antibodies' against'exogenously'supplied'enzyme'(Neverman'et#al.,#2015),'it'is'likely'that'no'one'single'therapy'will'be'completely'effective'at' treating'any'of' the'NCLs.'Especially'when'considering'the'potential'onset'of'secondary'systemic'pathology'even'if'the'brain'is'successfully'treated.'By'combining'various'therapies,'it'may'be'possible'to'more'effectively'target'the'diverse'range'of'pathogenic'mechanisms'involved'in'the'NCLs'(HawkinsMSalsbury' and' Sands,' 2011).' One' strategy,' is' to' combine' a' longMterm'source' of' the' deficient' protein' via' gene' therapy' or' stem' cell' transplantation' for'instance,' while' targeting' a' secondary' consequence' of' disease' with' a' more'transient' approach' e.g.' substrate' reduction,' antiMinflammatory' drugs' or'pharmacological'mimetics' (HawkinsMSalsbury' and' Sands,' 2011).' This' concept' of'
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combination'therapy'has'been'tested'for'CLN1'disease'using'multiple'approaches'as' discussed' in' section( 5.6( of' Chapter( 1,' which' have' resulted' in' modest' yet'greater'therapeutic'efficacy.'In'this'thesis,'we'explored'another'possible'avenue'by'combining' AAV' gene' therapy' with' ERT' (Chapter( 5).' For' CLN3' disease,' several'downstream' effects' of' CLN3Mdeficiency' such' as' autoimmunity' (Chattopadhyay,'2002a,b)' or' excitotoxicity' (Cooper,' 2008)' as'described' in'section(5.7.a(and'b(of'
Chapter( 1,' have' been' targeted' in' lieu' of' therapies' that' have' traditionally' been'based' on' the' concept' of' “crossMcorrection”' e.g.' gene' therapy' and' ERT.'However,'together'with'a'small'number'of'other'studies'(Sondhi'et#al.,#2014),'this'thesis'has'proved'that'gene'therapy'for'CLN3'now'holds'some'promise,'widening'the'scope'for'potential'treatments.'It'is'likely'that'combining'these'potential'treatments'will'also' be' useful,' if' not' necessary,' for' treating' CLN3' disease' given' its' apparent'complexity.'
'
The' concept' of' combination' therapy' has' also' been' explored' for' other' LSDs,' for'which'viralMmediated'gene'therapy'has'only'been'modestly'successful'as'a'single'approach' (HawkinsMSalsbury' and' Sands,' 2011).' For' example,' using' similar'“CNS/systemic”' approaches' to' our'AAV'+' ERT' combination' therapy' approach' in'
Chapter( 5,' combination' therapy' has' been' tested' in' mouse' models' of' Krabbe'disease'(globoidMcell'leukodystrophy,'GLD)'and'NiemannMPick'A'disease'(Lin'et#al.,#2007;' Passini' et# al.,# 2007).' Before' it' was' attempted' in' Ppt1Mdeficient' mice'(described'in'section(5.6(of'Chapter(1),'AAV2/5Mmediated'gene'therapy'and'BMT'combination'treatment'was'administered'to' the'murine'model'of'Krabbe'disease'(the' twitcher' mouse)' (Lin' et# al.,#2007).' Krabbe' disease' or' GLD' is' caused' by' a'deficiency' of' the' lysosomal' enzyme' galactosylceramidase' (GALC),' and' when'
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AAV2/5' expressing' GALC' and' BMT' were' combined' this' produced' a' dramatic'increase' in' life' expectancy' compared' to' either' therapy'alone,' increasing' lifespan'from' 45' –' 55' days' to' 105' days' (~' 130' days' with' intrathecal' administration' of'AAV2/5' gene' therapy' [Reddy' et# al.,2011])' (Lin' et# al.,#2007).' This' synergy' was'thought'to'arise'from'the'widespread'transgene'expression'within'the'CNS'and'the'immunomodulatory'effects'of'BMT' in' the'viscera,'which'on' its'own'confers' little'clinical' benefit' (Lin' et# al.,#2007).' Alternatively,' rather' than' using' two' separate'approaches'to'target'the'brain'and'body,'a'bimodal'approach'for'the'same'type'of'therapy'could'be'used'as'has'been'performed'in'a'mouse'model'of'NiemannMPick'A'disease' (acid' sphingomyelinase' (ASM)' knockMout' mice)' (Passini' et# al.,# 2007).'AAV2Mmediated' gene' therapy' and' i.v.' injection' of' AAV2/8' both' expressing' the'deficient'human'ASM'were'combined'and'resulted' in'a'synergistic' improvement,'whereby' survival' in' the' combination' treatment' group' was' 100%' by' 54' weeks,'whilst' none'of' the' animals' treated'with'CNSMdirected'AAV2'or' systemic'AAV2/8'alone'had'survived'(Passini'et#al.,#2007).'This'synergistic'effect'was'most'likely'due'to' the'widespread'systemic'and'CNS'expression'of'ASM'and' the' fact' that'a' liverMspecific'promoter'was'used'to'drive'transgene'expression'from'the'AAV2/8'vector,'which'itself'has'strong'tropism'for'the'liver'(Franco'et#al.,#2005),'thus'reducing'the'immune' response' to' the' enzyme' (HawkinsMSalsbury' and' Sands,' 2011).' These'examples'highlight'the'various'ways'in'which'combination'treatments'can'result'in'improved' therapeutic' efficacy.' However,' whilst' a' combination' approach' may'prove'promising'for'one'disease,' it'of'course'may'not'be'appropriate'for'another'(see'next'paragraph).'
'
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As' our' understanding' of' disease' pathogenesis' unfolds,' additional' therapeutic'targets'will'be'unveiled,'which'might'be'better'targeted'in'combination.'Although,'it' is' likely' that'attempts'at' combination' therapy' that'have'been'beneficial' so' far,'have'improved'therapeutic'efficacy'through'synergistic'rather'than'additive'effects'(Sands'et#al.,#2013)'and'therefore,'the'outcome'of'specific'combinations'are'likely'to'be'unpredictable.'Conversely,' combination' therapy'may'also'have'no'effect'or'actually'have'an'adverse'effect'on'disease'as'we'have'seen'in'this'thesis'(Chapter(
5).'Such'negative'effects'of'combination'therapy'have'also'been'reported'for'other'LSDs' such' as'MPSMIIIB,' for' which' the' combination' of' CNSMdirected' AAV2/5' and'BMT' (also' attempted' in' Ppt1///#mice' [Macauley' et#al.,#2012]' with' some' success)'improved' hearing' and' lysosomal' storage' but' had' a' negative' effect' on' motor'function' and' lifespan' (Heldermon' et# al.,# 2010).' Therefore,' while' combination'therapies' represent' a' potentially' effective' therapeutic' strategy,' selecting' the'correct'primary'and'secondary'defects'to'target'may'be'a'lengthy'process'of'trial'and'error.''
'
5! CLN1(and(CLN3(diseases(have(a(cardiac(phenotype(As'new'evidence'for'visceral'pathology'begins'to'emerge,'it'is'becoming'apparent'that'classing'the'NCLs'as'‘neuronal’'disorders'may'be'a'misnomer,'as'the'effects'of'disease'are'not'restricted'to'only'neurons,'or'even'the'brain'(Cooper'et#al.,#2015).'Adding' to' the'small'body'of'evidence' that'has'been'collected'so' far,'our' findings'provide' further' proof' for' the' existence' of' cardiac' pathology' in' both' CLN1' and'CLN3'mouse'models'(section(3(of'Chapter(4).'As'we'have'seen' from'this' thesis,'analysis' of' cortical' thickness,' neuron' loss,' astrocytsosis,' glial' activation' and'storage' burden' in' the' brain' have' not' only' provided' an' insight' into' NCL'
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neuropathology' (Cooper' et# al.,# 2006' and' the' references' within)' but' have' also'served' as' valuable' readMouts' for' judging' the' efficacy' of' CNSMdirected' treatments'like'gene'therapy.'In'the'same'way,'identifying'clear'cardiac'phenotypes'would'not'only' facilitate'a'broader'understanding'of'NCL'pathology'but' could'also'serve'as'pathological' measures' for' evaluating' the' systemic' effects' of' therapies' that'primarily'impact'the'body,'such'as'intravenously'administered'ERT.'In'Chapter(4,'we' identified' a' number' of' significant' functional' and' histological' cardiac'phenotypes,' including' increased' heart' rate' (section( 3.1.( a),' LV' hypertrophy'(section( 3.1.b)' and' fibrosis' (section( 3.2.b)' in' Ppt1///#mice' at' the' end' stage' of'disease' and' LV' hypertrophy' (section( 3.1.b),' potential' diastolic' dysfunction'(section( 3.1.b),' reduced' stroke' volume' and' cardiac' output' (section( 3.1.c)' and'some' cardiac' remodelling' i.e.' increased' endothelial' cell' number' accompanying' a'trend' towards'myocyte'hypertrophy' (section(3.2.a)' in' end' stage'Cln3///'mice.' In'addition,' we' also' qualitatively' identified' SA' node' pathology' in' Ppt1///# mice'(section(3.2.c)'and'lymphocyte'infiltration'in'Cln3///'mice'(section(3.2.d).'Further'analysis' of' functional' and' histological' cardiac' characteristics' in' CLN1' and' CLN3'disease,'as'well'as'in'other'subMtypes'of'NCL'will'help'to'complete'the'picture.'One'pathological'phenotype'that' is'well'described'in'the'heart'and'in'other'organs,' is'the'presence'of'storage'material,'which'will'be'discussed'in'the'following'section'(Staropoli'et#al.,#2012;'Galvin'et#al.,#2008).''
'
5.1! Visceral(storage(burden,(does(it(matter?(While' the' influence' of' storage' material' in' neuropathology' is' still' a' subject' of'debate' (Palmer' et#al.,#2013),' its' role' in' systemic' pathology' has' not' really' been'explored.' Perhaps,' because' of' the' assumption' that' storage' burden' is' less' of' an'
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issue' outside' of' the' brain' since' the' majority' of' somatic' cells' are' selfMrenewing'(BioNumbers' database' [http://book.bionumbers.org]).' As' such,' any' effects' of'accumulating' storage' may' be' limited' by' the' degree' of' cellular' turnover' in' a'particular'organ'or'cell'type.'However,'as'discussed'in'section(1.3(of'Chapter(4,'it'has' previously' been' suggested' that' storage' material' in' the' lysosomes' of' cells'within' the' conduction' system' of' the' heart' for' example,' may' contribute' to'conduction' abnormalities' such' as' arrhythmias' (Fukumura' et# al.,#2011).' Storage'burden'has'not'yet'been'analysed'in'our'CLN1'and'CLN3'heart'tissue'samples,'but'it'will'be'informative'to'see'if'the'distribution'of'storage'material'correlates'with'our'other'data.''
'
In' light' of' the' evidence' against' storage' material' as' a' key' determinant' of' NCL'pathology' (Autti' et# al.,# 1997;' Oswald' et# al.,# 2005;' Cooper' et# al.,# 2006,' 2010;'Pontikis' et# al.,# 2004)' and' because' of' the' lack' of' a' clearly' defined' pathway' of'substrate'synthesis'(Hobert'and'Dawson,'2006),'a'therapeutic'approach'that'is'less'attractive' as' a' treatment' for' the' NCLs' is' substrate' reduction' therapy' (SRT).' As'discussed'alongside'other'small'molecules'in'section(5.1(of'Chapter(1,'substrate'reduction' therapy' approaches' do' not' target' the' underlying' genetic' defect' but'instead'reduce'the'biosynthesis'of'the'substrate'of'the'defective'enzyme'to'prevent'the'accumulation'of'storage'material'(Jeyakumar'et#al.,#2005;'Vunnam'and'Radin,'1980;'Radin,'1996).'SRT,'has'been'successful'for'a'number'of'other'LSDs,'for'which'the'substrate'is'known'and'there'is'a'clear'causative'link'between'storage'material'accumulation'and'pathology' (Hobert' and'Dawson,'2006;' Jeyakumar'et#al.,#2005).'For' instance,' the'glycosphingolipidoses'respond'well' to'monosaccharide'mimetic'drugs,'which'inhibit'the'hydrolases'involved'in'the'processing'of'glycoconjugates'
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(Hobert'and'Dawson,'2006;'Winchester'and'Fleet,'1992;'Fischer'et#al.,#1995;'Fischl'
et#al.,#1994).' For' example,'N/butyldeoxynojirimycin' (NBMDNJ),'which' inhibits' the'initial' step' in' glycosphingolipid' (GSL)' biosynthesis' (Platt' et#al.,#1994),' has' been'shown'to'reduce'GSL'accumulation'and'improve'clinical'symptoms'in'animals'and'humans' with' GSL' storage' disorders' (Radin,' 1996;' Vellodi,' 2005)' and' the' drug'miglustat' is'now'an'approved' therapy' for' the'most'common'GSL,' type' I'Gaucher'disease'(Cox'et#al.,#2000;'Lachmann,'2003).''
'
As' storage' material' is' the' most' obvious' pathological' feature' of' NCL,' this'therapeutic' approach' of' breaking' down' the' storage' material' has' been,' and'continues' to' be,' explored' (Cooper' et# al.,# 2015).' Based' on' previous' studies'demonstrating'the'ability'of'phosphocysteamine'to'reduce'storage'burden'in'CLN1'fibroblasts' (Zhang' et# al.,# 2001),' clinical' studies,' which' have' recently' reached'completion' have' been' carried' out' to' investigate' the' combined' effectiveness' of'cysteamine'bitrate'and'NMacetylcyctein'for'the'treatment'of'CLN1'disease'(Levin'et#













6! Conclusion(In' this' discussion,' I' have' aimed' to' highlight' the' differences' between' CLN1' and'CLN3'disease'and'how'these'differences'have'influenced'the'development'of'gene'therapy' for'each'disease.'For'CLN3'disease,' the' therapeutic'options'available'are'perhaps'not'as' limited'now'as'has' traditionally'been' thought,'with'gene' therapy'potentially'proving'to'be'a'safe'and'efficacious'option,'surprisingly'moving'quickly'towards' clinical' trial.'While' gene' therapy' for' the' treatment' of' CLN1'disease' has'shown'promise'in'mice'for'some'time,'to'make'better'progress'will'require'studies'in'large'animal'models'and'the'identification'of'new'aspects'of'pathology'that'can'be' targeted' together' with' gene' therapy' to' provide' better' outcomes.' Visceral'pathology,' especially' within' the' heart,' is' a' part' of' overall' pathology' in' CLN1'disease,' however' treating' systemic' pathology' in' combination'with' gene' therapy'may'not'represent'the'most'advantageous'combinatorial'approach.''
'
Combination' therapy' is' also' relevant' for' CLN3' disease,' with' gene' therapy' now'established'as'a'potential'protein'replacement'strategy,'it'may'be'possible'to'boost'the' effects' of' already' established' therapies' which' target' secondary' effects' e.g.'inflammation' and' oxidative' stress.' Cardiac' symptoms' have' been' identified' in'human' patients' and' now' confirmed' in' Cln3/deficient' mice' and' are' more'pronounced' than' in' CLN1' disease.' Whether' treating' such' visceral' pathology' in'combination'with' CNSMdirected' gene' therapy'would' then' prove'more' successful'than'for'CLN1'disease'is'an'interesting'consideration'and'will'depend'on'the'extent'of'pathology'in'organs'other'than'the'heart.'Nonetheless,'extending'life'expectancy'through' the' attenuation' of' neurological' symptoms' for' both' diseases,' will' most'likely' reveal' additional' pathology' within' peripheral' organs' that' will' need' to' be'
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treated' eventually.' Even' though' CLN1' and' CLN3' represent' two' very' different'forms' of' NCL,' gene' therapy' eventually' shares' the' same' limitations' for' both'diseases'–' that' full' correction' is'unlikely' to'be'achieved'with'gene' therapy'alone'and'systemic'pathology'cannot'be'ignored'in'the'longMterm.'
'
This' thesis' has' only' concentrated' on' CLN1' and' CLN3' disease,' however,' our'findings'could'be' relevant' for'other' forms'of'NCL.'For'example,'CLN2,'CLN5'and'CLN10' disease' all' represent' enzymeMdeficient' forms' of' NCL,' with' gene' therapy'being' tested' in' small' and' large' animal'models' and'human'patients' (reviewed' in'Neverman' et# al.,# 2015).' Like' CLN1' disease,' these' NCLs' may' also' benefit' from'combination' therapy' approaches' and' it' appears' that' gene' therapy' could' also' be'extended' to' other' transmembrane' protein' deficient' forms' of' NCL' like' CLN3.' In'fact,'gene'therapy'has'already'been'tested'in'CLN6'sheep'(Neverman'et#al.,#2015)'and' is' being' tested' in' the' eye' of' CLN6' mice' (kleine' Holthaus,' personal'communication).'
'
The'animal'models,'both'large'and'small,'upon'which'these'conclusions'are'based'have' been' essential,' offering' valuable' insights' into' the' biology,' pathology' and'treatment'strategies'associated'with'NCL.'However,'we'must'always'keep'in'mind'the'final'goal'–'to'create'treatments'that'are'theoretically'sound'and'practical.'This'is' especially' important' when' considering' the' combination' of' therapies.' Is' it'practical' to' combine' repeated' ERT' with' and' immunosuppressant' drugs' for'example'and'what'impact'will'this'have'on'quality'of'life?'A'perfect'treatment'for'NCL' disease'would' treat' patients' in' the' early' stages' of' disease' and' in' the'most'
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nonMinvasive'way'possible'without'the'need'for'repeated'administration.'However,'with' no' therapies' currently' available,' any' progress' towards' a' treatment' for' the'devastating'consequences'of'this'group'of'diseases'is'worth'acknowledging.'
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,Neurobasal*medium*(Gibco*21103>049)* 9.5*ml** *DMEM*(Gibco*11960>044)** 9.5*ml** *









•! Combine*5*mg*of*progesterone* (Sigma>Aldrich:*Cat.* P8783)* and*200*μl* of*ethanol*to*make*a*progesterone*stock*solution*




(100×),BSA*(Sigma>Aldrich*A4161)* 2*g* 10*mg/ml*Transferrin*(Sigma>Aldrich*T1147)* 2*g* 10*mg/ml*Putrescine*(Sigma>Aldrich*P5780)* 320*mg* 1.6*mg/ml*Progesterone*stock*solution* 50*µl* 6*µg*Sodium*selenite*stock*solution* 2*ml* 4*µg**3.! 3.*Bring*to*a*total*volume*of*200*ml*in*DMEM,*and*then*filter>sterilize.***
Thyroxine,(T3),Stock,(4,µg/ml),
,Dissolve*3.2*mg*of*3,3′,5>triiodo>L>thyronine*sodium*salt* (T3;*Sigma>Aldrich:*Cat.*T6397)* in*400*µl*of*0.1*N*NaOH.*Add*10*µl*of*T3*solution* to*20*ml*of*Dulbecco's*phosphate>buffered* saline* (D>PBS;* Gibco:* Cat.* 14287).* Filter* through* a* 0.22* µm*filter,*discarding*the*first*10*ml.***
NAC,Stock,(5,mg/ml),To*prepare,*dissolve*50*mg*of*N>acetyl>L>cysteine*(NAC)*powder*(Sigma>Aldrich:*Cat.*A8199)*in*10*ml*of*Neurobasal*Medium*(Gibco/Life*Technologies:*Cat.*21103).*(The*solution*will*be*yellowish).*Filter*through*a*0.22*μm*filter.***
2.2! Recipe,for,Tagmentation,DNA,(TD),Buffer,(2x),1.! 20*mM*Tris(hydroxymethyl)aminomethane;* 10*mM*MgCl2;* 20%* (vol/vol)*dimethylformamide*2.! Before*the*addition*of*dimethylformamide,*adjust*the*pH*to*7.6*with*100%*acetic*acid.*3.! Sterilize*the*buffer*by*a*0.22*μm*filter.**
! 524 
2.3! Recipe,for,HEPESTbuffered,saline,(HBS),(2x),
Combine*the*following:*Dextrose*(12*mM)*HEPES*(50*mM)*KCl*(10*mM)*NaCl*(280*mM)*Na2HPO4•2H2O*(1.5*mM)*Adjust* the* pH* to* 7.05* with* 10* N* NaOH;* accurate* pH* is* critical* for* efficient*transfection.*Sterilize*by*filtration*through*a*0.45*μm*nitrocellulose*filter.***
2.4! PhosphateTBuffered,Saline,(PBS),(10×,,pH,7.4),
Combine*the*following:*1.37*M*NaCl*27*mM*KCl*80*mM*Na2HPO4*20*mM*KH2PO4**To*prepare*1* l*of*a*10×*stock*solution,*combine*80*g*of*NaCl*(Sigma>Aldrich:*Cat.*S3014),* 2* g* of* KCl* (Sigma>Aldrich:* Cat.* P9541),* 11.4* g* of* Na2HPO4*(anhydrous;*Sigma>Aldrich* Cat.* S3264),* and* 2.7* g* of* KH2PO4*(anhydrous;* Sigma>Aldrich:* Cat.*P9791).***Adjust*the*pH*to*7.4*with*HCl,*and*bring*the*final*volume*to*1*l*with*ultrapure*H2O.*****
! 525 
2.5! Plasmid,sequences,used,for,vector,production,,

















































































































































































































































































































































RPL13a, Forward* ccctccaccctatgacaaga* #108,(Cat.*04692276001)*Reverse* gccccaggtaagcaaactt*
ATP5b, Forward* catcctaaatgccctggaag* #56,(Cat.*04688538001*Reverse* gcaatagttctgaccgtgctc*
βTactin, Forward* aaggccaaccgtgaaaagat* #56,(Cat.*04688538001*Reverse* gtggtacgaccagaggcatac*
eGFP, Forward* gaagcgcgatcacatggt* #67,(Cat.*04688660001)*Reverse* ccatgccgagagtgatcc*
ires, Forward* gttgaatgtcgtgaaggaagc* #6,(Cat.*04685032001)*Reverse* caaagggtcgctacagacg*

































































































































































































































































































































































































































































































   
 






















































































































































































































































































































































































































































































































































































































































































































the) primary) somatosensory) barrel) field) cortex) (S1BF)) and) ventral) posteromedial/ventral) posterolateral)
(VPM/VPL))nuclei)of)the)thalamus!at)5)months)of)age)in)Ppt1Fdeficient)(Ppt1%/%))mice:)Significant)differences)
revealed) when) AAV) +) ERT) combination) group) is) removed) from) statistical) analysis.) Top:! Representative!images! of! microglial! reactivity! (AFH)! obtained! from! immunohistochemical! staining! for! cluster! of! differentiation!(CD68)!reveals!higher!intensity!and!darker!staining!with!more!rounded!and!enlarged!cell!bodies!in!untreated!Ppt1A/A!mice! and! AAV! +! ERT! treated! mice! (B,) D,) F,) H)! in! VPM/VPL! and! S1BF.! A! lighter! and! less! intense! staining! was!observed!in!the!AAV!only!treated!mice!(C,)G)!and!even!more!so!in!the!wildAtype!mice,!demonstrating!pale!staining!with!very!small!cell!bodies!(A,)E)!in!both!brain!regions.!Bottom:!histograms!presenting!the!mean!of!each!treatment!group,! with! an! error! bar! representing! the! SEM,! demonstrated! the! percentage! of! CD68! immunoreactivity! in!VPM/VPL! (on! the! left)! and! S1BF! (on! the! right)! obtained! by! thresholding! image! analysis.! Initial! analysis!with! all!group! combined! found!only! two! significant! differences! in! the!VPM/VPL;! difference! between!wildAtype!mice!with!untreated! Ppt1A/A! mice! and! with! AAV! +! ERT! treated! mice! (significance! bar! in! black).! In! red:! statistical! analyses!performed!without!the!AAV!+!ERT!treated!mice!revealed!significant!differences!between!untreated!Ppt1%/%!mice!and!AAV!only! treated!mice!and!between!AAV!only! treated!mice!and!wildAtype!mice! in!both!regions.! In!addition,!wildAtype!mice!were!significantly!different!to!untreated!Ppt1%/%!mice!in!VPM/VPL!and!S1BF.!Significance!determined!by!*!
p!<!0.05.!**!p'<!0.01,!***!p!<!0.001,!****!p!<!0.000.1.!Scale!bar:!20!μm.!Figure!and!legend!provided!by!Julia!Uporova.!!
!!!!!!!!“It!always!seems!impossible!until!it’s!done”!!Nelson!Mandela!!
